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Abstract
Comparison Of iNfliximab and ciclosporin in STeroid
Resistant Ulcerative Colitis: pragmatic randomised Trial and
economic evaluation (CONSTRUCT)
John G Williams,1* M Fasihul Alam,2 Laith Alrubaiy,1 Clare Clement,1
David Cohen,3 Michelle Grey,1 Mike Hilton,4 Hayley A Hutchings,1
Mirella Longo,2 Jayne M Morgan,1 Frances L Rapport,1
Anne C Seagrove1 and Alan Watkins1
1Swansea University Medical School, Swansea University, Swansea, UK
2Swansea Centre for Health Economics, College of Human and Health Science,
Swansea University, Swansea, UK
3Faculty of Health Sport and Science, University of South Wales, Pontypridd, UK
4Patient representative
*Corresponding author j.g.williams@swansea.ac.uk
Background: The efficacy of infliximab and ciclosporin in treating severe ulcerative colitis (UC) is proven,
but there has been no comparative evaluation of effectiveness.
Objective: To compare the clinical effectiveness and cost-effectiveness of infliximab and ciclosporin in
treating steroid-resistant acute severe UC.
Method: Between May 2010 and February 2013 we recruited 270 participants from 52 hospitals in
England, Scotland and Wales to an open-label parallel-group, pragmatic randomised trial. Consented
patients admitted with severe colitis completed baseline quality-of-life questionnaires before receiving
intravenous hydrocortisone. If they failed to respond within about 5 days, and met other inclusion criteria,
we invited them to participate and used a web-based adaptive randomisation algorithm to allocate them
in equal proportions between 5mg/kg of intravenous infliximab at 0, 2 and 6 weeks or 2mg/kg/day of
intravenous ciclosporin for 7 days followed by 5.5mg/kg/day of oral ciclosporin until 12 weeks from
randomisation. Further treatment was at the discretion of physicians responsible for clinical management.
The primary outcome was quality-adjusted survival (QAS): the area under the curve (AUC) of scores derived
from Crohn’s and Ulcerative Colitis Questionnaires completed by participants at 3 and 6 months, and then
6-monthly over 1–3 years, more frequently after surgery. Secondary outcomes collected simultaneously
included European Quality of Life-5 Dimensions (EQ-5D) scores and NHS resource use to estimate
cost-effectiveness. Blinding was possible only for data analysts. We interviewed 20 trial participants and
23 participating professionals. Funded data collection finished in March 2014. Most participants consented
to complete annual questionnaires and for us to analyse their routinely collected health data over 10 years.
Results: The 135 participants in each group were well matched at baseline. In 121 participants analysed
in each group, we found no significant difference between infliximab and ciclosporin in QAS [mean
difference in AUC/day 0.0297 favouring ciclosporin, 95% confidence interval (CI) –0.0088 to 0.0682;
p= 0.129]; EQ-5D scores (quality-adjusted life-year mean difference 0.021 favouring ciclosporin, 95% CI
–0.032 to 0.096; p= 0.350); Short Form questionnaire-6 Dimensions scores (mean difference 0.0051
favouring ciclosporin, 95% CI –0.0250 to 0.0353; p= 0.737). There was no statistically significant
difference in colectomy rates [odds ratio (OR) 1.350 favouring infliximab, 95% CI 0.832 to 2.188;
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p= 0.223]; numbers of serious adverse reactions (event ratio= 0.938 favouring ciclosporin, 95% CI 0.590
to 1.493; p= 0.788); participants with serious adverse reactions (OR 0.660 favouring ciclosporin, 95% CI
0.282 to 1.546; p= 0.338); numbers of serious adverse events (event ratio 1.075 favouring infliximab,
95% CI 0.603 to 1.917; p= 0.807); participants with serious adverse events (OR 0.999 favouring
infliximab, 95% CI 0.473 to 2.114; p= 0.998); deaths (all three who died received infliximab; p= 0.247) or
concomitant use of immunosuppressants. The lower cost of ciclosporin led to lower total NHS costs (mean
difference –£5632, 95% CI –£8305 to –£2773; p< 0.001). Interviews highlighted the debilitating effect of
UC; participants were more positive about infliximab than ciclosporin. Professionals reported advantages
and disadvantages with both drugs, but nurses disliked the intravenous ciclosporin.
Conclusions: Total cost to the NHS was considerably higher for infliximab than ciclosporin. Nevertheless,
there was no significant difference between the two drugs in clinical effectiveness, colectomy rates,
incidence of SAEs or reactions, or mortality, when measured 1–3 years post treatment. To assess long-term
outcome participants will be followed up for 10 years post randomisation, using questionnaires and
routinely collected data. Further studies will be needed to evaluate the efficacy and effectiveness of new
anti-tumour necrosis factor drugs and formulations of ciclosporin.
Trial registration: Current Controlled Trials ISRCTN22663589.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 44. See the NIHR Journals Library website
for further project information.
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SUSAR suspected unexpected serious
adverse reaction
TMG Trial Management Group
TSC Trial Steering Committee
UC ulcerative colitis
UK-IBDQ United Kingdom Inflammatory
Bowel Disease Questionnaire
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Plain English summary
U lcerative colitis can present rapidly with severe symptoms. Infliximab and ciclosporin, the trial drugs,can improve severe colitis, but their relative effectiveness in acute attacks is not known.
We recruited 270 patients admitted to 52 hospitals in the UK who had failed to respond to steroids given
into a vein, and allocated them at random between the trial drugs. They completed quality-of-life (QoL)
questionnaires on admission, 3 and 6 months after treatment, and then 6-monthly for 1–3 years.
We compared QoL scores between the trial drugs over patients’ time in the study. Both improved QoL,
but there was no real difference between them.
We also compared length of hospital stay following recruitment, number of colectomies (removal of the
colon) despite treatment with a trial drug, side effects and mortality. There was no real difference between
the two drugs in any of these measures. The much lower cost of ciclosporin meant that total NHS costs
over 30 months were also much lower with ciclosporin.
We conducted 35 interviews with 20 patients. Those who had received infliximab were generally more
positive about treatment than those on ciclosporin. We interviewed 23 doctors and nurses, who reported
advantages and disadvantages with both trial drugs. However, nurses particularly disliked the prolonged
intravenous ciclosporin regimen.
We concluded that ciclosporin is much cheaper than infliximab. Nevertheless, there is no difference in the
performance of these two trial drugs.
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Scientific summary
Introduction
Ulcerative colitis (UC) is a chronic debilitating disease that affects about 150,000 people in the UK. Acute
severe ulcerative colitis (ASC) affects 25% of patients, and requires hospital admission and treatment with
intravenous steroids. About 40% of these patients do not respond to steroid therapy and until 10 years
ago colectomy was the only available treatment.
The efficacy of ciclosporin and infliximab in treating steroid-resistant UC is proven, but their relative clinical
effectiveness and cost-effectiveness is not known.
Objectives
Our objectives were to compare quality of life (QoL), mortality, colectomy rates, adverse events (AEs) and
resource use for up to 3 years after treatment with infliximab or ciclosporin to estimate the clinical
effectiveness and cost-effectiveness of these two drugs in managing ASC that had failed to respond to
intravenous steroids. We also sought to explore the views of patients and professionals about the
two treatments.
Methods
We conducted an open-label parallel-group, pragmatic randomised trial using mixed quantitative and
qualitative methods. We recruited participants from a cohort of patients admitted with ASC to hospitals
across Great Britain.
We assessed QoL through patient-completed questionnaires at baseline, 3 and 6 months after treatment
and then 6-monthly for 1–3 years. Data on colectomy rates, mortality, AEs and resources were collected
on case report forms (CRFs) completed by research staff at the same intervals.
We assessed the relative cost-effectiveness of the trial drugs through cost–utility analysis, which estimated
differences between groups in NHS costs and quality-adjusted life-years (QALYs).
Our qualitative studies explored participants’ experiences of their disease and the trial drugs, and the
preferences of health-care professionals between the trial drugs and their use.
We used the Method for Aggregating The Reporting of Interventions in Complex Studies, which we had
previously developed in another complex study, to integrate and compare findings from the mixed
methods used in Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis:
pragmatic randomised Trial and economic evaluation (CONSTRUCT). We classified our outcomes into
effects on participants; effects on gastroenterological services and professionals; and effects on the rest of
the NHS and society.
In due course we shall supplement our designed research data with routinely collected data. We have
consent from trial participants to access their routine data and send them annual questionnaires for
10 years from recruitment.
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Participants
We created a comprehensive cohort of admitted patients because we expected difficulty in identifying
acutely ill patients who needed urgent treatment and in obtaining baseline data from them. We invited
patients with known or suspected UC to join this cohort soon after admission and collected their baseline
data as soon as possible after they gave consent.
We recruited from the cohort to the trial those patients who failed to respond to intravenous steroids,
fulfilled the trial inclusion and exclusion criteria and gave informed consent. The treatment of patients who
did not give consent did not change in any way.
Trial inclusion criteria
We included patients who had been admitted unscheduled with colitis judged as severe (by the criteria of
Truelove and Witts, a Mayo score of at least 2 on endoscopic finding, or clinical judgement); who then
failed to respond to about 2–5 days of intravenous hydrocortisone; and also had a proven histological
diagnosis of UC, indeterminate colitis where clinical judgement suggested a diagnosis of UC rather than
Crohn’s disease, or symptoms typical of UC awaiting histology.
Trial exclusion criteria
We excluded patients aged < 18 years; from vulnerable groups or unable to consent; with an enteric
infection or histological diagnosis inconsistent with UC; who were pregnant, lactating, or fertile but
unwilling to use contraception for 6 months after randomisation; suffering current malignancy, except for
basal cell carcinoma; with serious comorbidity, including immunodeficiency, recent myocardial infarction,
heart failure, acute stroke, respiratory failure, renal failure, hepatic failure, or severe infection; with known
hypersensitivity to infliximab, ciclosporin or polyethoxylated oils; using tacrolimus or rosuvastatin; whose
English was poor in the absence of local translator services; needing emergency colectomy without further
medical treatment; currently participating in another clinical trial; treated with either infliximab or
ciclosporin within 3 months of admission; or showing any other contraindication to treatment with
infliximab or ciclosporin.
Qualitative studies
We used purposive quota sampling to identify 12 representative consenting participants from each arm of
the trial for two interviews. We used purposive sampling to interview 15 consultants from three strata:
sites that recruited well to cohort and trial; sites that recruited well to cohort but less well to trial;
and sites that recruited poorly. We also interviewed eight nurses from good recruiting sites.
Interventions
Participants randomised to infliximab received Remicade® (Merck Sharp & Dohme Ltd) in 5-mg/kg
intravenous infusions over 2 hours – forthwith, and at 2 and 6 weeks after the first infusion – in
accordance with local prescribing guidelines.
Participants randomised to ciclosporin received Sandimmun® (Novartis Pharmaceuticals UK Ltd) by
continuous infusion of 2mg/kg/day, continued for up to 7 days if successful, when it was switched to
twice-daily Neoral® tablets (Novartis Pharmaceuticals UK Ltd) delivering 5.5mg/kg/day, with the dose
adjusted to achieve trough ciclosporin concentration of 100–200 ng/ml. After 12 weeks, treatment was at
the discretion of the participant’s consultant.
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For both treatments we gave centres discretion to start azathioprine or 6-mercaptopurine at therapeutic
doses in week 4 and use was similar in both groups. We asked them to discontinue steroids by week 12 in
participants who remained well but to reinstate them if symptoms returned. We also asked centres to give
co-trimoxazole as prophylaxis against Pneumocystis jiroveci (formerly carinii) pneumonia in both groups.
Outcomes
The primary outcome was the area under the curve (AUC) of scores derived from the Crohn’s and
Ulcerative Colitis Questionnaire (CUCQ), a disease-specific patient-reported outcome measure which
extends the validated United Kingdom Inflammatory Bowel Disease Questionnaire to cover acute illness
and colectomy, and which we validated concurrently.
Secondary outcomes included change in Short Form-12 items and European Quality of Life-5 Dimensions
(EQ-5D) scores; mortality; colectomies, both emergency and planned; serious adverse events (SAEs) and
serious adverse reactions (SARs); and length of stay.
Economic outcomes included NHS costs and health-related quality of life (HRQoL), measured by EQ-5D.
Qualitative outcomes covered participant and professional views of the drugs and their consequences.
Sample size
Our original target analysable sample size was 360 participants, based on a primary outcome of a change
in HRQoL over 2 years. However, in 2012 slower recruitment than predicted led us to revise the primary
outcome and reduce the target analysable sample size to 250.
The changes required statistical imputation to exploit the resulting data set and we estimated that data
from 250 participants would be sufficient to detect an effect size of 0.35 in CUCQ scores with 80% power
at a 5% significance level.
Randomisation
We allocated participants at random between infliximab and ciclosporin, using a web-based password-protected
adaptive algorithm to protect against subversion while ensuring that each trial arm was balanced by centre.
Blinding
As this was an open trial, there was no need for procedures to inform sites about allocated treatments.
However, the chief investigator, trial methodologist, outcomes specialist, health economists and
statisticians remained blind to them until the Trial Steering Committee and Data Monitoring and Ethics
Committee had reviewed and approved the analysis of the primary outcome.
Statistical methods
Clinical effectiveness
Primary analysis was by treatment allocated, reflecting the pragmatic nature of the trial design. We used a
general linear model to estimate differences in quality-adjusted survival (QAS) between groups, adjusting
for covariates including trial site; age; gender; ethnic group; QoL at baseline; disease severity at baseline;
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immunosuppressant therapy at baseline (using a binary indicator set equal to 1 for participants then taking
azathioprine, 6-mercaptopurine or methotrexate); and time in follow-up.
Secondary analyses adjusted for the same covariates as primary analysis and compared between groups:
QAS per day (again using general linear models); QoL scores (using methods for repeated measures);
proportion of participants undergoing colectomy (using binary logistic regression); time to colectomy
(censored at the end of follow-up and analysed by Cox regression); proportion of participants suffering
one or more AEs (using binary logistic regression); and mortality.
We examined residual diagnostics in analyses that assume normality, with the options of data
transformation and bootstrapping when residual distributions were markedly non-normal. We excluded
identified outliers and reanalysed the revised data sets. We reported analyses in accordance with
Consolidated Standards of Reporting Trials (CONSORT) guidelines, including estimated differences with
95% confidence intervals (CIs), representing two-tailed tests at the 5% significance level.
Imputation of missing data
We used statistical imputation of censored and missing data, to impute QoL and costs for all participants
who generated data on survival, colectomy or QoL after randomisation.
Cost-effectiveness
We collected data on NHS resource use from CRFs and Participant Follow-up Questionnaires (PFQs) completed
at each follow-up time point. To minimise recall bias, PFQs reported resource use over the previous 3 months,
leaving gaps in the data which we imputed. We estimated all costs in 2012–13 prices inflated when necessary
using the NHS Pay and Prices Index and applied a discount rate of 3.5% per annum.
Our primary economic analysis assessed cost-effectiveness over 30 months by aggregating costs
and QALYs for participants for whom we had EQ-5D data. We fitted statistical models for NHS costs and
QALYs using allocated drug days since randomisation and the logarithm of those days as independent
variables. We used the resulting coefficients to adjust NHS costs and QALYs to a period of 730 days.
Costs and QALYs were further adjusted for baseline covariates. We used non-parametric bootstrapping to
generate scatterplots on the cost-effectiveness plane and produced cost-effectiveness acceptability curves
(CEACs) to show the probability of treatments being cost-effective against thresholds of willingness to pay.
Results
Participant flow
We know of 2065 potentially eligible patients admitted between May 2010 and March 2013 to
62 participating hospitals in England, Scotland and Wales. Of those, 1614 were consented into the
CONSTRUCT cohort. From these, 52 hospitals recruited 270 participants into the trial and followed them
for 1–3 years. Each arm comprised 135 participants, of whom 121 (90%) contributed to definitive analysis
of the primary outcome. Funded data collection finished in March 2014.
Baseline characteristics
At baseline, there were no statistically significant differences between arms in demographic or disease
characteristics, or QoL scores.
Primary outcomes
There was no significant difference in QAS between infliximab and ciclosporin; the mean adjusted
difference in total area under the CUCQ curve was 7.9 favouring ciclosporin (95% CI –22.0 to 37.8;
p= 0.603); and mean adjusted difference in AUC per day was 0.0297 favouring ciclosporin (95% CI
–0.0088 to 0.0682; p= 0.129).
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Secondary outcomes
At no time point after randomisation was there any significant difference between groups in CUCQ scores
(mean adjusted difference in AUC/day of survivors 0.0195 favouring ciclosporin, 95% CI –0.0191 to
0.0581; p= 0.319), Short Form questionnaire-6 Dimensions scores (mean adjusted difference 0.0051
favouring ciclosporin, 95% CI –0.0250 to 0.0353; p= 0.737); EQ-5D scores (QALY mean adjusted
difference 0.021 favouring ciclosporin, 95% CI –0.032 to 0.096; p= 0.350). There was also no significant
difference between groups in: mortality (all three who died had taken infliximab; p= 0.25); colectomy
rates [odds ratio (OR) 1.350 favouring infliximab, 95% CI 0.832 to 2.188; p= 0.223]; or time to colectomy
(hazard ratio 1.234 favouring infliximab, 95% CI 0.862 to 1.768; p= 0.251). Although length of hospital
stay after randomisation ostensibly did not differ between groups (mean adjusted difference 1.542 days
more for ciclosporin, 95% CI –1.297 to 4.381 days assuming normal distribution of residuals in general
linear model; p= 0.286), that distribution was so skewed as to invalidate the assumption of normality;
hence, we transformed these stays by taking logarithms and estimated that the geometrical mean of
adjusted stays after ciclosporin was a factor of 1.527 times longer than that after infliximab (95% CI 1.278 to
1.817; p< 0.001).
Adverse events
There was no statistically significant difference between the two drugs in SARs or SAEs. Fourteen infliximab
participants reported 16 SARs and nine ciclosporin participants reported 10 SARs (event ratio 0.938
favouring ciclosporin, 95% CI 0.590 to 1.493; p= 0.788; OR 0.660 favouring ciclosporin, 95% CI 0.282 to
1.546; p= 0.338). Sixteen infliximab participants reported 21 SAEs and 17 ciclosporin participants reported
25 SAEs not related to disease progression or colectomy (event ratio 1.075 favouring infliximab, 95% CI
0.603 to 1.917; p= 0.807; OR 0.999 favouring infliximab, 95% CI 0.473 to 2.114; p= 0.998). There were
two malignancies on infliximab (basal cell carcinoma and colorectal cancer) and one on ciclosporin
(endometrial cancer). Three participants died, all following infliximab (p= 0.247). The cause of death was
disseminated malignancy from colorectal cancer in one and perioperative pneumonia with sepsis, in the
presence of multiple comorbidities, in two.
Cost-effectiveness
In the primary analysis at 30 months, total health service costs for ciclosporin (£14,609) were significantly
lower than for infliximab (£20,241) (mean adjusted difference –£5632, 95% CI –£8305 to –£2773;
p< 0.001): despite the average difference of nearly 2 days in length of hospital stay after recruitment
needed to complete ciclosporin treatment, the difference in cost was because of the much higher cost of
acquiring infliximab. QALY gains were similar in both groups: the mean adjusted difference of 0.021
QALYs favours ciclosporin, but is not statistically significant (95% CI –0.032 to 0.096 QALYs; p= 0.350).
The CEAC shows ciclosporin to have 85% probability of being cost-effective over a wide range of
thresholds of willingness to pay. Sensitivity analysis showed similar results at 12 and 24 months.
Technically, therefore, ciclosporin dominates infliximab.
Qualitative results
Interviews with participants revealed the substantial impact of UC on their QoL, and the potential benefits
from these medical treatments and from surgery. Participants treated with infliximab generally spoke more
positively about the treatment than those treated with ciclosporin. Interviews with nurses showed
preference for infliximab, largely because of the resource-intensive infusion protocol for ciclosporin.
Although some consultants favoured infliximab, most were indifferent, perceiving both drugs as effective,
with a more predictable speed of benefit with ciclosporin balancing a perceived higher rate of side effects.
Discussion
We have shown that ciclosporin costs the NHS much less than infliximab but is clinically no less effective.
Even so, 120 participants (45%) needed a colectomy. Our findings are consistent with those of the study
Comparing Cyclosporine with Infliximab in steroid-refractory severe attacks of ulcerative colitis (CySIF), the
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only other randomised trial of these two drugs for acute severe UC. However, CySIF was much smaller and
did not collect data on costs, QoL or the views of participants or professionals.
Our interviews highlighted the debilitating effect of UC; participants liked infliximab better than
ciclosporin, but doctors were more equivocal, whereas nurses disliked the more resource-intensive infusion
requirements of ciclosporin. By following participants over the next 10 years, through both questionnaires
and routine data, we plan to extend our quantitative findings, especially on colectomies and
other readmissions.
Trial registration
This trial is registered as ISRCTN22663589.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and literature review
Background
Ulcerative colitis (UC) is a chronic debilitating disease that affects about 150,000 people in the UK.1,2 Some
25% of patients with UC present either for the first time or later, with acute severe ulcerative colitis (ASC)
requiring hospital admission.3 In patients with ASC, intravenous steroids are the first-line treatment.4
However, about 30–40% of these patients are resistant to intensive steroid therapy.5,6 Previously,
colectomy was the only available option for these patients.5 Although mortality following emergency
colectomy has fallen over time, 10% of patients die within 3 months of surgery.7
The use of intravenous or oral ciclosporin (Sandimmun® or Neoral®, Novartis Pharmaceuticals UK Ltd),8,9
a calcineurin inhibitor that selectively inhibits T-cell function, and infliximab (Remicade®, Merck Sharp &
Dohme Ltd),10,11 a monoclonal antibody that targets tumour necrosis factor α, then offered hope for the
treatment of steroid-resistant UC.
Several studies support the use of infliximab in patients with moderate or severe UC,12–15 especially
steroid-resistant UC patients who do not tolerate ciclosporin.12 A recent systematic review and meta-analysis
of 34 infliximab studies found an average short-term response and remission of 68% and 40%, respectively,
and an average long-term response and remission of 53% and 39%, respectively.15 However, there are
concerns about high rates of later relapses.16,17 Two large randomised controlled trials (RCTs) also found highly
significant improvements in total Inflammatory Bowel Disease Questionnaire (IBDQ)18 score and Short Form
questionnaire-36 items physical and mental component scores19 for infliximab patients at 8 weeks when
compared with placebo.20 The current UK National Institute for Health and Care Excellence (NICE) guidelines
allow the use of infliximab only when ciclosporin is contraindicated or as part of a research study.21
Several studies support the use of ciclosporin as a safe and effective treatment for steroid-resistant UC,22–24
although it has been associated with side effects including dose-related toxicity23,25,26 and long-term
failure.23–25,27 A systematic review and meta-analysis of 31 ciclosporin studies reported a mean short-term
response rate of 71%;28 one study reported that 65% of patients relapsed after 1 year and 90% after
3 years.27 Another review of 32 studies reported a 51% short-term success rate.29 However, the relevant
Cochrane review concluded that there was limited evidence that ciclosporin was more effective than
standard treatment for severe UC and that long-term benefits were unclear.30 It also advocated research
into the long-term effects of ciclosporin on quality of life (QoL) and its cost-effectiveness.
Review of literature
We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials, original studies,
systematic reviews and meta-analyses that compare ciclosporin and infliximab in the management of acute
UC resistant to steroid therapy up to the 31 July 2014. We used the search terms: ‘ciclosporin’, ‘infliximab’,
‘ulcerative colitis’, ‘acute severe ulcerative colitis’ and ‘steroid resistant ulcerative colitis’. We included
synonyms, different spellings and drug brand names in our search to identify all relevant articles. We used
the electronic search strategies checklist of the Cochrane Collaboration.31
We identified nine observational studies and one RCT32–41 that compared the efficacy and safety of
ciclosporin with those of infliximab (Table 1). Although both ciclosporin and infliximab were effective in
steroid-resistant UC, results did not agree which drug was better.32–35 One small retrospective study34 of
38 patients with acute UC resistant to steroids showed a higher rate of colectomy in patients who received
ciclosporin (63% and 68% at 3 and 12 months, respectively) than in those who received infliximab
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TABLE 1 Results of the systematic review: studies that compare infliximab and ciclosporin use in steroid-resistant
acute UC
Study Number of patients Main outcomes reported Follow-up period
Laharie et al.,
201241
l 58 patients had ciclosporin
l 57 patients had infliximab
Treatment failure: 60% with
ciclosporin and 54% with infliximab
(p= 0.52)
SAEs: 16% with ciclosporin and
25% with infliximab
Mucosal healing: 47% with
ciclosporin and 45% with infliximab
(p= 0.85)
UK-IBDQ scores improved by
78 points with ciclosporin and
100 points with infliximab (p= 0.19)
Colectomies: 17% in the ciclosporin
and 21% in the infliximab group
98 days
Leblanc et al.,
201138
l 65 patients had infliximab
after ciclosporin failure
l 21 patients had ciclosporin
after infliximab failure
Colectomy rate: 54% in infliximab
group and 67% in ciclosporin group
Clinical remission: 25% in infliximab
group and 14% in ciclosporin group
AEs: 23% in infliximab group and
24% in ciclosporin group
22 months
Mañosa et al.,
200940
l 16 patients had infliximab
after failure of ciclosporin
Six patients (37.5%) required
colectomy and 19% of patients
had SAEs
195 days
Maser et al.,
200837
l 10 patients had infliximab
after ciclosporin failure
l 9 patients had ciclosporin
after infliximab failure
Clinical remission: 40% in the
infliximab-salvage group and 33%
in the ciclosporin-salvage group
The median duration of remission:
13.6 months in the infliximab-
salvage group and 21.0 months in
the ciclosporin-salvage group
Colectomy rate: 40% in the
infliximab group and 44% in the
ciclosporin group
SAEs: one in the infliximab group
and two in the ciclosporin group
Average duration of
follow-up was 7.8 months
for infliximab and
17.7 months for ciclosporin
Dean et al.,
201234
l 19 patients had infliximab
l 19 patients had ciclosporin
Colectomy rate: 63% for ciclosporin
and 21% for infliximab (p= 0.0094)
at 3 months. By 12 months the
rates were 68% and 37% for
ciclosporin and infliximab,
respectively (p= 0.06)
Steroid dependence at 12 months
was 50% for ciclosporin and 25%
for infliximab (p= 0.36)
There was no statistical difference in
AEs between the two groups
(p= 0.17)
12 months
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(21% and 37% at 3 and 12 months, respectively); there was no significant difference between groups in
adverse events (AEs) or steroid dependence. A prospective study36 found the colectomy-free rate at
discharge, and at 3 and 12 months from admission, was significantly higher in patients who had infliximab
as a rescue therapy (n= 45) compared with those who had ciclosporin (n= 38). A minute retrospective
study35 of two cohorts of patients (15 on ciclosporin and six on infliximab) showed a higher rate of
colectomy and opportunistic infection in patients who received ciclosporin compared with those who
received infliximab. A retrospective study of 49 patients on infliximab and 43 patients on ciclosporin showed
that colectomy frequencies were significantly lower after rescue with ciclosporin than with infliximab,
with no death or opportunistic infection.32 Mocciaro et al.33 retrospectively examined the outcomes of
30 patients who received ciclosporin and 30 patients who received infliximab for steroid-resistant acute UC
and reported that the rate of colectomy at 12 months was 48% in the ciclosporin group compared with
17% in the infliximab group (p= 0.01); both drugs were equally safe without severe AEs. A recent UK
inflammatory bowel disease (IBD) audit reported increased use of infliximab compared with ciclosporin in
managing ASC; the clinical response rate was higher in patients who received infliximab.42
TABLE 1 Results of the systematic review: studies that compare infliximab and ciclosporin use in steroid-resistant
acute UC (continued )
Study Number of patients Main outcomes reported Follow-up period
Chaparro et al.,
201239
l 47 patients had infliximab
after failure of ciclosporin
Colectomy rate was 30%
SAE rate was 23%
58 weeks
Croft et al.,
201336
l 45 patients had ciclosporin
l 38 patients had infliximab
Colectomy rate: 44% for ciclosporin
and 16% for infliximab at discharge
(p= 0.006). At 3 months the
colectomy rates were 47% vs. 24%
(p= 0.04), and at 12 months
colectomy rates were 58% vs. 35%
(p= 0.04) for ciclosporin and
infliximab, respectively
12 months
Sjoberg et al.,
201232
l 49 patients had infliximab
l 43 patients had ciclosporin
Colectomy rates: 5% vs. 27% at
15 days, 7% vs. 23% at 3 months
and 23% vs. 43% at 12 months
for ciclosporin and infliximab,
respectively (p< 0.05)
12 months
Mocciaro et al.,
201233
l 30 patients had infliximab
l 35 patients had ciclosporin
Colectomy rates: 28.5% vs.17%
(p= 0.25) at 3 months and 48% vs.
17% at 12 months (p= 0.007)
for ciclosporin and infliximab,
respectively
The 1–2–3 year cumulative
colectomy rates were 48%, 54%,
57% in the ciclosporin group and
17%, 23%, 27% in the infliximab
group (p< 0.05)
The mean follow-up was
74.7 months for ciclosporin
and 33.6 months for
infliximab
Daperno et al.,
200435
l 15 patients had ciclosporin
l 6 patients had infliximab
Clinical remission: 53% in the
ciclosporin group vs. 67% in
the infliximab group
Colectomy rates: 47% in the
ciclosporin group vs. 33% in
the infliximab group
49 months
AE, adverse event; SAE, serious adverse event.
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Four studies37–40 explored the use of infliximab and ciclosporin as a second-line rescue therapy by crossing
them over after failure of these agents as a first-line therapy. The studies concluded that the use of
ciclosporin or infliximab as second-line rescue therapy induced remission in up to two-thirds of patients.38
However, this remission was of limited duration, the rate of colectomy was around 40%, and the rate of
serious adverse events (SAEs) ranged from 16% to 23%.37–40
A recent meta-analysis of 321 patients in six retrospective cohort studies32–35,37,38 concluded that infliximab
and ciclosporin are comparable when used as rescue therapy in acute severe steroid-refractory UC.
However, the outcome measures were limited to colectomy rates, adverse drug reactions (ARs) and
postoperative complications over 12 months.43
Against this background of observational studies that compared these two drugs only indirectly, la Groupe
d’Etude Thérapeutique des Affections Inflammatoires Digestives (GETAID) recently reported on the trial
CycloSporine versus InFliximab (CySIF),41 the first head-to-head comparison of these two drugs. CySIF
found no significant differences in ‘treatment failure’ within 98 days, defined as any of the following: (i) no
clinical response after 7 days; (ii) no remission without steroids after 98 days; (iii) relapse between 7 and
98 days; (iv) SAE leading to treatment interruption; (v) colectomy; or (vi) death. However, CySIF recruited
only 110 patients, followed them for only 98 days, reported no data on QoL and collected no data on
costs or from participants.
The qualitative research reported in the literature on infliximab focuses on its role in treating rheumatoid
arthritis.44 There is no qualitative study that explores the use of ciclosporin in the treatment of acute UC.
One qualitative study exploring patient and parent experiences of infliximab in paediatric gastroenterology,
found favourable views of the drug when used in a hospital environment.45 To our knowledge, no studies,
qualitative or otherwise, have explored health professionals’ views of drug administration for treating
steroid-resistant UC. This is disappointing as qualitative methods are well suited to investigate personal
experience, individual perception and belief and meaning systems,46,47 enabling triallists to clarify patients’
and clinicians’ understandings of clinical practice and drug regimes.48,49 Therefore, there is a need for a trial
that also seeks the experiences and views of patients with acute UC about treatments and changes in
health over time and of health-care professionals about ease of drug handling and drug preference.
Patients with UC incur substantial health-care costs over many years. As well as the direct costs of
treatment by drug or surgery, UC patients consume a wide range of health-care resources including spells
in hospital, attendances at emergency departments, outpatient visits, endoscopies and other investigations.
Nevertheless, no study has assessed the cost-effectiveness of infliximab and ciclosporin in a head-to-head
clinical trial. Instead, Markovian economic models have created hypothetical cohorts of patients with
acute UC resistant to steroids to assess the cost-effectiveness of infliximab compared with ciclosporin
and surgery.50,51 These models used published evidence6,8,10,52 to extrapolate the costs and effects in
quality-adjusted life-years (QALYs) gained by each drug. Although these models conclude that infliximab is
a cost-effective treatment in comparison with ciclosporin and surgery, we need to interpret this claim with
caution. Theoretical models cannot capture all aspects of disease progression and their costs; and require
assumptions to replace unavailable primary data. Furthermore, they excluded patient mortality and side
effects while assuming that infliximab had a better side effect profile and mortality rate than both
ciclosporin and surgery. Therefore, direct comparison of the clinical effectiveness and cost-effectiveness of
infliximab and ciclosporin in patients with acute UC is essential.
In summary, infliximab and ciclosporin are often effective in the short term, but there is little long-term
evidence about their relative clinical effectiveness and cost-effectiveness. The Evidence Review Group
report commissioned by NICE concluded: ‘The results consistently indicate that the move from standard
care to ciclosporin is highly cost-effective’.53 Thus the policy issue is clear: should the NHS make a further
move from ciclosporin to infliximab?
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Hence we designed Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis:
pragmatic randomised Trial and economic evaluation (CONSTRUCT) to achieve a rigorous, comprehensive,
long-term comparison of these drugs. In particular, during the trial we enhanced measurement of QoL and
costs in four ways:
1. extending data collection for all trial participants, whenever recruited, until 28 February 2014
2. adding questionnaires at 18, 30 and 36 months to those at 3, 6, 12 and 24 months
3. adding four questionnaires following colectomy and any ensuing corrective surgery
4. planning to use the techniques of survival analysis and statistical imputation of missing values to impute
costs and QoL for all CONSTRUCT participants who generate data on survival, colectomy or QoL
after randomisation.
Aim and objectives
The aim of this trial was to compare the clinical effectiveness and cost-effectiveness of infliximab and
ciclosporin for patients with steroid-resistant UC over a period of up to 3 years.
Specific objectives were to:
1. compare health-related quality of life (HRQoL) after these two treatments
2. compare mortality, morbidity and disease activity between treatments
3. compare colectomy rates between treatments
4. compare cost-effectiveness of treatments in cost per QALY
5. investigate the views of patients about their health and treatments
6. investigate the views of health-care professionals about the treatments and their ease of administration.
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Chapter 2 Methods
Trial design
We conducted an open-label parallel-group, pragmatic randomised trial using mixed methods: quantitative
(including health economics and routinely collected data) and qualitative.54
Our primary outcome measure was quality-adjusted survival (QAS)55 weighted by participants’ scores on
the Crohn’s and Ulcerative Colitis Questionnaire (CUCQ), our extension of the validated UK-IBDQ to
include severe colitis and post-colectomy states. Secondary outcomes included two generic measures of
QoL [European Quality of Life-5 Dimensions (EQ-5D) and Short Form questionnaire-12 items (SF-12)],
emergency and planned colectomy rates, AEs and mortality.
We assessed the relative cost-effectiveness of the trial drugs through cost–utility analysis from the
perspective of the NHS and Personal Social Services, as recommended by NICE.56 These analyses assessed
differences between groups in total costs and QALYs.
Our qualitative studies aimed to enrich our quantitative results by exploring participants’ experiences of
UC and the trial drugs, and their priorities for health and well-being. We also explored health-care
professionals’ preferences between the trial drugs and their administration.
We used the Method for Aggregating The Reporting of Interventions in Complex Studies (MATRICS),
which we had previously developed in another complex study, to integrate and compare the findings from
the mixed methods used in CONSTRUCT.57 We classified our outcomes into effects on participants; effects
on gastroenterological services and professionals; and effects on the rest of the NHS and society. Using the
MATRICS template, we combined all comparable findings into summary statements and highlighted where
different methods resulted in inconsistent statements.
As we expected difficulty in recruiting acutely ill patients in hospital and completing their baseline data, we
created a comprehensive cohort. We invited patients with known or suspected UC to join this cohort soon
after admission. We explained that, if they had UC and did not respond to intravenous steroids, they might
need other drug treatment; so, if they were suitable, we would invite them to further treatment as part
of a clinical trial. To increase the chance of recruiting them, we collected their baseline data as soon as
possible after they had consented.
From May 2010 until the end of February 2013 we recruited from the cohort to the trial those participants
with UC who failed to respond to intravenous steroids over about 2–5 days, but did not then need
surgery. After full written and oral explanation we invited participants who fulfilled the trial inclusion and
exclusion criteria to consent to randomisation between infliximab and ciclosporin. Placebo controls would
have been unethical, as these severely ill patients need treatment, as the NICE Evidence Review
Group recognised.53
We shall supplement our designed research data with routinely collected data held by the Health & Social
Care Information Centre in England, the Secure Anonymised Information Linkage database in Wales, or
the Health Informatics Centre in Scotland. As these data are not yet available for the full period of the trial,
we shall analyse and report them in due course. We have consent from participants in both cohort and
trial to access their routine data for 10 years from recruitment, and from trial participants to send them
questionnaires over that period.
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Recruitment
Trial sites
Via the British Society of Gastroenterology we asked consultant gastroenterologists to express interest in
taking part in the study and to complete a questionnaire. We considered sites that had treated four or
more patients with steroid-resistant UC in the previous 12 months to be eligible and invited them to seek
local approval. As a result we initiated the trial in 67 NHS trusts or health boards, covering both teaching
and district general hospitals in England, Scotland and Wales. We phased the initiation of these sites,
reflecting the time needed to gain local research and development (R&D) approval.
Participants in cohort and trial
The target population for the cohort were inpatients with ASC, known or suspected, who were potentially
eligible for the trial. The target population for the trial were cohort members who failed to respond to a
course of about 2–5 days of intravenous steroid medication, but did not then need surgery. We invited eligible
patients into the cohort as soon as feasible and into the trial once the clinical team had confirmed steroid
resistance. The treatment of patients who did not consent to cohort or trial did not change in any way.
Participants in qualitative study
We used purposive quota sampling to identify 12 representative consenting participants from each arm of
the trial for interview on two occasions (see Appendix 1). To include participants from sites starting later
in the trial pro rata, we maintained a list of eligible participants.
We also interviewed principal investigators (PIs) and nurses responsible for administering and monitoring
the drugs across the trial sites. We included both professions to explore drug administration, physical
effects of both drugs on patients, personal preferences and their participation in CONSTRUCT. We used
purposive sampling to recruit 12 PIs from three strata: sites that recruited well to cohort and trial; sites that
recruited well to cohort but less well to trial; and sites that recruited poorly to both cohort and trial.
However, we recruited all eight nurses from good recruiting sites as others would have little relevant
experience of the trial drugs.
Informed consent
Patients eligible for the cohort received cohort participant information sheets (see Appendix 2) and oral
explanation from consultant gastroenterologists or research professionals (usually research nurses); in
response, patients gave written consent by signing and dating a cohort consent form (see Appendix 3).
Cohort participants who became eligible for the trial received the patient information sheet (RCT) (see
Appendix 4), and gave written consent by signing and dating a trial consent form (see Appendix 5). For both
cohort and trial, those taking consent countersigned and dated the form to confirm that the participant had
fully understood the nature of the study and had an opportunity to ask questions; they also put a copy of that
consent in the participant’s medical record and gave another copy to the participant.
Research professionals could take consent to the cohort if authorised to do so on the site delegation log
following appropriate training, including in good clinical practice (GCP). Although they could also explain
the trial to cohort patients, responsibility for countersigning lay with the site PI or another doctor with
delegated authority on the site delegation log. The trial consent form included consent to take part in
qualitative interviews.
Withdrawal
The procedure for consenting participants stressed that they could withdraw from the cohort or trial
whenever they wished without giving a reason and without affecting their care in any way. However, we
documented any reasons given. Participants could stipulate the level of withdrawal: from the allocated
treatment, from completion of further participant questionnaires, from consent to the use of any of their
routine, or from any combination of these. We also encouraged site staff to trace participants lost to
follow-up and document reasons when possible.
METHODS
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Between randomisation and the end of the trial, there were decisions to change allocated treatments, but
these did not require withdrawal from this pragmatic trial. These included failure to respond to treatment
with infliximab or ciclosporin, usually leading to surgical intervention.
Trial inclusion criteria
Patients admitted as emergency admissions with severe colitis (according to Truelove and Witts,4 a Mayo
score of at least 2 on endoscopic finding or clinical judgement) who fail to respond to about 2–5 days of
intravenous hydrocortisone therapy, who also had either:
l histological diagnosis of UC in this episode
l histological diagnosis of indeterminate colitis in this episode when clinical judgement (based on macroscopic
appearance, disease distribution or previous history) suggested a diagnosis of UC rather than Crohn’s disease
l symptoms typical of UC awaiting histology; or
l history of UC confirmed histologically.
Trial exclusion criteria
l Aged < 18 years of age on admission.
l Histological diagnosis before randomisation inconsistent with UC.
l Enteric infection confirmed before randomisation by stool microscopy, culture or histology (including
Salmonella, Shigella, Clostridium difficile, Campylobacter and cytomegalovirus).
l Vulnerable patient.
l Unable to consent.
l Positive pregnancy test or current lactation.
l Woman of childbearing potential unwilling to use contraception during and for 6 months after
treatment with infliximab in accordance with the Summary of Product Characteristics (SPC).
l Current malignancy, except basal cell carcinoma.
l Serious comorbidity, including immunodeficiency, myocardial infarction within last month, moderate or
severe heart failure (New York Heart Association class III or IV), acute stroke within last month,
respiratory failure, renal failure, hepatic failure and active or suspected tuberculosis.
l Other severe infections including sepsis, abscesses and opportunistic infections.
l History of hypersensitivity to infliximab, ciclosporin or polyethoxylated oils (notably Sandimmun
Concentrate for Solution for Infusion).
l Current use of tacrolimus or rosuvastatin.
l English not good in absence of local translator.
l Need for emergency colectomy without further medical treatment.
l Currently taking part in another clinical trial.
l Treatment with either infliximab or ciclosporin in the 3 months before admission.
l Any other contraindication to treatment with infliximab or ciclosporin.
Sample size and power
Our original target analysable sample size was 360 participants, based on a primary outcome of a change
in HRQoL over 2 years.54 However, in 2012 slower recruitment than predicted led us to seek agreement
from the Trial Steering Committee (TSC), Data Monitoring and Ethics Committee (DMEC) and Health
Technology Assessment (HTA) programme to revise the primary outcome and reduce the analysable
sample size to 250. We also proposed to analyse the area under the curve (AUC) of scores on the CUCQ
collected every 6 months up to 3 years from randomisation; and to include participants who had
undergone colectomy by developing and validating a post-colectomy extension to the CUCQ, which we
termed the Crohn’s and Ulcerative Colitis Questionnaire with post-colectomy extension (CUCQ+).
The changes required statistical imputation to exploit the resulting data set. As these techniques are
difficult to incorporate into power calculations, we used a simpler calculation based on t-tests of mean
CUCQ scores at 12 months. To detect an effect size of 0.35 in these scores with 80% power when using a
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5% significance level, required that we analyse at least 250 trial participants. We used the techniques of
statistical imputation applied successfully by the Cancer of the Oesophagous or Gastricus: New Assessment
of the Technology of Endosonography58 and Folate Augmentation of Treatment – Evaluation of Depression
(FolATED)59 trials to achieve an effective sample size of 250 for CONSTRUCT.
Randomisation
We allocated at random between infliximab or ciclosporin all participants who completed baseline
assessment, met the trial inclusion criteria and gave informed consent. We used a password-protected
website that accessed an adaptive algorithm to protect against subversion while ensuring that each trial
arm was balanced by centre.60 To validate each request for randomisation, the website asked:
l for the participant’s trial number, and month and year of birth
l for the name of person requesting randomisation (limited to those trained and authorised)
l if consent had been given
l if the participant had met the inclusion criteria
l if the participant had none of the exclusion criteria
l if the baseline questionnaire been completed.
If the responses to all four questions were ‘yes’, the website gave the name of the drug allocated to the
participant and immediately confirmed the trial number and drug by e-mail, and recorded those on
the randomisation database.
Hospital pharmacies at trial sites held the trial drugs. After each randomisation, the research staff
confirmed study number and drug by fax to the relevant pharmacy who labelled the drug with the
European Union Drug Regulating Authorities Clinical Trials number, sponsor, participant’s trial number,
name and address of supplier, dose and ‘For Clinical Trial Use Only’.
Blinding
As this was an open trial, there was no need for procedures to inform sites about allocated treatments.
However, the chief investigator, trial methodologist, outcomes specialist, health economists and statisticians
remained blind to them until the TSC and DMEC had reviewed and approved the analysis of the
primary outcome.
Interventions
Participants randomised to infliximab received it as Remicade in 5-mg/kg intravenous infusions over 2 hours –
forthwith, and at 2 and 6 weeks after the first infusion – in accordance with local prescribing guidelines.
Participants randomised to ciclosporin received it as Sandimmun by continuous infusion of 2mg/kg/day.
We asked sites to change the infusion every 6 hours, using non-polyvinyl chloride (PVC) bags and
administration sets. Intravenous treatment continued for up to 7 days if successful. They switched
participants responding to ciclosporin to twice-daily oral doses delivering 5.5mg/kg/day, and adjusted
doses to achieve trough ciclosporin concentration of 100–200 ng/ml. They measured whole-blood
ciclosporin levels according to local practice, ideally 48 hours after oral therapy and then every 2 weeks.
After 12 weeks, treatment was at the discretion of the participant’s consultant.
We asked centres to consult the SPC for Remicade or Sandimmun and oral ciclosporin (all available online)
at the time of first prescription.
For both treatments we gave centres discretion to start azathioprine or 6-mercaptopurine at therapeutic
doses in week 4. We asked them to eliminate steroids by week 12 in participants who remained well, but
to reinstate them in participants who became symptomatic. We also asked centres to give co-trimoxazole
as prophylaxis against Pneumocystis jiroveci (formerly carinii) pneumonia in both groups.
METHODS
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Outcome measures
Primary outcome
The primary outcome was the AUC of CUCQ scores. This is equivalent to QAS weighted by scores on the
disease-specific CUCQ. We concurrently validated the CUCQ, which extends the validated UK-IBDQ61
to cover acute illness and colectomy.
Secondary outcomes
(a) Disease-specific QoL, measured by the CUCQ.
(b) and (c) Generic QoL, measured by the SF-12.62
(d) Mortality.
(e) Colectomies, both emergency and planned.
(f) AEs.
(g) Readmissions, including those for causes other than UC.
(h) Malignancies.
(i) Serious infections.
(j) Renal disorders.
(k) Disease activity, using the criteria proposed by Truelove and Witts.4
Economic outcomes
(l) NHS costs.
(m) HRQoL, measured by EQ-5D.63
(n) Participants’ time off work.
Qualitative outcomes
(o) Participants’ views of their drugs and their consequences.
(p) Professional views of both drugs and their consequences.
Adverse events
Definitions
The Medicines for Human Use (Clinical Trials) Regulations 2004: SI 2004/1031 describe thus:64
l AE: any untoward medical occurrence in a subject to whom a medicinal product has been
administered, including occurrences which are not necessarily caused by, or related to, that product.
l AR: any untoward and unintended response to a medicinal product which is related to any dose
administered to the subject.
l Unexpected adverse reaction: an adverse reaction, the nature and severity of which is not consistent
with the information in the SPC for the medicinal product.
l SAE or serious adverse reaction (SAR) or suspected unexpected serious adverse reaction (SUSAR): any
AE, adverse reaction or unexpected adverse reaction, respectively, that:
i. results in death
ii. is life-threatening
iii. requires hospitalisation or prolongation of existing hospitalisation
iv. results in persistent or significant disability or incapacity; or
v. is a congenital anomaly or birth defect.
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Causality
Causality is the degree to which an untoward medical occurrence can be attributed to the trial intervention
rather than the underlying UC. We used the subjective scale: unrelated, unlikely to be related, possibly
related, probably related or definitely related. We classed only the last three as ARs or SARs having a
causal relationship. However, we did not class events caused by UC, notably worsening colitis or initial
steroid resistance, as ARs. We reported SARs to the Medicines and Healthcare products Regulatory Agency
(MHRA) annually.
Expectedness
We considered AEs, ARs, SAEs and SARs as ‘unexpected’ if their nature and severity was not consistent
with the relevant SPC. Expected events included:
l progression or exacerbation of the participant’s underlying UC, including clinical sequelae of
progression, such as worsening diarrhoea or abdominal pain
l medical or surgical procedures including surgery and endoscopy; however, we considered events that
led to procedures and surgical sequelae, such as pleural effusion or small bowel obstruction, separately
l conditions or symptoms present or detected before the first dose that did not worsen
l recognised undesirable effects found in the current SPCs for Remicade, Sandimmun or Neoral; as SPCs
updated regularly during the trial, we recommended that PIs consult the versions online.
Monitoring adverse events
In view of the extensive side effects of both trial drugs documented in their SPCs, and the many sequelae
of disease progression, the protocol stipulated that we did not require expedited reporting of serious
events from sites, unless they were unexpected, in which case we asked for notification within 24 hours.
We designed adverse event screening forms (AESFs) to enable local PIs to assess seriousness, causality and
expectedness in a logical sequence (see Appendix 6). Sites sent AESFs, once countersigned by local PI or
authorised person, securely via FaxPress to the trial office. The CONSTRUCT data manager was responsible
for initial screening of AESFs, paying particular attention to completeness, raising queries with the local
team and immediately notifying the chief investigator of events that might be classified as SUSARs. If
uncertain, the chief investigator discussed them with the local PI before the final decision. We entered
screened AESFs onto our Generic Clinical Information System (GeneCIS; version 10i, Swansea University,
Swansea) and regularly checked that they were consistent with data on colectomies reported through case
report forms (CRFs). Clinicians within the trial team reviewed the accumulating data on AEs, and
commented on GeneCIS, if necessary after discussion with the local team.
At the end of the study, two clinicians in the trial team reviewed all SAEs to ensure consistency of
interpretation in the final report, informed by data from sites on the duration of use of the drugs beyond
the 3-month intervention period specified in the protocol. Once that period was complete, clinical
management varied from participant to participant according to their progress and the clinical judgement
of the local team. The reviewers also took the different pharmacokinetic profiles of the trial drugs into
account because the bio-availability of ciclosporin is short-lived, whereas bio-availability of infliximab can
persist until 6 months after the last infusion. With the exception of malignancy, therefore, we judged
relatedness unlikely if the event occurred more than 1 month after ciclosporin, or more than 6 months
after infliximab.
Problems caused by UC and the trial drugs may coincide in a single event. When an AESF documented a
serious event, usually admission, and included more than one problem (e.g. abnormal liver and renal
function tests), we used clinical judgement to decide which related to the drug and which was the prime
cause of admission, and classified SAEs and reactions by body system.
METHODS
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Data collection
Baseline and follow-up data
At recruitment to cohort, we collected:
i. sociodemographic details: age, sex, ethnic group and truncated post codes, used to generate
measures of social deprivation (Indices of Multiple Deprivation for England, Welsh Index of Multiple
Deprivation, Carstairs Deprivation Scores for Scotland and Townsend scores for all three countries)
ii. details of admission
iii. disease history, including presenting complaint, time since first diagnosis and previous treatment,
including any previous surgery, or biologic or steroid therapies
iv. comorbidities, in particular cardiorespiratory, liver or renal disease, diabetes mellitus or hypertension
v. UC signs and symptoms, including duration of symptoms in current episode, stool frequency, blood
pressure, pulse and temperature
vi. current treatment, including type, dose and duration of steroid therapy
vii. pathology results, including full blood count, inflammatory markers, liver and renal function tests, and
total cholesterol
viii. site and extent of disease according to Montreal classification of IBD65
ix. histopathology results, including stool culture and histological diagnosis
x. family history of IBD
xi. height, weight and smoking status.
At 3 and 6 months after randomisation, and at 6-monthly intervals until 36 months, we collected clinical
and resource-use data from participants’ records (see Appendix 7).
Process of data collection
Research staff at trial sites asked all trial participants to complete the Participant Baseline Questionnaire
including the CUCQ, SF-12, EQ-5D and questions on primary care resource use (see Appendix 8); and the
similar Participant Follow-up Questionnaire (PFQ) which also included questions about intercurrent events
at 3, 6 and 12 months, and at 18, 24, 30 and 36 months if they reached these time points before March
2014 (see Appendix 9). Following admission a baseline CRF was completed by research staff to document
demographic and clinical details (see Appendix 10).
We asked trial sites to arrange outpatient appointments to coincide with these times whenever compatible
with routine clinical management. Local research staff posted PFQs to participants and asked them to bring
completed questionnaires to clinics. Participants could either complete and return them by post or seek
help at the clinic. We also asked sites to complete CRFs recording intercurrent events, secondary care
resource use and drug treatment at these times, preferably at the outpatient appointments, or else from
medical records (see Appendix 11).
The trial office sent Post-Colectomy Questionnaires (PCQs) and business reply envelopes to trial participants
who underwent colectomy on discharge following surgery and at 4, 8 and 12 weeks thereafter (see
Appendix 12). This PCQ included the CUCQ+, the post-colectomy version of the CUCQ and the EQ-5D.
Electronic data capture
We captured designed data on our existing GeneCIS, based on the Oracle(R) object-relational database
management system (RDBMS version 10g, Oracle Corporation UK Ltd, Reading). The system is
implemented in a three-tier architecture and remotely hosted in a professionally managed, secure
environment. With support from local information technology departments, we provided access to hospital
sites over the NHS N3 network.
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We customised GeneCIS to support the trial following a detailed evaluation of requirements, including
process mapping. The resulting electronic data capture structure reflected trial data requirements organised
in a clinically logical manner. GeneCIS includes data validity controls, including predefined pick lists, and
format and range constraints. We provided contextual guidance as help text and used system alerts to
warn users when specific combinations of entered data affected eligibility, the potential for AEs or other
important items.
Sites could choose either to enter data collection forms into GeneCIS locally or send completed forms by
secure FaxPress to the trial office. Sixteen sites used local data entry; the rest faxed paper forms. The basic
system and user interface were identical at sites and the trial office.
Data management and record keeping
All data acquisition, storage, transmission and use complied with the Data Protection Act.66 The trial office
recorded forms received on a bespoke Microsoft Access® 2007 database (Microsoft Corporation,
Redmond, WA, USA) for tracking paperwork, and stored all forms in locked cabinets within a secure office
with controlled access. We backed up GeneCIS and Access databases every day.
All GeneCIS users had role-based access to the system, including trial staff engaged in system
configuration, data entry, helpdesk support or quality assurance. Those with authorised access to
identifiable data did not contribute to analysis. Qualitative researchers had access to identifiable data to
contact participants, but not to their clinical data. Trial sites had access only to identifiable data for their
participants and could not view any other records.
We extracted data for analysis in pseudonymised form identified by participants’ trial numbers.
Data quality and information governance
We asked PIs to maintain site delegation logs authorising staff to perform defined tasks, to sign off any
changes and to send them to the trial manager. When we updated trial documents including CRFs, we
circulated new versions to sites with appropriate instructions. Sites replaced previous versions but retained
them in trial site files.
We asked those making essential changes to data collected on paper to strike the original entry only once,
insert the new data, and record the date and initials of the person responsible. GeneCIS maintained an
electronic audit trail by annotating all data with the user, date and time of entry. It also checked data at
entry, notably for correct format and within specified ranges. We subjected the resulting data to rigorous
quality assurance, compared all anomalies with the paper source documents and consulted local staff
when necessary.
We transcribed and reviewed interview data as soon as possible. We analysed the final transcripts without
identifying patient, professional or hospital.
Routine data
Funded research data collection continued until March 2014. We plan to supplement the designed
baseline data collected from cohort and trial participants with routinely collected data, including Hospital
Episode Statistics (and the equivalent in Wales and Scotland), and mortality from the Office for National
Statistics. We plan to continue follow-up for up to 10 years by linking routine mortality, inpatient and
primary care data. Record linkage will use the existing facilities of the Farr Institute at Swansea University
Medical School. Using these information sources, we plan to monitor all participants’ long-term outcomes,
notably mortality, colectomies both emergency and elective, and major morbidity including hospitalisation
and surgery, and thus most of their NHS costs. Hence we aim to achieve long-term follow-up of both trial
participants and a large comprehensive cohort of patients with UC.
METHODS
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Qualitative methods
Trial participant interviews
To understand trial participants’ experiences and perceptions of treatment by infliximab, ciclosporin and
surgery, we conducted telephone interviews at about 3 and 12 months after recruitment. We aimed to
investigate their priorities for their health and well-being, and their perceptions of taking the drugs,
side effects and response to treatment.
We first sought consent to interview when recruiting participants to the CONSTRUCT cohort. We sampled
interviewees from those subsequently recruited to the trial. Hence they had all been admitted with ASC
and received either infliximab or ciclosporin. We contacted those sampled following their first outpatient
appointment after discharge, invited them to take part and arranged convenient 1-hour slots to enable
them to talk freely without feeling rushed. As more than 50 trial sites across the UK contributed
participants, interviews by telephone to participants’ homes enabled us to cover the trial population,
minimise cost and ensure confidentiality.
Trained qualitative researchers used a semistructured approach to guide participants through the interview
questions and give them the opportunity to develop their responses and raise issues that were important
to them. The opening questions of the first interview schedule encouraged participants to think and talk
about their health, what was important about it, and what good and bad health meant to them (see
Appendix 13). More specific questions followed about their experiences of treatment, drug regimes and
health care, and about their outcomes. We soon recognised that some participants had already required
surgery for their colitis. We therefore adapted the interview schedule to capture the views of these
participants (see Appendix 14).
At the end of each of these initial interviews, we asked participants to take part in a second interview
about 12 months later to explore their subsequent experiences. For those, we used similar interview
schedules but added questions, notably to explore changes in their health, in their opinions of treatment
and in their interactions with health-care professionals (see Appendix 15). Again, we arranged convenient
1-hour slots for telephone interviews.
Health-care professional interviews
These aimed to gain insight into professional preferences between the two drugs and their personal
contribution to the trial. Our specific objectives were to explore their views about:
l administration of the two drugs, including ease of handling
l effects of the drugs on health-care provision
l personal preferences between the drugs
l drug regulation and current policy
l surgery for UC
l equipoise in recruiting to the trial.
We therefore planned semistructured interviews lasting 30–40 minutes with flexibility for interviewees to
expand on important issues and access their broad knowledge base. Our schedule covered interviewees’
beliefs and ways of working; aspects of drug provision that may affect preferences; their interaction with
patients and others; and their contribution to the trial (see Appendices 16 and 17). We offered interviews
face to face or over the telephone. We conducted separate interviews with consultants and nurses to
provide a richer understanding of differences between professional groups. With participants’ consent we
recorded and transcribed interviews for analysis.
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Definition and validation of outcome measures
Background
We are entirely committed to the philosophy, expounded by NICE and implemented by the National
Institute for Health Research (NIHR), that the ultimate criteria for interventions in health care are clinical
effectiveness and cost-effectiveness in improving the survival and QoL of patients over extended periods.
Although we admire how the GETAID investigators implemented the CySIF trial with little funding, they
recruited only 110 patients, followed them for only 98 days and reported only on ‘treatment failures’. This
is not a good basis for NHS investment decisions worth hundreds of millions of pounds. Instead we chose
QAS as our primary outcome and recruited enough participants to yield the power to discriminate between
two contrasting drugs. That still left us with the task of developing and validating a comprehensive
patient-reported outcome measure (PROM) applicable across the broad spectrum of disease severity
within UC.
There are several disease-specific QoL measures for patients with IBD.18,67–71 The most widely used is the
McMaster Inflammatory Bowel Disease Questionnaire.18,67,68,72,73 As it had not been validated for the UK,
we previously conducted a development and validation study to anglicise it as the UK-IBDQ.61 As this was a
community study, however, we recognised in designing CONSTRUCT within acute care that, to avoid
ceiling effects, we had to modify the UK-IBDQ by extending the range of responses for all items to include
more severe replies; the number of items to include more questions addressing severe symptoms; and the
frequency of administration in participants undergoing surgery. Furthermore, the UK-IBDQ has no
questions about the impact on QoL of colectomy, which reportedly happens to 9–21% of those with
UC.74–76 We therefore derived from the UK-IBDQ a PROM for patients suffering from moderate to severe
symptoms of Crohn’s or UC with or without stoma. We called this the CUCQ in its basic form, and the
CUCQ plus stoma extension (CUCQ+) in its extended form. Preliminary validation of the CUCQ confirmed
that it met essential psychometric criteria,77 with the result that the national IBD registry adopted it.
Although we developed the CUCQ as a tool for both conditions, we validated it only on UC patients.
As the development and concurrent validation of CUCQ and CUCQ+ underpin the primary analysis of
CONSTRUCT, we now describe that validation.
Methods
We used the standard psychometric approach outlined by Streiner and Norman78 to develop and validate
the CUCQ and CUCQ+ in three stages:
l item generation
l initial development in the CONSTRUCT cohort
l definitive validation in the CONSTRUCT trial sample.
We used the 32 UK-IBDQ items [see Appendix 8, Section A: Crohn’s and Colitis Questionnaire (CCQ)],
as the basis for developing the CUCQ and CUCQ+. We also reviewed the literature on PROMs in
gastroenterology to identify additional items. After drafting the CUCQ and CUCQ+, we recruited an expert
panel of gastroenterologists, outcome specialists, statisticians and patients to review the resulting questions
and response options, and ensure they were appropriate for UC patients.
We piloted the draft questionnaires on a sample of 20 UC patients with or without stoma from Neath Port
Talbot Hospital, Port Talbot, who were not participating in CONSTRUCT. We asked them to complete
CUCQ or CUCQ+ as appropriate and added four supplementary questions:
l Did you find any of the questions difficult to understand?
l Was there any question you did not want to answer?
l Was there any aspect of your bowel condition not covered by these questions?
l Did you find any of these questions not applicable to you?
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For our initial validation, we used patients recruited to the CONSTRUCT cohort but not the trial, who had
therefore completed the CUCQ at baseline. Of the 32 CUCQ questions (see Appendix 18), six were not
relevant to post-colectomy participants:
l Q1: On how many days over the last 2 weeks have you had loose or runny bowel movements?
l Q2: On how many days in the last 2 weeks have you noticed blood in your stools?
l Q6: On how many days over the last 2 weeks have you opened your bowels more than three times a day?
l Q9: On how many days over the last 2 weeks have your bowels opened accidentally?
l Q24: On how many days over the last 2 weeks have you wanted to go back to the toilet after you
thought you had emptied your bowels?
l Q26: On how many days over the last 2 weeks have you had to rush to the toilet?
We therefore designed the CUCQ+ (see Appendix 9, For patients with stoma), with 10 stoma-specific
questions replacing these six questions, making a total of 36 questions.
l S1: On how many days over the last 2 weeks have you been afraid that other people might hear your stoma?
l S2: On how many days over the last 2 weeks have you been worried that other people might smell
your stools?
l S3: On how many days over the last 2 weeks have you been worried about possible leakage from your
stoma bag?
l S4: On how many days over the last 2 weeks have you had problems with care for your stoma?
l S5: On how many days over the last 2 weeks have you found the skin around your stoma irritated?
l S6: In the last 2 weeks have you felt embarrassed because of your stoma?
l S7: In the last 2 weeks have you felt less complete because of your stoma?
l S8: In the last 2 weeks have you felt less attractive as a result of your stoma?
l S9: In the last 2 weeks have you felt less feminine/masculine as a result of your stoma?
l S10: In the last 2 weeks have you been dissatisfied with your body as a result of your stoma?
To calculate scores for participants who had not undergone surgery, we used the 32 CUCQ questions.
For post-colectomy participants, we used the 10 stoma-specific questions and the 26 stoma-relevant CUCQ
questions to calculate CUCQ+ scores. In analysing and validating both CUCQ and CUCQ+, we calculated
scores as follows:
1. We scored questions with four responses as 0, 1, 2 or 3 in ascending severity.
2. We scored questions with responses between 0 and 14 days as the actual value.
3. We reversed the scoring of questions with wording in the reverse direction (Q7, Q22 and Q32) to code
all questions in the same direction.
4. We rescaled questions between 0 and 1 by dividing actual responses by their maximum score (3 or 14).
5. We calculated CUCQ scores for non-colectomy participants, and CUCQ+ scores for post-colectomy
participants, by summing all valid responses and dividing by the number of completed questions.
6. So the lower the CUCQ+ (or CUCQ score), the better the respondent’s health. In analysing the AUC,
however, it is necessary to subtract the total CUCQ+ (or CUCQ) score from 1, so that higher scores
show better health, consistent with both EQ-5D and SF-12.
However, we calculated CUCQ and CUCQ+ scores only when participants had responded to at least 75%
of the questions – 24 out of 32 or 27 out of 36, respectively. If participants had completed fewer than
75% of questions, we treated the total CUCQ or CUCQ+ score as missing. To give equal weight to each
question answered, our analysis plan used the original 32 CUCQ questions for non-colectomy participants
and the 36 CUCQ+ questions for post-colectomy participants. To test the sensitivity of our findings to this
simple approach, we repeated the analysis in two ways. First, we gave equal weight to core scores and
stoma-specific scores, thus giving more weight to the latter. Second, we gave the stoma-specific scores
6 out of 26 of the weight given to core scores, as the original UK-IBDQ comprised 26 questions relevant to
stomas and 6 questions inapplicable to stomas, thus giving less weight to stoma-specific scores.
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Still following Streiner and Norman,78 we conducted initial psychometric development of the CUCQ on
CONSTRUCT cohort patients (who had not had a colectomy):
1. We examined the 32 sets of response frequencies for floor or ceiling effects.
2. We calculated the Kaiser–Meyer–Olkin measure of sampling adequacy and Bartlett’s test to judge
whether or not principal component analysis was appropriate.
3. We calculated Cronbach’s alpha (which should exceed 0.7 for good internal consistency).
4. We calculated item-total correlations for each question (which should exceed 0.2 for
good homogeneity).
5. We undertook principal component analysis to assess the underlying structure; we considered factors
important if their eigenvalues were clearly > 1, and individual questions as useful if their factor loadings
exceeded 0.4.
6. We assessed the construct validity of the scale by examining the correlation between the CUCQ and
two generic QoL questionnaires (EQ-5D and SF-12).
Then we undertook definitive validation of the CUCQ and CUCQ+ on the CONSTRUCT trial sample.
First, we compared demographic characteristics of that sample with the cohort to ensure that they were
similar. Then we analysed the trial sample in essentially the same psychometric way as the cohort, and
tested whether or not the principal components arising from these two analyses were consistent. Finally,
we repeated the principal component analysis of the trial sample after 12 months and tested whether or
not principal components arising from the CUCQ for non-colectomy patients and those arising from the
CUCQ+ for post-colectomy patients were consistent.
We also analysed reliability and responsiveness for the trial sample, initially combining CUCQ and CUCQ+
and then comparing them. We assessed test–retest reliability of the scales on participants who reported
no change in their condition at successive assessments; we considered scales reproducible if intraclass
correlation exceeded 0.75. We assessed responsiveness of the scales to change on participants who reported
a change in their condition; we considered scales responsive if the responsiveness ratio exceeded 0.5.
Analysis
Clinical effectiveness
Primary analysis was by treatment allocated, reflecting the pragmatic nature of the trial design. Figure 1
illustrates the primary outcome measure – the AUC defined by CUCQ scores at baseline and all available
time points before 31 March 2014 – also known as ‘QAS’. Within research into PROMs, there is a general
convention that for generic PROMs ‘higher is better’ whereas for condition-specific PROMs ‘lower is
better’. However, in order to be consistent with both EQ-5D and SF-12 we have subtracted calculated
CUCQ scores from 1, so that higher is better.
We calculated this area by summing the areas of the component trapezia, thus assuming linearity between
successive CUCQ scores, and setting the score at the end of follow-up equal to the last recorded score
(last one carried forward). This method accommodates both missing values and extra values like those
arising from PCQs.
The main analysis used a general linear model to estimate differences in QAS between groups, adjusting
for covariates that may affect this measure, including trial site; data collected while assessing eligibility for
cohort and trial, notably the sociodemographic variables age, gender, ethnic group, QoL, disease severity;
current immunosuppressant therapy (using a binary indicator set equal to 1 for participants taking
azathioprine, 6-mercaptopurine or methotrexate); and time in follow-up. We combined rare categories in
factors like ethnic group, taking account only of observed numbers in each category and the coherence of
new groupings.
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Secondary analyses adjusted for the same covariates as primary analysis and compared between groups:
QAS per day (again using general linear models); QoL scores (using methods for repeated measures);
proportion of participants undergoing colectomy (using binary logistic regression); time to colectomy
(censored at the end of follow-up, and analysed by Cox regression); proportion of participants suffering
one or more AEs (using binary logistic regression); and mortality.
We examined residual diagnostics in analyses that assume normality, with the options of data
transformation and bootstrapping when residual distributions were markedly non-normal. We excluded
identified outliers and reanalysed the revised data sets. We supplemented analyses by descriptive
comparisons between groups in accordance with Consolidated Standards of Reporting Trials (CONSORT)
guidelines, including estimates with 95% confidence intervals (CIs), representing two-tailed tests at the 5%
significance level.
Imputation of missing data
We used statistical imputation of censored and missing data to impute costs and QoL for all participants
who generate data on survival, colectomy or QoL after randomisation. Thus we excluded participants
without follow-up data, as calculation of QAS requires one or more CUCQ scores in follow-up.
None of the questionnaires has an official algorithm for imputing missing answers. So we imputed missing
values within participant interviews using the Expectation Maximisation option in the Missing Value
Analysis module within Statistical Package for the Social Sciences version 22 (SPSS Inc., Chicago, IL, USA),
and calculated scores according to the instructions for the measure in question. When necessary we
imputed missing scale and subscale scores by regression using the available values of that score at other
times and the allocated treatment group. To avoid introducing outliers, we restricted imputed scores to the
range observed for that measure in that group.
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FIGURE 1 Primary outcome measure: area under the CUCQ curve.
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Cost-effectiveness
We collected data on NHS resource use from CRFs and PFQs completed at each follow-up time point,
supplemented by data from other sources, notably, PCQs completed by patients undergoing colectomy,
SAE forms and any relevant information provided by sites. Together CRFs covered resource use over the
whole period during which participants were in the trial because each CRF recorded resource use since
the previous CRF. To minimise recall bias, however, PFQs reported resource use over the previous 3 months.79
This left gaps in the data, which we imputed. We estimated all costs in 2012–13 prices inflated when necessary
using the NHS Pay and Prices Index. We applied a discount rate of 3.5% per annum to costs occurring beyond
12 months. We applied the same annual discount rate of 3.5% for QALYs beyond 12 months.
Participant Baseline Questionnaires recorded data on resource use in the 3 months before their consent for
use as a covariate to account for any existing imbalances in resource use. As this resource use preceded
randomisation, we did not include it in the costs analysed.
We based the cost of infusing ciclosporin (Sandimmun) on reported dose and duration in whole vials; and
oral ciclosporin on reported dose and duration in whole dispensing packs (Table 2). We also added the
cost of monitoring ciclosporin levels. We based the cost of infliximab (Remicade) on the reported dose in
whole vials and, for infusions after the initial episode in hospital, we added the cost of admitting
participants as day cases (£311).
We also estimated the cost of preparing and delivering drug infusions from a questionnaire completed by
42 trial sites (81% of the 52 recruiting sites). For typical infusions they reported who mixes the infusion
(nurse or pharmacist); the time taken to prepare the infusion; and the frequency of bag changes for
ciclosporin participants. We multiplied by relevant unit costs:81 nurse £41 per hour; pharmacist £47 per
hour; and £1.50 per infusion or bag change. For centres that did not respond to the questionnaire we
imputed preparation and delivery costs by mean substitution.
Case report forms recorded data on hospital episodes, including the episode leading to recruitment.
PFQs reported data on admissions to hospitals other than the trial site. To these we applied unit costs from
either the 2012–13 Healthcare Resource Group (HRG) code FZ37 (non-elective episodes of inflamatory
bowel disease without interventions, 19 years and over) or the HRG code FZ74 (non-elective episodes
complex large intestine procedure, 19 years and over) and ‘complications and comorbidity’ (CC) codes
based on participants’ length of stay in hospital (see Table 3). We costed days in hospital beyond the
average for that HRG-CC at the published rate. For subsequent surgical procedures we used expert clinical
opinion to identify the 2012–13 HRG code most appropriate to the information recorded as free text on
the CRF, which often detailed specific procedures undertaken during each operation. Table 3 shows
selected secondary procedures and their HRG codes, but not the many CC codes per HRG. Again, we used
CC codes based on participants’ lengths of stay and costed excess days at published rates.
TABLE 2 Trial drugs: published unit costs (£)
Drug Dose Unit cost (£)
Ciclosporin (Sandimmun) 50mg/ml, 1-ml ampoules £1.94
Oral ciclosporin 100mg, 30-capsule pack
Neoral £72.57
Deximune® (Dexcel Pharma Ltd) £51.30
Capimune® (Mylan) £51.30
Infliximab (Remicade) 100-mg vial £419.62
Source of costs: British National Formulary.80
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Case report forms also recorded data on non-trial drugs administered to participants as inpatients. When
the CRF did not record dose, we assumed that the participant had received the lowest dose recommended
in the British National Formulary.80 When the CRF did not record duration, we assumed that participants
took any prescribed gastroenterology drugs throughout their hospital stay; we extended this rule to seven
other drugs – alendronic acid, amlodipine, bisoprolol fumarate, clopidogrel, gliclazide, losartan potassium
and rampiril. For all other inpatient drugs without specified duration we costed a single day’s dose.
As we costed over 1800 drugs and formulations, we do not report them all here.
Participant Follow-up Questionnaires also reported data on non-trial drugs prescribed while participants
were in the community. We costed these according to the dose and duration of treatment recommended
by the British National Formulary in whole packs. Where duration was not recorded we assumed that the
participant received a single pack.
Finally, PFQs reported on participants’ other encounters with the NHS, including general practitioners (GPs),
nurses and other professionals at surgery, at home, in the community or by telephone; NHS Direct or
NHS24; hospital emergency departments; and outpatient clinics (Table 4). Our main source of unit costs
was Curtis,81 who included salaries and expenses, costs of training and qualifications, and capital and
overhead costs.
TABLE 3 Published unit costs for hospital admission (£)
HRG code
National average
unit cost (£)
Average length
of stay (days)
Cost per
day (£)
Excess bed-day
rate (£)
Without surgerya
Non-elective: IBD without
interventions, 19 years and
over (FZ37)
CC 0 1546 3.78 409 243
CC 1–2 1692 4.39 385 237
CC 3–4 2218 5.62 395 230
CC 5+ 12,630 7.82 336 229
With surgery (primary procedure)a
Non-elective: complex large
intestine procedure, 19 years
and over (FZ74)
CC 0–2 5822 8.92 653 196
CC 3–5 7573 12.60 601 162
CC 6–8 8623 17.21 501 390
CC 9+ 10,136 19.93 509 229
With surgery (selected subsequent procedures)b
Closure of stoma FZ13 Costs dependent on CC code
Ileoanal pouch FZ69
Reversal of ileostomy FZ83
Proctecomy, ileoanal pouch,
loop ileostomy
FZ73
Completion proctectomy FZ77
a NHS reference costs 2012–13.82
b Expert clinical opinion.
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TABLE 4 NHS resource use unit costs (£)
Resource Details Source Unit cost (£)
NHS contacts
A&E visits Treatments leading to admitted (not admitted) £146 (£112) Curtis 201283 112.00
Admitted nights NIHR Clinical Research Network industry costing template NIHR 201484 386.37
Clinic visit As outpatient appointment. Weighted average £135
(p. 107)
Curtis 201381 135.00
Consultant: medical (p. 245) – per contract hour £139
Clinic visit Length of contact assumed same as GP (11.7 minutes)
at £27.11
Curtis 201381 27.11
Telephone call Length of telephone call assumed same as GP (7.1 minutes)
at £16.45
Curtis 201381 16.45
Consultant: psychiatric (p. 246) – per contract hour £140
Clinic visit Length of contact assumed same as GP (11.7 minutes)
at £27.29
Curtis 201381 27.29
Telephone call Length of telephone call assumed same as GP (7.1 minutes)
at £16.57
Curtis 201381 16.57
Consultant: surgical (p. 246) – per contract hour £140
Clinic visit Length of contact assumed same as GP (11.7 minutes)
at £27.30
Curtis 201381 27.30
Dietitian (p. 226) Hourly rate £35. Assumed session length same as
GP practice nurse – 15.5 minutes
Curtis 201381 9.04
GP (including travel, direct staff and qualification costs) (p. 191)
At practice Per patient contact lasting 11.7 minutes Curtis 201381 45.00
Home visit Per out of surgery visit lasting 23.4 minutes Curtis 201381 114.00
Telephone call Per telephone consultation lasting 7.1 minutes Curtis 201381 27.00
Health visitor
Home visit (p. 185) Per hour of home visiting – £71. Assumed length of
visit same as GP home visit – 23.4 minutes
Curtis 201381 27.69
Telephone call (p. 185) Per hour of patient-related work – £59. Assumed
length of telephone call same as GP practice nurse
(6 minutes)
Curtis 201381 5.90
Hospital
(telephone call)
Assumed contact with clinical nurse specialist (p. 189) per
hour of client contact – £90. Rate per 6 minutes’ telephone
contact – £9
Curtis 201381 9.00
Midwife (p. 186) Costed as nurse specialist (community) band 6
– £49 per hour. Length of contact assumed same as GP
practice nurse – 15.5 minutes
Curtis 201381 12.66
NHS Direct
(telephone call)
Digitalhealth.net
201385
20.00
Nurse (GP practice) GP practice nurse (p. 188) per hour of face-to-face contact
rate – £52. Per average contact lasting 15.5 minutes
– £13.43
Curtis 201381 13.43
Nurse (home visit) Community nurse (including district nursing sister, district
nurse) (p. 183) per hour of home visiting (including travel)
– £70. Assumed length of home visit same as GP
(23.4 minutes) – £27.30
Curtis 201381 27.30
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TABLE 4 NHS resource use unit costs (£) (continued )
Resource Details Source Unit cost (£)
Nurse specialist (p. 186) hourly rate £49
Clinic visit Assumed length of visit same as GP practice nurse –
15.5 minutes
Curtis 201381 12.66
Home visit Assumed length of visit same as GP home visit –
23.4 minutes
Curtis 201381 19.11
Telephone call Length of telephone call assumed as calls to hospital
(6 minutes) at £4.90
Curtis 201381 4.90
Outpatient visit:
gastroenterology
Service code 301 Department of
Health 201582
137.00
Outpatient
visit: general
Weighted average £135 (p. 107) Curtis 201381 135.00
Paramedic visit Ambulance services – see, treat and refer (p. 107) Curtis 201381 177.00
Pharmacist (p. 228) Per hour of direct clinical patient time – £94.
Assumed length of session same as GP visit – 11.7 minutes
Curtis 201381 18.33
Phlebotomist: NHS Jobs (www.jobs.nhs.uk) specify that phlebotomists are
clinical support workers with a salary between £14,000 and
£22,000 p.a.
Curtis 201381 4.10
Clinic visit Clinical support worker (p. 237) hourly rate £21. Assumed
length of contact same as GP visit – 11.7 minutes
Curtis 201381 4.10
Home visit Clinical support worker (community) (see p. 187) hourly rate
– £30. Assumed length of contact same as GP home visit
23.4 minutes
Curtis 201381 11.70
Physiotherapist (p. 223) Hourly rate – £36. Assumed session length –
30 minutes
Curtis 201381 18.00
Psychologist (p. 179) Clinical psychologist – £134 per hour of client
contact. Length of contact assumed same as GP practice
nurse – 15.5 minutes
Curtis 201381 34.62
Ultrasound Less than 20 minutes Department of
Health 201582
51.00
Walk-in centre (p. 109) Walk-in services leading to not admitted Digitalhealth.net
201385
41.00
Tests and investigations
Ciclosporin levels Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
22.00
Abdominal X-ray Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
65.00
Barium enema Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
215.00
continued
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TABLE 4 NHS resource use unit costs (£) (continued )
Resource Details Source Unit cost (£)
Barium follow through Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
350.00
Barium meal Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
175.00
Calcium and phosphate Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
4.10
Chest X-ray Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
50.00
Clotting profile Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
3.28
Colonoscopy with biopsy Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
827.00
Colonoscopy without biopsy Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
767.00
C-reactive protein Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
3.00
CT scan Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
475.24
Erythrocyte sedimentation rate Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
3.28
Flexible sigmoidoscopy Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
344.00
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TABLE 4 NHS resource use unit costs (£) (continued )
Resource Details Source Unit cost (£)
Full blood count Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
3.95
Liver function tests Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
4.45
MRI scan Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
574.91
Oesophagogastroduodenoscopy Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
610.00
Rigid sigmoidoscopy Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
210.11
Stool culture/testing Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
2.70
Thiopurine methyltransferase testing Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
31.70
Urea and electrolytes Cardiff and Vale
and Abertawe
Bro Morgannwg
University Health
Boards
3.65
A&E, accident and emergency; CT, computerised tomography; MRI, magnetic resonance imaging; p.a., per annum.
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Case report forms also recorded data on the number and type of investigations undertaken. We estimated
unit costs for these from two local but dissimilar trial sites – in Cardiff and Swansea (see Table 4). When
participants died or withdrew further access to medical records, sites completed the next CRF from data
available up to that time.
The primary outcome for economic analysis was QALYs estimated from the EQ-5D questionnaire within
the PFQ administered at baseline and subsequent assessments. Participants who underwent colectomy also
completed the EQ-5D within the PCQ at discharge from surgery and 4, 8 and 12 weeks thereafter. EQ-5D
assesses HRQoL on five dimensions – mobility, self-care, usual activities, pain or discomfort, and anxiety or
depression – using three levels for each dimension. We converted these to a single utility using the
UK tariff.86
We used the methods described above to impute missing data, which can happen in three ways:
1. CRF or PFQ received missing individual resource items
2. CRF or PFQ received but not covering the entire period since previous CRF; or
3. CRF or PFQ due but not received.
In these three scenarios we imputed thus:
1. We used age, gender, weight, ethnic group, smoking status and hospital data to impute missing items.
If more than two were missing, we used mean regression imputation; as regression assumes normally
distributed errors, we used log-transformation when the data broke this assumption.
2. We assumed that resource use varied linearly and therefore replaced missing data by the mean of the
data available before and after, weighted if necessary.
3. After checking whether or not non-responders differed from responders in sociodemographic
characteristics, we using the method described in (2).
4. Censoring data occurred because of the change to protocol which meant that not every participant
could be followed up for the same length of time. We studied the mechanism of censoring87 on a
range of variables including study arm. As these showed all censoring to be missing completely at
random, no adjustments were made to resource data to account for any censoring effects.
We estimated total costs by aggregating participants’ resource use. Although data collection for early
participants could extend for 36 months, there were very few of these. Our primary analysis therefore
compared costs and assessed cost-effectiveness over 30 months.
The calculation of the cost-effectiveness point estimate included all participants for whom we had EQ-5D
data. In principle we aggregated their costs and QALYs over their (variable) periods in the study. To ensure
that costs and QALYs covered the same periods, we compared the number of days covered by CRFs and
PFQs. We fitted statistical models for NHS costs and QALYs using allocated drug, days since randomisation
and the logarithm of those days as independent variables. We used the result coefficients to adjust NHS
costs and QALYs to a period of 730 days.
We undertook two contrasting sensitivity analyses: the first restricted analysis to 12 months, and thus
analysed all 270 participants but none of their data beyond 12 months; the second restricted analysis to
24 months and those participants who took part for at least that duration.
To account for uncertainty in the costs and QALYs used to estimate incremental cost-effectiveness in these
analyses, we used non-parametric bootstrapping to generate 5000 replicates, shown in the scatterplots
of the cost-effectiveness planes. The resulting cost-effectiveness acceptability curves (CEAC) show the
proportion of replicates considered cost-effective at each threshold of willingness to pay for an additional
QALY (including the £20,000 and £30,000 thresholds currently used by NICE).56
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We are developing a Markov model to predict costs and QALYs beyond the follow-up period of the study.
As the long-term effectiveness of both trial drugs in UC is unknown, the model will explore uncertainty
in outcomes over 20 years. It will estimate the long-term probability of colectomy effects on costs
and QALYs.88
Data to be collected for 5 years after the end of recruitment will monitor costs and effects of both trial
drugs on trial patients. At regular intervals we or our successors will update the Markov model, and thus
our conclusions, using the most recent data from trial participants. Any discrepancies between costs and
effects modelled beyond the trial period and those actually demonstrated by the long-term follow-up will
help to validate the use of economic modelling in economic evaluation for this condition.
Qualitative analysis of trial participant interviews
We analysed the 3-month interviews using both thematic and schematic methods. Thematic analysis is a
structured approach that uses coding to conceptualise research data and classify them into meaningful and
relevant categories.89 Schema analysis identifies patterns and themes within data in line with study aims
and interview topics; it thus combines elements of the linguistic and sociological traditions. It posits that
people use cognitive simplifications to help make sense of the complex information they receive. Analysis
starts with careful reading of the texts to identify linked themes paying attention to patterns of speech and
the repetition of key words and phrases, noting metaphors and commonalities in their reasoning.90
We began thematic analysis of the initial interviews after completing four interviews. Three qualitative
researchers (ACS, SW, FLR) read the transcripts and met to discuss emerging findings. They developed an
analysis framework and iterative process for subsequent transcripts to refine and clarify themes and their
linked categories.
A subset of the CONSTRUCT trial team then undertook the schema analysis as a group. We chose this
sequence for three reasons: to validate the thematic framework by verifying that all elements were cogent
and comprehensible; to engage a range of contributing disciplines; and to give those analysing other trial
data sets insight into the lives of participants. We asked each subgroup member to read transcripts from
three participants; one treated with infliximab, another with ciclosporin and the last with ciclosporin
followed by surgery; and to write one-page schematic overviews of the main features of each transcript
about participants’ stories relating to QoL and treatment regimes. We circulated these overviews to all
group members for discussion and synthesis; and the thematic analysis framework for refinement
and validation.
We began the thematic analysis of the 12-month interviews after completing the analysis of the 3-month
interviews. The same three qualitative researchers read the transcripts of the first four interviews and again
met to discuss their findings. Another iterative process followed to identify themes that had not emerged
at 3 months.
Qualitative analysis of health-care professional interviews
These transcripts underwent a thematic analysis technique known as ‘framework analysis’ to develop
a template linking data to study aims and objectives (see Appendix 19). Framework analysis is a
semistructured approach that, like generic thematic analysis, uses coding to conceptualise and classify
research data.89 Three qualitative researchers (FLR, CC, ACS) individually coded transcripts as they were
completed. Then they met to derive a unified coding structure including essential and incidental themes
and their linked categories. Continuing group work enabled them to refine the developing framework as
interviews progressed, with major themes retaining both nuance and ambiguity.
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Using MATRICS to synthesise results
We used the MATRICS from our previous study57 to synthesise CONSTRUCT’s findings in five steps.
The MATRICS proforma comprises three ‘layers’ (see Appendix 20):
1. potential effects of the intervention(s) under evaluation (derived from the aims and objectives of the study)
2. methods used in that evaluation
3. research findings.
Step 1: identify, categorise and code effects
We derived the potential effects of CONSTRUCT from its aims and added effects that emerged over the
course of the trial; we grouped them in three columns:
1. on participants
2. on gastroenterology services and professionals
3. on the rest of NHS and society.
We populated layer 1 with these effects using one cell per effect under the three defined columns, and
numbered each effect.
Step 2: code methods used by CONSTRUCT
We listed each method or instrument used (e.g. CRFs, questionnaires, interviews and routine data) in layer 2
and gave each method a unique letter.
Step 3: create joint alphanumeric codes
We assigned letters to each effect in layer 1 showing how we had investigated them. For example, if
disease-specific QoL was effect 2 investigated by the CUCQ questionnaire labelled B, we recorded B
alongside effect 2 in layer 1. Similarly, we assigned numbers to each method in layer 2 showing all the
effects they had investigated. For example, we recorded effect 2 alongside method B in layer 2. Effects
investigated by more than one method have extra letters in layer 1; methods investigating more than one
effect have extra numbers in layer 2.
Step 4: identify and code all research findings
We listed the individual findings from each component of CONSTRUCT in layer 3 of the MATRICS
proforma. We illustrated them textually or by summary statistics, and labelled them with codes derived
from layers 1 and 2 to identify the corresponding effects and methods.
Step 5: synthesise complementary findings and reorder contrasting findings
We merged comparable findings into composite statements, irrespective of which effects were investigated
or methods used and listed all codes associated with each. This enabled us to show that more than one
effect or method had reported the same outcome. When findings were not comparable, even opposing,
we kept them as separate rows in layer 3, but put them together.
Governance and management
Ethics and research governance
The Research Ethics Committee (REC) for Wales gave ethical approval (Ref 08/MRE09/42) and each
participating trust or health board gave NHS R&D approval. The trial has European Union Drug Regulating
Authorities Clinical Trials number (2008-001968-36) and clinical trial authorisation from the MHRA. We have
sought to conform with the Research Governance Frameworks for England,91 Scotland92 and Wales;93 the
principles of GCP outlined by the International Conference on Harmonisation (www.ich.org/), the European
Union Directive 2001/20/EC94 and The Medicines for Human Use (Clinical Trials) Regulations 2004.64
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Trial management
We established:
l a TSC which oversaw the trial by meeting twice per year
l a DMEC which monitored trial data in accordance with an agreed charter (see Appendix 21) and
reported to the TSC
l a Trial Management Group (TMG) comprising academics, health professionals, researchers and a
representative of service users which undertook general management of the trial, met every month and
reported to the TSC and funders through reports every 6 months.
The available members of the research team also met every week.
Service users
In accordance with the relevant West Wales Organisation for Rigorous Trials in Health standard operating
procedure,95 we included service users as active contributors at all stages of this trial. They provided separate
members of TSC, DMEC and TMG, contributed to the research process and provided valuable insights into
UC. In particular they contributed to the development of the CUCQ+, the primary outcome measure; helped
to maximise recruitment rates; attended the series of report writing days; and gave much valuable help and
advice outside these meetings. Appendix 22 summarises the personal experience of one service user.
Feasibility and piloting
Before the trial began, we undertook a feasibility study to refine our understanding of the patient
pathway, the CUCQ and the economic resource-use questionnaires. We then conducted a pre-pilot study
to test the recruitment process up to but not including randomisation. Thereafter we used the resulting
cohort of between 20 and 40 patients to test aspects of trial design beyond initial recruitment. Following
the pre-pilot study, we piloted GeneCIS (our online trial data management system), participant recruitment
and randomisation, and data collection processes. We asked each active centre to recruit and randomise
one trial participant. We then met site PIs to learn from the pilot. As we encountered no major problems
we incorporated cohort and trial participants recruited during the pilot in the main study.
Safety monitoring and reporting
Clinical trial agreements were in place at each site. Thus we delegated responsibility for adhering to GCP and
reporting AEs in accordance with clinical trial regulations to site PIs and their research teams. These PIs, or
others authorised by the site delegation log, recorded all AEs on AESFs and assessed the seriousness, causality
and expectedness of each. If sites could not make these decisions, they referred them to the chief investigator.
In view of the established and extensive side effect profile of both drugs, the protocol required expedited
reporting of SUSARs, but not AEs, ARs, SAEs or SARs. We reported the number of notified SAEs and SARs to
each meeting of the DMEC; and of SARs in annual safety reports to MHRA and the REC for Wales.
To help identify AEs, we gave trial participants membership cards showing their trial numbers and asked
them to show this whenever they saw doctors outwith the team treating them for UC.
Quality assurance
We sought to comply with the principles of quality assurance described by the Medical Research Council
(MRC) Guidelines for Good Clinical Practice in Clinical Trials96 the European Union Directive 2001/20/EC,94
The Medicines for Human Use (Clinical Trials) Regulations 2004,64 and the Research Governance
Frameworks for England,91 Scotland92 and Wales.93
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We anonymised all research data and stored them securely. All research team members attended GCP
training every 2 years and undertook trial-specific training in the protocol, recruiting participants,
completing CRFs and reporting AEs. The TMG developed and reviewed a quality plan describing the quality
assurance and quality control processes implemented within the trial to ensure a high level of quality.
We developed fieldwork, data collection and GeneCIS handbooks to maintain consistency across trial sites.
Dissemination
We seek to comply with the CONSORT guidelines.97 We seek to publish widely in high-impact
peer-reviewed journals and disseminate trial findings at national and international conferences. We are
committed to give appropriate recognition to all who have worked on the trial. We have registered
CONSTRUCT in the public registry (www.controlled-trials.com/isrctn) with ISRCTN22663589.
Data sharing
In accordance with the MRC–Wellcome Trust data sharing policy, we shall make data from CONSTRUCT
available to the scientific community with as few restrictions as feasible, while retaining exclusive use until
the publication of major outputs. In particular we shall deposit anonymised data in the University of Essex
data archive and thereby encourage wider use.
Summary of protocol changes
Changes to the protocol were approved by the DMEC, TSC, MHRA, REC and the NIHR HTA programme.
Before protocol publication
Number of sites
We had initially planned to work with 40 sites, but it became clear that a smaller number of patients were
being recruited per site than we had anticipated so we increased the number of sites.
Power calculation
In June 2012 we obtained approval to increase the target effect size from 0.3 to 0.35, still in the range of
small ‘effect’ sizes; this needed at least 250 patients to provide data on survival, colectomy or QoL in
each group.
The design of CONSTRUCT required a combination of survival analysis and statistical imputation to get full
value from the resulting data set. As these techniques were difficult to incorporate into power calculations,
we presented a simpler calculation based on t-tests of mean CUCQ scores at 12 months. For CONSTRUCT
to detect an effect size of 0.35 in these scores (i.e. a difference between infliximab and ciclosporin groups
of at least 0.35 of the population standard error), with 80% power when using a 5% significance level,
required that we analysed at least 250 of the 270 participants recruited to the trial. Although more than
10% of CONSTRUCT participants were likely to drop out over the follow-up period of at least 12 months,
all analyses exploited the techniques of statistical imputation used successfully by the Cancer of the
Oesophagus or Gastricus: New Assessment of the Technology of Endosonography58 and Folate
Augmentation of Treatment – Evaluation of Depression59 trials to maintain the effective sample size at 250.
Our initial, more conservative, power calculation had proposed to recruit 480 participants (to yield an
analysable sample of 360); not to impute missing data statistically, therefore to allow for 25% loss to
follow-up; and thus to yield 80% power to detect a slightly smaller effect size of 0.30 in CUCQ scores.
We amended our target to 270 participants once the difficulty of identifying patients with acute steroid-
resistant UC became clear early in recruitment.
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Trial intervention
Our original protocol stated that ciclosporin should be given for up to 5 days, but it was felt that stopping
at 5 days might deprive patients of a response. On 21 January 2010 approval was given to increase
this to 7 days and included approval for a recommendation that sites should use non-PVC bags and
administration sets for ciclosporin.
Analysis
On 21 January 2010, following a suggestion by our DMEC to change the analysis, we obtained approval
to change from ‘quality of life at 24 months’ to ‘analysis using an area under the curve approach to obtain
each patient’s quality of life over 24 months’.
On 6 June 2012 approval was given for the primary analysis of CONSTRUCT to use full
statistical imputation.
Trial inclusion/exclusion criteria
Without changing the basic content of our inclusion/exclusion criteria, we rewrote them to make them
clearer to follow and approval was given on 21 January 2010.
To ensure that cohort patients were not missed, on 22 September 2010 we gained approval to:
l amend the protocol to clarify that potential patients for the cohort were those admitted with
‘suspected or known colitis’ rather than ‘acute severe colitis’
l remove ‘with blood apparent’ from the cohort inclusion criteria as it may not always be apparent in
patients with colitis.
To ensure that trial participants were not missed approval was given to:
l change the Mayo score (colitis severity score) in the RCT inclusion criteria from 3 to ≥ 2 as it was felt
eligible patients would be excluded because of the higher score.
In June 2012 we gained approval to relax the requirement for sigmoidoscopy to assess eligibility, as
feedback from sites indicated that in a patient with a previous history of UC, further sigmoidoscopy might
not be done.
We were also permitted to clarify that 2–5 days of intravenous steroid treatment before a decision was
made whether or not a patient had responded, was an approximate length of time as this reflected what
happens in normal clinical practice.
Recruitment of participants
We had initially planned to complete recruitment over a 1-year period. However, following unforeseen
delays in R&D approval and a smaller number of patients recruited per site than we had anticipated,
we realised this would not be possible. Approval to lengthen the recruitment period until recruitment to
the trial was complete was given on 22 September 2010. Subsequently, the NIHR HTA programme
granted us a 24 month-funded extension to complete the trial.
In December 2010 we gained approval to make payments to sites to cover investigator costs at £50 per
cohort and £100 per trial participant recruited.
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Data collection
We took the opportunity of the 24-month extension to enhance our data collection to capture more data
about QoL post colectomy and to collect this more frequently. We did this by:
l extending data collection for all trial participants, whenever recruited, until early 2014
l adding questionnaires at 18, 30 and 36 months; participant reconsent was sought where necessary
l adding four questionnaires following colectomy and any ensuing corrective surgery; participant
reconsent was sought where necessary
l planning to use survival analysis, statistical missing value imputation and economic modelling to impute
QoL and costs for all participants who generate data after randomisation.
We also sought approval to:
l conduct interviews with health-care professionals to elicit their views about the two drugs and their
different modes of administration in response to emerging evidence of potential hidden costs in the
administration of ciclosporin in particular
l conduct the second participant interview at 12 months rather than at 6 months.
Outcome measures
With agreement of the TSC and DMEC we changed the primary outcome measure to QAS weighted by
scores on CUCQ and approval was given on 6 June 2012.
Since protocol publication
Economic analysis
l The economic analysis covered a 30-month period.
l The comparison of NHS resource use between the two groups did not adjust for inpatient stay in
intensive care unit and high-dependency unit.
l Patient-borne costs were limited to time off work.
l The proposed long-term economic modelling has not yet been completed.
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Chapter 3 Results
Recruitment
A total of 68 sites agreed to take part in the study: 62 in England, three in Scotland and three in Wales.
The sites ranged from large teaching hospitals to large and small district general hospitals. One site was
deactivated because of a protocol deviation.
Sixty-four sites recruited patients to the cohort and 52 of these recruited participants to the trial. The first
site was activated in March 2010 with the first cohort patient recruited in May 2010 and the first trial
participant randomised in June 2010. We randomised the last trial participant in February 2013 and
completed follow-up in February 2014.
Over the course of the study, two sites that had recruited a total of eight cohort patients, withdrew citing
the following reasons:
l one replacement PI with a treatment preference
l one site not recruiting and felt unlikely to recruit in the near future.
In addition, two sites that had not recruited to the cohort withdrew citing the following reasons:
l one PI leaving and no replacement
l one site lack of research support.
Figure 2 shows that 2065 patients were screened for the cohort and 1614 consented to join it. Of these,
276 were eligible for the trial and were randomised. Six participants were randomised in error: five
randomised to ciclosporin were found to have raised cholesterol levels between randomisation and
treatment and one randomised to infliximab was found to have cytomegalovirus after randomisation and
one dose of infliximab. These six were therefore judged to have been randomised in error and were
removed from analysis.
Centre differences in recruitment patterns
Eight sites recruited 11 or more trial participants, 17 sites recruited four to eight participants, 18 recruited
two or three participants, nine recruited one participant, with 12 sites recruiting to the cohort only,
whereas three sites did not recruit at all (see Appendix 23).
Participant flow
Figure 2 presents the CONSORT flow diagram and summarises patient throughput from recruitment of the
first participant in May 2010 to randomisation of the final participant in February 2013.
Figure 3 summarises participant follow-up over the 3-, 6-, 12-, 18-, 24-, 30- and 36-month time points to
the end of follow-up on 28 February 2014; 90% of participants contributed to definitive analysis.
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Adults admitted acutely 
with symptoms of colitis
(n = 2065)
Excluded (n = 261)
• Known Crohn’s, n = 7
• No endoscopic appearance of colitis, n = 83
• Histology inconsistent with IBD, n = 15
• From a vulnerable group, n = 47
• Not possible to approach patient, n = 104
• Unable to consent for themselves, n = 5
Excluded (n = 190)
• Patient declined to consent to participation, n = 104
• No reason stated, n = 46
• Patient discharged prior to consent, n = 31
• Patient had emergency surgery, n = 5
• RP misundestood cohort entry criteria, n = 3
• Patient already recruited to CONSTRUCT at another site, n = 1
Excluded (n = 1078)
• Under 18 years of age, n = 34
• Histology inconsistent with UC, n = 106
• Stool culture positive for infection, n = 32
• Colitis not severe, n = 119
• Responded to i.v. steroids, n = 604
• Required surgery (after failing steroids), n = 67
• Required surgery (before receiving steroids), n = 7
• Not started in i.v. steroids for other unspecified 
   reasons, n = 52
• Has current malignancy (other than BCC), n = 1
• Has serious comorbidity, n = 6
• History of hypersensitivity to either trial drug/
   constituents, n = 6
• Recent treatment with either of the trial drugs, n = 22
• Currently taking tacrolimus or rosuvastatin, n = 3
• Is pregnant or lactating, n = 3
• Is participating in another trial, n = 6
• Has a(nother) contraindication to either of the trial 
   drugs, n = 4
• Is unwilling to take contraception (if required), n = 1
• From a vulnerable group, n = 1
• Treated with i.v. steroids for longer than 5 days, n = 4
Excluded (n = 82)
• Known Crohn’s patient, consented in error, n = 54
• No evidence of IBD on histology/stool culture, n = 28
Excluded (n = 178)
• Clinician choice of drug, n = 11 (1 ciclosporin vs. 10 infliximab)
• Patient choice of drug, n = 6 (4 ciclosporin vs. 2 infliximab)
• Patient declined to consent, n = 6
• Other clinical decision not to include patient in RCT, n = 3
• Patient discharged prior to consent, n = 2
• Local staffing issues, n = 3
• Eligible but reasons for non-consent, not known, n = 36
• Reasons unknown, n  =  111
Excluded (n = 0)
• Not randomised, n = 0
Excluded (n = 6)
Randomised in error
• Ciclosporin, n = 5
• Infliximab, n = 1
Retained in cohort and
assessed for eligibility
for RCT
(n = 1532)
Eligible for cohort
(n = 1804)
Eligible for RCT
(n = 454)
Consented to cohort
(n = 1614)
Consented to RCT
(n = 276)
Randomised
(n = 276)
Infliximab
(n = 135)
Ciclosporin
(n = 135)
FIGURE 2 Participant recruitment. BCC, basal cell carcinoma; i.v., intravenous; RP, research professional.
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Infliximab
(n = 135)
Died between 0 and
3 months (n = 2)
Withdrew between 0
and 3 months (n = 2)
Died between 6 and 
12 months (n = 1)
Withdrew between 6
and 12 months (n = 4)
Withdrew between 12 
and 18 months (n = 4)
Recruited too late for
18-month follow-up (n = 26)
Withdrew between 18
and 24 months (n = 1)
Recruited too late for
24-month follow-up (n = 34)
Withdrew between 24 
and 30 months (n = 2)
Recruited too late for
30-month follow-up (n = 23)
Withdrew between 30
and 36 months (n = 1)
Recruited too late for
36-month follow-up (n = 18)
3-month follow-up
(n = 131)
(PFQs completed n = 101)
6-month follow-up
(n = 131)
(PFQs completed n = 102)
12-month follow-up
(n = 126)
(PFQs completed n = 82)
18-month follow-up
(n = 96)
(PFQs completed n = 52)
24-month follow-up
(n = 61)
(PFQs completed n = 37)
30-month follow-up
(n = 36)
(PFQs completed n = 17)
36-month follow-up
(n = 17)
(PFQs completed n = 6)
(Includes n = 4 cases with PFQ 
completed in month 36)
Ciclosporin
(n = 135)
Withdrew between 0
and 3 months (n = 1)
Withdrew between 6
and 12 months (n = 7)
Withdrew between 12 
and 18 months (n = 5)
Recruited too late for
18-month follow-up (n = 24)
Recruited too late for
24-month follow-up (n = 29)
Withdrew between 24 
and 30 months (n = 1)
Recruited too late for
30-month follow-up (n = 26)
Withdrew between 30
and 36 months (n = 1)
Recruited too late for
36-month follow-up (n = 21)
Withdrew between 3
and 6 months (n = 3)
3-month follow-up
(n = 134)
(PFQs completed n = 105)
6-month follow-up
(n = 131)
(PFQs completed n = 100)
12-month follow-up
(n = 124)
(PFQs completed n = 86)
18-month follow-up
(n = 95)
(PFQs completed n = 40)
24-month follow-up
(n = 66)
(PFQs completed n = 40)
30-month follow-up
(n = 39)
(PFQs completed n = 11)
36-month follow-up
(n = 17)
(PFQs completed n = 4)
FIGURE 3 Participant follow-up.
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Table 5 shows the data that were obtained as the trial progressed.
Table 6 lists the secondary data available for analysis at each time point. The patients who withdrew from
further access to medical records are included in the data available when there were enough data to
impute the rest of the secondary care resources. For example, if the patient withdrew soon after the
surgery at baseline, the data on hospital costs and trial drugs was used to impute the remainder of
resource use to 3 months.
Feasibility and pilot study
Because of the complexity of CONSTRUCT, we conducted a feasibility study at our local health board to
test our patient identification and recruitment processes up to randomisation, pilot a modified version of
the UK-IBDQ and health resource-use questionnaire, and construct a list of frequently used drugs. The
feasibility study ran from March 2009 to June 2009 when 20 patients had been recruited. A report from
the local research professional provided helpful insights about points of admission for patients with colitis
and how best to identify them; demonstrated that the consent process worked; and showed how to
capture a discharge to ensure appropriate study follow-up. It allowed us to refine some of our study
documentation and test the drugs list and health resource-use questionnaire. The data from the
20 patients were used to validate the modified UK-IBDQ (see Appendix 8).
TABLE 5 CONSTRUCT data flow
Follow-up
period (months)
In trial at
period start
Data
obtained Died
Withdrew further access
to medical records
Yielded no further data
after period end
Infliximab
0–3 135 135 2 2 0
3–6 131 130 0 0 0
6–12 129 124 1 1 21
12–18 105 76 0 0 38
18–24 67 63 0 0 28
24–30 38 32 0 0 23
30–36 15 8 0 0 –
Ciclosporin
0–3 135 135 0 2 0
3–6 133 132 0 0 0
6–12 133 129 0 1 28
12–18 104 70 0 0 32
18–24 72 67 0 1 30
24–30 41 28 0 0 23
30–36 18 10 0 0 –
Note
The number of participants in the trial at the end of each period is equal to the number in the trial at the start of that
period minus those who died during that period, minus those who withdrew access to medical records and minus those
who left the study on 28 February 2014.
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We planned a pre-pilot study, including pseudo-randomisation, in five sites and, during the training for
this, queries and suggestions from PIs and research professionals led us to make some amendments;
where appropriate approval was sought from REC for Wales and the MHRA for these amendments.
The pre-pilot study started in September 2009 in our local health board, but did not commence at the
other four sites because of delays caused by R&D approval, staff on leave and staff requiring consent
training. By January 2010 several other sites had obtained R&D approval for the full study and to avoid
further delay a decision was made at the TMG that our local health board had fulfilled the pre-pilot
requirements and we should start the main study. A decision was reached by the TMG that as sites gained
R&D approval they would start the study using paper documentation prior to GeneCIS implementation.
The documentation would have a ‘pilot’ watermark to distinguish the documents used pre GeneCIS and
sites were encouraged to feed back so that amendments could be made before GeneCIS was finalised.
When GeneCIS implementation began, sites were sent a revised set of documents with the ‘pilot’
watermark removed.
The first trial participant recruited at each site was considered to be a pilot. After the first trial participant
was recruited, we checked the documentation and processes and sought feedback from the PI or research
professional about any issues that had occurred.
TABLE 6 Secondary data available for analysis at each time point
Follow-up
period (months)
In trial at
period start
Data
obtained Died
Withdrew further access
to medical records
Yielded no further data
after period end
Infliximab
0–3 135 135 2 2 0
3–6 131 131 0 1 0
6–12 131 131 1 3 21
12–18 106 84 0 1 38
18–24 67 65 0 0 28
24–30 39 27 0 1 23
30–36 15 8 0 0 –
Ciclosporin
0–3 135 135 0 2 0
3–6 133 133 0 0 0
6–12 133 133 0 2 28
12–18 103 85 0 1 32
18–24 72 71 0 1 30
24–30 49 30 0 0 23
30–36 26 9 0 0 –
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Validation of outcome measures
Item generation: devising the items for the CUCQ and CUCQ+
Following exploration of the UK-IBDQ and the gastrointestinal literature related to PROMs, we developed
the CUCQ and CUCQ+. Appendix 18 shows the major differences between the UK-IBDQ and the CUCQ
and CUCQ+. Question 7 from the original UK-IBDQ (related to admission to hospital) was removed from
the CUCQ and CUCQ+. A new question was added to the CUCQ/CUCQ+ (Q15, related to getting up to
use the toilet after going to bed). In addition, where the original UK-IBDQ had four fixed-response options
relating to questions ‘in the past 2 weeks, how often . . .?’, the CUCQ/CUCQ+ used open-response
options to take account of any potential floor and ceiling effects.
As the UK-IBDQ did not have any questions for post-colectomy patients, we developed 10 specific
stoma-related questions for the CUCQ+ (S1–S10).
Piloting the CUCQ and CUCQ+
We did not modify the CUCQ or CUCQ+ following piloting as none of the patients regarded any of the
questions difficult to answer or that there were any specific aspects that were not covered by the
questionnaire. The patients with a stoma did not answer the six questions that we had previously identified
as not being relevant and instead completed the additional 10 stoma questions.
Baseline demographics of the development and validation samples
We had data from a total of 1240 patients in our cohort development sample and 270 patients in our RCT
validation sample (total 1510). We compared the baseline demographic characteristics of the two samples.
Table 7 gives details of the characteristics of the two samples.
Psychometric validation of the CUCQ in the validation sample
(CONSTRUCT cohort sample)
We examined the data prior to undertaking principal component analysis. The Kaiser–Meyer–Olkin
measure of sampling adequacy was 0.924 and the Barlett’s test of sphericity was 0.000, indicating that the
data were suitable principal component analysis.
All 32 CUCQ questions had a response rate of at least 93% in the cohort development sample (Table 8).
Based on our set criteria of responding to at least 24 out of the 32 (75%) total questions, there were 1226
(99%) patients for whom we were able to calculate a CUCQ score.
The internal consistency of the CUCQ was excellent with a Cronbach’s alpha of 0.900. Correlations of all
32 questions with the total score exceeded 0.2 (Table 9). None of the questions had a response frequency
> 80%. The data therefore did not exhibit any floor or ceiling effects.
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TABLE 7 Clinical and demographic characteristics of cohort and RCT participants (maximum N= 1510)
Patient characteristic
Cohort sample
(maximum n= 1240)
RCT sample
(maximum n= 270) p-value
Gender
Male 656 170 0.003*
Female 584 100
Mean age at recruitment, years (SD) 41.42 (17.66) 40.06 (15.31) 0.240
Ethnicity
White 1133 250 0.377
Asian or Asian British 65 12
Black or black British 8 3
Other ethnic groups 18 2
Mixed 11 0
Missing 5 3
Smoking status
Never smoked 514 112 0.829
Non-smoker (history unknown) 95 19
Current smoker 102 27
Ex-smoker 481 105
Mean weight, kg (SD) 73.05 (17.63) 74.14 (15.09) 0.353
Mean height, m (SD) 1.70 (0.11) 1.71 (0.09) 0.160
Truelove and Witt classification4
Severe 1033 251 0.000*
Not severe 174 16
Mayo score
0 35 4 0.000*
1 103 4
2 391 68
3 483 183
Family history
Yes 147 46 0.023*
No 1072 221
Comorbidity: IHD
Yes 49 6 0.165
No 1179 263
Comorbidity: CVD
Yes 16 2 0.446
No 1213 267
continued
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TABLE 7 Clinical and demographic characteristics of cohort and RCT participants (maximum N= 1510) (continued )
Patient characteristic
Cohort sample
(maximum n= 1240)
RCT sample
(maximum n= 270) p-value
Comorbidity: resp
Yes 70 15 0.934
No 1157 254
Comorbidity: liver
Yes 7 3 0.320
No 1221 266
Comorbidity: BP
Yes 102 18 0.376
No 1112 248
Mean duration of symptoms (SD) 32.71 (43.64) 39.60 (51.95) 0.025*
Mean EQ-5D (SD) 0.57 (0.31) 0.51 (0.30) 0.040*
Mean CUCQ (SD) 0.40 (0.16) 0.36 (0.13) 0.001*
Mean SF-6D (SD) 0.57 (0.11) 0.56 (0.11) 0.090
Mean blood: Hb (SD) 12.30 (2.10) 12.82 (2.16) 0.918
Mean blood: ESR (SD) 39.63 (28.52) 41.50 (27.24) 0.607
Mean blood: CRP (SD) 61.30 (70.62) 83.30 (81.13) 0.000*
Mean blood: Alb (SD) 36.71 (6.88) 33.18 (6.57) 0.000*
Mean blood: Cr (SD) 77.02 (26.33) 77.20 (19.44) 0.915
Mean blood: Chol (SD) 4.09 (1.37) 3.81 (1.03) 0.147
Mean TW-CCRF-SF (SD) 11.15 (6.77) 12.63 (6.76) 0.021*
Mean TW-CCRF-BSF (SD) 10.48 (6.71) 11.75 (6.95) 0.007*
Mean TW-CCRF-HR (SD) 88.79 (17.79) 89.55 (16.76) 0.526
Mean TW-CCRF-Temp (SD) 36.80 (0.69) 36.91 (0.69) 0.021*
Alb, albumin; BP, blood pressure; Chol, cholesterol; Cr, creatinine; CRP, C-reactive protein; CVD, cerebrovascular disease;
ESR, erythrocyte sedimentation rate; Hb, haemoglobin; IHD, ischaemic heart disease; resp, respiratory disease; SD, standard
deviation; SF-6D, Short Form Questionniare-6 items; TW-CCRF-BSF, Truelove and Witts cohort case report form bloody stool
frequency; TW-CCRF-HR, Truelove and Witts cohort case report form heart rate; TW-CCRF-SF, Truelove and Witts cohort
case report form stool frequency; TW-CRF-Temp, Truelove and Witts cohort case report form temperature.
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TABLE 8 Frequency of missing values for each of the 32 CUCQ questions within the cohort development
sample (N= 1235)
Question Number of missing responses, n (%)
1 9 (0.73)
2 14 (1.13)
3 12 (0.97)
4 12 (0.97)
5 13 (1.05)
6 15 (1.21)
7 14 (1.13)
8 19 (1.54)
9 19 (1.54)
10 13 (1.05)
11 10 (0.81)
12 15 (1.21)
13 14 (1.13)
14 15 (1.21)
15 11 (0.89)
16 18 (1.46)
17 26 (2.11)
18 14 (1.13)
19 17 (1.38)
20 11 (0.89)
21 17 (1.38)
22 10 (0.81)
23 13 (1.05)
24 12 (0.97)
25 14 (1.13)
26 15 (1.21)
27 11 (0.89)
28 86 (6.96)
29 17 (1.38)
30 16 (1.30)
31 18 (1.46)
32 18 (1.46)
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 9 The 32 CUCQ questions, their item-total correlations and their maximum response rate
Question
Item-total
correlation
Maximum response
rate (%)
On how many days over the last 2 weeks have you had loose or runny
bowel movements?
0.344 76.2
On how many days in the last 2 weeks have you noticed blood in your stools? 0.257 49.3
On how many days over the last 2 weeks have you felt tired? 0.530 66.8
In the last 2 weeks have you felt frustrated? 0.532 38.7
In the last 2 weeks has your bowel condition prevented you from carrying out your
work or other normal activities?
0.513 33.5
On how many days over the last 2 weeks have you opened your bowels more than
three times a day?
0.425 72.2
On how many days over the last 2 weeks have you felt full of energy? 0.347 73.3
In the last 2 weeks did your bowel condition prevent you from going out socially? 0.539 36.4
On how many days over the last 2 weeks have your bowels opened accidentally? 0.261 42.9
On how many days over the last 2 weeks have you felt generally unwell? 0.554 58.6
In the last 2 weeks have you felt the need to keep close to a toilet? 0.586 47.1
In the last 2 weeks has your bowel condition affected your leisure or
sports activities?
0.549 50.2
On how many days over the last 2 weeks have you felt pain in your abdomen? 0.441 47.5
On how many nights over the last 2 weeks have you been unable to sleep well
(days if you are a shift worker)?
0.516 46.9
On how many nights in the last 2 weeks have you had to get up to use the toilet
because of your bowel condition after you have gone to bed?
0.466 50.1
In the last 2 weeks have you felt depressed? 0.539 49.7
In the last 2 weeks have you had to avoid attending events where there was no
toilet close at hand?
0.524 35.8
On how many days over the last 2 weeks have you had a problem with large
amounts of wind?
0.207 32.5
On how many days over the last 2 weeks have you felt off your food? 0.423 24.5
Many patients with bowel problems have worries about their illness. How often
during the last 2 weeks have you felt worried?
0.540 33.7
On how many days over the last 2 weeks has your abdomen felt bloated? 0.415 33.1
In the last 2 weeks have you felt relaxed? 0.460 46.9
In the last 2 weeks have you been embarrassed by your bowel problem? 0.480 37.1
On how many days over the last 2 weeks have you wanted to go back to the toilet
immediately after you thought you had emptied your bowels?
0.501 27.9
In the last 2 weeks have you felt upset? 0.586 57.6
On how many days over the last 2 weeks have you had to rush to the toilet? 0.561 48.2
In the last 2 weeks have you felt angry as a result of your bowel problem? 0.444 45.0
In the last 2 weeks, has your sex life been affected by your bowel problem? 0.361 41.0
On how many days over the last 2 weeks have you felt sick? 0.419 27.2
In the last 2 weeks have you felt irritable? 0.505 53.7
In the last 2 weeks have you felt lack of sympathy from others? 0.314 61.5
In the last 2 weeks have you felt happy? 0.398 55.1
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The principal component analysis indicated that there were seven factors with an eigenvalue of > 1 and
which explained approximately 57% of the variance in the data. The scree plot indicated that there was an
elbow in the scree plot between the fourth and fifth factors. We rotated the solution based on four factors
using direct oblimin principal component analysis (Table 10). The principal component analysis identified
that the first factor covered emotional symptoms; the second bowel symptoms; the third social activities;
and the fourth general symptoms.
TABLE 10 Principal component analysis of the CONSTRUCT CUCQ questions from the development sample based
on a four-factor solution
Factor
1 2 3 4
Percentage of factor’s contribution 26.716 8.408 6.162 5.452
Eigenvalue 8.549 2.691 1.972 1.745
CUCQ16 0.760
CUCQ25 0.744
CUCQ27 0.740
CUCQ30 0.708
CUCQ4 0.610
CUCQ20 0.607
CUCQ23 0.558
CUCQ31 0.530
CUCQ22
CUCQ32
CUCQ1 0.754
CUCQ6 0.751
CUCQ26 0.642
CUCQ2 0.615
CUCQ24 0.563
CUCQ15 0.535
CUCQ14
CUCQ18
CUCQ8 –0.837
CUCQ12 –0.790
CUCQ5 –0.768
CUCQ17 –0.723
CUCQ11 –0.623
CUCQ28
CUCQ10 0.629
CUCQ3 0.611
CUCQ13 0.578
CUCQ7 0.554
CUCQ19 0.497
CUCQ29 0.433
CUCQ9 –0.403
CUCQ21
Notes
Extraction method: principal component analysis.
Rotation method: oblimin with kaiser normalisation (rotation converged in 11 iterations).
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The CUCQ scores achieved significant correlations with the two generic HRQoL scales (SF-12 mental and
physical component scores and the EQ-5D) scores demonstrating good construct validity (Table 11).
Table 12 illustrates the percentage variance that each of the 32 questions contributed to the total CUCQ
score in the CONSTRUCT cohort development sample. Ten of the 32 questions contributed over 90% of
the variance in the total score. These 10 questions could be future candidates for a shortened version
of the CUCQ. We will undertake further work to test the validity of a shortened version of the CUCQ.
Psychometric validation of the CUCQ in the validation sample (CONSTRUCT
randomised controlled trial sample)
For the purposes of this report, we calculated CUCQ+ scores for stoma extension patients on the basis
of equal weighting for each score. Further analysis will be carried out to explore weighting of the
stoma-specific questions.
The internal consistency of the CUCQ in the RCT sample was excellent, with a Cronbach’s alpha of 0.845.
Table 13 illustrates the percentage variance that each of the 32 questions contributed to the total CUCQ
score in the RCT validation sample.
Table 14 indicates the number of patients for whom we collected a CUCQ/CUCQ+ score at each time
period within the RCT validation sample.
The CUCQ scores achieved significant correlations at baseline with the two generic HRQoL scales (SF-12
mental and physical component scores and the EQ-5D) in the RCT validation sample scores demonstrating
good construct validity (Table 15).
Testing reliability and responsiveness of the CUCQ
We assessed the reproducibility or test–retest reliability of the CUCQ on those patients who reported no
change in their condition between completion of follow-up questionnaires. We included those patients
who had indicated no change in their bowel condition on the transition question between the 3- and
6-month periods (How has your QoL changed since the last time you filled in a questionnaire?).
There were 34 patients who reported no change in their condition at 3–6 months. The Cronbach’s alpha
was 0.582, indicating moderate agreement between the CUCQ scores. Further exploration of the
test–retest scores is needed to determine any differences in the reliability of the CUCQ scale between
stoma and non-stoma patients. The judgement of ‘stability’ was based on subjective assessment by the
patient. The clinical assessment of stability and how this affects the test–retest reliability will also be
explored. In addition, the correlation between the CUCQ test–retest reliability and the generic EQ-5D and
SF-12 reliability requires further analysis.
TABLE 11 Correlations between the CUCQ score and the SF-12 mental and physical component scores and EQ-5D in
the CONSTRUCT development sample
Scale CUCQ
SF-12 MCS 0.588a
SF-12 PCS 0.444a
EQ-5D 0.429a
MCS, mental component score; PCS, physical component score.
a p< 0.001 Pearson’s correlation.
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TABLE 12 Model summary of the CUCQ questions within the CONSTRUCT cohort development sample
Question
Cumulative %
of variance
Q25: In the last 2 weeks have you felt upset? 38.6
Q11: In the last 2 weeks have you felt the need to keep close to a toilet? 59.5
Q3: On how many days over the last 2 weeks have you felt tired? 70.6
Q14: On how many nights over the last 2 weeks have you been unable to sleep well (days if you are a
shift worker)?
76.3
Q21: On how many days over the last 2 weeks has your abdomen felt bloated? 79.9
Q17: In the last 2 weeks have you had to avoid attending events where there was no toilet close
at hand?
82.9
Q4: In the last 2 weeks have you felt frustrated? 85.4
Q26: On how many days over the last 2 weeks have you had to rush to the toilet? 87.4
Q19: On how many days over the last 2 weeks have you felt off your food? 89.2
Q23: In the last 2 weeks have you been embarrassed by your bowel problem? 90.4
Q12: In the last 2 weeks has your bowel condition affected your leisure or sports activities? 91.5
Q6: On how many days over the last 2 weeks have you opened your bowels more than three times
a day?
92.5
Q30: In the last 2 weeks have you felt irritable? 93.3
Q13: On how many days over the last 2 weeks have you felt pain in your abdomen? 94.2
Q28: In the last 2 weeks has your sex life been affected by your bowel problem? 94.9
Q16: In the last 2 weeks have you felt depressed? 95.6
Q18: On how many days over the last 2 weeks have you had a problem with large amounts of wind? 96.2
Q29: On how many days over the last 2 weeks have you felt sick? 96.7
Q5: In the last 2 weeks has your bowel condition prevented you from carrying out your work or other
normal activities?
97.1
Q24: On how many days over the last 2 weeks have you wanted to go back to the toilet immediately
after you thought you had emptied your bowels?
97.4
Q20: Many patients with bowel problems have worries about their illness. How often during the last
2 weeks have you felt worried?
97.8
Q15: On how many nights in the last 2 weeks have you had to get up to use the toilet because of your
bowel condition after you have gone to bed?
98.1
Q2: On how many days in the last 2 weeks have you noticed blood in your stools? 98.3
Q32: In the last 2 weeks have you felt happy? 98.7
Q31: In the last 2 weeks have you felt lack of sympathy from others? 98.9
Q10: On how many days over the last 2 weeks have you felt generally unwell? 99.1
Q9: On how many days over the last 2 weeks have your bowels opened accidentally? 99.3
Q27: In the last 2 weeks have you felt angry as a result of your bowel problem? 99.5
Q8: In the last 2 weeks did your bowel condition prevent you from going out socially? 99.6
Q22: In the last 2 weeks have you felt relaxed? 99.8
Q7: On how many days over the last 2 weeks have you felt full of energy? 99.9
Q1: On how many days over the last 2 weeks have you had loose or runny bowel movements? 100
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TABLE 13 Model summary of the CUCQ questions within the CONSTRUCT RCT validation sample
Questions
Cumulative %
of variance
Q10: On how many days over the last 2 weeks have you felt generally unwell? 34.5
Q30: In the last 2 weeks have you felt irritable? 58.8
Q12: In the last 2 weeks has your bowel condition affected your leisure or sports activities? 67.4
Q3: On how many days over the last 2 weeks have you felt tired? 74.0
Q23: In the last 2 weeks have you been embarrassed by your bowel problem? 79.1
Q24: On how many days over the last 2 weeks have you wanted to go back to the toilet immediately
after you thought you had emptied your bowels?
81.8
Q16: In the last 2 weeks have you felt depressed? 84.0
Q29: On how many days over the last 2 weeks have you felt sick? 86.2
Q5: In the last 2 weeks has your bowel condition prevented you from carrying out your work or other
normal activities?
87.8
Q18: On how many days over the last 2 weeks: have you had a problem with large amounts of wind? 89.5
Q32: In the last 2 weeks have you felt happy? 90.8
Q28: In the last 2 weeks has your sex life been affected by your bowel problem? 91.7
Q14: On how many nights over the last 2 weeks have you been unable to sleep well (days if you are a
shift worker)?
92.7
Q20: Many patients with bowel problems have worries about their illness. How often during the last
2 weeks have you felt worried?
93.7
Q17: In the last 2 weeks have you had to avoid attending events where there was no toilet close
at hand?
94.5
Q2: On how many days in the last 2 weeks have you noticed blood in your stools? 95.2
Q26: On how many days over the last 2 weeks have you had to rush to the toilet? 95.8
Q31: In the last 2 weeks have you felt lack of sympathy from others? 96.3
Q21: On how many days over the last 2 weeks has your abdomen felt bloated? 96.7
Q27: In the last 2 weeks have you felt angry as a result of your bowel problem? 97.1
Q22: In the last 2 weeks have you felt relaxed? 97.5
Q19: On how many days over the last 2 weeks have you felt off your food? 97.8
Q13: On how many days over the last 2 weeks have you felt pain in your abdomen? 98.1
Q11: In the last 2 weeks have you felt the need to keep close to a toilet? 98.4
Q9: On how many days over the last 2 weeks have your bowels opened accidentally? 98.7
Q4: In the last 2 weeks have you felt frustrated? 98.9
Q15: On how many nights in the last 2 weeks have you had to get up to use the toilet because of your
bowel condition after you have gone to bed?
99.2
Q7: On how many days over the last 2 weeks have you felt full of energy? 99.4
Q8: In the last 2 weeks did your bowel condition prevent you from going out socially? 99.6
Q25: In the last 2 weeks have you felt upset? 99.7
Q1: On how many days over the last 2 weeks have you had loose or runny bowel movements? 99.9
Q6: On how many days over the last 2 weeks have you opened your bowels more than three times
a day?
100
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We assessed the responsiveness of the CUCQ on those patients who had reported an improvement or a
deterioration in their condition on the transition question between the 3- and 6-month period. There were
146 patients who reported a change in their condition in this period. The responsiveness ratio (mean
change in scores for those patients who reported a change divided by the standard deviation (SD) of the
scores of the stable patients) was 0.200. This indicated moderate responsiveness. Further analysis is required
to explore differences in the responsiveness of the scale between the stoma and non-stoma patients.
Principal component analysis of the CUCQ showed that there were four underlying dimensions that made
clinical sense. Internal consistency of the total CUCQ score was demonstrated by an excellent Cronbach’s
alpha. The construct validity of the CUCQ was demonstrated by significant correlations with the SF-12
mental and physical component scores and with the EQ-5D. Moderate intraclass correlations between the
test and retest scores demonstrated the reproducibility of the instrument. In addition, the scale was found
to be responsive to change.
We will undertake further work to explore whether or not there are any differences in the validity of the
scale between the stoma and non-stoma patients. In addition, we will carry out additional analysis to
explore the CUCQ clinical subscales and the potential for developing a shortened version of the CUCQ.
TABLE 14 Response rate to baseline and follow-up questionnaires in the RCT validation sample
Time point
Scale (total sample, N= 270)
CUCQ/CUCQ+, n (%)
Baseline 267 (98.9)
3 months 202 (74.8)
6 months 200 (74.1)
12 months 168 (62.2)
18 months 91 (33.7)
24 months 77 (28.5)
30 months 27 (10)
36 months 10 (3.7)
TABLE 15 Correlations between the CONSTRUCT total score and the SF-12 mental and physical component scores
and EQ-5D in the CONSTRUCT validation sample
Scale CUCQ
SF-12 MCS 0.588a
SF-12 PCS 0.452a
EQ-5D 0.459a
MCS, mental component score; PCS, physical component score.
a p< 0.001 Pearson’s correlation.
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Clinical effectiveness
Baseline characteristics
We compared the trial participants in the two groups in terms of various characteristics (Table 16); there
are no statistically significant differences between the groups.
TABLE 16 Baseline demographic and clinical characteristics for each group
Variables Infliximab (n= 135) Ciclosporin (n= 135)
Age at randomisation (years), mean (SD) [n] 39.3 (15.5) [135] 39.8 (15.0) [135]
Gender: proportion, n/N (%)
Female 46/135 (34.1) 54/135 (40.0)
Male 89/135 (65.9) 81/135 (60.0)
Ethnicity: proportion, n/N (%)
White 126/134 (94.0) 124/133 (93.2)
Asian or Asian British 5/134 (3.7) 7/133 (5.3)
Black or black British 2/134 (1.5) 1/133 (0.8)
Other ethnic groups 1/134 (0.7) 1/133 (0.8)
Weight (kg), mean (SD) [n] 74.3 (15.0) [135] 73.9 (15.3) [134]
Smoking: proportion, n/N (%)
Never smoked/non-smoker 58/130 (44.6) 75/134 (56.0)
Current/ex-smoker 72/130 (55.4) 59/134 (44.0)
Family history: proportion, n/N (%)
Yes (any one of mother, father, sibling, child) 28/132 (21.2) 19/135 (14.1)
No 104/132 (78.8) 116/135 (85.%)
Condition severity (using Truelove and Witt’s criteria4): proportion, n/N (%)
Severe 97/133 (72.9) 95/131 (72.5)
Not severe 36/133 (27.1) 36/131 (27.5)
Montreal Score: proportion, n/N (%)
E1 7/124 (5.6) 10/126 (7.9)
E2 64/124 (51.6) 54/126 (42.8)
E3 53/124 (42.7) 62/127 (49.2)
Mayo score: proportion, n/N (%)
0 2/131 (1.5) 1/128 (0.8)
1 2/131 (1.5) 2/128 (1.6)
2 35/131 (26.7) 35/128 (27.3)
3 92/131 (70.2) 90/128 (70.3)
Receiving any of azathioprine, 6-mercaptopurine or methotrexate at baseline, n/N (%)
At least one 16/135 (11.9) 26/135 (19.3)
None 119/135 (88.1) 109/135 (80.7)
Duration of symptoms for current episode (days), mean (SD) [n] 37.6 (46.0) [135] 41.4 (57.5) [131]
EQ-5D, mean (SD) [n] 0.5185 (0.2961) [132] 0.4958 (0.3142) [133]
CUCQ score, mean (SD) [n] 0.3664 (0.1334) [134] 0.3574 (0.1325) [133]
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Data analysed
Recruitment to the RCT started when participant UCL0001 was randomised on 24 June 2010 and
continued until participant ABH0016 was randomised on 26 February 2013; the CONSORT diagram (see
Figure 2) summarises recruitment between these dates and the number of PFQs (see Figure 3) actually
completed at each stage. Our primary outcome, the QAS,55 can be computed for n= 242 cases with at
least one post-randomisation value of the CUCQ or CUCQ+.
Analysis
Outcomes were analysed using an appropriate model. Specifically, we used linear models for measurement
outcomes (assuming normality, also assessed via residual diagnostics) in which trial site appeared as a
random factor; logistic regression for binary (yes/no) outcomes; Cox survival regression models for times to
events; we also analysed the three profiles of QoL scores for each participant using a repeated-measures
linear model. Analyses, in which a group effect was always included, considered the following covariates
and factors: gender; weight; age at randomisation; ethnicity; smoking status; family history; duration of
symptoms; disease severity (as assessed by the criteria proposed by Truelove and Witt4); immunosuppressant
therapy (using binary indicator set equal to 1 for participants taking azathioprine, 6-mercaptopurine or
methotrexate at baseline); EQ-5D and CUCQ scores at baseline; and time in follow-up. We progressed
by eliminating, in turn, and starting with the least significant, all covariates and factors found to be
not statistically significant at the 5% level, and concluded when all remaining covariates and factors
were statistically significant.
Tables 17–20 provide raw and adjusted comparisons between groups, some indication of the extent of the
intracluster correlation in variables between participants at the same site and details of statistically
significant factors and covariates. The adjusted comparison reflects the nature of the variable under
consideration: we present an odds ratio (OR) for logistic regression models for binary variables; a hazard
ratio for survival analyses and an additive group effect (Δ, in same units as dependent variable)
for linear models for continuous variables.
Quality-adjusted survival and quality-adjusted survival per day
Figures 4 and 5 show the mean QAS and QAS per day for the two groups, together with 95% CIs for the
means. For both variables, the mean for the ciclosporin group is higher than its infliximab counterpart,
although the clear overlap in the 95% CIs indicate that observed differences are not statistically significant,
as is confirmed in our analysis. There are relatively high values for the intracluster correlations in these
variables, albeit with wide CIs (reflecting the relatively small – in statistical terms – sample sizes).
Proportions undergoing colectomy: time to colectomy
Table 17 shows that the observed difference in the proportions of participants subsequently undergoing
colectomy in the two groups is not statistically significant; nor is the difference in time to colectomy.
Figure 6, the Kaplan–Meier curves of the time to colectomy in the two groups, illustrates the higher
proportion of colectomies in the ciclosporin group.
TABLE 17 Primary and safety outcomes, analysed by treatment allocated
Outcome
Raw data
Adjusted
comparison 95% CI
Intracluster correlation
Infliximab Ciclosporin Estimate 95% CI
QASa
Mean 564.0 587.0 Δ= 7.90
(p= 0.60)
–21.97 to
37.77
0.065 0.015 to
0.147
SD 241.9 226.2
n 121 121
continued
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TABLE 17 Primary and safety outcomes, analysed by treatment allocated (continued )
Outcome
Raw data
Adjusted
comparison 95% CI
Intracluster correlation
Infliximab Ciclosporin Estimate 95% CI
QAS per dayb
Mean 0.7052 0.7331 Δ= 0.0297
(p= 0.129)
–0.0088 to
0.0682
0.094 0.028 to
0.189
SD 0.1811 0.1580
n 121 121
Participants subsequently
undergoing colectomy:
proportion, n/N (%)
55/135
(40.7)
65/135
(48.1)
OR= 1.350
(p= 0.223)
0.832 to
2.188
0 n/a
Time to colectomy (days)c
Mean 810.8 744.1 HR= 1.234
(p= 0.251)
0.862 to
1.768
0 n/a
n 135 135
Total number of SARs 16 10 ER = 0.938
(p= 0.788)
0.590 to
1.493
0 n/a
One SAR per participant 12 8
Two SARs per participant 2 1
Participants with one or more
SARs proportion, n/N (%)d
14/135
(10.4)
9/135 (6.7) OR= 0.660
(p= 0.338)
0.282 to
1.546
0.050 0.008 to
0.132
Total number of SAEs 21 25 ER= 1.075
(p= 0.807)
0.603 to
1.917
0 n/a
One SAE per participant 12 13
Two SAEs per participant 3 2
Three SAEs per participant 1 0
Four SAEs per participant 0 2
Participants with one or more
SAEs proportion, n/N (%)e
16/135
(11.9)
17/135
(12.6)
OR= 0.999
(p= 0.998)
0.473 to
2.114
0 n/a
Post-randomisation LOS (days)f
Mean 10.32 12.21 Δ= 1.542
(p= 0.28
–1.297 to
4.38
0.025 0.002 to
0.089
SD 13.55 10.18
n 135 135
Logarithm of post-randomisation LOSg
Mean 1.878 2.289 Δ= 0.421
(p< 0.001)
0.245 to
0.597
0.024 (0.001 to
0.085)
SD 0.887 0.626
n 135 135
Mortality: proportion, n/N (%) 3/135
(2.2)
0/135 (0)
ER, event ratio; HR, hazard ratio; LOS, length of stay; n/a, not applicable.
Figures; significant covariates and factors:
a Figure 4; days in follow-up (p< 0.001); CUCQ at baseline (p< 0.001); EQ-5D at baseline (p= 0.015).
b Figure 5; CUCQ at baseline (p< 0.001); weight (p= 0.011).
c Figure 6; intracluster correlation assessed using time to event.
d Age at randomisation (p= 0.006).
e Age at randomisation (p= 0.031); symptoms duration (p= 0.049).
f Figure 7a; age at randomisation (p< 0.001); gender (p= 0.034); smoking (p= 0.032).
g Figure 7b; age at randomisation (p< 0.001); gender (p= 0.013); EQ-5D at baseline (p= 0.007).
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TABLE 18 Quality-of-life measures, analysed by treatment allocated
Outcome
Raw data, mean (SD) [n]
Adjusted comparison 95% CIInfliximab Ciclosporin
CUCQa
Month 0 0.3664 (0.1334) [134] 0.3574 (0.1325) [133] Δ= 0.0195 (p= 0.319) –0.0191 to 0.0581
Month 3 0.7455 (0.1830) [99] 0.7187 (0.1855) [103]
Month 6 0.7497 (0.1952) [101] 0.7505 (0.2083) [99]
Month 12 0.7284 (0.2110) [82] 0.7927 (0.1738) [86]
Month 18 0.7837 (0.1769) [52] 0.8179 (0.1321) [39]
Month 24 0.8102 (0.1702) [36] 0.8264 (0.1256) [40]
Month 30 0.8099 (0.1644) [17] 0.8502 (0.1140) [10]
Month 36 0.7611 (0.0966) [6] 0.8380 (0.1390) [4]
SF-6Db
Month 0 0.5632 (0.1066) [128] 0.5517 (0.1047) [127] Δ= 0.0051 (p= 0.737) –0.0250 to 0.0353
Month 3 0.7194 (0.1357) [96] 0.7066 (0.1383) [100]
Month 6 0.7401 (0.1439) [99] 0.7384 (0.1513) [95]
Month 12 0.7610 (0.1479) [78] 0.7624 (0.1551) [85]
Month 18 0.7449 (0.1459) [50] 0.7954 (0.1323) [39]
Month 24 0.7782 (0.1485) [37] 0.7867 (0.1197) [37]
Month 30 0.7947 (0.1190) [17] 0.8095 (0.1065) [11]
Month 36 0.7413 (0.1159) [6] 0.7603 (0.1334) [4]
EQ-5Dc
Month 0 0.5185 (0.2961) [132] 0.4958 (0.3142) [133] Δ= 0.0144 (p= 0.527) –0.0304 to 0.0592
Month 3 0.8000 (0.2090) [99] 0.7791 (0.2409) [103]
Month 6 0.7957 (0.2387) [102] 0.8107 (0.2111) [100]
Month 12 0.8021 (0.2235) [81] 0.8327 (0.2336) [86]
Month 18 0.8238 (0.2179) [51] 0.8821 (0.1290) [40]
Month 24 0.8634 (0.1835) [37] 0.8678 (0.1871) [38]
Month 30 0.8815 (0.1229) [17] 0.9225 (0.1193) [11]
Month 36 0.8430 (0.1361) [6] 0.8203 (0.1300) [4]
SF-6D, Short Form Questinnaire-6 items.
a Figure 8; significant covariates, weight (p= 0.010), gender (p= 0.026).
b Figure 9; no significant covariates.
c Figure 10; significant covariates, weight (p= 0.001), age at randomisation (p= 0.029), smoking (p= 0.037),
gender (p= 0.039).
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TABLE 19 Post-randomisation CUCQ QoL measure for all participants, analysed by treatment allocated, adjusting
for colectomy status
Outcome
Raw data:a outcome, mean (SD) [n]
Adjusted comparisonb,c 95% CIInfliximab Ciclosporin
Interval 1d ΔGroup= 0.0130 (p= 0.511) –0.0259 to 0.0519
All 0.6877 (0.2128) [145] 0.6926 (0.1951) [157] ΔColectomy= –0.0476 (p= 0.004) –0.0800 to –0.0152
BC 0.7658 (0.1822) [75] 0.7216 (0.1941) [76]
PC 0.6041 (0.2125) [70] 0.6653 (0.1932) [81]
Interval 2
All 0.7425 (0.2076) [112] 0.7398 (0.2008) [118]
BC 0.7750 (0.1856) [72] 0.7881 (0.1918) [68]
PC 0.6841 (0.2338) [40] 0.6743 (0.1957) [50]
Interval 3
All 0.7313 (0.2134) [87] 0.7700 (0.1783) [100]
BC 0.7648 (0.1983) [55] 0.8168 (0.1530) [50]
PC 0.6737 (0.2289) [32] 0.7231 (0.1906) [50]
Interval 4
All 0.7577 (0.1903) [58] 0.8099 (0.1352) [45]
BC 0.7782 (0.1779) [38] 0.8358 (0.1403) [27]
PC 0.7190 (0.2112) [20] 0.7710 (0.1206) [18]
Interval 5
All 0.7999 (0.1742) [38] 0.8226 (0.1267) [39]
BC 0.8054 (0.1812) [27] 0.8407 (0.1168) [28]
PC 0.7861 (0.1633) [11] 0.7763 (0.1446) [11]
Interval 6
All 0.8140 (0.1684) [17] 0.7190 (0.2588) [16]
BC 0.8770 (0.1006) [11] 0.8446 (0.1284) [8]
PC 0.6983 (0.2137) [6] 0.5934 (0.3016) [8]
Interval 7
All 0.7611 (0.0966) [6] 0.8380 (0.1390) [4]
BC 0.7398 (0.1158) [4] 0.8948 (0.0978) [3]
PC 0.8039 (0.0313) [2] 0.6673 (n/a) [1]
BC, denotes scores from questionnaires completed by participants before a colectomy; n/a, not applicable; PC, denotes
scores from questionnaires completed by participants following a colectomy.
a The study design, enabling participants to complete questionnaires relatively soon after a post-randomisation colectomy,
makes it rather difficult to reconcile numbers in Tables 18 and 19; in Table 18, each participant contributes no more
than one value per stage, but, in Table 19, it is possible that one participant completes several questionnaires in an
interval, and, furthermore, that an earlier questionnaire contributes to the BC subgroup while one (or more) later
questionnaires contribute to the PC subgroup.
b Significant covariates: weight (p= 0.019).
c Omitting the group variable makes only minor differences to the estimate of the effect of a colectomy on CUCQ scores.
d Post-randomisation follow-up is divided into seven intervals, as follows: interval 1, up to (and including) 135 days post
randomisation; interval 2, from 136 to (and including) 274 days post randomisation; interval 3, from 275 to (and including)
456 days post randomisation; interval 4, from 457 to (and including) 639 days post randomisation; interval 5: from 640 to
(and including) 821 days post randomisation; interval 6, from 822 to (and including) 1004 days post randomisation;
interval 7: ≥ 1005 days post randomisation.
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TABLE 20 Post-randomisation CUCQ QoL measure for participants undergoing a colectomy, analysed by treatment
allocated, adjusting for colectomy status
Outcome
Raw data, mean (SD) [n]
Adjusted comparisona 95% CIInfliximab Ciclosporin
Interval 1b ΔGroup= 0.0266 (p= 0.367) –0.0317 to 0.0848
All 0.6119 (0.214) [84] 0.6649 (0.1979) [104] ΔColectomy= 0.0271 (p= 0.244) –0.0185 to –0.0726
BC 0.6510 (0.2091) [14] 0.6631 (0.2184) [23]
PC 0.6041 (0.2125) [70] 0.6653 (0.1932) [81]
Interval 2
All 0.6842 (0.2254) [53] 0.6903 (0.1980) [61]
BC 0.6847 (0.2077) [13] 0.7630 (0.2008) [11]
PC 0.6841 (0.2338) [40] 0.6743 (0.1957) [50]
Interval 3
All 0.6701 (0.2248) [39] 0.7207 (0.1928) [52]
BC 0.6537 (0.2209) [7] 0.6596 (0.3299) [2]
PC 0.6737 (0.2289) [32] 0.7231 (0.1906) [50]
Interval 4
All 0.7001 (0.2159) [23] 0.7752 (0.1186) [19]
BC 0.5740 (0.2481) [3] 0.8512 (n/a) [1]
PC 0.7190 (0.2112) [20] 0.7710 (0.1206) [18]
Interval 5
All 0.7673 (0.1689) [123] 0.7763 (0.1446) [11]
BC 0.5595 (n/a) [1] (n/a)
PC 0.7861 (0.1633) [11] 0.7763 (0.1446) [11]
Interval 6
All 0.6983 (0.2137) [6] 0.5934 (0.3016) [8]
BC (n/a) (n/a)
PC 0.6983 (0.2137) [6] 0.5934 (0.3016) [8]
Interval 7
All 0.8039 (0.0313) [6] 0.6673 (n/a) [1]
BC (n/a) (n/a)
PC 0.8039 (0.0313) [2] 0.6673 (n/a) [1]
BC, denotes scores from questionnaires completed by participants before a colectomy; n/a, not applicable; PC, denotes
scores from questionnaires completed by participants following a colectomy.
a Significant covariates: none.
b Post-randomisation follow-up is divided into seven intervals, as follows: interval 1, up to (and including) 135 days post
randomisation; interval 2, from 136 to (and including) 274 days post randomisation; interval 3, from 275 to (and
including) 456 days post randomisation; interval 4, from 457 to (and including) 639 days post randomisation; interval 5:
from 640 to (and including) 821 days post randomisation; interval 6, from 822 to (and including) 1004 days post
randomisation; interval 7: ≥ 1005 days post randomisation.
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FIGURE 4 Means and 95% CI for QAS (the QAS or area under the CUCQ curve from randomisation until end of
follow-up on 28 February 2014) for the two groups.
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FIGURE 5 Means and 95% CI for QAS per day [defined as QAS divided by the time (in days) from randomisation
until the end of follow-up] for the two groups.
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Proportions with serious adverse reactions and serious adverse events
Table 17 shows that the observed difference in the proportions of participants reporting a SAR in the two
groups is not statistically significant; the same is also true for the proportions of participants reporting a SAE.
Post-randomisation length of stay
Figure 7a displays box plots of the post-randomisation length of stay data for the two groups, and, together
with the numerical summaries in Table 17, illustrates the skewed nature of these values. Transformed values
(based on taking natural logarithms) are shown in Figure 7b, which shows that the transformation has
considerably reduced the original skewness. Formal analysis shows that, although differences in the raw
data are deemed to be not statistically significant, the corresponding analysis of the transformed data leads
to the contrary conclusion that differences on the logarithmic scale are statistically different. As assumptions
underpinning statistical models are more appropriate to the analysis of the transformed data, we should
not readily accept conclusions based on the analysis of the raw data: the evidence on the equality of
post-randomisation lengths of stay is thus rather more nuanced than an initial examination indicates.
Quality-of-life profiles
Table 18 presents numerical summaries of the three QoL measures [namely CUCQ, Short Form
Questinnaire-6 dimensions (SF-6D), EQ-5D] at the various stages in follow-up. As discussed elsewhere,
these summaries include, for the CUCQ, values obtained from the CUCQ+ when the extended version of
the questionnaire was administered to patients post colectomy, and treats these as pari passu with other
CUCQ scores; however, the summaries do not include values generated via specific PCQs, as such
questionnaires are not always readily associated with a specific time in follow-up. (For the avoidance of
doubt, it may again here be emphasised that CUCQ+ scores obtained from PCQs are included in
participants’ CUCQ profiles, and hence contribute to QAS and QAS per day.)
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FIGURE 6 Kaplan–Meier plots showing the proportion remaining colectomy-free in the two groups over time
(in days) in follow-up, censored at the end of follow-up on 28 February 2014.
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FIGURE 7 Box plots of post-randomisation LOS for the two groups. (a) Post-randomisation LOS in days; and
(b) natural logarithms (Ln) of post-randomisation LOS. LOS, length of stay.
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The profiles of the three QoL measures, shown in Figures 8 (CUCQ), 9 (SF-6D) and 10 (EQ-5D) are broadly
very similar. They show an initial rise over 1 year from values at baseline followed by a levelling off; the
profile for the two groups are also very similar to each other. Formal analysis, summarised in Table 18,
confirms that the observed differences are not statistically significant.
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FIGURE 8 Mean CUCQ scores and 95% CI for the two groups at specific points in follow-up.
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FIGURE 9 Mean SF-6D values and 95% CI for the two groups at specific time points in follow-up.
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Adverse events
Tables 21–23 summarise the categories of AEs reported on each drug and the clinical system affected.
Overall, 16 patients who had infliximab and 17 patients who had ciclosporin reported 21 and 25
(respectively) SAEs that were not related to disease progression or surgery. Fourteen patients who had
infliximab and nine patients who had ciclosporin had 16 and 10 (respectively) SARs. There was no
statistical significant difference between the two drugs in relation to the total SAEs (p= 0.807) and
SARs (p= 0.788).
Three participants died, all following infliximab. In two cases this was due to sepsis in the presence of
multiple comorbidities (including diabetes mellitus), at 20 days (preoperative) and 65 days (postoperative)
following randomisation. One participant died from disseminated colorectal cancer at 278 days. This case
was unusual in that signet ring cells were identified on histology of the resected specimen, raising the
possibility of a lung primary but the multidisciplinary team concluded that primary was colorectal.
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FIGURE 10 Mean EQ-5D values and 95% CI for the two groups at specific time points in follow-up.
TABLE 21 Summary of all AEs reported
Event Infliximab Ciclosporin
SUSAR 0 0
SAR 16 10
SAE total 145 178
SAE IBD related 36 47
SAE surgery related 88 106
SAE other 21 25
AR 48 75
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TABLE 22 Summary of the clinical system affected in SAEs
SAE Infliximab Ciclosporin
Infection 8 16
Gastrointestinal 1 1
Chest infection 1 4
Skin infection 1 2
Post surgical 4 4
UTI 0 2
Non-specific 1 3
Neurological 1 0
Gastrointestinal 5 2
Renal 0 0
Respiratory 2 0
Cardiovascular 0 3
Haematological 0 0
Psychiatric 1 1
Musculoskeletal 1 1
Venous thromboembolism 1 1
Other 2 1
UTI, urinary tract infection.
TABLE 23 Summary of the clinical system affected in SARs
SAR Infliximab Ciclosporin
Infection 8 1
C. diff 1 0
Chest infection 3 0
Skin infection 0 1
Post surgical 1 0
Others 3 0
Neurological 2 3
Gastrointestinal 1 2
Renal 0 2
Malignancya 1 (colorectal cancer) 1 (endometrial cancer)
Allergy/infusion reaction 2 0
Psychiatric 1 0
Respiratory 1 0
Hepatic 0 1
Others 0 0
a One participant on infliximab developed a cutaneous basal cell carcinoma, but was not admitted for treatment, and the
event was therefore classified as an AR. There were therefore two malignancies on infliximab and one on ciclosporin.
The colorectal cancer was unusual in that it had some histological features suggestive of a lung primary. The local
multidisciplinary team considered the case carefully and concluded that this was a single colorectal primary.
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Continuation of treatment
As this was a pragmatic trial, local PIs were able to continue treatment with the trial Investigational
Medicinal Products (IMPs) at their discretion and to add immunosuppressive drugs. Figure 11 displays the
continuation of infliximab and ciclosporin.
Tables 24–30 show the numbers of individual patients on immunosuppressants at baseline and following
randomisation. Table 24 summarises the number of patients receiving immunosuppressants prescribed
(azathiporine, 6-mercaptopurine, methotrexate) and Tables 25–30 break the figures down by individual
drugs and those given in combination. No patient received more than two immunosuppressants at
any one time. No significant differences have been identified. These data are derived from the
patient-completed questionnaires at each time point.
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FIGURE 11 Kaplan–Meier plot of the treatment duration (in days) for the two groups; there is no attempt to
distinguish further subgroups with different reasons for discontinuation of treatment, nor is there any censoring
for cases when the end of treatment is not recorded.
TABLE 24 Total number of patients on immunosuppressants at each time period
Period Total Infliximab, n (% within arm) Ciclosporin, n (% within arm)
Pre baseline 42 16 (11.9) 26 (19.3)
3 months 122 56 (42.7) 66 (49.3)
6 months 113 56 (42.7) 57 (43.5)
12 months 84 39 (31.0) 45 (36.3)
18 months 42 23 (24.0) 19 (20.5)
24 months 38 18 29.5) 20 (30.3)
30 months 19 10 (27.8) 9 (23.1)
36 months 7 4 (23.5) 3 (17.6)
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TABLE 25 Occurrence of azathioprine (alone) prescribing in each trial period
Period Total Infliximab, n (% within arm) Ciclosporin, n (% within arm)
Pre baseline 28 14 (10.4) 14 (10.4)
3 months 100 50 (38.2) 50 (37.3)
6 months 80 40 (30.5) 40 (30.5)
12 months 62 28 (22.2) 34 (27.4)
18 months 31 16 (16.7) 15 (15.8)
24 months 25 12 (19.7) 13 (19.7)
30 months 14 8 (22.2) 6 (15.4)
36 months 6 3 (17.6) 3 (17.6)
TABLE 26 Occurrence of 6-mercaptopurine (alone) prescribing in each trial period
Period Total Infliximab, n (% within arm) Ciclosporin, n (% within arm)
Pre baseline 8 2 (1.5) 6 (4.4)
3 months 13 3 (2.3) 10 (7.5)
6 months 24 15 (11.5) 9 (6.9)
12 months 19 11 (8.7) 8 (6.5)
18 months 9 6 (6.3) 3 (3.2)
24 months 13 6 (9.8) 7 (10.6)
30 months 5 2 (5.6) 3 (7.7)
36 months 1 1 (5.9) 0
TABLE 27 Occurrence of methotrexate (alone) prescribing in trial period
Period Total Infliximab, n (% within arm) Ciclosporin, n (% within arm)
Pre baseline 2 0 2 (1.5)
3 months 3 0 3 (2.2)
6 months 5 1 (0.8) 4 (3.1)
12 months 3 0 3 (2.4)
18 months 1 0 1 (1.1)
24 months 0 0 0
30 months 0 0 0
36 months 0 0 0
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TABLE 28 Occurrence of azathiporine+ 6-mercaptopurine in combination in trial period
Period Total Infliximab Ciclosporin
Pre baseline 0 0 0
3 months 2 1 1
6 months 2 0 2
12 months 0 0 0
18 months 0 0 0
24 months 0 0 0
30 months 0 0 0
36 months 0 0 0
TABLE 29 Occurrence of azathiporine+methotrexate in combination in trial period
Period Total Infliximab Ciclosporin
Pre baseline 4 0 4
3 months 1 0 1
6 months 1 0 1
12 months 0 0 0
18 months 1 1 0
24 months 0 0 0
30 months 0 0 0
36 months 0 0 0
TABLE 30 Occurrence of 6-mercaptopurine+methotrexate in combination in trial period
Period Total Infliximab Ciclosporin
Pre baseline 0 0 0
3 months 3 2 1
6 months 0 0 0
12 months 0 0 0
18 months 0 0 0
24 months 0 0 0
30 months 0 0 0
36 months 0 0 0
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Cost-effectiveness
Analysis of missing data
Table 31 reports the number of observations missing at each data collection time between the two arms of
the trial.
The amount of missing data was greater for items reported on the PFQ which was completed by the
participant as compared with the CRF which was completed by the research nurse. Participants who
withdrew from the study were more likely to withdraw only from responding to further questionnaires
(PFQ) than from accessing their medical records (CRF) leading to more missing data from the PFQ.
Data on trial drug administration costs were missing for 41 infliximab and 24 ciclosporin participants. Data
on oral ciclosporin were missing for two participants who had completed the protocol single infusion.
We used age, gender, study arm, ethnicity, smoking, weight, and baseline SF-6D, EQ-5D and CUCQ scores
to assess randomness of missing data.
For CRF data, the pattern of missing data on tests and investigations and drugs delivered to inpatients was
studied at 18, 24 and 30 months and no significance was shown.
At 3 months, the pattern of missing PFQ data showed statistical significance for gender, with 41 males
(25%) and 12 females (12%) not providing responses (p= 0.017). At 12 months, younger people (mean
age 36.35 years, SD 14.59 years) were less likely to provide responses than the rest of the cohort (mean age
40.44 years, SD 15.85 years) (p= 0.045). This was also the case at 24 months, younger people (mean age
36.89 years, SD 14.10 years) versus the rest of the cohort (mean age 43.52 years, SD 14.56 years) (p= 0.012).
At each follow-up point, however, missing data were evenly distributed between study arms, suggesting
that the imputation process adopted should not have led to any estimation bias.
Comparison of costs
For cost comparisons, we analysed data on all participants for whom we had cost data for each follow-up
period. In these comparisons, we performed tests for statistical significance independently for each period,
owing to the different sample sizes at each time point. For the incremental cost-effectiveness analysis we
analysed cost data for those participants for whom we had effectiveness data and summed total costs over
the whole of the follow-up period.
Trial drug costs
A total of 42 of 52 of sites that recruited participants to the RCT responded to our survey regarding
preparation and delivery of trial drugs. Pharmacists prepared infliximab infusions at 11 sites and prepared
ciclosporin infusions at seven sites. All other infusions were prepared by nurses. For infliximab, the mean
administration costs were £17.66 (SD £25.05) per infusion. For ciclosporin they were £35.41
(SD £28.48) per day during which the infusion was received.
Eighty-eight infliximab participants received the three infusions specified in the protocol; 98 received two
infusions and 134 received a single infusion. Thirty-four participants received additional infusions
(minimum= 1, maximum= 13) with a mean of 1.20 (SD 2.71) additional infusions.
One hundred and thirty-two ciclosporin participants received the single infusion specified in the protocol
with a mean (SD) infusion duration of 5.0 (SD 1.8) days. Of these, 100 were switched to oral following
their single infusion with a mean duration on oral ciclosporin of 52.0 (SD 48.8) days.
Table 32 shows the mean costs of treatment with the two trial drugs. As most participants on oral
ciclosporin completed their treatment within 3 months, all oral ciclosporin costs have been attributed to
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the first 3 months. Infliximab is clearly the more costly treatment with a mean cost in the first
3 months of £4823 (SD £2199) compared with £880 (SD £649) for ciclosporin and with costs for
additional infliximab infusions continuing beyond this period.
Baseline spell in hospital: length of stay
All participants were recruited and randomised while inpatients. Mean length of stay of this baseline
spell in hospital (i.e. from randomisation to discharge) was slightly higher for ciclosporin participants
but the difference was not statistically significant: ciclosporin 12.21 (SD 10.18) days, infliximab 10.32
(SD 13.55) days (95% CI –1.06 to 4.69 days; p= 0.20) as shown in Table 33.
Twenty-eight participants in the infliximab arm (20.7%) had surgery during the baseline spell compared
with 34 in the ciclosporin arm (25.2%). The mean length of stay for those who had surgery was
similar between groups: infliximab 22.89 (SD 14.90) days versus ciclosporin 21.38 (SD 14.65) days
(95% CI –9.03 to 5.91 days; p= 0.68).
A total of 107 participants in the infliximab arm (79.2%) were discharged from their baseline spell in
hospital without having surgery compared with 101 in the ciclosporin arm (74.8%). For those who did not
have surgery, the mean length of stay was higher for ciclosporin participants at 9.13 (SD 5.45) days versus
7.02 (SD 11.07) days for infliximab, although the difference was not statistically significant
(95% CI –9.03 to 5.91 days; p= 0.08).
Cost of hospitalisation without surgery
The cost of the baseline spell in hospital for participants who did not have surgery is shown in Table 34,
which also shows costs for all subsequent non-surgical hospital admissions. The mean differences were not
statistically significant in any period.
TABLE 33 Mean (SD) length of baseline spell in hospital (days)
Participants
Ciclosporin Infliximab
Mean difference
(ciclosporin –
infliximab) (days)
95% CIa (days)
p-valuen
Mean (SD)
(days) n
Mean (SD)
(days) Lower Upper
All 135 12.21 (10.18) 135 10.32 (13.55) 1.90 –1.06 4.69 0.20
No surgery 101 9.13 (5.45) 107 7.02 (11.07) 2.11 –0.34 4.17 0.08
Surgery 34 21.38 (14.65) 28 22.89 (14.90) –1.55 –9.03 5.91 0.68
a Bias-corrected 10,000 bootstrap replications.
TABLE 32 Mean (SD) costs of infliximab and ciclosporin (£)
Follow-up period
(months)
Ciclosporin Infliximab
n
Mean (SD)
cost (£) 95% CI (£)a n
Mean (SD)
cost (£) 95% CI (£)a
0–3b 135 880 (649) 569 to 734 135 4823 (2199) 4464 to 5181
4–6 – – – 131 638 (1474) 399 to 902
7–12 – – – 131 837 (2179) 486 to 1232
13–18 – – – 84 773 (1942) 385 to 1211
19–24 – – – 65 337 (1450) 37 to 693
25–30 – – – 27 175 (907) 0 to 510
Total (£) 118,800 935,837
a Bias-corrected 10,000 bootstrap replications.
b Cost of oral ciclosporin attributed to 3 months.
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Cost of hospitalisation with surgery
Table 35 shows the number of participants who had colectomies or other surgical procedures by follow-up
period. None of the differences was statistically significant (chi-squared test).
Table 36 shows the costs of surgical admissions at each follow-up point. There were no statistically
significant differences between groups at any point.
NHS resource use
The costs of NHS resource use in the 3 months prior to baseline are shown in Table 37. There were no
statistically significant differences across individual resource items apart from prescription drugs in
which the mean cost for ciclosporin participants was significantly higher: £224 (SD £223) versus £166
(SD £185), mean difference £58 (95% CI £9 to £107; p= 0.020). Total costs were not significantly
different with a mean cost for ciclosporin participants of £1115 (SD £1291) versus with £1034
(SD £1047), mean difference £80 (95% CI –£194 to £352; p= 0.573).
The total costs of all NHS contacts (as itemised above) are shown in Table 38. Table 38 also shows the
costs of prescribed drugs other than the trial drugs given to participants as inpatients and by prescription in
the community, and the costs of tests and investigations. There were no statistically significant differences
between arms for any items during any period.
Incremental cost-effectiveness
Results relate to a ‘within-trial’ cost-effectiveness analysis using primary data collected within the period of
study and without lifetime extrapolation. Base-case costs and QALYs to be reported below cover 30 months
adjusted by the number of days over which each participant contributed data. Table 39 shows that the
mean number of days that ciclosporin participants contributed CRF data was slightly higher than for
infliximab participants: 645.9 (SD 204.8) days versus 623.7 (SD 224.0) days, but the mean difference of
22.2 days was not statistically significant (95% CI –32.2 to 77.4 days; p= 0.433). A similar pattern was
shown for PFQ data: 673.0 (SD 226.0) days versus 653.2 (SD 224.8) days, mean difference 19.7 days
(95% CI –36.8 to 76.5 days; p= 0.509).
Base-case costs and QALYs are shown in Table 40. The mean difference in QALYs was 0.023 in favour of
ciclosporin, but this is not statistically significant (95% CI –0.053 to 0.101; p= 0.563). The mean difference
in costs was –£5632 in favour of ciclosporin and is statistically significant (95% CI –8348 to –2880; p< 0.001).
TABLE 35 Colectomy and other surgical procedures
Follow-up period
Ciclosporin (n= 135) Infliximab (n= 135)
p-valueaColectomy, n Other procedures, n Colectomy, n Other procedure, n
Baseline spell 34 – 28 – 0.235
Discharge to 3 months 8 1 10 1 0.533
4–6 months 9 3 4 4 0.356
7–12 months 11 13 5 13 0.239
13–18 months 2 11 5 7 0.169
19–24 months 1 67 2 5 0.279
25–30 months 0 1 1 3 0.460
a Chi-squared test.
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The cost-effectiveness plane representing 5000 bootstrap replications is shown in Figure 12. Most
observations are in the south-east quadrant suggesting that ciclosporin dominates infliximab.
The CEAC shown in Figure 13 shows ciclosporin to have a 73–74% probability of being cost-effective over
virtually all willingness-to-pay thresholds. The almost horizontal curve is due to the difference in effects
being close to zero.59,98
Table 41 shows base-case costs and QALYs over 30 months further adjusted using baseline EQ-5D and
CUCQ scores and participants’ weight as covariates for QALYs and baseline cost as a covariate for costs.
The mean difference in QALYs remains in favour of ciclosporin but is slightly reduced by 0.002 to 0.021
QALYs, which is not statistically significant (95% CI – 0.032 to 0.096; p= 0.35). The mean difference in
costs (–£5632) is unchanged and is statistically significant (95% CI –£8305 to –2773; p< 0.001).
The cost-effectiveness plane is shown in Figure 14. The decrease in spread is due to reduced standard
errors. Ciclosporin continues to dominate infliximab with the CEAC (Figure 15) showing ciclosporin to have
an 85% chance of being cost-effective over all willingness-to-pay thresholds.
TABLE 40 Mean (SD) QALYs and costs over 30 months and mean difference (ciclosporin – infliximab) weighted by
participants’ time in study
QALYs and
costs
Ciclosporin Infliximab Mean difference
(ciclosporin –
infliximab)
95% CIa
p-valuen Mean SD n Mean SD Lower Upper
QALYs 113 1.921 0.29 117 1.898 0.31 0.023 –0.053 0.101 0.563
Costs (£) 113 14,609 10,838 117 20,241 10,433 –5632 –8348 –2880 0.000
a Bias-corrected 10,000 bootstrap replications.
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FIGURE 12 Base-case (30-month) cost-effectiveness plane adjusted for by participants’ length of time in study.
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FIGURE 13 Base-case (30-month) CEAC adjusted by participants’ length of time in study.
TABLE 41 Mean (SD) QALYs and costs over 30 months and mean difference (ciclosporin – infliximab) adjusted for
baseline covariates
QALYs and costs
Ciclosporin Infliximab Mean difference
(ciclosporin –
infliximab)
95% CIa
p-valuen Mean SD n Mean SD Lower Upper
QALYs 113 1.921 0.18 117 1.900 0.16 0.021 –0.032 0.096 0.350
Costs (£) 113 14,609 593 117 20,241 695 –5632 –8305 –2773 0.000
a Bias-corrected 10,000 bootstrap replications.
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FIGURE 14 Base-case (30-month) cost-effectiveness plane weighted for participants’ time in study and adjusted for
baseline covariates.
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Sensitivity analyses
Table 42 below shows results at 12 and 24 months which are similar to the base case, in that the
differences in QALYs at both time points are in favour of ciclosporin and are small (0.027 and 0.022
QALYs at 12 and 24 months, respectively). The mean difference at 12 months is marginally statistically
significant (p= 0.049), but not at 24 months (p= 0.479). Mean differences in costs in both cases are again
in favour of ciclosporin (–£4568 and –£4498 and are statistically significant; 12 months (p< 0.001),
24 months (p< 0.001). These two sensitivity analyses are consistent with the base case showing ciclosporin
to dominate infliximab.
Participants’ time off work
Mean participants’ time off work in the 3 months prior to baseline was similar at 7.70 (SD 15.62) days
and 8.27 (SD 14.32) days for infliximab and ciclosporin participants, respectively. There were very few
differences between groups at other follow-up points suggesting that treatment had no differential impact
on participants’ time off work as shown in Table 43.
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FIGURE 15 Base-case (30-month) CEAC weighted for participants’ time in study and adjusted for
baseline covariates.
TABLE 42 Mean (SD) QALYs and NHS costs and mean difference (ciclosporin – infliximab) at 12 and 24 months:
complete-case analyses
QALYs and costs
Ciclosporin Infliximab Mean difference
(ciclosporin –
infliximab) 95% CIa p-valuen Mean (SD) n Mean (SD)
QALYs: 12 months 109 0.802 (0.106) 115 0.775 (0.079) 0.027 –0.001 to 0.054 0.049
Total NHS costs (£):
12 months
109 10,796 (138) 115 15,364 (169) –4568 –4609 to –4528 0.000
QALYs: 24 months 62 1.650 (0.166) 58 1.628 (0.169) 0.022 –0.039 to 0.082 0.479
Total NHS costs (£):
24 months
62 14,773 (1607) 58 19,271 (2181) –4498 –5231 to –3799 0.000
a Bias-corrected 10,000 bootstrap replications.
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Participant interviews
Number of interviews completed
The qualitative section in Chapter 2 explained that we planned to conduct a total of 24 interviews
at 3- and 12-month intervals with participants after randomisation and treatment. However, after 20
3-month interviews had been analysed, data saturation was reached and the TMG confirmed that no
further interviews were needed.
The number of 3-month interviews completed was split evenly between those randomised to infliximab
and those to ciclosporin, with 10 participants in each group, of which three in each group had also had a
colectomy. There were three females and seven males in each treatment group and their ages ranged from
21 to 75 years, as shown in Table 44.
To assess the representativeness or otherwise of the 20 participants selected for interview, we compared
the primary outcome, QAS per day, in terms of group and interview status. The numerical summaries of
means and SDs in Table 45 are consistent with the box plots in Figure 16, and show that, in both groups,
those interviewed are reasonably similar to those not interviewed.
It is worth noting the wide age range of the interviewees, but that their views and experiences were
similar and the only differences seemed to relate to views about reversal procedures for those who had
had surgery to treat their UC. This is explained below.
The length of time since the participants had been diagnosed with UC varied from just a few weeks to as
long as 30 years. However, those who had only recently been diagnosed had generally been experiencing
symptoms for several months.
TABLE 43 Mean (SD) participants’ time off work (days) and mean difference
Period
Ciclosporin Infliximab Mean difference
(ciclosporin –
infliximab) p-value (95% CI)n Mean (SD) n Mean (SD)
Baseline 133 8.27 (14.32) 131 7.70 (15.62) 0.57 0.76 (–3.06 to 4.20)
3 months 103 16.19 (29.45) 101 15.64 (27.39) 0.55 0.89 (–7.30 to 8.40)
6 months 96 6.48 (15.97) 102 3.92 (15.75) 2.56 0.26 (–1.89 to 7.01)
12 months 85 4.31 (16.67) 81 4.30 (14.34 0.01 1.00 (–4.77 to 4.79)
18 months 40 5.68 (18.03) 52 1.71 (3.62) 3.96 0.18 (–1.88 to 9.81)
24 months 40 2.74 (10.52) 40 2.99 (13.56) –0.25 0.93 (–5.65 to 5.15)
30 months 13 1.15 (3.87) 18 1.58 (5.62) –0.43 0.80 (–3.92 to 3.06)
TABLE 44 Details of interview participants
Participants
Infliximab Ciclosporin
Males Females Males Females
Number interviewed 7 3 7 3
Age range (years) 23–64 21–44 27–75 31–59
Mean age (years) 44 32 51 43
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With many participants working, the interviews often took place when people returned home from work.
The interviews lasted between 15 minutes (unusually short) and 45 minutes in length (more common),
and all participants agreed that the interviews could be recorded.
As soon as possible after an interview had taken place, recordings were transcribed and then reviewed by
the interviewer. The interview transcripts were anonymised and any names or geographical details were
removed from the transcripts.
At 12 months, 15 of the interviewees agreed to a second interview (eight infliximab, seven ciclosporin);
one participant had died, two did not want to take part in the second interview and two could not be
contacted. One participant in each treatment group, one male and one female, had undergone colectomy
since their first interview and one male participant who had undergone a colectomy before the first
interview had since had two further operations, pouch surgery followed by ileostomy closure. In total,
35 interviews were conducted with 20 participants.
TABLE 45 Numerical summaries of QAS per day
Group Infliximab, mean (SD) [n] Ciclosporin, mean (SD) [n]
Interview status
Interviewed 0.6863 (0.2227) [9] 0.7754 (0.0778) [10]
Not interviewed 0.7062 (0.1786) [112] 0.7293 (0.1630) [111]
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FIGURE 16 Graphical summaries of QAS per day.
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Analysis of data
Thematic analysis
When the three qualitative study researchers met (including the interviewer and qualitative study lead),
they concurred on the themes that were emerging from the four completed 3-month interviews and
developed a first draft of an analysis framework. An iterative process followed as more interviews were
completed and the analysis framework continued to develop (see Appendix 24).
When 20 interviews had been completed, the three researchers met to discuss whether or not any new
themes were emerging and considered that data saturation had been reached. A proposal was put to the
TMG that sufficient interviews had been undertaken and it was agreed that no more 3-month interviews
were required.
Once the 3-month interview analysis was complete, analysis of the 12-month interviews commenced.
The same iterative process followed as more 12-month interviews were completed and the analysis
framework extended.
Group analysis
Seven members of the study team (in addition to the three qualitative researchers) agreed to take part in
group analysis of the 3-month interviews and were sent three transcripts each (one from a participant who
had taken infliximab, one who had taken ciclosporin and one who had taken ciclosporin followed by a
colectomy). Following clear instructions (see Chapter 2), each person wrote three one-page schematic
overviews, which were circulated to all those taking part together with the draft analysis framework.
Group members looked through the various documents ahead of a full group meeting.
During the meeting, each one-page overview was reviewed and it was clear that each member of
the group had created something that covered the main emergent themes derived from the
analysis framework.
Findings
Main issues arising
The main issues that emerge from the findings are presented ahead of a more detailed presentation of the
qualitative findings for ease of access by the reader and to ensure the main points are not lost:
l Participants express a liking for infliximab because of its positive outcome, relatively simple method of
administration and lack of side effects.
l The dramatically debilitating symptoms of UC that impact on participants’ QoL and, consequently,
on family and friends, is particularly noticeable in this disease type.
l Participants have to live with the ongoing unpredictability of symptoms and treatment and it is this
unpredictability of the disease that makes it particularly difficult for patients and health-care
professionals to manage their health.
l Unlike other chronic diseases, UC is considered an embarrassing disease making it an isolating and
awkward experience for patients because of its impact on managing their life and work.
l The lack of apparency and visibility of either symptoms or outcome also impacts on patients’ sharing
knowledge of the disease with others.
l Surgery is feared, but following it most participants at 3 months experience relief and recognise the
health benefits.
l At 12 months the difficulties for some of living with a stoma were coming to the fore.
l Participants would like to understand what causes UC and its links with stress and diet and would
welcome greater information provision.
l Ready access to an IBD nurse was suggested as particularly important for members of this
patient group.
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Introduction
In spite of the variation in the duration of the disease among participants, similar stories were revealed
about living and coping with UC; the physical, mental and emotional impact of the condition; the
treatments; and people’s concerns and hopes for the future.
The findings that follow are presented as a story so the 13 themes derived from the analysis framework
(see Appendix 24), are presented as a narrative rather than under thematic headings. This enables data to be
understood in accordance with participants’ presentations of their own illness story, according to a progressive
journey from their realisation of the problem, receipt of treatment and management of the condition, to their
views of the future. Presenting the findings in this way indicates how UC becomes present and understandable
in people’s lives as time passes, whereas presenting the findings thematically would have provided a much
more disjointed picture of an illness which is, in effect, often a very long-term chronic condition.
As one of the main aims of CONSTRUCT is the comparison of the two drugs in the treatment of
steroid-resistant ASC, after a brief section about interviewees’ views on their general health, we will
present their views on the drugs themselves. During their admission all the participants had received one
of the drugs and their views illuminate strength of opinion around both.
Following the comparison of participants’ views of the drugs, is a presentation of how the disease impacts
on participants’ lives and the effect of symptoms on participants’ health; the impact on wider family
members and friends and their understanding of the disease; participants’ experiences of treatment and
sharing in the decision-making process with health-care professionals; views on surgery and experiences of
undergoing a colectomy; and finally, hopes and expectations for the future.
As there were similarities in participant dialogue at 3 and 12 months, any similarities will not be reiterated.
Rather, the report concentrates on new views and experiences in relation to the original 13 themes.
By presenting outcomes in this way, we have aimed to identify both personal experiences of health and
illness, and care and treatment options from an individualistic perspective over a period of a year.
All the quotes in this section are from trial participants; they are shown in italics and include an
anonymised code and the line number of the quote in the transcript.
Participants’ views on their general health
For many of the participants their UC was the only significant illness they had experienced, and even for
those with longer term UC, their recent inpatient stay was often their first admission with the disease.
Thus, it soon became apparent that many participants had not given much thought to their health, up to
that point, considering themselves fit and healthy. It is against this background that participants reflected
on more general questions about their health.
A basic desire to lead a ‘normal’ life, to have sufficient energy and to be fit and healthy to do everyday
things was a strong element of the response to general health questions. Participants considered ‘normal
life’ and ‘everyday things’ as including the ability to be able to socialise, work and travel, and spoke in
terms of wanting to have the freedom and be without constraints, to allow them to pursue these activities.
They considered good health as having plenty of energy, not being reliant on medication, not having
symptoms or pain and not having to go to the toilet every few minutes. In contrast, participants related
bad health to being ‘imprisoned’ by their illness symptoms, by which they meant being housebound,
unable to socialise, as well as being physically constrained to having pain and discomfort, lacking energy
and being dependent on others.
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These issues were raised again when people were asked how their UC had affected their QoL and it was
here that the intensity of the suffering caused by UC became strongly apparent. This was particularly the
case for those who had experienced symptoms for a only a few weeks or months before becoming so ill
that they had to be admitted to hospital, it was a shock that they had reached this state so quickly: ‘a bit
of a bolt out of the blue’ (GHI0028.164), it had been a frightening experience and at only 3 months after
their treatment they were still trying to adjust to this life-changing event.
At 12 months, while the course of the disease for the participants had differed, their basic desire to live a
normal life, to be able to socialise, work and travel, had not changed.
Treatment in the trial: participants’ views of infliximab and ciclosporin
When participants discussed their views of either ciclosporin or infliximab, for some recall about the earliest
days of their treatment was hazy as they were so ill that they just could not remember: ‘For the first few
days I wasn’t sure what they were giving me’ (PQR0053.216). However, most were able to recall details
later on, and their views are presented below.
Ciclosporin
Intravenous infusion and tablets Participants who were randomised to ciclosporin recalled having this
while in hospital as an intravenous infusion or drip. There was a sense of relief that treatment was being
provided and that this just ‘happened’. However, some found being hooked up to a drip continuously,
and for several days, a nuisance. It was also restrictive, because either the drip stand had to be taken
everywhere: ‘me and my mate’ (RST0021.271) or the participant had to ask a nurse to disconnect them:
‘loss of freedom, I found that quite irritating, personally found that frustrating’ (BCD0012.218).
Some found the fact that the intravenous ciclosporin bag needed changing frequently was also
inconvenient as it meant being woken at night, and for one participant it meant not being able to relax,
knowing that the bag needed changing. No one criticised nursing staff and there was praise for the
care received. However, a participant at a site with no previous experience of ciclosporin, suggested that
more training was required as the participant found himself ‘telling them but they couldn’t do it until
someone else came so could be waiting for bag to be changed’ (RHS0021.348).
Some found the intravenous ciclosporin easier than the oral form of ciclosporin because once they started
the tablets they had to have tests to monitor the levels in their blood which meant going back to hospital
for the test and then returning for the results and further treatment. The oral ciclosporin was noted as
having a distinctive smell, a ‘different’, ‘strange’ smell like beer. While none of the participants said it was
unpleasant, one said there were others in hospital who disliked it. The tablets were also noted for their
large size: ‘they’re like horse pills’ (SHT0001.109), although no one said this made taking them difficult.
The advantage of the tablets was that there were ‘no needles’ involved and they could be taken at home.
Side effects of ciclosporin Participants described the following side effects from ciclosporin: mood
swings; tingling in the fingers and toes; a head rush; increased facial and body hair; tiredness; a rash on
the arms; hand tremors; and cramping in hands and feet. Women were particularly concerned about an
increase in facial hair, but found that it fell out or decreased once they stopped the ciclosporin.
Short-term outcomes with ciclosporin Two participants did not respond to intravenous ciclosporin and
required emergency surgery. The others did respond and started oral ciclosporin and made comments
such as: ‘It worked so we love ciclo. It saved my bowel’ (TUV0001.310); ‘unbelievably, not unbelievably
better but miles better than what I had been’ (RST0021.319); ‘feel myself getting progressively better’
(BCD0012.403); ‘got the condition under control’ (CDE0010.190).
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One participant who initially responded to ciclosporin had a relapse and the tablets were restarted, but
there was no improvement and she was switched to infliximab. After the switch the participant reported
that she realised she had not been feeling that good on ciclosporin: ‘You sort of think yeah I’m sort of
finally cured, I’m managing well but now I think, uh, uh, I wasn’t’ (PQR0053.344).
Longer-term outcome with ciclosporin It was difficult for participants to comment on whether or not
they felt the ciclosporin was still having an effect and working for them, as most were no longer taking it,
or were on other medications so found it difficult to attribute their current health to a specific medication.
Infliximab
Intravenous infusions Participants who were randomised to infliximab recalled having their first infusion
as an inpatient in hospital. There was a sense that being hooked up to a drip for a few hours was not an
issue, you were in hospital anyway: ‘I was just lying in a hospital bed so I could doze off, read a book’
(KLM0010.153) and: ‘it was fantastic, machine did it all, just pumped into me’ (FGH0011.87). A couple of
participants felt that having treatment given as an intravenous infusion meant that it was more ‘direct’
and reached ‘your system’ more quickly.
After discharge participants returned every 6–8 weeks for a further infusion and this was viewed as a good
way of having treatment as they did not have to take tablets: ‘there is not any managing of it because it’s
a 2-hour infusion and then you’re not due back in for another 6–8 weeks so in that way it’s fantastic,
I’m not having to get up every morning and take about 20 different tablets’ (OPQ0005.395).
Side effects of infliximab The side effects reported from infliximab tend to be fairly immediate with
separate participants commenting on a weird sensation in the legs; feeling a bit strange – vague, sort of
dopey; becoming ‘roasting hot’ during the first infusion; feeling a little hot and cold after the second
infusion; getting hot and sweaty in bed for a week, some 2–3 weeks following infusion.
Short-term outcome with infliximab Three participants did not respond to infliximab and required
surgery. The participant mentioned above who switched from ciclosporin to infliximab, noticed the
difference with her condition improving within a day. Others who responded used comments such as:
‘straightaway noticed a difference. All benefits and no negatives. Saved me from surgery’ (JKL0033.347);
‘It was my saviour . . . real amazing cure . . . miracle drug for me’ (MNO0034.331); ‘It does work,
it definitely does work’ (OPQ0005.213); ‘Really worked on me so they might not have to operate’
(IJK0014.170); ‘Colon saver’ (FGH0011.167).
Longer-term outcome with infliximab As with ciclosporin, it was difficult for participants to comment
on whether or not they felt infliximab was still having an effect and working for them, as most were taking
other medications so it was difficult to attribute their current health to a specific medication: ‘whether
it is still the infliximab having an effect, it’s possible kind of thing . . . ‘ (MNO0034.368). A couple of
participants felt that the effects were still lasting, but two participants did comment that as they neared
the time of their next infusion, they felt that the effects were beginning to wear off.
Reflections on ciclosporin and infliximab at 12 months
By the time of the second interview none of the participants was receiving ciclosporin or infliximab. One
infliximab participant had been concerned about stopping after just three doses but was relieved that he
had experienced no problems since. Four of those randomised to infliximab and two to ciclosporin had
experienced no flare-up of their UC since they completed their treatment with the trial drugs. Flare-ups
had occurred for two participants, one from each group, but at the time of the interview both
were improving.
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The majority of participants spoke more about the treatments they had received since the trial treatment
(see Treatment for ulcerative colitis), but thinking back, one ciclosporin participant recalled that she
developed ‘terrible facial, arm and leg hair’ which took 3 months to settle, but she reiterated ‘we love
ciclosporin, apart from the smell’ (TUV0001.348). Another stated that ciclosporin ‘kept him going’ but
that he could not stay on it because ‘it was quite toxic’ (ABC0010.82). One interviewee, randomised to
infliximab but who did not respond and had surgery during the same admission, had been treated with
ciclosporin several years ago and considered it one of the most successful of all treatments he had
received. In contrast, one participant was relieved not to be on ciclosporin and steroids because of side
effects and ‘autoimmune issues’ (BCD0012.597)
Three participants commented on infliximab as ‘convenient’ (LMN0009.87), ‘easy in comparison with just
having ordinary pills’ (QRS0028.336), and that they ‘would have it again’ (FGH0011.283) and that it meant
‘not taking medication daily’ (PQR0053.509). A participant who initially had infliximab followed quickly
by surgery, thought that having treatment with infliximab ‘every so often would have been easy-peasy’
(QRS0028.342) in comparison with the living with a ‘bag’.
One participant had responded well to three doses of infliximab and wanted to continue it as she wanted
to start a family. Because of funding restrictions, a case was put to the local primary care trust to allow her
to continue but this was refused which she described as ‘quite a blow’ (MNO0034.352). At the time of
the second interview she was 3 months pregnant and having a flare-up: ‘colitis and the pregnancy don’t
seem to get along’ (MNO0034.170). She felt that infliximab would have kept her well and her ‘quality
of life would be much better now if I was able to continue it’ (MNO0034.780).
To reiterate, the presentation of participant views and experiences has begun with their views about the
two drugs, ciclosporin and infliximab, at 3 and 12 months, in line with the study’s main aim of comparing
clinical effectiveness and the objectives of comparing QoL and investigating participant views of the two
treatments. From here on we discuss outcomes of the qualitative interviews in terms of the participants’
journey through their experiences of symptoms, diagnosis, treatment and the impact of UC on their lives.
Onset and diagnosis
It was clear from the interviews that the onset of UC varies from person to person. There were some
people who were diagnosed many years ago, some in the last year and some who were diagnosed when
they were admitted with severe symptoms that had only been present for a few weeks.
A picture has emerged of a convoluted and sometimes frustrating treatment story from early onset to
misdiagnosis. If often begins with mild symptoms such as going to the toilet more frequently and having
some bleeding, to an eventual GP visit with a misdiagnosis of haemorrhoids:
I went to the doctor a couple of times but he told me I’d got piles. So I wasted about a month going
to see the doctor and he just gave me stuff for piles.
LMN0009.111
Some participants visited their GP several times but it was only when their symptoms did not settle and indeed
became worse, particularly if participants reported weight loss, that they were referred for an endoscopy:
I kept going back and saying something is not right. It wasn’t until I went to the doctors and said,
I know I’m overweight . . . 100K [kg] and a week, 8, 9, 10 days after I had lost 10K [kg] in that short
time and they thought there is something seriously wrong and then they decided to ‘let’s get you in
and get a scope done’.
NOP0004.349
At endoscopy some participants were given a clear diagnosis of UC and some were told that they had
some ‘inflammation of the bowel’ and the word ‘colitis’ may have been used.
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There were some examples of people who knew that they had UC but soldiered on nevertheless with their
symptoms: ‘you just put up with it because you just think well I’m just getting old or just, you know, that’s
how life is, I can’t afford time off’ (RST0021.90), but this particular participant explained that ‘it shook
me to the core’ (RST0021.86) when his consultant would not let him go home and he realised just how
ill he was.
An interesting observation from a couple of participants was their attitude to being in hospital as they felt
like ‘frauds’ among some of the seriously ill people in beds nearby: ‘I’m looking around going I feel like
a fraud really . . . there are a lot of sick people in there that you know, weren’t probably coming out of the
place’ (RST0021.289).
Unpredictability of ulcerative colitis
The unpredictability of the course of the disease was a problem for many people who had no idea when
their next flare-up might occur. Some commented that between flare-ups, having UC does not impact on
one’s QoL, but that when a flare-up occurs, experiences are of pain and discomfort. These are exacerbated
by an increase in bowel movements, often with urgency and bloody diarrhoea, which necessitates frequent,
very rushed visits to the toilet. Participants described this loss of bodily function as being unable to rely on
their body, leading to a sense of giving up control over their bodies. Some people, with longer-term
disease, used the term ‘rumbling along’ to describe the way in which their UC was generally controlled
by medication, but with occasional flare-ups that required an adjustment to their medication. These
participants were used to planning their lives around toilets because of the urgency and frequency their
UC caused and would often have a change of clothing with them; some spoke about the worry of what
would happen if they were on a train and had an ‘accident’ when they could not reach a toilet in time:
Get used to the fact that you are going to have to change your clothes once maybe twice a day . . .
even though you are prepared for it because you know it’s going to happen but actually you are
fighting it every minute of the day.
QRS0028.109
I was quite impressed by my planning – it feels like a military procedure at times.
RST0021.223
However, participants jokingly commented on their knowledge of all the toilet stops on a regular car
journey, for example to and from work, or the distances between motorway service stations and explained
that their first action in a new venue or location was to locate the toilets as soon as they arrived; thus,
planning outings around toilets just became a part of their lives.
Participants described how, if a flare-up was not controlled adequately with medication, within a matter
of weeks their symptoms began to have a massive impact on their life, and how normal life ceased and
many everyday activities were curtailed. On a practical side, there was a need to be near a toilet, as
participants had increased bowel movements and for some the increasing symptoms eventually meant not
being able to leave the home:
When I’m ill, you’re a bit stuck, especially with UC, when you’re having a flare-up you’re on the edge,
you can be a bit worried about going out if you’ve got to think about going to the loo and things
like that.
KLM0010.22
Colitis can make you a prisoner that you don’t venture far away from a toilet . . . have to memorise
where all the toilets are and things like that. It makes you a prisoner to the disease.
DEF0016.60&67
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At 12 months the disease had caused no further problems for four infliximab and two ciclosporin
participants; one had been so well that at times she felt as though she did not have UC. One ciclosporin
and two infliximab participants had experienced flare-ups; one of the latter associated the flare-up with
pregnancy. All were on medication and continued to be followed up and were clear that if symptoms
developed they would quickly make contact with their IBD nurse or GP for advice because they ‘would
want to catch it earlier’ (BCD0012.214). They understood that a prompt change in medication could
prevent them becoming as ill as they had been before.
This section has highlighted some of the practicalities of living with UC, but, as described, when the
symptoms are not adequately controlled they can have a massive impact on the life of someone with UC.
Impact of symptoms on life is described in more detail below.
Impact of symptoms on life
The impact of symptoms like diarrhoea and disturbed nights resulted in people’s health deteriorating,
often within only a few weeks, reducing them from leading an active life – socialising, going to work and
exercising – to being housebound. They often suffered from a lack of energy, weight loss and exhaustion,
the latter being an issue that many emphasised and referred to several times during their interview:
Basically tiredness was one of the things that was really difficult.
NOP0004.91
Participants spoke frequently about how an important part of their life was being able to go out and
socialise with friends and family. However, for many participants life had to be put on hold and they spoke
about this as being hard to cope with and a significant change:
Flare-up – it was dictating to me what I was able to do, not me dictating it.
RST0021.25
The condition made attending sporting events, such as football and cricket, particularly difficult because
of the travel involved and the busy toilets during break times. One participant explained that before his
diagnosis he had followed his football team across the country but had been unable to do so as he could
not risk needing the toilet urgently while travelling on coaches for hours:
I used to do a lot of football and travel to football all over the country, that’s what I love doing, but
the last year I haven’t been able to do that . . . have to sit on a bus . . . don’t feel comfortable doing
that . . . used to travel every weekend but haven’t done it for the last, oh since I got diagnosed. I don’t
feel comfortable doing it.
NOP0004.27
A cricket goer explained that he could not eat with everyone else but had to wait until after the
lunch break:
Go and watch the cricket . . . take some lunch but I was conscious that you know getting close to
lunch, . . . I’m thinking to myself well I can’t have anything to eat at lunch because the moment I have
something to eat within minutes I have got to go to the loo and I know there are 20,000 people
coming out of the ground going into the toilet and I can’t queue for the toilet.
RST0021.204
Those in employment explained that they had tried to continue working for as long as possible, coping
with frequent visits to the toilet, until they reached a point at which it was simply physically impossible
for them to carry on. This could depend on the type of employment people were in; for instance, people
working as teachers or nurses could not simply drop what they were doing to dash to the toilet: ‘you can’t
just walk off at any given moment because you are responsible for patients and you may well be the only
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nurse in a certain area so it was very difficult’ (MNO0034.85). One participant commented on how difficult
it was at work when speaking to somebody and suddenly knowing that there was a need to urgently go
to the toilet, meaning that they were no longer able to pay attention. An issue for some younger UC
participants was the potential impact on careers which could be affected by ongoing flare-ups requiring
time off work. The condition can cause huge changes in lifestyle, impacting on not only the participant
but close others as well:
I couldn’t be around my kid when I was feeling pretty low.
QRS0028.101
There appears to be a trajectory for participants of any age in that they go from being someone with an
active life, to the disease having an increasingly detrimental physical impact, when they are tied to home
and too unwell to do anything more than sit or lie down, which often leads to mental and emotional
stress as life narrows:
I was spending all day in a chair or in bed barely able to eat and my life just consisted of going to the
toilet and sitting still trying to occupy my mind and not go crazy.
GHI0028.119
It is clear that for some participants, UC had taken them entirely by surprise, changing from someone with
good health to someone with a chronic condition that is difficult to control. For many, life had taken a
different and unexpected path:
Holidays were a nightmare because like just going to an airport or flying became a major chore.
QRS0028.100
For those wishing to travel there was the added difficulty of obtaining travel insurance following an
admission with their UC.
During the second-round interviews, with their symptoms under control, the QoL for participants had
improved; the football fan was pleased to report that he had returned to watching games and following
surgery and the cricket goer was able to plan his days more easily. Several people commented on the fact
that they had been on holiday and could plan events with more confidence.
Participants reflected on the last 12 months of their lives according to changes at work following extreme
illness and being diagnosed with a chronic disease. One participant had ‘grabbed’ the opportunity to take
a job which involved travelling all over the country, saying: ‘I can’t not do it, you just never know what
could happen but I’m not going to say no, just in case’ (NOP0004.36). The period off work made a
participant realise that she could get by and as a result she moved house and starting working for herself.
Another explained that the experience had made her and her husband rethink and plan their lives a bit
more; they got paperwork organised, went on holiday and had long weekends away (TUV0001.414). A
surgery participant who had moved from manual to office work reversed the situation as he could wear
more comfortable clothes which made managing his stoma easier.
It is clear that the symptoms of UC and being diagnosed with a chronic illness can have a massive impact
on participants’ lives but it is the nature of the symptoms of UC that can make it difficult for sufferers to
talk about their disease with others, as shown in the next section.
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Embarrassment about sharing knowledge with others
In contrast to some other chronic conditions, many UC sufferers consider it an embarrassing illness
because of its association with ‘bottoms’, ‘bleeding from your bottom’, diarrhoea and going to the toilet.
Because of the embarrassing connotations, participants explained how they select who they share
knowledge with, often discussing it only with close family members and friends:
. . . three men wouldn’t stand around a bar and one say to the other two ‘I’ve been for a camera
today’, you know, it’s not the sort of thing . . . I sort of relate it a bit to probably to ladies, to breast
cancer a few years ago and I think men with the prostate cancer, ‘cos that’s a bit of a taboo subject
but it is starting to come out there now.
RST0021.127
It was often in the context of work that participants started to describe the embarrassment that they felt
about their condition, as it is an illness that is difficult to talk about with colleagues: ‘it’s hardly a
glamorous disease that you wish to chit chat about’ (MNO0034.88). However, participants found that
when they did explain their disease to their employers and colleagues, those people were understanding
and supportive; several participants emphasised just how supportive they found their place of work to be:
Work have been absolutely brilliant, I couldn’t ask for any more to be perfectly honest with you.
NOP0004.150
Some participants felt that their UC made going out as part of a larger group more difficult. On occasion
the group needed to be made aware that a very urgent toilet stop was required but this was difficult to
communicate to a group and caused embarrassment for the person needing the toilet.
We go on motorcycle trips and they’ll just think, oh we’ll go from A to B and that will take us
two and a half hours without having to go to the loo. Me and my partner we can just stop but it’s
difficult if you’re in a group of, might be 10 people on bikes, it’s difficult to . . . it’s that kind of . . .
that’s where you think we won’t go on this trip or something, we’ll just go by ourselves.
KLM0010.97
It is a disease that for the most part does not manifest itself openly and, thus, others are unaware of UC
patients’ suffering; several participants raised the issue about the lack of a broader awareness of UC as
a chronic condition. They felt that it had a low media profile in comparison with some other chronic
conditions (such as asthma), and participants wished that more famous people with the condition might
come forward to champion their disease and raise awareness. Those coping with the outcomes of bowel
surgery for UC raised the same issues. In general, the low profile was attributed to the embarrassing
nature of the disease, which was seen to set it apart from other chronic conditions.
At 12 months similar issues arose, but a participant reflected that ‘you need to be able to speak to people
and share what’s happened to you’ (TUV0001.584), whereas two surgery participants were keen to share
their experiences with other sufferers to help them to understand the impact of surgery and coping with
a stoma.
Impact of ulcerative colitis on family and friends
The life-changing nature of UC clearly impacts on families and friends, particularly during periods of a
flare-up. Those with young children described how their UC left them unable to look after and play with
their children, increasing the need for others to help. Others acknowledged that it affected aspects of their
partner’s social life and, for some, the limitations on travel impacted on family travel plans:
I’m retired and one of the things I would like to do is to go around the world with my wife and we
can afford to do it now but I simply, at the moment haven’t really got the energy for it.
ABC0010.86
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However, the predominant observation made by participants was about the support provided by their
families and friends. The different types of support included hospital visits, the understanding shown by
relatives to participants’ needs and their support in practical aspects of a participant’s life, such as helping
to plan a journey. This support also helped participants emotionally as the condition became more difficult
to cope with when a flare-up occurred:
My mum . . . ended up working a bit less and my dad . . . having to go into hospital . . . at the end of
the day he was working. And my older brother . . . he was having to visit me, so he had to forego a
few things he would usually do. . . so mainly in hospital that it had the biggest impact on my family.
GHI0028.69
At 12 months, the impact of UC on family and friends was spoken about in particular by those who had
had surgery, either before the first interview or since (see Surgery). However, one participant felt that
friends and family got bored with the disease: ‘so talking to an absolute, vague stranger, there’s
something quite soothing about it . . . just go through it from start to finish’ (MNO0034.729).
One participant explained that he had visited his workplace to discuss returning to work and was aware
that word had got out that he had a stoma. He said that some individuals did not look at his face but
were ‘constantly staring to see if they could see this thing’ (DEF0016.860). He felt that this was rude and
said that his wife was so annoyed that she had to walk away.
Acquiring knowledge about ulcerative colitis
Participants appeared to be well informed about their condition. For those diagnosed many years ago their
experiences and interactions with doctors and nurses had informed them about the condition and its
treatment, while many UC sufferers have used the internet to find out more information. One participant,
diagnosed 30 years ago, regretted not using the internet to look for developments in treatment over the
years, as he felt that he may have missed out on a treatment that might have helped, instead of putting
up with his symptoms all those years.
Those newly diagnosed with UC can be provided with information about ‘Crohn’s and Colitis UK’ a
national organisation dedicated to ‘Inform, Support and Research’ or be put in touch with an IBD nurse
specialist at their local hospital. Crohn’s and Colitis UK (previously National Association for Crohn’s and
Colitis) provides a lot of information about UC, living with and managing the condition and about its
treatment. It provides information on a website, or paper information can be provided, and has local
support groups in many parts of the country.
Some spoke about their IBD nurse, explaining that they had direct access and could contact the nurse at
any time for information and help when their symptoms increased:
I do come up with questions from time to time but I must admit the IBD nurse is brilliant, you just pick
the phone up to him and he is more than happy to speak to you about anything so definitely the
support I have received is excellent.
NOP0004.423
However, IBD nurses are not necessarily available in all hospitals and a couple of participants expressed
strong opinions about the need for their presence and the very valuable role they play in helping to
manage UC.
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In spite of the information that was available, participants had a number of unanswered questions about
the cause of their disease and mentioned the need for more research in this area in order to ensure that
other family members could be supported if they did get UC. Participants were also unsure about what
triggered a flare-up and wanted more information on this particular aspect of their disease, including
information about the links between UC, stress and diet:
Colitis is very difficult, it’s very difficult to manage and certain foods can set it off, etc. and stress is
another thing so trying to identify the foods that set it off and stay away from stress is key.
OPQ0005.370
With regard to diet it was acknowledged that there may be some misinformation on the internet, and
several people commented on contradictory advice about whether or not there is a link between diet
and UC.
Ultimately, participants wanted to see a cure for the condition; although they recognised that it might be
too late for them, they wished to prevent others from having to suffer with the condition:
I would love somebody to come up with a cure for it even though the stable door has . . . been bolted
for me.
DEF0016.767
Participants appeared to be less questioning about UC at 12 months, as only a few comments arose about
a cure for UC and the relationship between stress, diet and disease. The fact that they knew they had easy
access to care appeared to be more important for the stage they were in and the course of the disease.
Treatment for ulcerative colitis
The cacophony of drugs
If diagnosed with UC, participants were started on medication; they spoke about this ‘controlling’ their
symptoms, some for many years without any problems, and how, when experiencing a flare-up, an
adjustment to existing medication or a change in therapeutic pathway brought their symptoms back under
control. However, some participants had experienced greater difficulties in keeping their UC under control
and spoke about various medications – azathioprine, mesalazine (Pentasa®, Ferring Pharmaceuticals Ltd;
Asacol®, Warner Chilcott Ltd), 6-mercaptopurine, methotrexate, steroids and foam enemas – effectively a
cacophony of drugs, that they had tried, but against a background of the unpredictability of not knowing
what might work and for how long and when a different treatment might be required:
Other things like Salazopyrin [Pfizer Ltd], you’re having 2, 4 times a day, imagine that during the day if
you’re based at the office or something, it’s quite hard work.
QRS0028.161
All of the participants had been admitted to hospital approximately 3 months earlier because their UC
symptoms were uncontrolled and they needed treatment with intravenous steroids. Those who knew that
they had UC before admission appeared to have had a good understanding of their situation and knew
that if they failed to respond to intravenous steroids their treatment options were narrowing to a more
powerful drug or surgery; they recognised this as a last chance before surgery:
I’m in the last chance saloon I suspect.
ABC0010.281
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However, although many were very familiar with the drugs, some were less familiar with infliximab and
ciclosporin; they knew of them but perhaps not in as much detail. One participant said that had she been
at home when she knew one of these drugs was going to be used, she would have looked it up on the
internet, as she would have liked a bit more information, particularly about the long-term effects.
Those who were newly diagnosed had to assimilate the information about their condition and treatment
options quickly, at a time when they were extremely ill. It was clear from all participants’ comments that
they were so ill at the time that decisions about their treatment almost passed them by:
I was having so many injections and blood tests at the time in hospital that I didn’t even notice it.
QRS0028.134
You could have put a blank cheque in front of me and I would have signed it.
STU008.216
Once discharged, participants had to continue taking medication and more often than not they were on
more than one drug. For those who had previously been well, there was a period of adjustment, not only
coming to terms with their diagnosis but also getting used to taking medication: ‘just remembering to
always have them with me and going on holiday . . . suddenly settle into a routine . . . I mean now it’s so
much part of my life but that just seems normal but to begin with seemed quite alien’ (BCD0012.375).
On the whole, people were fairly philosophical about having to take medication and were prepared to
take anything that would work: ‘whatever is going to help me to get better or at least help me fight
towards getting better’ (OPQ0005.414).
There were mixed experiences for those who had remained on medical therapy over the 12-month period,
and these participants spoke about how it had been trial and error to find treatments they could tolerate
that would keep their disease under control. Some participants explained that taking medication had
become part of their normal life, whereas for one it was a ‘challenge fitting taking medication into
routine’ (MNO0034.452).
The unpredictability of treatment was still clear, with participants understanding that some treatments,
such as 6-mercaptopurine, could be taken for a limited time only. The uncertainty as to what would
happen after that was highlighted by the view that medical treatments were not always successful.
Shared treatment decisions
As mentioned earlier, participants were well informed about their UC; they knew the signs and symptoms
that indicated a flare-up and the various treatments available and, armed with this knowledge, they took
part in shared decision-making with clinicians about their treatment. This was particularly evident when
participants spoke about surgery as a treatment option:
Been hospitalised more in last 5 years than previous 30 and spoke long and hard to the surgeon and
medical doctors and we all agreed that my QoL would be improved if the bowel was gone basically.
DEF0016.362
Discussed surgery quite strongly really but again the consultant is quite happy to try and get it treated
first, you know, try and get it under control with some medication.
RST0021.677
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However, participants clearly understood that if they failed to respond to the various treatments, there may
be a time when their ‘body’ made the treatment decision for them:
If you are so bad and it gets to the point where it could put your life at risk then obviously you have to
have it done.
JKL0033.521
Several participants commented on their reasons for taking part in the trial. They felt that it was a positive
step as they received more attention and had ready access to the research nurse if they had any queries.
One participant was relieved to enter the trial because it removed the responsibility of making a decision
between ciclosporin and infliximab: ‘there could never be any comeback on what decision I made’.
(MNO0034). However, several participants said that they just wanted to help others and to prevent others
suffering in the same way.
The participants all continued to attend hospital for follow-up at 12 months and commented on positive
relationships with their doctors and IBD nurses. Some also highlighted how helpful their GPs had been.
However, one participant had become frustrated by seeing different doctors at each appointment and
having to explain his history and treatment on each occasion.
Those on medical treatment understood that they had to take responsibility and seek out help when they
experienced symptoms that could indicate a flare-up of their UC and, over the course of 12 months,
became familiar with the medical therapies and side effects. Although it was apparent that they discussed
their treatment with their doctors and nurses, there was also a sense that shared treatment decisions were
limited, as decisions had to be based on whether a treatment worked or caused side effects.
Surgery
The majority of participants spoke about surgery as being absolutely the last treatment they wanted to
have. It was certainly a shock to the newly diagnosed that they could be facing surgery. Terms such as
‘saving’ or ‘losing’ colons were used, and participants did not want to have to wear a bag:
It was worthwhile because I walked out of there without a bag [laughs] . . . that’s what meant the
most to me. It’s just the fear of the unknown, the effect it can have on your life I suppose,
life changes.
TUV0001.242
So realistically if it wasn’t, didn’t try this, it was going to be down the route of surgery which I didn’t
want to go down that route at this moment . . . it’s quite a high probability at some point . . . but I’m
28 and I’d rather try and leave it for as long as I possibly could.
NOP0004.266
However, most were philosophical about the possibility of future surgery and realised that they would have
very little choice if it became necessary:
If it presents me, if Dr X said to me, I won’t have choice, my body will make it for me.
TUV0001.262
If it’s something I have to have done, I can’t say no I don’t want it, I have to anyway and to be fair
they’ve explained the operation and it’s not so bad, come on, they’re trying to fix me you know, there
will be no need for any pills, no need for running to the hospital and all the NHS spending money on
me if they can just cut it out. I know I would have to have the bag for a few months but then they
stitch me back so it’s not permanent, it’s temporary again. That would annoy me if I were to end up
with a bag really, just the idea . . . if I know it is for 3 months, fine.
PQR0053.533
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. . . rather have it now when I’ve still got some energy left than in my 70s when I’m too old to
do anything.
ABC0010.354
Those who had undergone surgery actually appeared to reach a point during their hospital admission at
which they became resigned to the fact that it was going to happen; they knew that the infliximab or
ciclosporin was not working and that an operation was inevitable, and there was an acceptance of what
was to come:
I felt really fed up so I was actually quite happy, to be honest to have the operation by the time it
came round. . . it wasn’t really a difficult decision to make in the end.
GHI0028.207
I’ve had it for 30 years, mentally I was prepared for the surgery so to a degree maybe we could have
carried on with the drug but I had had enough by then. So it was frustrating really, the drug had
improved it but it hadn’t improved enough, they were prepared to maybe stick it out more but I
mentally wasn’t prepared for much more.
QRS0028.214
Those who had undergone surgery acknowledged that had the drug treatment worked they would have
been happy to continue with that, as they would not have known any different, but after the surgery they
were actually relieved that it had been done, as it meant an end to their UC:
Once I’d had the operation there was a sort of a bit of a peace in my body, it was like there was a
fight going on forever, even when I think it’s under control, there’s still this sort of underlying . . .
that’s what I think of it as a fight, because it’s not settled . . . my body shouting at me and that’s not
there anymore.
KLM0010.262
I wish [patient emphasis] I’d had this operation the day I was diagnosed to tell you the truth. It was
the moment I woke up after the operation I thought, cor this is fantastic, . . . the fog had cleared and
when you are living with it you just deal with it, you just get on with life, you don’t realise how much
it did effect me over those 10 years. So yeah, quite honestly, if I could have had the operation then I
would have had it done and now I would have been 10 years down the line . . . it’s like hindsight
isn’t it.
STU008.188
However, the relief was not felt by all. One man who had fought against surgery when diagnosed 55 years
before said ‘I’m so glad I did because I now know the pitfalls of surgery now I’ve had it and I wouldn’t
have liked to have thought that I had that as a young man’ (DEF0016.99). He had felt suicidal after his
surgery, saying that he ‘felt like jumping off a roof’ but ‘my wife and family have been instrumental in
making me shake myself and realise that basically it’s either that or end up in a graveyard and when you
look at it in that respect it’s not so bad’ (DEF0016.580).
Although most felt that surgery had been a good thing, it did create issues for some in relation to the
practicalities of managing the stoma and the bag, restrictions with regard to clothing and concerns about
how others would react to seeing the bag, which for some led to a change in attitude to being able to
go swimming:
Go down to the beach . . . I’ve got to keep my T-shirt on which is something I wouldn’t look forward
to because I like to jump in the sea . . . I don’t want people staring all the time.
STU008.155
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it’s cumbersome and it’s a pain but what price is being healthy really, . . . I’m happy to have it but in a
way I’m not happy to have it, because of the inconvenience, but no I’m just happy I’m well.
STU008.256
Participants conveyed that being older made it a little easier to cope mentally with the outcomes of surgery
and suggested that they would have been less tolerant when they were younger:
Old enough now that it’s a bit of a laugh and joke. If I was younger I’m sure I wouldn’t have taken to
it. It is quite intrusive but I think when you’re a bit older it is a lot easier to deal with, mentally really.
QRS0028.307
In the same way that participants were selective about whom they told about the condition, they were
selective about who knew about their surgery, in part because they felt that people would not understand
and in part ‘because some people can be cruel’ (DEF0016.613). Participants tended to tell family and close
friends, and would inform colleagues where necessary:
. . . with friends and family I haven’t found it difficult talking about the illness and having the stoma
and what needs to happen with it. Not had too much of an impact on my relationship with my
girlfriend . . . she’s been very understanding about it.
GHI0028.268 & 281
In spite of the support and understanding, some participants were clearly very conscious of the physical
changes to their body and referred to how this impacted on personal relationships: ‘my love life is not
what it was’ (DEF0016.496). They empathised with their partners having to see the bag but would then
comment on how understanding and supportive their partners were.
As with UC, there was a feeling that there was a low media profile about living with a stoma because of
the stigma associated with it: ‘there is nobody famous with a colostomy that will admit to having
one’ (DEF0016.779).
Several participants spoke about the possibility of having reversal surgery and, again, age was shown to
influence attitudes, with younger participants keen to get on with the process of getting life back to
normal and older participants appearing more likely to accept life with the stoma:
If I was, don’t know, 20 years younger, I’d probably go for reversal and take my chance because I
wouldn’t want to live with the bag but at 50 I’m hardly likely to head down the beach and stuff
like that.
QRS0028.289
The surgery participants were aware that the outcome of reversal surgery was more successful if it was
completed sooner rather than later and were well informed of the risks involved in further surgery. They
were also aware that they would still need to use the toilet more frequently than most people but, having
suffered from UC, that was not a concern:
They say I’m always going to be a little bit more regular than a normal human being [laughs], if you
see what I mean, but it’s something you live with anyway with colitis, don’t you, because you’re
always going to the loo a lot more times than people without it so that’s something I can live with
because I’ve already got used to that bit.
STU008.146
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One participant felt that the consultant treating him was quite keen that he should have surgery, but as a
self-employed person he expressed concern about needing extra time off work for the initial surgery
and reversal operations, saying that ‘financially I can’t afford to have this time off work at the
moment’ (RST0021.652).
Reflections on surgery after 12 months
The views and experiences of the participants who had had a colectomy were markedly different. Just one
participant, a young man diagnosed with UC followed by infliximab and then surgery within the same
admission, had gone on to have two further operations to achieve reversal. He said it had been a ‘long
haul’ and that surgery was ‘not a magic wand that could make me as healthy and normal as I was before’
(GHI0028.189), but that his QoL improved by not having a stoma. He had no regrets and was happy not
to have to medically manage UC.
Two men had found that intimate relationships had suffered, one from the outset because he ‘does not
like to look at the bag’, a ‘constant reminder’ (QRS0028.452), and the other when he had experienced a
significant deterioration in his sex life:
My personal and sex life has absolutely plummeted because . . . well, it’s not a very nice thing to have
flapping about and you wear shirts and things like that but it’s not the same, my wife is very frustrated
about it and we try to deal with it but . . .
STU0008.250
In contrast, a young woman reported that her relationship with her partner had not been affected by the
stoma and was so pleased with the outcome of laparoscopic colectomy and the control having a stoma
gave her that she did not think she would have the procedure reversed. An older man had a similar view;
he was not convinced by what he had heard of the success of reversal surgery but did state that had he
been younger, with an active sex life, ‘reconnection’ would have been important.
The 12-month interviews highlighted that although some considered surgery as a cure, two participants
spoke about still having colitis, as the rectal stump was affected by UC which meant they continued on
medical treatment as well as managing their stoma. Although one was coping with this, the other said
that he ‘still felt like a prisoner’ as he was waiting for surgery to remove the remaining bowel. In addition,
the practicalities of emptying the bags were mentioned, which required an ongoing awareness of the
location of public toilets.
A couple of participants commented on the conflict of provision of stoma bags and equipment by stoma
nurses funded by manufacturers. This resulted in being offered a limited choice when there may be more
suitable styles; these other styles were available to patients, but the onus was on the patient to know what
to ask for.
The two participants who had surgery since the first interview felt that there could be better information
provision before and after surgery, particularly with regard to the stoma, with one commenting that they
would have liked to have spoken to someone who actually had a stoma.
Concerns, hopes and aspirations for the future
The most significant concern for participants who had not had surgery was the unpredictable nature of the
course of UC and, as a consequence, the uncertainty surrounding their future treatment. For those
concerned with what the future would bring, surgery was often at the back of their mind:
If you can ward off the surgery for a decade it’s worth, I think it’s worth doing. It may come to it, I
may have to have it one day and it is always at the back of my mind but I would rather have it later
than sooner.
JKL0033.533
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Some of those who were only recently diagnosed were finding it hard to adjust to the fact that they had a
chronic disease that would require ongoing care. They reflected on others they knew learning to cope with
long-term chronic conditions such as asthma, but although they had responded to treatment and were
reasonably physically fit, they were mentally vulnerable:
My symptoms have been non-existent since the infliximab pretty much but all of my emotions and
everything else is still kind of, almost seems way out of proportion to the bowel symptoms.
MNO0034.286
A lot of the stuff that I like to do that I couldn’t do and even now I probably could do it but I’m wary
about doing anything. So it’s still in the back of my mind all the time.
NOP0004.119
Participants were interviewed only a few months after they had been hospitalised and many were going
through a transition period with their medication. They spoke about the drugs they were on and what was
planned, but did so in the context of uncertainty about what would work and for how long: ‘where we
need to go, where do we go from here, stay on the ciclosporin or what really’ (RST0021.474). Some were
aware about the funding issues with infliximab and were concerned about whether or not they would be
allowed to continue on it in spite of the fact that it was working for them.
Many participants spoke about what had become their ‘normal for me’ health and were happy to accept
an increased need to use the toilet only three or four times per day in comparison with 20–30 times per
day, understanding that this could be achieved only by using medication. However, for those whose
symptoms had completely resolved, taking medication was a constant reminder: ‘I could almost sort of
forget that I have been ill . . . it’s a shame that I always have to take them because that’s a constant
reminder actually that you know, I’ve been ill and it might come back’ (BCD0012.520&600).
Some younger participants expressed concerns about the impact of the various drugs on their future
plans of having a family and were worried about the effects on their fertility: ‘only got married last year
and we haven’t had a family yet and with most of these drugs there are issues with getting
pregnant’ (MNO0034.513).
Some of those who had surgery said that they hoped to have the reversal procedures and looked forward
to a time when it was all over and they could get their life back on track. Others, who tended to be the
older participants, were less interested in having a reversal; they accepted the stage they had reached,
were relieved that their UC had been dealt with and were prepared to live with a stoma and with the
practicalities and restrictions it presented.
The future 12 months later
Life had changed for the participants by the time of the second interview. Seven of the eight who had not
required surgery appeared to have come to terms with having a chronic illness that required ongoing
treatment and living with the uncertainties of that treatment, but seemed more confident about being
able to control the disease. They appeared to be reassured by the ready access to advice from IBD nurses;
in particular, those who had a flare-up commented on the speed of the response when it was needed.
The eighth stated that that she had ‘not adjusted to it from the point of view of . . . just feeling angry or
sorry for yourself . . . I feel I should feel happier’ (MNO0034.240). However, this participant was coping
with a flare-up that she associated with being pregnant, the pregnancy being classed as high risk because
of her disease and the fact that she had not been allowed to stay on infliximab. She said that it ‘. . . is not
how I ever pictured being pregnant’ (MNO0034.220).
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At the time of the second interviews it was some of the surgery participants who were unsure of what the
future held as they were thinking about whether or not to have reversal surgery and the ongoing impact
of the stoma on their personal relationships, and two expressed concerns about managing the stoma as
they got older and the thought of someone else having to deal with it for them.
Conclusion
The findings from these interviews confirm the liking that patients have for infliximab, because of the
treatment regime described, fewer side effects and ease of handling the drug. Ciclosporin was less
favourably described, with more side effects, greater problems of drug handing and a more onerous
treatment regime.
The physical symptoms that UC sufferers described, particularly when experiencing a flare-up, are dramatic
and debilitating clearly indicated by these data in terms of the effects of symptoms on patients’ lives,
leading to social isolation as their health deteriorates. Efforts should be made to ensure prompt diagnosis,
to encourage known UC patients to report changes in their symptoms as soon as possible and to offer
appropriate treatment that patients favour, which should be administered as quickly as possible.
A significant issue that emerged was the need for better support and greater information to enable
patients to manage the impact of unpredictable symptoms and ongoing treatment regimes.
More research needs to be conducted to explore the views of UC patients post surgery, and to provide
more information that could support the decision-making process of those facing surgery. As the views of
participants following surgery were generally positive, there should be further research into the surgical
treatment of UC as a real alternative to medical treatment.
An awareness raising campaign about UC (and Crohn’s disease) including details about surgery would
encourage people to seek help earlier and help to destigmatise UC, thereby reducing the embarrassment
felt by sufferers and those living with the outcomes of surgery.
Professional interviews
Main issues arising
The main issues that emerge from the findings above are:
l Professional interviews indicate a clear preference for infliximab among nurses.
l Most doctors are more equivocal and prepared to wait for evidence of effectiveness and safety before
making up their minds.
l Some doctors are strongly in favour of infliximab, wishing to see it as the drug of choice in view of its
ability to deal with the many complex symptoms this disease group displays; its ease of administration;
fewer adverse side effects; greater familiarity; convenience; greater perceived effectiveness; and ease
of handling.
l Ciclosporin is more cumbersome to administer and requires additional monitoring, which puts pressure
on an already overstretched workforce.
l Professionals view nurse colleagues as more familiar with the administration of infliximab and note the
fewer demands it puts on nurses’ time.
l Ciclosporin is more restrictive on patients’ movements, leaving them frustrated and in need of more
intensive support from nurses who must be present to manage complications.
l Professionals question current NICE guidelines and government regulations around drug use and the
restrictions that this places on their professional autonomy.
l Professionals want to gain a clearer understanding of how the drugs affect patients’ lives.
l Professionals complement the trial for shining a light on this area of study which they see as seriously
under-researched.
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Introduction
Data saturation was achieved following the completion of 23 interviews. Fifteen consultants and eight
nurses formed the interview cohort. The consultant stratification was as follows: eight from high trial and
cohort recruiting sites; four from high cohort/no or low trial sites; and three from poor cohort and trial
sites. The nurses were all from high trial recruiting sites (the same sites as the eight consultants) and nurses
from nil or low trial sites, or poor overall trial and cohort sites were not included (see Chapter 2). The
analysis framework (see Appendix 19), led to a rich data set comprising (a) descriptions of the practicalities
of administering and monitoring the two drugs and (b) contextual factors influencing professionals’ views
of the effects of infliximab and ciclosporin on the alleviation of symptoms or QoL. In addition, analysis led
to (c) greater understanding of professional personal preference for one or other drug or other therapies;
(d) clarification of professional experience and entry into the trial; and (e) perspectives on current
government policy regarding the regulation of drugs and of NICE guidelines. Underpinning views and
preferences from both nurses and consultants was an ongoing concern for patient welfare, informed
patient choice and joint decision-making.
The main themes and categories derived from interviews are displayed in Box 1 and described in detail
below alongside verbatim quotations. All quotations are coded to indicate whether a consultant or nurse
was speaking and the transcription line numbers.
Drug administration and management
Consultants and nurses, when asked about the administration of infliximab and ciclosporin, were keen to
point out that consideration must not only be given to the administration process but also to the lead-up
procedure (‘work up to treatment’, consultant, HP7.45). Patient work-up was seen as a vitally important
step in administering the drugs. However, work-up was said to be something that was neither given
enough consideration within the drug guidelines, nor discussed in terms of positive and negative
consequences and its effect on the rest of the administration process, such as its effect on drug handling.
Interviewees described the work-up necessary for the provision of infliximab and ciclosporin in similar
terms; however, following initial work-up administration, infliximab was much easier to handle than the
administration activities necessary for the provision of ciclosporin. First, there was less to be concerned
about during that period of time, and, second, the process had less impact on workload, especially for
nurses, while both drugs demanded due care and attention. Attention to detail was described according to
the careful mixing of drugs and other preparations necessary for treatment, prescreening of patients and
patient preparedness for the intravenous infusions. In this respect ciclosporin was consistently described as
the more complicated of the two, with a longer administration time (continuous as opposed to 2 hours for
infliximab), and with the need for frequent changes of intravenous bags (infliximab is a one-off infusion).
This had a knock-on effect on health-care professionals’ work schedules:
It [ciclosporin] goes on over a longer period of time obviously, so the need [for nurses] to continually
make up bags and things over a longer period of time rather than just the one off infusion.
Consultant, HP13.25
It’s [ciclosporin] time consuming for the nurses and slightly messy. You know it’s complicated and it’s
work for the nursing staff.
Consultant, HP15.19
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BOX 1 Thematic framework: main themes and categories
Drug administration and management
Lead-up to treatment.
Drug administration and effectiveness.
Adverse effects.
Drug management.
Longer-term effects and drug maintenance.
Personal preference and involvement in the trial
Personal preference of consultants and nurses.
Views on other health-care professionals’ preferences.
Being part of a trial.
Surgery.
Equipoise.
Negotiated care and shared decision-making.
Costs
Costs of the two drugs.
Comparative costs.
Evidence and guidelines
Evidence related to NICE guidelines.
The regulation of drugs and drug policy.
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Nurses’ views accorded with consultant opinion on this matter. In addition, nurses were keen to emphasise
the complexities resulting from contextual and geographical factors that had to be contended within a
busy hospital setting, such as managing patients on different wards requiring an infusion and, as a
consequence, the greater number of nurses with advanced prescribing capabilities necessary on the wards
at any one time:
Having to make it up [ciclosporin] every 6 hours is time consuming, changing lines, always having two
nurses to check it because the way the GI [gastrointestinal] unit is split is there’s a corridor up between
the two wards so obviously bed cover etc. but only to have one trained [nurse] each side is a bit
difficult . . . geography of the wards . . . we’ve no one else to check the drugs.
Nurse, HPN19.21/28/29
You have to be mindful that the continuous infusion [ciclosporin] has to be prescribed to cover the
weekend until Monday.
Nurse, HPN18.27
The practicalities of a lengthier ciclosporin infusion had implications for patients’ well-being too, with
health professionals having to spend more extensive periods of time in hospital dealing with patients who
were ‘frustrated’ (nurse, HPN21.98) with highly restricted movement:
[Ciclosporin] fairly cumbersome for both the staff and equally importantly for patients because once
you are tied to the drip and associated drip stand, it sort of restricts patients moving around.
Consultant, HP12.10
Patients don’t particularly like being hooked up to it for such a long period . . . it’s
[ciclosporin] restrictive.
Nurse, HPN25b.52/57
Views on the ease of administering individual drugs were clearly influenced by an individual’s familiarity
with the drug in question. Thus, those with more experience of ciclosporin tended to be more positive
about that drug, and there were suggestions that nurses should be trained in both drugs as they faced a
steep ‘learning curve’ (consultant, HP13.123) particularly in relation to ciclosporin. Nevertheless, support
for the administration of infliximab was stronger and it was repeatedly described as the ‘easier’ (consultant
HP5.18 and nurse HPN18.169) and more ‘convenient’ (consultant, HP12.78) drug:
Infliximab has an advantage (over ciclosporin) in that it’s just a 2 hour infusion and then it’s done . . .
there’s no problem with infliximab, I think it’s a good drug to administer, I think it’s an easy drug to
administer . . . I like infliximab because once you’ve done it, you’ve done it for two weeks.
Consultant, HP14.26/30/33
Although both drugs were perceived to be effective, ciclosporin was faster acting and the slower response
time with infliximab presented a challenge in terms of whether to continue with infliximab or look towards
a different treatment. Ciclosporin was more ‘clear-cut’ (consultant, HP11.81) and consultants felt more
confident in their decision-making and timings with regard to this drug. In addition, consultants worried
about the ambiguous information available for ciclosporin response rates, as these did not appear to
match patients’ actual responsiveness, made all the more complex by the need for an extended
administration period:
Tend to use ciclosporin as acting more quickly.
Consultant, HP4.171
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This is the one thing I don’t like about infliximab, because there is no data to give us a clear timescale
or timeline for decision-making.
Consultant, HP11.94
Sometimes it’s a bit challenging that you have given them infliximab if they are going to take sort of a
week to 10 days time would you hold your nerve?
Consultant, HP12.47
In addition to response times, adverse effects were of major importance in treating patients with one or
other drug. Ciclosporin in particular was seen to have a range of associated adverse effects, which
included drug toxicity, renal failure, neurological impairment, seizures, tremors and hypertension.
Consultants were ‘uneasy’ (consultant, HP9.56) about the drug, seeing it as ‘dangerous’ (consultant,
HP6.72). Even those advocating its use tended to be apprehensive about the adverse effects in the longer
term, thus viewing it as more of a bridging therapy. These views were reinforced by a perceived lack of
evidence of ciclosporin’s longer-term benefits.
Don’t want to use it [ciclosporin] in the longer term because of side effects, so switch to azathioprine
as soon as possible.
Consultant, HP6.99
I’m always a little bit more nervous with it [ciclosporin] . . . and I think that’s from the side effects of
renal impairment . . . I think the side effects profile of ciclosporin, although maybe it has not come out
in studies, still concerns us more.
Consultant, HP16.278/281
. . . potentially quite significant side effects that can happen . . . slightly uncomfortable feeling about
it [ciclosporin].
Consultant, HP9.60
It’s [ciclosporin] a bit debatable although I use it, I worry about toxicity and the liver, use it
half-heartedly, when no choice.
Consultant, HP3.29/32/33
An adverse risk profile for ciclosporin, we were told, results in increased patient monitoring and checking
of drug and blood levels, which, in addition to a more resource-intensive process, impacts on nurses’ time.
This is particularly noticeable on a busy ward where there are difficulties with nurse-to-patient ratios, and
nurses had the sense that their profession was struggling with workload increases, impacting on their
ability to give equal time to all patients under their care. They reported occasionally ‘forgetting’ (nurse,
HPN24.255) to monitor ciclosporin patients fully. Infliximab, on the other hand, did not warrant any
additional monitoring and no issues associated with monitoring were raised:
It’s [ciclosporin] time consuming with regards to observation, particularly on a busy ward when you’ve
got one nurse to 10 patients, it can take quite a huge part of your workload.
Nurse, HPN21.16
We have to monitor this patient closely for any side effects . . . it [ciclosporin] takes 3 hours because
you’ve got to do obs [observations] for a couple of hours, but then sometimes we tend to forget
because we get busy with other patients . . . so ideally it should be one to one.
Nurse, HPN24.249/255
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Although infliximab also carried a risk profile that included adverse reactions, causing particular hesitancy
in prescribing it for the older patient, it was favoured for its fewer side effects and longer-term efficacy:
Most of the time it [infliximab] goes without incident.
Nurse, HPN19.83
Have only ever seen minor reactions to the infliximab.
Nurse, HPN21.82
However, consultants pointed out that they felt frustrated about policy restrictions and government
guidelines that prevented them from using infliximab in the way in which they wished to, including the
need to justify its use in the longer term:
We now have to request the funding for patients with UC on long-term infliximab so that’s a bit of a
challenge and it means that decisions are made differently to whether a patient is going into
maintenance infliximab.
Nurse, HPN19.154/156
It’s already an issue because we can’t really treat as maintenance with infliximab so obviously if a
patient responds well we’ve had to get exceptional funding and things like that so there is a case for it
I think.
Nurse, HPN22.103
Personal preference and trial involvement
Consultants clearly recognised the effect that their own experience of using one or other drug had on their
personal preference. Some consultants, as indicated in Drug administration and management, have a
preference for infliximab, based on its ease of preparation; easier administration; lower negative impact
on nurse care provision, staffing and workloads; longer-term benefits; and reduced adverse effects. In
addition, both consultants and nurses pointed to greater patient tolerance and enhanced patient
convenience. Further reasons for stated preferences included familiarity with the drug, drug effectiveness,
greater clinical expertise and knowledge and general sense of ‘unease’ (consultant, HP9.58) with the use
of ciclosporin:
My personal view is that they probably have equal efficacy, I think infliximab has less side effects so if I
was given a free choice, if I was asking it for me or for my loved ones, I would opt for infliximab.
Consultant, HP5.65
When a patient was given infliximab I was rather pleased and when they were given ciclosporin I was
less enthusiastic . . . we wondered about the tolerance for the patient and convenience for the patient.
Consultant, HP15.380/394
Nurses’ views mimicked those of their consultant counterparts, expressing a preference for infliximab
based on its ease of administration, perceived patient benefits and personal experience and familiarity with
the drug. They highlighted the restrictions of patients being hooked up to a ciclosporin infusion for longer
periods of time while suffering from bowel disturbances, and noted patients’ preference for infliximab in
this respect. Ciclosporin was described as ‘high maintenance’ (nurse, HPN25a, 174):
I prefer it when they have infliximab . . . I think it’s easier for the patients because it’s just one infusion
. . . it’s a couple of hours, instead of being hooked up. I mean keep in mind they have profuse
diarrhoea . . . I think it’s easier to administer as a nurse and it’s easier for the patient to receive.
Nurse, HPN18.165/169/173/178/189
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Personally I feel that the infliximab is better but that’s only because of the experiences we’ve had with
the infliximab rather than the ciclosporin . . . seen patients do very well on it, particularly when before
perhaps there wouldn’t have been any other outcome than surgery.
Nurse, HPN21.209/217
This personal preference was not, however, across the whole interview cohort, with two consultants
describing their preference for ciclosporin, based on personal familiarity with the drug, its quicker-acting
properties and its ability to disappear from the system once the drug administration had been halted.
However, even these two interviewees stressed the need to retain a level of vigilance and to ‘be
more wary’:
Rather more relaxed about it [ciclosporin], paradoxically, simply because I know when the IV
[intravenous] infusion is stopped then the drug disappears.
Consultant, HP10.75
I’ve used it [ciclosporin] for a very long time and I’m comfortable with it.
Consultant, HP11.160
In spite of these personal preferences, there remained a genuine sense of uncertainty as to which drug
was the more beneficial at the time of the trial, particularly in relation to people’s views of trial entry, trial
management and patient recruitment. Most health-care professionals commented that effectiveness was
equivocal across the two drugs, genuinely wanting answers from the trial team as to the ‘better’ of the
two. This desire was described as patient-driven, based on which of the two was more effective and well
received by patients.
If the result was that ciclosporin was a lot better we’d use it and if the results were that infliximab was
a lot better we’d use it.
Consultant, HP16.622
The difference (between drugs) is not sufficiently dramatic that I would say it was unethical to put
them into a randomised study.
Consultant, HP15.460
Professionals welcomed the CONSTRUCT trial and congratulated the trial team for moving this body of
work forward so successfully, in spite of what was described as a somewhat ‘ambiguous’ area of research.
They discussed the fact that they had attempted to actively recruit patients into the trial, despite, in the
lower recruiting sites, a lack of success, which was put down to busy workloads and lack of joined-up
working patterns.
Surgery
Health professionals had mixed views about using alternative therapies, such as surgery, for acute UC.
Colectomy, for example, was generally seen as a ‘last resort’ (nurse, HPN21.247) when all other therapies
had failed, with some health-care professionals describing feeling ‘disappointed’ (consultant, HP9.210)
with colectomy being needed. Consultants argued that although surgery was an option, other medical
avenues should be exhausted first before reaching that point:
It’s [colectomy] always a last resort . . . It’s not something I’m comfortable sending them off to
have surgery.
Nurse, HPN21.247
Having a colectomy was also seen as a difficult decision to get patients to agree to, and discussions around
surgery had to be highly individualised and dealt with on a patient-by-patient basis. Most professionals
described colectomy as an option that needed discussion first, to provide both counselling for patients and
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an assessment of patients’ views: ‘once it comes out you cannot put it back’ (consultant, HP13.338).
Patients were seen to be often ‘nervous’ (consultant, HP13.330) of surgery and wanted to put it off for as
long as possible, and for this reason alone it was important to have medical options available to prolong
the time before surgery. However, at times surgery was seen as being put off for ‘too long’ (consultant,
HP20.192), resulting in more difficult decision-making and complications for patients:
I think it comes down to a personal decision, I think it’s very important to have lots of discussions
about the options, medical or surgical . . . it’s very difficult if they’re newly diagnosed and they come in
with their first presentation . . . some people can come with obvious pre-conceived ideas about things
anyway and I think it’s important to explore those feelings.
Nurse, HPN19.254/267
Colectomy was recognised as a ‘lifesaving’ procedure for some patients to which patients responded
positively once surgery was over and symptoms were alleviated:
My personal thoughts are that you know that’s their last resort and I think the majority of patients feel
the same that they would try any form of medical management.
Nurse, HPN25b.137
Policy development and drug regulation
Health-care professionals were clearly aware of the cost of infliximab and saw the implications of the high
cost to be driving policy development and guidelines for practice. Guidelines around the use of the drug
ultimately affected clinical decision-making:
There is an issue of cost of course, we’re pushed all the time to stop it for cost reasons.
Consultant, HP15.120
Although health-care professionals understood the need for rigorous guidelines around the use of the
drugs, many also linked guidelines to an enforced restriction of the use of infliximab, emphatically arguing
that the NICE guidelines were outdated, outmoded and out of step with more recent evidence. This left
them feeling frustrated and constrained in their ability to provide the best and most appropriate care for
their patients. They described the situation as one in which they had ‘their hands tied’ (consultant, HP6,
127.131), indicating that the more recent clinical evidence and their own personal experience showed
infliximab as the drug that needed to be used more widely. As a consequence, they urged that guidelines
became more flexible in order to accommodate patients’ needs more appropriately:
It’s very hard to find anyone who supports the NICE guidance in its present format.
Consultant, HP16.516
I sort of treat it with a bit of contempt.
Consultant, HP9.239
The point was repeatedly reinforced that, although the guidelines were there to be adhered to, there was
a clear sense of rebellion within the profession, with clinicians ‘ignoring’ (consultant, HP9.236) guidelines
when they could find ways around them in order to best meet patient needs. Thus, health-care
professionals welcomed a much-needed change to the NICE guidelines that allowed for the greater
flexibility of drug use, led primarily from an assessment of patient need:
You can usually find a reason why ciclosporin would be contraindicated . . . I don’t think it’s a
particularly sensible NICE guidance based on the lack of evidence that they have to make their decision
and therefore in all honesty because we can, we slightly ignore it.
Consultant, HP9.232/236
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I think it’s unduly restrictive and I think it will eventually change. I think it’s actually quite hard to
adhere to as well. I mean you’ve got a patient who you want to give treatment to, you’re duty bound
to give the best treatment and in some cases that’s going to be infliximab.
Consultant, HP14.208
Patient benefit and negotiated care
Throughout the discussions around the administration of the drugs, treatment of patients, personal
preference, the value of surgery, and adherence to guidelines and regulations, was a professional focus on
patient benefit and need. Nurses and consultants gave many examples of the decisions that were being
made that took into account what was best for the patient, especially when it came to a consideration of
a patient’s personal circumstances:
I like to tailor the treatment to the patient.
Consultant, HP10.144
The drug we choose ultimately depends on the patient.
Consultant, HP5.75
Nurses were more influenced by the patient experience than the consultants were, perhaps as a result of
their extended contact with the patients, and nurses discussed their preference in the context of patient
convenience and QoL:
It worked really well on that patient . . . there’s a quicker response time with infliximab . . . patients
pass comments and they always tell me I feel much better after this one.
Nurse, HPN24.33/118
It’s whatever is best for the patient . . . I think it’s different for each patient and I think that they need
to be given the choice and have all the information because for some patients it can be a very good
treatment [colectomy] and give them back their quality of life.
Nurse, HPN22.139/157
As evident in the last quote, the notion of negotiated care was central to the consultation as far as
consultants were concerned, and ongoing patient care and decision-making was perceived as being shared
across and within multidisciplinary teams. This led to a shared professional responsibility, with the
patient–clinician interaction the ultimate example of this:
Our surgeons are very active in decision-making, and multidisciplinary team meetings twice a week.
Consultant, HP5.121
Care is negotiated with the patient, patient input is important, but predefined pathways are according
to previous discussions.
Consultant, HP4.113
Patient views are as important as anything else, combined with weighing up risks and benefits, we
involve them hugely.
Consultant, HP7.103
The results of this interview study indicate that doctors would make a judgement between the two drugs
largely on effectiveness but that there is a clear preference among nurses for infliximab. Ciclosporin is
more complex and cumbersome to administer, requiring additional monitoring which tends to be
particularly problematic on busy wards with extensive demands on an already overstretched health-care
professional workforce. The longer administrative process restricts patient’s movements and leaves them
feeling frustrated. It is also excessively demanding on the time of specialist nurses and other health-care
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professionals, who need to be present to manage any complications, and there is more intensive patient
monitoring due to the drug’s adverse risk profile. Consequently, professionals question current NICE
guidelines and government regulations around drug use and suggest a sense of rebellion about the
restrictions placed on their autonomy and their practice.
Not only are professionals keen to change regulations surrounding current prescribing and drug
administration, they also want changes to longer-term patient maintenance and monitoring, preferring
infliximab as the longer-term drug of choice in view of its success in dealing with the many complex
symptoms that the disease group displays, as well as it being the more familiar, convenient, effective and
easy to handle of the two.
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105

Chapter 4 Results synthesis MATRICS
Table 46 illustrates the effects that we investigated in the CONSTRUCT trial, in relation to effects onpatients; effects on gastroenterology services and professionals; and effects on the rest of NHS and
society. Some effects related to more than one category. We decided that patient views about the drugs
and side effects and patient views about their illness including family involvement were effects related to
both the patient and the rest of NHS and society. We also decided that professional views about the
drugs, preferences, guidelines and equipoise were an effect related to both gastroenterology services, and
the NHS and the rest of society.
Table 46 illustrates layer 1 and Table 47 illustrates layer 2 of the MATRICS and the specific methods that
we used to investigate the effects.
Table 48 illustrates layer 3 of the MATRICS with the synthesised findings from CONSTRUCT.
TABLE 46 Layer 1 illustrating the effects being investigated and the methods used to do so
Layer 1: effects
Effects on patients
Effects on gastroenterology services
and professionals
Effects on the rest of NHS
and society
1. Quality-adjusted patient
survival [A]
2. Patient disease-specific QoL [B]
3. Patient generic QoL [C, D]
4. Health gain [C]
5. Mortality [E]
6. Colectomies – planned and
emergency [E][H][I]
7. Readmissions [E]
8. AEs [E]
9. Malignancies [E]
10. Serious infections [E]
11. Renal disorders [E]
12. Other new symptoms [E]
13. Disease activity [F]
14. Patient time off work [G]
15. Patient views about the drugs
and side effects [H]
15. Patient views about the drugs and
side effects [H]
16. Patient views about their
illness including family
involvement [H]
16. Patient views about their illness
including family involvement [H]
17. Professional views about the drugs,
preferences, guidelines and
equipoise [I]
17. Professional views about the drugs,
preferences, guidelines and
equipoise [I]
18. NHS costs [J, K]
19. Patient time off work [G]
Note
Each number denotes the effects being investigated and the letters identify the specific method used in the study.
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TABLE 47 Layer 2 illustrating the methods used and the effects that they were investigating
Layer 2: methods
Code Method
A [1] Analysis of AUC using the CUCQ
B [2] Analysis of CUCQ scores (patient questionnaire)
C [3, 4] Analysis of EQ-5D scores (patient questionnaire)
D [3] Analysis of SF-12 scores (patient questionnaire)
E [5, 6, 7, 8, 9, 10, 11, 12] Hospital administrative data patient questionnaires
F [13] Calculation of TrueLove and Witts score,4 full blood count, inflammatory
markers and albumin
G [14, 18] Patient time off work (patient questionnaire)
H [15, 16] Semistructured patient interviews
I [17] Semistructured interviews with health professionals
J [18] NHS costs (patient questionnaire)
K [18] Hospital activity data
Note
Each number denotes the effects being investigated and the letters identify the specific method used in the study.
TABLE 48 Layer 3 illustrating the summarised findings of the study
Layer 3: findings
Code Finding(s)
Effects on patients
1A, 2B, 3C, 3D, 5E, 6E, 7E, 8E, 9E, 10E, 11E,
12E, 13F
There was no significant difference between ciclosporin and infliximab in
QAS; disease-specific and generic QoL; mortality and colectomy rates;
readmissions; AEs; malignancies; serious infections; renal disorders; other
new symptoms
17I Nursing preference for infliximab because of resource-intensive
intravenous administration of ciclosporin. Some doctors perceive fewer
side effects, greater patient benefits and easier management of
long-term care
4C: health gain EQ-5D There was no significant difference in generic health gain
14G: patient time off work There was no significant difference in patients’ time off work
15H: patient views about the drugs and
side effects
Patients participants want to normalise their lives, go back to work,
feel well again and be less drug dependent
From experience, patients who received infliximab reported fewer side
effects and more manageable treatment regime when compared with
patients who received ciclosporin
However, they would favour whichever drug will enable this to happen as
easily and quickly as possible
16H: patient views about their illness
including family involvement
Patients emphasised extensive impact of the disease on their QoL
Patients would welcome early diagnosis and reduction to the effect of
lengthy illness and the cacophony of drugs on their lives and the lives of
their families
Family understanding and support is crucial
RESULTS SYNTHESIS MATRICS
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TABLE 48 Layer 3 illustrating the summarised findings of the study (continued )
Layer 3: findings
Code Finding(s)
Patients have to live with unpredictability of symptoms and treatment
This is, unlike other chronic conditions, considered an embarrassing
disease, making it isolating and awkward
Lack of visibility of symptoms makes it hard to share experiences with
others
Patients and family members seek better and more readily available
information and more IBD specialist nurses to support their specific needs
Patients fear and avoid surgery for stoma, but many who undergo surgery
report on its positive effects on QoL
Patients want to understand what causes the disease and possible links to
diet and stress
Effects on gastroenterology services and professionals
17I: professional views about the drugs,
preference, guidelines and equipoise
Clinician preference for infliximab over ciclosporin as regards treatment
and ongoing management: easier administration, fewer side effects,
greater patient benefits, easier management of long-term care
Views that NICE guidelines need to be brought in line with professional
preference suggesting current practice and regulations around drug use
should be reconsidered. Maintenance and monitoring easier with
infliximab
Lack of equipoise among those interviewed
Benefits of trial for seeking answers to which drug is more efficacious and
supporting regulatory change
Consultants’ views that nurses are less familiar with administering
ciclosporin and increased nurse workload for ciclosporin patients
Effects on the rest of NHS and society
18J, 18K: NHS costs Total health-care costs were higher for infliximab patients due solely to the
higher drug acquisition cost
19G: patient time off work Treatment given had no effect on patients’ time off work
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Chapter 5 Discussion
Summary of findings
The CONSTRUCT trial recruited 270 participants from 52 hospitals in England, Scotland and Wales
between May 2010 and February 2013 and followed them up until March 2014, that is, for between
1 and 3 years following treatment with either infliximab or ciclosporin, allocated at random. Rigorous
analysis of 242 (90%) patients, excluding 28 who provided no analysable data, showed no significant
difference between the two drugs in the primary outcome of QAS, equivalent to the AUC of QoL scores
from the CUCQ (mean difference in AUC/day 0.0297 favouring ciclosporin, 95% CI –0.0088 to 0.0682;
p= 0.129). There was also no significant difference in EQ-5D scores (QALY mean difference 0.021
favouring ciclosporin, 95% CI –0.032 to 0.096; p= 0.350); SF-6D scores (mean difference 0.0051
favouring ciclosporin, 95% CI –0.0250 to 0.0353; p= 0.737); colectomy rates (OR 1.350 favouring
infliximab, 95% CI 0.832 to 2.188; p= 0.223); time to colectomy (hazard ratio 1.234 favouring infliximab,
95% CI 0.862 to 1.768; p= 0.251), the incidence of SARs (14 participants on infliximab vs. 9 on
ciclosporin, OR 0.660 favouring ciclosporin, 95% CI 0.282 to 1.546; p= 0.338) or the incidence of SAEs
(16 participants on infliximab vs. 17 on ciclosporin, OR 0.999 favouring infliximab, 95% CI 0.473 to 2.114;
p= 0.998). Three patients died, all of whom had received infliximab (p= 0.25).
Although length of hospital stay after randomisation ostensibly did not differ between drugs (mean
adjusted difference 1.542 days more for ciclosporin, 95% CI –1.297 to 4.381 days, assuming normal
distribution of residuals in general linear model; p= 0.286), that distribution was so skewed as to
invalidate the assumption of normality; hence, we transformed these stays by taking logarithms and
estimated that the geometrical mean of adjusted stays after ciclosporin was a factor of 1.523 times longer
than that after infliximab (95% CI 1.278 to 1.817; p< 0.001). Although infliximab thus used fewer
hospital resources, its much higher acquisition cost resulted in a much lower total NHS cost for ciclosporin
(mean difference –£5632, 95% CI –£8305 to –£2773; p< 0.001).
Interviews with patients revealed the substantial impact of UC on their QoL and the potential benefits from
these medical treatments and from surgery. Participants treated with infliximab generally spoke more
positively about the treatment than did those treated with ciclosporin. Interviews with nurses showed a
preference for infliximab, largely because of the resource-intensive infusion protocol for ciclosporin and the
resulting restrictions on patients. Although some consultants favoured infliximab, most were indifferent,
perceiving both drugs as effective, with the more predictable speed of benefit with ciclosporin balancing
its perceived higher rate of side effects.
Trial progress and conduct
This trial took nearly 7 years to complete from the first notification of intention to fund in November 2007.
Recruitment started in 2010. Our initial plan was to recruit 480 patients and follow them all for 2 years,
measuring change in disease-specific QoL as our primary outcome. Research governance delays99 and slow
recruitment led us to seek approval from the DMEC, TSC and HTA for a change in the primary outcome in
2010 and a funded trial extension in 2011. The essential changes were:
l Change in the primary outcome from change in disease-specific QoL scores at 2 years to QAS.55 QAS is
derived from the AUC described by scores from disease-specific QoL questionnaires completed by
participants 6-monthly for 1–3 years after randomisation.
l Reduction in target analysable sample size from 360 to 250.
l Follow-up to last for 1–3 years depending on recruitment date.
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The implementation of these changes required additional follow-up visits and patient-completed questionnaires.
Sixty-seven hospitals from England, Scotland and Wales collaborated with us on this study, of which
62 recruited patients to the cohort and 52 recruited participants to the trial. This large number of sites was
necessary because of the relative infrequency of admission with ASC, which is a life-threatening condition
and patients are very sick when admitted to hospital. To facilitate recruitment to the trial the opportunity
was explained to patients on admission and baseline data collected at that time. This generated a cohort
of 1532 patients with ASC, from which the trial participants were recruited when they failed to respond
adequately to treatment with intravenous hydrocortisone. The patients in this cohort have given consent
for their progress to be monitored for 10 years using routinely collected data. Fifty per cent of the patients
in the cohort (n= 775) settled without steroids or responded to initial treatment with intravenous
hydrocortisone and 74 were so ill they went for colectomy before randomisation was possible. We
eventually recruited 270 patients to the trial and followed them up for 1–3 years.
We measured disease-specific QoL using the CUCQ and used the scores to compare QAS. The CUCQ is
derived from the UK-IBDQ, an anglicised version of the Inflammatory Bowel Disease Questionnaire that
we validated 14 years prior to this study.61 Modification was required because the UK-IBDQ has only been
validated for stable or moderately active IBD and we needed an instrument that would be appropriate to
use when the disease was severe as well as mild or in remission. We validated the CUCQ concurrently with
the trial, using data from participants and other sources.100
The validated 32-question CUCQ that we used is different from the McMaster Inflammatory Bowel Disease
Questionnaire18 in several aspects (see Appendix 18). The wording of the questions in the CUCQ are
modified and anglicised to use in the UK. The response options of the CUCQ were simplified using a
combination of close-ended and a four-level Likert scale answers instead of the seven-level Likert answers
used in the IBDQ. In order to avoid acquiescence bias (yes-set),101,102 three questions about happiness,
being relaxed and having energy were phrased in a way that the higher the number, the higher level of
QoL for that attribute. Their scores were then reversely coded before adding them to the total score. The
items covered by the 32 questions in both the CUCQ and IBDQ are relatively the same. Therefore, we did
not use the IBDQ in the construct validity testing of the CUCQ and used the SF-12, EQ-5D and disease
severity indices instead. However, the CUCQ includes a question about urgency and rushing to toilet,
which does not exist in the IBDQ. The IBDQ asks about the need to get up at night to go to toilet and the
lack of good sleep in one question, whereas the CUCQ asks about these two items in two separate
questions. The advantages of using the CUCQ are its simplicity, wider coverage of the symptoms of acute
IBD, and that it is free to use by health-care professionals.
To be able to continue to measure QoL after surgery we developed and validated an extension to the
CUCQ which asked questions more relevant to patients with a stoma (CUCQ+). This was sent to
participants post colectomy by the trial office, on discharge and 4, 8 and 12 weeks post discharge.
Deaths and withdrawals meant that QoL questionnaire scores were available from 121 participants in each
group up to the end of their participation in the trial, a retention rate for the primary outcome of 90%.
Secondary outcomes were measured using data extracted from patient records by research professionals
and recorded in CRFs (with completion rates as shown in Table 6). The retention rate to 2 years is excellent
but falls off at 30 and 36 months, reflecting mainly non-attendance of participants as their condition has
improved. The completion rate at 18 months is low because the 18-month data collection point was
added after the protocol was modified and required reconsent, meaning that some participants
were missed.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
The 121 participants in each group with evaluable primary outcome data were sufficient to demonstrate
clearly that there is no significant difference between the two treatments in clinical effectiveness over the
first 3 years after treatment. This does, however, also reflect the QoL after surgery, a high colectomy rate
in both arms of the study (41% following infliximab; 48% after ciclosporin) and continuation of treatment
with infliximab or ciclosporin beyond the prescribed intervention period at the discretion of the attending
physician. Ciclosporin was discontinued by all participants by 180 days, whereas infliximab was continued
for 1 year in one-quarter of participants and up to 3 years in a few.
In 2009 we applied to the HTA programme and the MRC to use the CONSTRUCT trial to explore the
possibility and validity of using data collected at the point of care to support a pragmatic trial that was
embedded in clinical care. This Electronic records Underpinning REsearch and CAre (EURECA) proposal was
not funded but we nevertheless took the opportunity to explore the feasibility and acceptability of using
GeneCIS, a non-commercial clinical management system that has been successfully deployed for many
years in a small number of disciplines in six hospitals, to support the trial, while also giving participating
sites the opportunity to use this system to support clinical care. The system required customisation to
underpin some aspects of the trial and enabled extensive quality control to be applied to the data,
especially where it was possible to triangulate data received from different sources (CRFs, AE reports and
patient questionnaires). Intensive efforts were made to verify or clarify data that was ambiguous or in
conflict (e.g. the dates and nature of an operation). Sixteen sites took up the opportunity to enter data
directly into the system, the rest returning their CRFs and patient questionnaires to the trial office for data
entry. Although our experience with CONSTRUCT has shown that an operational clinical information
system can support a pragmatic RCT and it is likely that the concept of integrated data collection for
clinical care and research will take some time to take root. In spite of the failure of the EURECA proposal
to secure funding to evaluate this in detail, we believe the principle of using high-quality point-of-care
clinical data to support prospective pragmatic trials remains valid, particularly if national standards are
applied to the structure and content of electronic patient records.103
The management and co-ordination of the CONSTRUCT trial was based on PRojects IN Controlled
Environments Version 2 principles. We held weekly meetings of the core team in the trial manager’s office,
at which we reviewed recruitment and retention, SAEs that needed discussion and any other issues raised,
such as progress with the concurrent validation of the CUCQ. All of the research team attended monthly
TMG meetings and we used these meetings more formally to review trial progress, including action, risk
and issue logs. When specific issues needed to be addressed we set up one-off TMG ‘operational group
meetings’ to resolve the issues or make plans. The TSC and DMEC met to review progress and give
valuable advice at key milestones in the project. The chief investigator and trial manager liaised with sites
mainly through e-mail, or by telephone if the issue was complex or urgent.
We were fortunate in this study to have benefited from enthusiastic, expert and thoughtful input from
representatives of the patient community. Mike Hilton was a regular and wise contributor to our monthly
TMG meetings, providing particularly useful advice when we were developing a post-colectomy extension
to the primary outcome QoL instrument. He was also instrumental in improving recruitment by jointly
authoring a letter to sites with the chief investigator. Laura Hawes and Peter Canham regularly attended
the TSC and DMEC meetings, respectively, and provided feedback and useful advice over the course of the
study. Clare Baggridge also gave us very useful insights from the perspective of a health professional who
has undergone colectomy for UC. They have all given us permission to recognise their input in this way.
Mike Hilton’s thoughts on his engagement with the study are included at Appendix 22. The input of lay
members throughout has been invaluable and we believe it adds weight to the external validity of
our findings.
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Strengths and weaknesses of the study
The CONSTRUCT trial has been a complex trial to run for many reasons. The severity of the illness, nature
of the symptoms and relative rarity of the presentation of ASC meant that case ascertainment, recruitment,
retention and data collection have all been challenging. Methodologically we took a pragmatic approach,
allowing local investigators flexibility in the clinical situation. For example, we allowed local clinical
judgement to over-ride the results of objective tests when assessing the response to intravenous steroids.
This was important, as it is well known that high doses of steroids can suppress markers of disease
severity, giving a false and dangerous impression of recovery. We also allowed local flexibility in the
duration of treatment with steroids and clinicians were allowed to exercise clinical judgement regarding
the continuation or change in treatment once the per-protocol intervention was complete. As a result
many participants continued on the allocated treatment for some time, more continuing for longer on
infliximab than ciclosporin. The use of concomitant immunosuppressive therapy with azathioprine or
6-mercaptopurine after the intervention period was similar in both groups. We believe that this pragmatic
acceptance of clinical judgement means that the results of the trial genuinely reflect current clinical practice.
Because of the severe and incapacitating nature of the symptoms suffered by patients with ASC we
informed them about the trial at the earliest opportunity after admission and sought their consent for
baseline data collection at that time. This meant that disease-specific QoL (the primary outcome measure)
was completed by potential participants before treatment with steroids and some days before they
were randomised into the trial. In spite of this, the two groups were well matched at baseline in terms
of demographic characteristics and baseline CUCQ scores. There was, however, an unexpected
preponderance of males in the trial in both groups. There are a number of possible explanations for this,
which we are investigating.
The transition from cohort to trial varied from site to site, and the CONSORT diagram identifies
178 paticipants who were not randomised, although they were potentially eligible. For some of these
potential participants, we have not been able to ascertain the reasons why they did not take part in the
trial, but we suspect that patient or professional preference for a treatment may have inhibited consent
and randomisation in some cases. The participants interviewed had experience of only one treatment, but
there appeared to be more enthusiasm and satisfaction for infliximab than for ciclosporin. For both
participants and professionals this was largely because of the cumbersome and constraining requirements
for intravenous infusion of ciclosporin and it is possible that oral treatment may be more popular.
We chose intravenous ciclosporin, before a transfer to the oral version, as we feared that tablets might
be poorly tolerated and absorbed in very sick patients; however, given the effectiveness of ciclosporin,
we feel that first-line oral therapy should be explored further, particularly as colonic release preparations
become available.104
The primary outcome (QAS) was compared using data from QoL questionnaires (PFQs) completed at
baseline, 3 months and 6 months and then 6-monthly until February 2014. All participants were,
therefore, eligible for follow-up for 1 year, but only 34 (17 in each arm) were recruited early enough to be
followed up for 3 years. The number of PFQs completed at each time point, and the reasons for shortfall,
are shown in the CONSORT diagram. Some participants failed to return a PFQ at one or more time points
but, overall, primary outcome data were available for 121 participants in each arm. There were three
deaths and 31 withdrawals (14 infliximab and 17 ciclosporin) over the course of the study, which account
for some gaps, but in some cases, and despite reminders, expected questionnaires were not returned.
This is understandable: UC is a debilitating and depressing condition for the sufferer and, when well,
patients do not like being reminded of their illness.
The incidence of SARs was similar in both arms of the trial. As the known side effect profile of both drugs
is very extensive, we specified in the protocol that we did not require expedited reporting of serious events
unless they were thought to be unexpected. Assessment of expectedness included featuring in the
specification of product characteristics or being attributable to disease progression or surgical intervention.
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At the start of the trial we stressed in the Fieldwork Handbook that AESFs have dual purpose. The first is
to aid the decision process that will define whether or not the event is unexpected and, through this,
enable us to detect any trend towards SUSARs to the treatment which might indicate a threat to patient
safety. We detected no SUSARs, which is not surprising given the very extensive clinical experience with
drugs that have both been in use for the treatment of IBD for over 20 years. The second purpose of
the reporting system was to give us the data to be able to compare the incidence of events which are
known side effects of the two drugs as a secondary outcome measure. This was a complex process that
we addressed as rigorously as possible. Although all events had been monitored during the course of the
study, two clinicians in the research team reviewed all SAEs again at the end of the study in order to
ensure the consistency of our interpretation of their relatedness to the IMPs. When considering the
relatedness of each event to the IMP, decisions were informed by data from sites on the duration of use of
treatment with the IMP beyond the 3-month intervention period specified in the protocol. It was important
that we did this because once the intervention period was complete, clinical management was no longer
per protocol and therefore varied from subject to subject according to their progress and the clinical
judgement of the local team. We also took into account the different pharmacokinetic profiles of the two
IMPs. It is known that the bio-availability of ciclosporin is short-lived after cessation of treatment, whereas
bio-availability of infliximab, although varying from subject to subject, can persist up to 6 months after the
last infusion.105 Therefore, with the exception of malignancy, we considered that relatedness would be
unlikely if the event occurred more than 1 month after cessation of treatment with ciclosporin, but could
be related up to 6 months after infliximab. These principles were agreed with the Clinical Trials Unit and
the DMEC before we undertook the review.
Both UC and the drugs being evaluated are known to cause many clinical problems, some of which may
be manifest together in a single event. When an AE report documented a serious event (usually admission)
but included more than one problem (e.g. abnormal liver and renal function test results), we used our
clinical judgement to decide which (if any) could be related to the IMP and which was the prime cause for
admission. In addition, and in order to capture all problems reported, we analysed the events by both the
total number of events, and the total number of problems, which we categorised by affected body system.
The results of this re-evaluation of serious events led to few changes in category (which were all agreed
with local PIs) and overall there was no difference between the two drugs in their toxicity profile in
the study.
There were three malignancies: a case of endometrial cancer on ciclosporin, and a basal cell skin cancer
and a colorectal cancer on infliximab. The last of these was unusual in that, although it was detected in
the colonic specimen removed at colectomy, the histology identified signet ring cells, suggestive of a lung
primary. Although dual primaries were considered, this was thought to be unlikely on review by the local
multidisciplinary team.
Three participants died, all following treatment with infliximab, a difference from ciclosporin that is not
statistically significant. Two deaths were due to sepsis (one pre operative and one post operative). In both
cases this was associated with multiple comorbidities, including diabetes mellitus. One was from
disemminated malignancy from colorectal cancer.
We took a rigorous approach to data quality. We maintained close contact with sites by e-mail and
repeatedly stressed the importance of data completeness. We reviewed all the primary outcome data
entered onto GeneCIS before analysis. The overall item omission or transcription error rate was < 1% and
those identified were corrected. Many secondary outcome data were derived from a variety of sources,
giving us the opportunity to triangulate many items. We undertook monitoring visits to eight sites,
including six of the highest recruiting hospitals. These did not identify any data issues except for a few AEs
that had not been reported. None of these was a SUSAR but two were SARs.
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An evidence review commissioned by NICE in 200853 expressed concerns over the uncertainty in
estimates of effectiveness, particularly with regard to colectomy rates, which had been used to model the
cost-effectiveness of infliximab versus ciclosporin. This was because of the very small number of RCTs,
which themselves were small, and to criticism of the use of evidence from mixed-treatment comparisons.
The CONSTRUCT trial provided the opportunity to gain trial-based data from a sufficiently powered
head-to-head comparison.
The economic evaluation showed very little difference in effectiveness at 30 months using all available data
and adjusting for the number of days each patient had been in the study (0.021 QALYs in favour of
ciclosporin). Very similar results were shown using more conventional complete-case analyses at 12 and
24 months where the mean difference in QALYs were 0.027 and 0.022 QALYs, respectively, in favour of
ciclosporin. Infliximab, however, is considerably more costly in terms of direct treatment costs, whereas the
two treatments did not differ significantly in terms of other NHS resources. Given the similar clinical
effectiveness this means that infliximab is dominated by ciclosporin. The probabilistic sensitivity analysis,
which takes into account the joint uncertainty in costs and effects, shows ciclosporin to have an 85%
chance of being cost-effective when considered against a range of willingness-to-pay thresholds, including
the £20,000–30,000 per extra QALY currently used by NICE.
These results differ from a modelling exercise by Punekar and Hawkins,51 which showed infliximab to be
more costly but also more effective than ciclosporin. The base-case incremental cost per additional QALY
gained was £19,545, which, being below the current NICE threshold, was judged to be cost-effective.
A more recent application of the same model to the Netherlands50 produced an incremental
cost-effectiveness ratio of €24,277. Modelling, however, requires assumptions which may not be borne
out in clinical practice. For example, both studies assumed that infliximab patients receive three infusions
as per protocol, whereas in our pragmatic study the number of infliximab infusions was at the discretion of
clinicians who delivered more than three infusions to 34 of 135 infliximab patients and up to 13 infusions
in one case, and not all participants received the initial three infusions. Similarly, cost-effectiveness results
of the models were shown to be sensitive to assumptions about body weight which the UK base case
assumed was 80 kg per patient and the Netherlands base case assumed was 70 kg. We were able to use
each participant’s treatment using their actual weights: mean 74.0 kg for ciclosporin participants and
74.4 kg for infliximab participants.
The mixed-methods approach we adopted for the study shows the importance of considering a wider
range of information. Given the lack of any significant difference between the two drugs in quantitative
comparison of their clinical effectiveness, the results of our qualitative research assume greater importance
and the validity of our findings requires detailed scrutiny. The views we obtained from participants about
infliximab, ciclosporin and surgery are important, unique, detailed, from a broad age range and UK wide.
The interviewees were chosen at random, but stratified by age, treatment and surgery, and the
demographic and baseline characteristics of the 20 participants who were interviewed were no different
from the rest of the participants in the study. Applying the criteria of credibility, transferability,
dependability and confirmability set out by Guba,106 we believe we used a rigorous qualitative approach
which we have described and reference in detail (see Appendix 19).107–111
Our approach and conduct of interviews with professionals were similarly rigorous. Many doctors
volunteered a treatment preference and those who preferred infliximab tended to hold strong views,
although most stressed that clinical effectiveness and safety were their prime concerns, hence their support
for the trial and willingness to adopt a position of equipoise. Nurses were more strongly critical of
ciclosporin, in particular the cumbersome and constraining intravenous regimen. We were alert to a
potential lack of equipoise at some sites and monitored this. We believe that the final distribution of
participants from across the UK, and the close matching of baseline data from the two groups,
demonstrates that there was no bias relating to this.
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The establishment of a cohort of 1532 subjects who were admitted to hospital with ASC, and have given
their consent for us to monitor their clinical progress over 10 years, is a considerable strength of the study,
particularly as we also have consent to monitor the progress of the trial participants by questionnaires over
this time.
As a trial to explore effectiveness rather than efficacy our outcome measures were subjectively patient
focused, rather than objective measures of disease activity, but the value of both drugs in terms of efficacy
has already been established by the CySIF trial41 and our results are concordant with their findings.
Owing to the small number of participants who contributed cost data at 36 months, we conducted the
economic evaluation to 30 months rather than 36 as in the effectiveness evaluation. The number of
missing data varied between resource items. However, this was low for the main cost drivers and all
missing data were randomly distributed according to patients’ clinical and sociodemographic variables and
study arm.
We are aware that our attempt to capture all costs may have led to some double counting. For example,
although the CRF would capture all accident and emergency attendances at the centre in which the
participants was receiving their treatment (case notes), it would miss any that may have occurred at
other hospitals (e.g. while the participant was on holiday). A question about accident and emergency
attendances at other hospitals was therefore included in the PFQ but despite the clarity of the instruction
it is possible that some participants reported study centre accident and emergency attendances which
were already recorded on the CRF.
Our qualitative data from participants were obtained by telephone interview. We confirmed that the
demographic characteristics matched those of the overall study participation and saturation was reached
with professional interviews as with patient interviews.
External validity
Participants were recruited from a good mix of large and small district general and teaching hospitals,
distributed throughout Great Britain, and we believe our study population is representative of severe UC in
the UK. The participants were predominantly Caucasian and further analysis is needed to explore the
extent to which ethnicity and age reflect the UK distribution of ASC.
Our findings are concordant with the results of the GETAID CySIF study,41 an efficacy trial in 116 subjects
that found no difference in patient response rates, colectomy rates or AEs 3 months after treatment
(Table 49).
TABLE 49 GETAID CySIF study
Outcome Infliximab (%) Ciclosporin (%)
Treatment failure 54 60
Response at day 7 86 84
Colectomy rate at 3 months 23 18
SAEs 29 18
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
The methodologies and the findings of the two studies are complementary. CySIF used evidence from
hospitals in Western Europe to establish that both drugs are equally effective, whereas we used a UK-wide
study to show that this also applies to their clinical effectiveness.
The CySIF and CONSTRUCT trials are the only two fully reported randomised trials of these two drugs
in this condition, and provide compelling evidence that there is no difference between ciclosporin and
infliximab in efficacy or clinical effectiveness. Although, overall, ciclosporin is cheaper than infliximab, the
single infusion is more resource intensive to administer and is less well liked by both patients and nurses
who administer the infusions. The side effect profile is similar and, given orally, it would be much cheaper
to administer. We were concerned that oral administration would not be feasible in very sick patients, but
this would undoubtedly be possible in some patients, and we believe that the use of oral ciclosporin to
pre-empt admission is worth evaluating. A very small trial comparing oral ciclosporin with intravenous
infliximab in 30 participants has been reported in abstract form only and found no difference in efficacy
2–3 years after treatment.112
The study started to recruit in 2010 and, now that Remicade is off patent, biosimilar biologic treatments
have started to appear,113 but this study will provide a benchmark for their effectiveness. The cost of
infliximab is likely to reduce with this competition. Newer biologic treatments are also appearing, some
of which can be given orally.
The pragmatic approach taken in CONSTRUCT reflects the real world of clinical practice. In particular, we
believe that the clinical judgement allowed in determining how ill potential participants were, the flexibility
permitted in assessing their response to intravenous steroids and the clinical freedom encouraged in
deciding how long to continue treatment after the intervention period was complete all contribute to the
external validity of our results.
Similarly, our primary outcome includes the impact of continuing medical treatment and of colectomy
undertaken when treatment fails. Although the impact of surgery on the participant tends to be positive,
this is seen equally in both arms of the study. Although this may distort the apparent beneficial effect of
the primary intervention, both in terms of clinical outcome and cost, it will not impact on the comparative
results. As would be expected, we have shown that there is a dip in QoL after surgery, but this recovers.
Our data so far do suggest that colectomy is not a bad outcome. This conclusion reflects our previous
analysis of routinely collected data about IBD from the whole of England, which demonstrated a
continuing mortality after admission with UC without colectomy.7
Patients fear colectomy, largely because of the threat of an ileostomy, but surgical techniques and
expertise mean that a stoma is not necessarily a long-term outcome. The patients we interviewed who had
undergone surgery were pleased with the result, particularly those who had suffered long-term ill health
before their final exacerbation. Given the epidemiological evidence that mortality after admission with UC
without surgery is as high 3 years later as mortality from emergency colectomy,7 there are reasons to
consider surgery earlier rather than later. Whether or not this requires a large-scale randomised trial to
compare medical and surgical treatment should be debated, particularly as observational studies have
shown that treatment with both drugs is associated with a rising colectomy rate as time goes on – as high
as 80% at 7 years after treatment with ciclosporin (Table 50) – although the rate appears to be lower, and
declining, after infliximab.122 Long-term follow-up of our trial and cohort patients will be very important
to corroborate or refute these findings. We will analyse routinely collected data about readmission,
colectomy and mortality over 10 years to look at this.
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Implications
The comprehensive design of CONSTRUCT has greatly strengthened the conclusions of CySIF, a small
European trial that studied few clinical outcomes. There is no difference between infliximab and ciclosporin
in the effectiveness with which they treat steroid-resistant ASC, not only in the incidence of ‘treatment
failure’ but also in HRQoL, both generic and specific to UC. Nevertheless, nurses generally disliked the
greater resource demands of intravenous ciclosporin, which led to participants on that drug spending a
mean of 2 extra days as inpatients. Although 20 representative trial participants generally spoke more
favourably about infliximab, gastroenterologists were more equivocal. Given current NHS budgetary
constraints the dominant finding of our rigorous evaluation is that, even after subtracting the difference in
hospital costs because of longer hospital stays, the net mean cost of ciclosporin to the NHS per participant
was still £5632 lower than that of infliximab.
As NICE is currently consulting on the use of infliximab in severe colitis, these findings are timely. The clear
conclusion from our quantitative data is that, despite the substantial difference in cost, the two drugs are
similar in effectiveness and toxicity. Nevertheless, nurses prefer to administer infliximab and patients who
received it seem to be more satisfied than those who were given ciclosporin. In designing CONSTRUCT we
chose to start with ciclosporin given intravenously before switching to oral administration, as we believed
that most patients would be too sick for immediate oral treatment. However, it is clear from our qualitative
findings that intravenous ciclosporin is inconvenient and disliked by many patients and professionals and
hence we wonder whether or not oral ciclosporin would have been effective from the start, and could
even pre-empt admission in patients who are developing severe symptoms. These are important questions
for research, especially as colonic release formulations are already in development.
TABLE 50 Colectomy rates after treatment in observational cohorts since 2000
Study Drug 2 weeks Late Details
Teisner et al., Denmark114 Infliximab 37% Median follow-up 22 months; range 4–57 months
Mortensen et al., Denmark115 Infliximab 18% 39% Median follow-up 17 days; range 2–651 days
Jarnerot, Sweden116 Infliximab 46% At 2 years
Jakobovits et al., Oxford117 Infliximab 15% 57% At 3 months
Waters et al., Exeter118 Infliximab 16% 64% At 4 years
Campbell et al., Oxford119 Ciclosporin 58% At 7 years
Molnar et al., Hungary120 Ciclosporin 22% 63% Mean follow-up 2.9 years
Actis et al., Italy9 Ciclosporin 65% At 7 years
Moskovitz et al., Belgium121 Ciclosporin 88% At 7 years
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
Future research
We hope to follow both trial and cohort patients for up to 10 years, thus yielding important conclusions
on long-term outcomes, notably on further colectomies and hospital admissions. Before then, CONSTRUCT
has generated several questions which we plan to address through further analysis including:
1. How representative are our participants of UK patients with ASC?
2. Do females respond to steroids better than males?
3. How well do our baseline data predict subsequent need for colectomy?
4. How quickly does QoL improve after colectomy?
5. Can CONSTRUCT help to address whether or not colectomy is more clinically effective and
cost-effective than medical treatment?
6. Do the characteristics of investigators influence their attitude to treatments?
We suggest that there is a strong case for new trials to evaluate:
1. the relative clinical effectiveness and cost-effectiveness of medical and surgical treatment for ASC
2. the relative clinical effectiveness and cost-effectiveness of intravenous versus oral ciclosporin for acute
UC especially if colonic release ciclosporin becomes available
3. the relative clinical effectiveness and cost-effectiveness of using oral ciclosporin to pre-empt admission
in severe but pre-acute colitis
4. the relative clinical effectiveness and cost-effectiveness of new anti-tumour necrosis factor drugs,
currently the subject of a NICE appraisal and intravenous or oral ciclosporin.123
Conclusions
The total cost to the NHS was much higher for infliximab than ciclosporin. Nevertheless, there was no
significant difference between the two drugs in clinical effectiveness, colectomy rates, incidence of SAEs or
reactions, or mortality.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
Acknowledgements
Contributions of authors
All 13 authors contributed to design and data collection or analysis and interpretation, commented on
successive drafts and approved the version to be published. More specifically:
John G Williams (Professor of Health Services Research and Consultant Gastroenterologist) was principal
applicant and chief investigator of the trial. He wrote the first draft and co-ordinated the editing of the
final report.
M Fasihul Alam (Health Economist and Modeller) contributed to analysing and interpreting the economic
data and drafting this report, and led designing the cost-effectiveness modelling.
Laith Alrubaiy (Clinical Academic Trainee in Gastroenterology) contributed to the validation of the CUCQ
and CUCQ+, screening and analysing AEs and drafting this report, in which he contributed in particular
the first draft of the background and literature review.
Clare Clement (Qualitative Research Officer) collected and analysed qualitative data; she led the writing of
the professional views.
David Cohen (Professor of Health Economics) was coapplicant and PI for health economics.
Michelle Grey (Data Manager) co-ordinated data collection.
Mike Hilton (service user) contributed to the design of the trial and drafting this report.
Hayley A Hutchings (Associate Professor) developed and validated the CUCQ and CUCQ+ analysis, led
the MATRICS results and contributed to interpreting data and drafting this report.
Mirella Longo (Health Economist) contributed to analysing and interpreting the economic data, and
drafting this report.
Jayne M Morgan (Information Scientist) was co-applicant and led the development and operational use
of the data management system, GeneCIS.
Frances L Rapport (Professor of Qualitative Health Research) was coapplicant and the PI for the
qualitative research.
Anne C Seagrove (Trial Manager/Research Officer) was co-applicant and trial manager; she contributed to
developing and implementing the design and management of the trial. She also collected and analysed
qualitative data, led the writing of the participant views and contributed to drafting and co-ordinating
this report.
Alan Watkins (Senior Trials Statistician) was the trial statistician; he undertook primary statistical analysis
and contributed to interpreting data and drafting this report.
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
Other acknowledgements
We would like to thank the external members of the TSC for their advice and support for the project:
Professor Chris Hawkey, chairperson (University of Nottingham), Ms Laura Hawes (service user),
Dr Stephen Grainger (Barking, Havering and Redbridge University Hospitals NHS Trust), Dr John Mansfield
(Newcastle upon Tyne Hospitals NHS Foundation Trust) Professor Jon Rhodes (University of Liverpool) and
Dr Simon Travis (Oxford Radcliffe Hospitals NHS Trust). Our thanks go also to the DMEC comprising
Professor Stirling Bryan (University of British Columbia), Mr Peter Canham (service user), Professor Tim Peters
(University of Bristol), Dr Chris Probert (University of Liverpool) and Professor Phil Routledge (Cardiff University).
We would like to thank a number of people who helped towards the successful completion of the study:
The NIHR HTA programme for funding CONSTRUCT and their staff for generous and patient support. The
study was adopted by the NIHR research portfolio.
The study participants, giving so generously of their time and sharing their experiences with us, especially
for completing questionnaires for up to 3.5 years.
Ian Russell gave methodological support until his retirement in March 2015.
Claire Baggridge, Peter Canham and Laura Hawes provided useful advice from a service user perspective.
Peter Canham and Laura Hawes also played a helpful role on the TSC and DMEC.
The PIs and the research nurses who played an invaluable role in helping to identify, recruit, randomise
participants and collect data; their clinical colleagues for referrals to the study and pharmacy personnel
who helped dispense trial treatment. In addition, the research support teams who provided helpful
assistance throughout the study.
PI Trust/health board
Dr Tariq Ahmad Royal Devon and Exeter Foundation Trust
Dr Navneet Alhuwalia Stockport NHS Foundation Trust
Dr Yeng Ang and Dr Neeraj Prasad Wrightington, Wigan and Leigh NHS Foundation Trust
Dr Anurag Argawal Doncaster and Bassetlaw Hospitals NHS Foundation Trust
Dr Ian Arnott NHS Lothian
Dr Bijay Baburajan Maidstone and Tunbridge Wells NHS Trust
Dr Jamie Barbour Gateshead Health NHS Foundation Trust
Dr P Basumani and Dr Yousif Mohamed Rotherham NHS Foundation Trust
Dr Conrad Beckett Bradford Teaching Hospitals NHS Foundation Trust
Dr Stuart Bloom University College London Hospitals NHS Foundation Trust
Dr Jake Burdsall Wye Valley NHS Trust
Dr Faheem Butt South Tyneside NHS Foundation Trust
Dr Simon Campbell Central Manchester University Hospitals NHS Trust
Dr Tim Card and Dr A Shonde Sherwood Forest Hospitals NHS Foundation Trust
Dr Andy Cole Derby Hospitals NHS Foundation Trust
Dr Tom Creed University Hospitals Bristol NHS Foundation Trust
Dr Fraser Cummings University Hospital Southampton NHS Trust
Dr Howard Curtis South London Healthcare NHS Trust
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
PI Trust/health board
Dr Helen Dallal and Dr Arvind Ramadas South Tees Hospitals NHS Foundation Trust
Dr Jayne Eaden University Hospital Coventry and Warwickshire NHS Trust
Dr Cathryn Edwards South Devon Healthcare NHS Foundation Trust
Dr David Elphick Chesterfield Royal Hospital NHS Foundation Trust
Dr Alex Ford Leeds Teaching Hospitals NHS Trust
Dr Carol Francis Countess of Chester Hospital NHS Foundation Trust
Dr Vivek Goel Aneurin Bevan University Health Board
Dr John Gordon Hampshire Hospitals NHS Foundation Trust
Dr Stephen Grainger Barking Havering and Redbridge University Hospitals NHS Trust
Dr Barney Hawthorne Cardiff and Vale University Health Board
Dr David Hobday City Hospitals Sunderland NHS Foundation Trust
Dr Chris Hovell Dorset County Hospitals NHS Foundation Trust
Dr Tariq Iqbal University Hospitals Birmingham NHS Foundation Trust
Dr Alan Ireland Brighton and Sussex University Hospitals NHS Trust
Dr Peter Isaacs Blackpool Teaching Hospitals NHS Foundation Trust
Dr Sauid Ishaq The Dudley Group NHS Foundation Trust
Dr Aida Jawhari Nottingham University Hospitals NHS Foundation Trust
Dr Sarah Langlands Frimley Park Hospital NHS Foundation Trust
Dr Keith Leipera and Dr S Subramanian Royal Liverpool and Broadgreen University Hospitals NHS Trust
Dr Andy Li Western Sussex Hospitals NHS Trust
Dr Chee Lim Heart of England NHS Foundation Trust
Dr Jimmy Limdi Pennine Acute Hospitals NHS Trust
Dr James Lindsay Barts Health NHS Trust
Dr Alan Lobo Sheffield Teaching Hospitals NHS Foundation Trust
Dr Chris Macdonald North Cumbria University Hospitals NHS Trust
Dr A di Mambro and Dr David Parker Weston Area Health NHS Trust
Dr John Mansfield The Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Joel Mawdsley West Middlesex University Hospital NHS Trust
Dr Brian McKaig Royal Wolverhampton NHS Trust
Dr John O’Donohue Lewisham and Greenwich NHS Trust
Dr Richard Pollok St George’s University of London
Dr Lindsay Potts NHS Highland
Dr Munuswamy Pushpakaran Basildon and Thurrock University NHS Foundation Trust
Dr S Ramakrishnan Warrington and Halton Hospitals NHS Foundation Trust
Dr Andrew Robinson Salford Royal NHS Foundation Trust
Dr Matt Rutter North Tees and Hartlepool NHS Foundation Trust
Dr Othman Saraj York Teaching Hospital NHS Foundation Trust
Dr Sebastian Shaji Hull and East Yorkshire NHS Trust
Dr Ian Shaw Gloucestershire Hospitals NHS Foundation Trust
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
PI Trust/health board
Dr Achuth Shenoy Colchester Hospital University NHS Foundation Trust
Dr Mark Smith Royal Shrewsbury and Telford NHS Trust
Dr Alan Steel Chelsea and Westminster NHS Foundation Trust
Dr Linzi Thomas Abertawe Bro Morgannwg University Health Board
Dr Paul Thomas Taunton and Somerset NHS Foundation Trust
Dr Simon Travis Oxford Radcliffe Hospitals NHS Trust
Dr David Watts NHS Forth Valley
Dr Gill Watts University Hospital South Manchester NHS Foundation Trust
Dr Sean Weaver Royal Bournemouth and Christchurch Hospital NHS Foundation Trust
Dr Greg Whatley Tameside Hospital NHS Foundation Trust
a Deceased.
Dr John Mansfield (Newcastle upon Tyne) for his advice and support in acquiring adoption of CONSTRUCT
by the NIHR Research Portfolio.
Mr Hugh Barr (Gloucester), Mr John Beynon (Abertawe Bro Morgannwg University Health Board),
Dr Keith Bodger (University of Liverpool), Mr Martyn Evans (Abertawe Bro Morgannwg University Health
Board) and Dr Chris Venables (retired surgeon, Newcastle upon Tyne) for their help with the costing of surgery.
Dr Sam Groves (University of South Wales) and Mr Morro Touray (University of South Wales) for their help
with economic data analysis.
Gaynor Demery, Jane Draper, Emma Riordan and Judy Williams (Swansea University Medical School) who
provided administrative support to the trial.
Ashley Akbari (Information and Data Analyst/Research Officer, Swansea University Medical School) and
Dr Kym Thorne (Data Analyst/Research Officer, Swansea University Medical School) who helped develop
the data collection tools and the implementation of GeneCIS.
Giles Croft (Clinical Informatics Specialist), Hayley Dickinson (GeneCIS Technical Manager) and
Tracy Hughes (Clinical Coding Specialist) supported the use of GeneCIS.
Sarah Wright (Swansea University Medical School) who helped with analysis of the participant
interview data.
Dr Stephen Roberts (Swansea University Medical School) for development of the routine data element of
the study.
Dr Wai-Yee Cheung (Swansea University Medical School) for her contribution to the design of the study
and PROMs.
Dr Daphne Russell (Swansea University Medical School) for her contribution to the design of the study.
Kathy Malinovsky and Leanne Quinn (National Institute for Social Care and Health Research – Clinical
Research Centre (NISCHR CRC) who provided helpful guidance in the set up of CONSTRUCT.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
Kathie Wareham (Director, Joint Clinical Research Facility, Abertawe Bro Morgannwg University Health
Board/Swansea University Medical School) who provided most helpful advice about data quality, study
closure and archiving.
Publications and presentations
Williams JG. CONSTRUCT Breaking News. Oral presentation at British Society of Gastroenterology Annual
Meeting, 17 June 2014, Manchester, UK.
Seagrove AC, Clement C, Rapport FL, Wright S, Williams JG. Infliximab or Ciclosporin: Patient Views on
Treatment and the Impact of Ulcerative Colitis (UC) on Their Lives. Poster presentation at British Society of
Gastroenterology Annual Meeting, 17 June 2014, Manchester, UK.
Williams JG. CONSTRUCT. Oral presentation at United European Gastroenterology Week, Vienna,
October 2014.
Williams JG, Fasihul Alam M, Alrubaiy L, Arnott I, Clement C, Cohen D, et al. Infliximab versus ciclosporin
for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic
randomised trial [published online ahead of print 22 June 2016]. Lancet Gastroenterol Hepatol 2016.
Sponsor
Swansea University agreed to act as sponsor for the research.
Data sharing statement
All available data can be obtained from the corresponding author via e-mail to construct@swansea.ac.uk.
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125

References
1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in
adults. Gut 2004;53:V1–16. http://dx.doi.org/10.1136/gut.2004.043372
2. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and
management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553–9.
http://dx.doi.org/10.1046/j.1365-2036.2000.00886.x
3. Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, et al. The pattern and
outcome of acute severe colitis. J Crohns Colitis 2010;4:431–7. http://dx.doi.org/10.1016/j.crohns.
2010.02.001
4. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J
1955;2:1041–8. http://dx.doi.org/10.1136/bmj.2.4947.1041
5. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment
Pharmacol Ther 2004;20:88–92. http://dx.doi.org/10.1111/j.1365-2036.2004.02056.x
6. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis.
Gastroenterology 1985;89:1005–13.
7. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy
admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ
2007;335:1033. http://dx.doi.org/10.1136/bmj.39345.714039.55
8. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe
ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–5. http://dx.doi.org/
10.1056/NEJM199406303302601
9. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral
microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the
treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm
Bowel Dis 1998;4:276–9.
10. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in
the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis
2001;7:83–8. http://dx.doi.org/10.1097/00054725-200105000-00001
11. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis.
Am J Gastroenterol 2001;96:2373–81. http://dx.doi.org/10.1111/j.1572-0241.2001.04039.x
12. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am
2006;35:821–36. http://dx.doi.org/10.1016/j.gtc.2006.09.002
13. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis:
a randomized pilot study. Eur J Gastroenterol Hepatol Eur 2004;16:1167–71. http://dx.doi.org/
10.1097/00042737-200411000-00014
14. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for
induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
http://dx.doi.org/10.1056/NEJMoa050516
15. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis.
Aliment Pharmacol Ther 2007;25:19–37. http://dx.doi.org/10.1111/j.1365-2036.2006.03131.x
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
16. Yamada S, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y, et al. Long-term efficacy
of infliximab for refractory ulcerative colitis: results from a single center experience. BMC
Gastroenterol 2014;14:80. http://dx.doi.org/10.1186/1471-230X-14-80
17. Zhou YL, Xie S, Wang P, Zhang T, Lin MY, Tan JS, et al. Efficacy and safety of infliximab in
patients with ulcerative colitis: experiences from a single medical center in South China. J Dig Dis
2014;15:483–90. http://dx.doi.org/10.1111/1751-2980.12161
18. Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, et al. Quality of life in patients
with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306–10. http://dx.doi.org/
10.1097/00004836-198806000-00014
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual
framework and item selection. Med Care 1992;30:473–83. http://dx.doi.org/10.1097/
00005650-199206000-00002
20. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The effects of
infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol
2007;102:794–802. http://dx.doi.org/10.1111/j.1572-0241.2007.01094.x
21. National Institute for Health and Care Excellence (NICE). Ulcerative Colitis (Acute Exacerbations) –
Infliximab (TA163). London: NICE; 2008.
22. Naftali T, Novis B, Pomeranz I, Leichtman G, Maor Y, Shapiro R, et al. Cyclosporin for severe
ulcerative colitis. Isr Med Assoc J 2000;2:588–91.
23. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003;15:239–44.
http://dx.doi.org/10.1097/00042737-200303000-00005
24. Message L, Bourreille A, Laharie D, Quinton A, Galmiche JP, Lamouliatte H, et al. Efficacy of
intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol
Clin Biol 2005;29:231–5. http://dx.doi.org/10.1016/S0399-8320(05)80754-7
25. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease:
limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000;12:657–60.
http://dx.doi.org/10.1097/00042737-200012060-00015
26. Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized,
double-blind comparison of 4mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative
colitis. Gastroenterology 2003;125:1025–31. http://dx.doi.org/10.1016/S0016-5085(03)01214-9
27. Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease –
mechanisms and therapeutic strategies. Aliment Pharmacol Ther 2007;25:111–22. http://dx.doi.
org/10.1111/j.1365-2036.2006.03156.x
28. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe
attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005;28:607–14.
http://dx.doi.org/10.1016/S0210-5705(05)71523-5
29. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative
colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol
2007;5:103–10. http://dx.doi.org/10.1016/j.cgh.2006.09.033
30. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of
remission in severe ulcerative colitis. Cochrane Database Sys Rev 2005;1:CD004277. http://dx.doi.
org/10.1002/14651858.cd004277.pub2
31. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org
(accessed 3 November 2015).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
32. Sjoberg M, Walch A, Meshkat M, Gustavsson A, Jarnerot G, Vogelsang H, et al. Infliximab or
cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis:
a retrospective observational study. Inflamm Bowel Dis 2012;18:212–18. http://dx.doi.org/
10.1002/ibd.21680
33. Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, et al. Cyclosporine or infliximab
as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a
retrospective observational study. J Crohns Colitis 2012;6:681–6. http://dx.doi.org/10.1016/
j.crohns.2011.11.021
34. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative
colitis: a retrospective analysis. J Gastroenterol Hepatol 2012;27:487–92. http://dx.doi.org/
10.1111/j.1440-1746.2011.06958.x
35. Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, et al. Outcome of a
conservative approach in severe ulcerative colitis. Dig Liver Dis 2004;36:21–8. http://dx.doi.org/
10.1016/j.dld.2003.04.001
36. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy
for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol
Ther 2013;38:294–302. http://dx.doi.org/10.1111/apt.12375
37. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and
infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.
Clin Gastroenterol Hepatol 2008;6:1112–16. http://dx.doi.org/10.1016/j.cgh.2008.04.035
38. Leblanc S, Allez M, Seksik P, Flourie B, Peeters H, Dupas JL, et al. Successive treatment with
cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol
2011;106:771–7. http://dx.doi.org/10.1038/ajg.2011.62
39. Chaparro M, Burgueno P, Iglesias E, Panes J, Munoz F, Bastida G, et al. Infliximab salvage therapy
after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
Aliment Pharmacol Ther 2012;35:275–83. http://dx.doi.org/10.1111/j.1365-2036.2011.04934.x
40. Mañosa M, López San Roman A, Garcia-Planella E, Bastida G, Hinojosa J, Gonzalez-Lama Y, et al.
Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion
2009;80:30–5. http://dx.doi.org/10.1159/000212075
41. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab
in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label
randomised controlled trial. Lancet 2012;380:1909–15. http://dx.doi.org/10.1016/S0140-6736(12)
61084-8
42. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in
acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.
Aliment Pharmacol Ther 2013;38:935–45. http://dx.doi.org/10.1111/apt.12473
43. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe
steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis
2013;28:287–93. http://dx.doi.org/10.1007/s00384-012-1602-8
44. Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients’ perceptions of treatment with anti-TNF
therapy for rheumatoid arthritis: a qualitative study. Rheumatology 2004;43:1034–8.
http://dx.doi.org/10.1093/rheumatology/keh237
45. Hazen ACM, Smith FJ, Taylor KMG, Rawcliffe C, Medcalf L, Keady S. Paediatric infliximab therapy,
patients and parents perspectives on treatment options. Paediatr Perinat Drug Ther 2008;8:177–81.
http://dx.doi.org/10.1185/146300908X292097
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
46. Silverman S. Qualitative Research: Theory, Method and Practice. 2nd edn. London: Sage
Publications Ltd; 2004.
47. Denzin NK, Lincoln YS. The SAGE Handbook of Qualitative Research. 3rd edn. London: Sage
Publications Ltd; 2005.
48. Rapport F, Storey M, Porter A, Snooks H, Jones K, Peconi J, et al. Qualitative research within trials:
developing a standard operating procedure for a clinical trials unit. Trials 2013;14:1–8.
http://dx.doi.org/10.1186/1745-6215-14-54
49. Popay J, Williams G. Qualitative research and evidence-based healthcare. J R Soc Med
1998;91:32–7.
50. Chaudhary MA, Fan T. Cost-effectiveness of infliximab for the treatment of acute exacerbations
of ulcerative colitis in the Netherlands. Biol Ther 2013;3:45–60. http://dx.doi.org/10.1007/
s13554-012-0007-0
51. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations
of ulcerative colitis. Eur J Health Econ 2010;11:67–76. http://dx.doi.org/10.1007/s10198-009-
0199-5
52. D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous
cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative
colitis. Gastroenterology 2001;120:1323–9. http://dx.doi.org/10.1053/gast.2001.23983
53. Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A, Want D. Evidence Review Group Report
on Behalf of NICE: Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis. 2010.
URL: www.journalslibrary.nihr.ac.uk/hta/volume-14/suppl-1-article-2 (accessed 4 November 2015).
54. Seagrove AC, Alam MF, Alrubaiy L, Cheung WY, Clement C, Cohen D, et al. Randomised
controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis:
trial design and protocol (CONSTRUCT). BMJ Open 2014;4:e005091. http://dx.doi.org/10.1136/
bmjopen-2014-005091
55. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990;9:1259–76.
56. National Institute for Health and Care Excellence (NICE). Process and Methods Guides: The
Guidelines Manual. London: NICE; 2012.
57. Thorne K, Jezembek GS, Cheung WY, Cohen D, Hutchings HA, Rapport F, et al. MATRICS: a
method for aggregating the reporting of interventions in complex studies. Trials 2011;12:A147.
http://dx.doi.org/10.1186/1745-6215-12-S1-A147
58. Russell IT, Edwards RT, Gliddon AE, Ingledew DK, Russell D, Whitaker R, et al. Cancer of the
oesophagous or gastricus: new assessment of the technology of endosonography (COGNATE).
Health Technol Assess 2013;17(39). http://dx.doi.org/10.3310/hta17390
59. Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, et al. Folate augmentation of
treatment-evaluation for depression (FolATED): randomised trial and economic evaluation.
Health Technol Assess 2014;18(48). http://dx.doi.org/10.3310/hta18480
60. Russell D, Hoare ZS, Whitaker R, Whitaker CJ, Russell IT. Generalized method for adaptive
randomization in clinical trials. Stat Med 2011;30:922–34. http://dx.doi.org/10.1002/sim.4175
61. Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ-a British version of the
inflammatory bowel disease questionnaire. Development and validation. J Clin Epidemiol
2000;53:297–306. http://dx.doi.org/10.1016/S0895-4356(99)00152-3
62. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and
preliminary tests of reliability and validity. Med Care 1996;34:220–33. http://dx.doi.org/10.1097/
00005650-199603000-00003
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
63. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. http://dx.doi.org/
10.1016/0168-8510(96)00822-6
64. Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London:
The Stationery Office; 2004.
65. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory
bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53. http://dx.doi.org/
10.1136/gut.2005.082909
66. Great Britain. Data Protection Act. London: The Stationery Office; 1998.
67. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health
status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–10.
68. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid
and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease.
Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287–96.
69. Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. The rating form of IBD
patient concerns: a new measure of health status. Psychosom Med 1991;53:701–12.
http://dx.doi.org/10.1097/00006842-199111000-00010
70. Drossman DA, Li Z, Leserman J, Patrick DL. Ulcerative colitis and Crohn’s disease health status
scales for research and clinical practice. J Clin Gastroenterol 1992;15:104–12. http://dx.doi.org/
10.1097/00004836-199209000-00005
71. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel
disease. Cleve Clin J Med 1992;59:35–42. http://dx.doi.org/10.3949/ccjm.59.1.35
72. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory
bowel disease change the results? J Clin Epidemiol 1996;49:1177–85. http://dx.doi.org/10.1016/
0895-4356(96)00136-9
73. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality
of life instrument for community physicians managing inflammatory bowel disease. CCRPT
Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571–8.
74. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. Low colectomy rates in
ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology
2007;132:507–15. http://dx.doi.org/10.1053/j.gastro.2006.11.015
75. Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal
cancer in inflammatory bowel disease: a population-based study from Olmsted County,
Minnesota. Gastroenterology 2006;130:1039–46. http://dx.doi.org/10.1053/j.gastro.2005.12.037
76. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative
colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol
2004;2:1088–95. http://dx.doi.org/10.1016/S1542-3565(04)00543-9
77. Alrubaiy L, Cheung WY, Russell I, Williams J. Developing a short form Crohn’s and Colitis
Questionnaire (CCQ) for patients with inflammatory bowel disease. J Crohns Colitis 2012;6:S46–47.
http://dx.doi.org/10.1016/S1873-9946(12)60112-3
78. Streiner GL, Norman RD. Health Measurement Scales. A Pratical Guide to Their Development and
Use. 4th edn. Oxford: Oxford University Press; 2008. http://dx.doi.org/10.1093/acprof:oso/
9780199231881.001.0001
79. Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, et al. Resource-use
measurement based on patient recall: issues and challenges for economic evaluation. Appl Health
Econ Health Policy 2013;11:155–61. http://dx.doi.org/10.1007/s40258-013-0022-4
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
80. Joint Formulary Committee. British National Formulary (Online). London: BMJ Group and
Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 28 June 2015).
81. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2013.
82. Department of Health. National Schedule of Reference Costs: 2012–13. London: Department of
Health; 2015.
83. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2012.
84. National Institute of Health Research. NIHR Clinical Research Network Industry Costing Template.
2014. URL: www.crn.nihr.ac.uk/wp-content/uploads/Industry/Secondary%20care%20medtech%
20costing%20template-Apr14.xls (accessed 22 September 2014).
85. Digitalhealth.net. NHS Direct 0845 closure costs £70m. 2013. URL: www.digitalhealth.net/news/
28663//nhs-direct-0845-closure-costs-£70m (accessed 30 July 2015).
86. EuroQol. 2014. URL: www.euroqol.org/ (accessed 28 July 2015).
87. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. 2nd edn. Oxford:
Oxford University Press; 2014. http://dx.doi.org/10.1093/med/9780199685028.001.0001
88. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford:
Oxford University Press; 2006.
89. Ryan GW, Bernard HR. Data Analysis and Management Methods. In Denzin NK, Lincoln US,
editors. Handbook of Qualitative Research. 2nd edn. Newbury Park, CA: Sage; 2000.
pp. 769–902.
90. Rapport F, Iredale R, Jones W, Sivell S, Edwards A, Grey J, et al. Decision aids for familial breast
cancer: exploring women’s views using focus groups. Health Expect 2006;9:232–44.
http://dx.doi.org/10.1111/j.1369-7625.2006.00392.x
91. Department of Health. Research Governance Framework for Health and Social Care. 2nd edn.
London: Department of Health; 2005.
92. Scottish Executive Health Department. Research Governance Framework for Health and
Community Care. Edinburgh: Scottish Executive Health Department; 2006.
93. Wales Office for Research and Development for Health and Social Care. Research Governance
Framework. 2nd edn. Cardiff: Wales Office for Research and Development for Health and Social
Care; 2009.
94. European Parliament and Council. Directive 2001/20/EC of the European Parliament and of the
Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative
Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the
Conduct of Clinical Trials on Medicinal Products for Human Use. URL: http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF (accessed 18 February 2014).
95. Evans BA, Bedson E, Bell P, Hutchings H, Lowes L, Rea D, et al. Involving service users in trials:
developing a standard operating procedure. Trials 2013;14:219. http://dx.doi.org/10.1186/
1745-6215-14-219
96. Medical Research Council (MRC). Guidelines for Good Clinical Practice in Clinical Trials.
MRC Clinical Trials Series. London: MRC; 1998.
97. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010
explanation and elaboration: updated guidelines for reporting parallel group randomised trials.
BMJ 2010;340:c869. http://dx.doi.org/10.1136/bmj.c869
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
98. Fenwick E, Marshall DA, Lev AR, Nichol G. Using and interpreting cost-effectiveness acceptability
curves: an example using data from a trial of management strategies for atrial fibrillation.
BMC Health Serv Res 2006;6:52. http://dx.doi.org/10.1186/1472-6963-6-52
99. Snooks H, Hutchings H, Seagrove A, Stewart-Brown S, Williams J, Russell I. Bureaucracy stifles
medical research in Britain: a tale of three trials. BMC Med Res Methodol 2012;12:122.
http://dx.doi.org/10.1186/1471-2288-12-122
100. Alrubaiy L, Cheung WY, Dodds P, Hutchings HA, Watkins A, Russell IT, et al. Development of a
short questionnaire to assesss the quality of life in Crohn’s disease and ulcerative colitis. J Crohns
Colitis 2015;9:66–76. http://dx.doi.org/10.1093/ecco-jcc/jju005
101. Messick SJ. The psychology of acquiescence: an interpretation of research evidence. ETS Research
Bulletin Series 1966;1966:i–44.
102. Hinz A, Michalski D, Schwarz R, Herzberg PY. The acquiescence effect in responding to a
questionnaire. Psychosoc Med 2007;4:Doc07.
103. Health and Social Care Information Centre (HSCIC), Academy of Medical Royal Colleges.
Standards for the Clinical Structure and Content of Patient Records, 2013. URL: www.aomrc.org.
uk/publications/reports-a-guidance# (accessed 3 December 2014).
104. Keohane K, Rosa M, Coulter IS, Griffin BT. Enhanced colonic delivery of ciclosporin A self-
emulsifying drug delivery system encapsulated in coated minispheres [published online ahead of
print June 2015]. Drug Dev Ind Pharm 2015. http://dx.doi.org/10.3109/03639045.2015.1044905
105. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association
between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology 2014;147:1296–307. http://dx.doi.org/10.1053/j.gastro.2014.08.035
106. Guba EG. Criteria for assessing the trustworthiness of naturalistic inquiries. ECTJ 1981;29:75–91.
107. Denscombe M. The Good Research Guide for Small-Scale Social Research Projects. Buckingham:
Open University Press; 1998.
108. Lincoln YS, Guba EG. Naturalistic Inquiry. Berverly Hills, CA: Sage; 1985.
109. Shenton AK. Strategies for ensuring trustworthiness in qualitative research projects. Educ Info
2004;22:63–75.
110. Stake RE. Case Studies. In Denzin NK, Lincoln YS, editors. Handbook of Qualitative Research.
Thousand Oaks, CA: Sage; 1994. pp. 236–47.
111. Yin RK. Case Study Research: Design and Methods. 2nd edn. Thousand Oaks, CA: Sage
Publishing; 1994.
112. Scimeca D, Bossa F, Annese V, Biscaglia G, Caruso N, Accadia L, et al. Infliximab vs Oral
Cyclosporin in Patients with Severe Ulcerative Colitis Refractory to Intravenous Steroids: A
Controlled, Randomised Study. United European Gastroenterology Week. URL: www.ueg.eu/
education/document-detail/?name=infliximab_vs_oral_cyclosporin_in_patients_with_severe_
ulcerative_colitis_refractory_to_intravenous_steroids._a_controlled_randomized_study&file=98100
(accessed 4 November 2015).
113. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a
biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci
2015;60:951–6. http://dx.doi.org/10.1007/s10620-014-3392-z
114. Teisner AS, Ainsworth MA, Brynskov J. Long-term effects and colectomy rates in ulcerative colitis
patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol
2010;45:1457–63. http://dx.doi.org/10.3109/00365521.2010.510572
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
115. Mortensen C, Caspersen S, Christensen NL, Svenningsen L, Thorsgaard N, Christensen LA, et al.
Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish
hospitals. J Crohns Colitis 2011;5:28–33. http://dx.doi.org/10.1016/j.crohns.2010.09.004
116. Jarnerot G. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2006;130:286.
http://dx.doi.org/10.1053/j.gastro.2005.11.037
117. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in
Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;25:1055–60. http://dx.doi.org/10.1111/
j.1365-2036.2007.03300.x
118. Waters O, Saunders M, Clarke M, Daneshmend T, Ahmad T. Infliximab rescue therapy for steroid
refractory acute severe ulcerative colitis in the Exeter IBD cohort. Gut 2011;60:A215.
http://dx.doi.org/10.1136/gut.2011.239301.454
119. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience.
Eur J Gastroenterol Hepatol 2005;17:79–84. http://dx.doi.org/10.1097/00042737-
200501000-00016
120. Molnar T, Farkas K, Szepes Z, Nagy F, Wittmann T. Long-term outcome of infliximab therapy is
highly comparable in a Danish and in a Hungarian tertiary centre. Scand J Gastroenterol
2011;46:248–9. http://dx.doi.org/10.3109/00365521.2010.522725
121. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of
colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative
colitis. Clin Gastroenterol Hepatol 2006;4:760–5. http://dx.doi.org/10.1016/j.cgh.2006.04.001
122. Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, et al. The incidence rate of
colectomy for medically refractory ulcerative colitis has declined in parallel with increasing
anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014;40:629–38. http://dx.doi.org/
10.1111/apt.12873
123. National Institute for Health and Care Excellence (NICE). Ulcerative Colitis (Moderate, Severe) –
Infliximab (Review TA140), Adalimumab (Review TA262) and Golimumab (2nd Line). London:
NICE; 2015.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
Appendix 1 CONSTRUCT flow chart
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Appendix 2 Patient information sheet (cohort)
PATIENT INFORMATION SHEET (COHORT) 
(Pt Info Cohort V13 10Oct2011.doc) 
 
You have been admitted to hospital because you have bowel problems.  This might be a new problem and  
you will have tests to find out what is causing this or it may be a flare-up of a disease that you already 
know about. 
 
This information leaflet is about an important study that is doing research into inflammatory bowel 
diseases called ulcerative colitis and Crohn’s disease.  Specifically, it is looking into the long term effects 
ulcerative colitis has on people’s quality of life.  About 150,000 people in the UK have ulcerative colitis and 
it is one of the most important diseases seen by gastroenterologists. 
 
We would like to invite you to take part in this research study.  This leaflet gives you information about the 
study - please take time to read it carefully to decide whether or not you wish to take part.  Your consultant 
or specialist nurse will talk to you about the study.  Please talk to others, such as your family about it if you 
wish.  Please ask if there is anything that is not clear or if you would like more information. 
 
What is the purpose of the study? 
We want to find out more about the progress of these conditions and the outcomes following treatment for 
the diseases.  By taking part in this study, you will be helping us to learn more about ulcerative colitis and 
Crohn’s disease and their treatment. 
 
Why have I been invited? 
We are inviting all patients admitted to hospital who might have ulcerative colitis or Crohn’s disease, to 
take part. 
 
Do I have to take part? 
No.  Your participation in this study is entirely voluntary.  It is up to you to decide whether to take part or 
not.  Even if you do decide to take part, you are free to leave the study at any time and without giving a 
reason.  This will not affect your future medical care in any way.  If you do decide to participate you will be 
given this information sheet to keep and be asked to sign a consent form. 
 
What will happen to me if I take part? 
If you agree to take part, we will first ask you to: 
• Sign the consent form which is your indication that you understand the study and agree to take 
part. 
• Complete a questionnaire that will include questions about your health, feelings and quality of life 
and use of health services.  The questionnaires take around 30 minutes to complete. 
• If you are found to have inflammatory bowel disease you will stay in the study.  If not, then you 
are not able to take part. 
• In addition, we will follow your progress over 10 years, using hospital information about any 
investigations, treatment or surgery you may have. 
 
If you are found to have ulcerative colitis rather than Crohn’s disease, you will be treated over the next few 
days with drugs known as steroids (although both illnesses may be treated with steroids).  Steroids work 
in the majority of cases of ulcerative colitis but not in all.  If they do not make you better, surgery may be 
needed.  There are also two powerful drug treatments that some hospitals use to try to treat the attack and 
avoid the need for surgery.  We are comparing these two treatments in a clinical trial to see which is best.  
If steroids are not sufficiently effective in treating you, we will tell you more about this clinical trial to see if 
it would be suitable for you.  Taking part in the first section of the study would not oblige you to take part in 
the treatment trial. 
 
What will I have to do? 
At the moment all we are asking you to do is to be part of the group of patients who will complete one 
questionnaire  and whose progress will be followed over the next ten years. 
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Will my taking part in this study be kept confidential? 
Yes.  All information which is collected about you during the course of the research will be kept strictly 
confidential in accordance with ethical and legal practice and the Data Protection Act. 
 
You will be given a unique study number and any data will be collected and stored with this number.  Any 
personal identification will be stored separately from the data.  The clinical team looking after you and the 
research team are the only people who will know specific personally identifiable information that would 
allow someone to identify you and contact you.  Your personal information (name, date of birth, home 
postcode and NHS number) will not be revealed in any audit, study report or publication, at any time. 
 
If you agree to take part your GP will be informed.   
What will happen to the results of the research study? 
The results of the study will be used to help doctors understand the progress and outcomes following 
treatment of inflammatory bowel disease. 
 
Who is organising and funding research? 
The study is being run by the College of Medicine at Swansea University in collaboration with the 
University of Glamorgan and Bangor University.  The study is funded by the National Institute for Health 
Research Health Technology Assessment Programme. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity.  This study has been reviewed and 
approved by Wales Research Ethics Committee. 
 
What happens when the research study stops? 
As a patient with ulcerative colitis or Crohn’s disease you will continue to be reviewed in the 
gastroenterology clinic so your follow up will be as normal. 
 
What will happen if I don’t want to carry on with the study? 
You may withdraw your consent and discontinue your participation in this study at any time without the 
need to give us a reason. This would not in any way affect the normal standard of care you receive. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the Trial Manager, Anne 
Seagrove,  XXXX or the Trial Administrator, Emma Riordan, XXXX, who will do their best to answer your
 questions. 
 
For information regarding your treatment, you should speak to [PI details]. 
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Appendix 3 Consent form (cohort)
CONSENT FORM (COHORT) 
(Patient Consent Form Cohort V2-0 10Oct2011) 
 
 Participant study ID:         
 
Title of Project: CONSTRUCT 
 
Name of person taking consent: 
 Please initial each 
box 
1. I confirm that I have read and understand the information sheet dated 10  
October 2011 Version 13 for the above study.  I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
 
 
3. I understand that relevant sections of my medical notes may be looked at 
by a research nurse, regulatory authorities or the NHS Trust, where it is 
relevant to my taking part in this research.  I give permission for these 
individuals to have access to my records. 
 
 
4. I agree to the research team holding personally identifiable information 
 
 
5. I agree that a copy of this Consent Form is sent to the CONSTRUCT 
 Trial Office 
 
 
6. I agree to data being collected through the research computer  
 
 
7. I agree to the completion of a questionnaire  
 
 
8. I give my permission for my  progress to be followed for up to ten years 
 using information taken from my NHS records 
 
 
9. I agree to my GP being informed of my participation in the study 
 
 
10. I agree to aspects of my anonymised data being used for reports about 
 the research 
 
 
11. I agree to take part in the above study 
 
 
 
Your name in capitals Date Signature 
 
 
 
  
 
Name of person taking consent in capitals Date Signature 
 
 
 
  
 
When completed, the original should be kept in the Trial Site File, a copy should be kept in the medical 
notes, a copy be given to the patient and one sent to the CONSTRUCT Trial Office. 
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Appendix 4 Patient information sheet
(randomised controlled trial)
PATIENT INFORMATION SHEET (RCT) 
(Patient Info RCT V18 10Oct2011) 
 
CONSTRUCT: COmparison of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis; a Trial 
(CONSTRUCT) 
 
About 150,000 people in the UK have ulcerative colitis and it is one of the most important diseases seen 
by gastroenterologists.  CONSTRUCT is an important study set up to improve the treatment of ulcerative 
colitis. 
 
We would like to invite you to take part in this research study.  We appreciate that you are not feeling well 
at the moment but before you decide you need to understand why the research is being done and what 
your involvement would be.  This leaflet gives you information about the study - please take time to read it 
carefully to decide whether or not you wish to take part.  Your consultant or specialist nurse will talk to you 
about the study.  Please talk to others, such as your family about it if you wish.  Please ask if there is 
anything that is not clear or if you would like more information. 
 
What is the purpose of the study? 
Patients with ulcerative colitis that is resistant to steroid treatment may need to change to a different 
treatment or require surgery.  Two treatments are available for treatment in these circumstances infliximab 
(which would be prescribed as Remicade) and ciclosporin (which would be prescribed as 
Sandimmun/Neoral).  These drugs are often an effective treatment in the short term but we don’t know 
which is best and there is little information about their longer term effects on health and quality of life. 
 
To help doctors recommend the best drug treatment for patients we want to find out how effective these 
drugs are for patients in the long term and understand if one drug is more effective than the other.  By 
taking part in this study, you will be helping doctors to decide which drug they should recommend. 
 
Why have I been invited? 
You have been diagnosed with ulcerative colitis and are being treated as an inpatient in a hospital that is 
taking part in this study of people with your condition.  Your ulcerative colitis has not responded 
adequately to steroids and you now need additional treatment.  
 
Do I have to take part? 
No.  Your participation in this study is entirely voluntary.  It is up to you to decide whether to take part.  If 
you decide to take part, you are free to leave the study at any time and without giving a reason.  This will 
not affect your medical care in any way.  If you decide to participate you will be given this information 
sheet to keep and be asked to sign a consent form. 
 
What will happen to me if I take part? 
• If you agree to take part, we will first ask you to sign a consent form which is your indication that 
you understand the study and agree to take part. 
• You will be treated with either infliximab or ciclosporin.  The treatment will be chosen randomly (by 
chance) by a computer 
• You will have an equal chance of receiving either infliximab or ciclosporin.  You will know which 
drug you are being given.  Whichever drug is chosen for you, it will be given to you in the same 
way that it would be given if you were not taking part in the study. 
• If you are given infliximab this will be given into a vein via a drip.  If you are given ciclosporin, the 
initial treatment is given into a vein, with further doses given in capsule form. 
• Infliximab will be given at 0, 2 and 6 weeks, unless there is any problem.  Because it is an 
antibody it normally stays in the body for 6-8 weeks.  Ciclosporin will be given for 12 weeks, 
unless there is any problem.  Because it is not long-lasting in the body, it is given every day.  
• No normal treatment will be withheld whilst you take part in the study. 
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· It is important that you realise that treatment is not always effective.  If the trial treatment doesn’t 
make you better, you are likely to need surgery.  There are no other medical treatments that have 
been shown to be effective in this situation. 
· If you agree to take part we will ask you to complete a questionnaire, if you have not already done 
so.  This needs to be done before you receive the trial drug treatment.  The questionnaires will 
include questions about your health, feelings and quality of life and use of health services and 
take around 30 minutes to complete. 
 
· We will ask you to complete further questionnaires at three, six, 12. 18 and 24 months after your 
treatment followed by one questionnaire a year over the next eight years.  The questionnaires 
take around 30 minutes to complete.  These questionnaires may be completed on a computer 
with the help of a nurse when you attend for follow up appointments so you will not be required to 
make additional visits to the hospital. 
· If a questionnaire cannot be completed at the hospital, we will telephone you to make 
arrangements to complete it, possibly over the phone. 
· If you agree to take part and then require an operation on your bowel, we will also ask you to 
complete questionnaires when you are discharged from hospital after your operation and then 
monthly for 3 months. 
· In addition, we will follow your progress over 10 years, using hospital information about any 
investigations, treatment or surgery you may have. 
· You will also be giving permission for us to have copies of the results of the blood tests you will 
have done as part of your normal care.  This includes the tests done while you are an inpatient 
and the tests that will be done after you have been discharged from hospital at three, six, 12, 18 
and 24 months after your treatment.  These tests should be done at your routine follow up 
appointments so we will not be asking you to make additional hospital visits or have additional 
blood tests.  The blood tests over the two years will show us how inactive or active your ulcerative 
colitis is and the questionnaires will allow us to see how your quality of life and general health 
changes following the drug treatment 
 
· A sample of patients will be asked to take part in a telephone interview with a researcher three 
months and twelve months after treatment to find out their views about the treatment and 
progress.  These interviews will be recorded and typed up but will be stored under a number so it 
will not be possible to identify you.  You will be given the opportunity to indicate whether you 
agree to this when you complete the consent form. 
 
 
What will I have to do? 
You will be expected to take the medication as directed by your doctors and they will advise you on 
whether you can continue to take other medication or other prescribed or over-the-counter drugs and 
whether you will need to make any changes to your diet. 
 
You might already be or have recently been involved in another drug study.  If th is is the case, you cannot 
participate in this study. 
 
When you are discharged from hospital, you will be attending for outpatient appointments as part of your 
normal clinical care and we are not asking you to make additional visits but would urge you to keep your 
scheduled hospital appointments. 
 
An important part of this study is the information we gain from the questionnaires that you complete so we 
do ask that you complete all the questionnaires so that we have a complete set of data for you. 
 
 
What is the drug that is being tested? 
The two drugs that are being studied are infliximab and ciclosporin.  These are not new drugs.  The drugs 
are already used to treat patients with your condition but we do not yet know which is better, or the long 
term effects of either drug. 
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The drugs will be given to you in the same way as they would if you were not taking part in the study.  
Both drugs will initially be given via a drip into one of your veins.  Sometimes further doses of the drugs 
will be given. 
 
What are the alternatives for treatment? 
For patients with ulcerative colitis who have become resistant to treatment with steroids, advanced 
medical therapies are required and the two drugs that we are studying are available for the treatment of 
this condition.  The only other treatment available is surgery and this is usually only undertaken if patients 
fail to respond to the advanced medical therapies. 
 
 
What are the possible disadvantages and risks of taking part? 
There are no additional risks associated with taking part in this trial as you would be prescribed one of the 
two drugs whether or not you take part in the trial. 
 
 
What are the side effects of any treatment received when taking part? 
Like all medicines infliximab and ciclosporin sometimes cause side effects in some people.  Please 
remember that when you first receive the treatment you will be an inpatient and will be monitored closely 
by the specialist team looking after you. 
 
You should be aware that the following side effects have been reported: 
 
Infliximab 
Most side effects are mild to moderate.  However some may be serious and may require treatment.  Side 
effects may appear up to six months after the last treatment. 
 
Up to 10% (one in 10) people have experienced:  Headache, dizziness, nausea, abdominal symptoms, 
allergic reactions, rash, urticaria, viral infections (for example herpes), respiratory infections (cold, sinus 
infections, bronchitis, pneumonia). 
 
Up to 1% (one in 100) people have experienced:  Depression, agitation, sleep disturbances, impaired 
wound heeling, bacterial infections, (for example tuberculosis, urinary tract infections, deep skin infections, 
sepsis), fungal infections, asthma, abnormal liver function, low blood cell counts including anemia, 
worsening of demyelinating nerve disease, autoimmune disease activation (SLE, lupus), worsening of 
heart failure, hair loss, bleedings, allergic anaphylactic reactions, injection site reactions. 
 
Less than 0.1% (one in 1000) people have experienced:  Gastrointestinal bleedings or perforation, 
circulatory failure, multiple sclerosis, lymphoma. 
 
  
Ciclosporin 
Most side effects are mild to moderate.  However some may be serious and may require treatment. 
  
More than 10% of people have experienced:  Kidney problems, high blood pressure, headache, tremor 
and increased levels of lipids (for example cholesterol) in the blood.  
 
Up to 10% of (one in 10) people have experienced:  Numbness or tingling, loss of appetite, feeling or 
being sick, stomach pain, diarrhoea, swollen gums, liver problems, high level of uric acid or potassium in 
the blood, low levels of magnesium in the blood, muscle pain or cramp, increased hair growth on the body 
and tiredness. 
 
Up to 1% of people (one in 100) have experienced:  Seizures, confusion, disorientation, decreased 
responsiveness, agitation, sleeplessness, visual disturbances, blindness, coma, partial paralysis, loss of 
co-ordination, changes in blood (for example anaemia), allergic rash, water retention which may cause 
swelling and weight increase. 
 
Up to 0.1% of people (one in 1000) have experienced:  Problems with the nerves that control muscles, 
inflammation of the pancreas, high levels of glucose in the blood, muscle weakness, wasting of muscles, 
destruction of red blood cells which may be associated with kidney problems, changes in the menstrual 
cycle in women and slight enlarging of the breasts in men. 
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Up to 1 in 10,000 people have experienced:  Swelling at the back of the eye which may be associated 
with an increase in pressure inside the head (benign intracranial hypertension) and visual disturbances. 
 
Like other medicines that dampen down the immune system ciclosporin may cause tumours or other 
malignancies, particularly of the skin.  It may also make you more likely to get infections which may be 
serious. 
 
What are the possible benefits of taking part? 
You will be receiving one of the two drugs as part of your treatment and by taking part in the trial you will 
be helping to identify which of the two drugs is the most effective treatment for people with your condition.  
This means that if you need this type of treatment in the future, your doctors will be better informed about 
which of the two drugs to give you. 
 
What happens when the research study stops? 
As a patient with ulcerative colitis you will continue to be reviewed in the gastroenterology clinic so your 
follow up will be as normal. 
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied.  If this happens, your research 
doctor will tell you and discuss whether you should continue in the study.  If you decide not to carry on, 
your research doctor will make arrangements for your care to continue.  If you decide to continue in the 
study he may ask you to sign an updated consent form. 
 
If the study is stopped for any other reason, we will tell you and arrange your continuing care. 
 
What will happen if I don’t want to carry on with the study? 
You may withdraw your consent and discontinue your participation in this study at any time without the 
need to give us a reason. This would not in any way affect the normal standard of care you receive. 
 
What if there is a problem? 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to the local research team 
who will do their best to answer your questions.  Alternatively you may wish to contact the coordination 
team in Swansea (Trial Manager Anne Seagrove, XXXX or   Professor John G Williams,  XXXX 
Trial Secretary, Emma Riordan, XXXX  ).  
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure.  Details can be obtained from [details] 
Harm 
Non-negligent harm:  As sponsor of this trial, Swansea University have insurance should you suffer non-
negligent harm. 
Negligent harm:  As sponsor of this trial, Swansea University have insurance should you suffer negligent 
harm. 
 
NHS based research 
In the event that something does go wrong and you are harmed during the research and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation but you may have 
to pay your legal costs.  The normal National Health Service complaints mechanisms will still be available 
to you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
Yes.  All information which is collected about you during the course of the research will be kept strictly 
confidential in accordance with ethical and legal practice and the Data Protection Act. 
 
You will have a unique trial number and any data will be collected and stored with this number.  Any 
personal identification will be stored separately from the data.  The clinical team looking after you and the 
research team are the only people who will know specific personally identifiable information that would 
allow someone to identify you and contact you. 
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If you agree to take part your GP will be informed.  If you do not want your GP to be informed you can 
indicate this on the consent form.   
 
What will happen to any samples I give? 
Any samples you give will be part of your routine clinical care and will therefore be dealt with as normal in 
the hospital.  We will be given copies of the results by your hospital doctor. 
 
Will any genetic tests be done? 
No genetic tests will be done as part of this study. 
 
What will happen to the results of the research study? 
The results of the study will be used to help doctors choose the best treatment for patients with steroid 
resistant ulcerative colitis.  Your personal information (name, date of birth, home postcode and NHS 
number) will not be revealed in any audit, study report or publication, at any time. 
 
You will be asked if you would like to receive a summary of the results of the research. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity.  This study has been reviewed approved 
by Wales Research Ethics Committee. 
 
The study has also been given Clinical Trial Authorisation by the Medicine and Healthcare Products 
Regulatory Agency (MHRA) and permission from the hospital’s Local Research Ethics Committee and 
Research and Development Office. 
 
Who is organising and funding research? 
The study is being run by the College of Medicine at Swansea University in collaboration with the 
University of Glamorgan and Bangor University.  The study is funded by the National Institute for Health 
Research Health Technology Assessment Programme. 
 
What happens when the research study stops? 
As a patient with ulcerative colitis you will continue to be reviewed in the gastroenterology clinic so your 
follow up will be as normal. 
 
What will happen if I don’t want to carry on with the study? 
You may withdraw your consent and discontinue your participation in this study at any time without the 
need to give us a reason. This would not in any way affect the normal standard of care you receive. 
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Appendix 5 Consent form (randomised
controlled trial)
CONSENT FORM (RCT) 
(Patient Consent RCT V2-0 10Oct2011) 
 
 Participant study ID:         
 
Title of Project:  CONSTRUCT 
 
Name of person taking consent: 
 Please initial 
each box 
1. I confirm that I have read and understand the information sheet dated 10 October 
2011 Version 18 for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any 
 time without giving any reason, without my medical care or legal rights being 
 affected. 
 
3.  I understand that relevant sections of my medical notes may be looked at by a 
 research nurse, regulatory authorities or the NHS Trust, where it is relevant to my 
 taking part in this research.  I give permission for these individuals to have access to 
 my records. 
 
4. I agree to the research team holding personally identifiable information 
 
 
5. I agree that a copy of this Consent Form is sent to the CONSTRUCT Trial Office 
 
 
6. I agree to the random selection of my drug treatment 
 
 
7. If I am a woman of child-bearing potential, I agree to use adequate contraception 
during treatment and for 6 months afterwards if given Remicade. 
 
8. I agree to data being collected through the research computer 
 
 
9. I agree to the completion of questionnaires for two years 
 
 
10. I agree to complete an annual questionnaire and my progress being followed for a 
further eight years using information taken from my NHS records 
 
11. I agree to my GP being informed of my participation in the study 
 
 
12. I agree to aspects of my anonymised data being used for reports about the research 
 
 
13. I agree to take part in the above study 
 
 
14. I agree, if requested, to take part in two telephone interviews (optional) 
 
 
15. I agree to the telephone interviews being audio recorded (optional) 
 
 
 
Your name in capitals Date Signature 
 
 
  
 
Name of person taking consent in capitals Date Signature 
 
 
  
 
When completed, the original should be kept in the Trial Site File, a copy should be given to the patient, one kept in 
the medical notes and one sent to the CONSTRUCT Trial Office. 
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Appendix 6 Adverse event screening form
EudraCT Number: 2008-001968-36  FAX :  01792 606599 Email: CONSTRUCTHelpdesk@swansea.ac.uk
 
Participant study ID:        
PLEASE COMPLETE THIS FORM IF THE PARTICIPANT HAS ANY NEW SIGNS OR SYMPTOMS OR 
A COLECTOMY 
 
Start date: d d m m y y Start time: h h m m (or 
Duration):  
 
End date: d d m m y y End time: h h m m 
Event description (please give as much detail as possible): 
 
 
Severity:  Outcome: 
 Mild  Complete resolution 
 Moderate  Persisting problem 
 Severe  Irreversible consequences:  Surgery required 
Trial drug: (please state which one)  Death 
 Remicade®   Other (please specify) 
 Sandimmun®   Unknown 
 Neoral®  Other (please specify) 
 
 
QUESTIONS TO DETERMINE THE “EXPECTEDNESS” OF THE ADVERSE EVENT: 
“Yes” should only be ticked for ONE of the four questions below.  As soon as a “Yes” has been ticked, 
complete the seriousness and causality categories overleaf. 
1) Is the symptom/problem a known, undesirable effect of the trial drug, please check the 
Summary of Product Characteristics (SPC), in terms of its nature and severity? 
   Yes 
   No 
If Yes, please turn over, if No go to Question 2 
2) Is the symptom/problem a stable symptom of a pre-existing condition?   
NOTE: This question only concerns symptoms of medical conditions (other than UC) that were 
identified prior to the first treatment dose, and that have NOT significantly worsened since 
treatment commenced. If symptoms of a pre-existing symptom have worsened following trial 
treatment, select "No" 
   Yes 
   No
If Yes, please turn over, if No go to Question 3 
3) Is the symptom/problem in keeping with an exacerbation or progression of the 
underlying disease (ulcerative colitis)?  
NOTE: If the problem resulted in surgery/colectomy, please answer “No” and go to Question 4. 
   Yes 
   No
If Yes, please turn over, if No go to Question 4 
4) Is the event a medical or surgical procedure e.g colectomy/colonoscopy? 
 
   Yes 
   No
Whether Yes or No, please turn over    PTO for further instructions 
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Participant study ID:        
******************************************************************************************************** 
If you have selected “Yes” for any of the earlier questions (1 – 4) the adverse event is expected and, 
by definition, cannot be a SUSAR. Please complete the seriousness and causality categories below for 
the “expected” event, sign the form and fax to the CONSTRUCT Trial Office: 
 
 Relation to trial drug (causality) Seriousness of event 
  Not related  Resulted in death 
  Unlikely to be related  Is/was life threatening 
  Possibly related  Resulted in disability / incapacity 
  Probably related  Required hospitalisation / prolonged hospital stay 
  Definitely related  Resulted in congenital abnormality / birth defect 
  
Not serious (none of the above) 
 
 
If you have selected “No” for all of the earlier questions (1 – 4) the adverse event is unexpected and 
could be a SUSAR. Please complete the seriousness and causality categories below for the “unexpected” 
event: 
 
 Relation to trial drug (causality) Seriousness of event 
  1) Not related  1) Resulted in death 
  2) Unlikely to be related  2) Is/was life threatening 
  3) Possibly related  3) Resulted in disability / incapacity 
  4) Probably related  4) Required hospitalisation / prolonged hospital stay 
  5) Definitely related  5) Resulted in congenital abnormality / birth defect 
  
6) Not serious (none of the above) 
 
 
If causality = 3, 4 OR 5 AND seriousness = 1, 2, 3, 4 OR 5, the event is a Suspected Unexpected 
Serious Adverse Reaction (SUSAR).   
You MUST now complete a SUSAR Report Form and send both the AE Screening and SUSAR 
Forms to the CONSTRUCT Trial Office within 24 hours of becoming aware of the event.  Please 
refer to the Fieldwork Handbook for further instructions. 
 
If the unexpected event is either not serious, not related or both, only fax the completed AE 
Screening Form as the event is not a SUSAR. 
 
 
 
 
 
 
Once completed, please fax this form to the CONSTRUCT Trial Office on 01792 606599 as soon as 
possible. 
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Appendix 7 Summary of data to be collected
and source
Summary of data to be collected and source of data
Type of data
Initial
inpatient stay
3.5-year designed research data collection and
record linkage
Potential annual
follow-up
(years 3.5–10)
RCT and cohort RCT Cohort RCT Cohort
Time (months) 0+ 3 6 12 18 24 30 36 12 24 Yearly Yearly
Demographic O
Administrative O
Clinical O O/R O/R O/R O/R O/R O/R O/R R R R R
Pathology results O O O O O O O O R R
Outcomes
QoL P P P P P P P P R R P
Mortality O/R O/R O/R O/R O/R O/R O/R R R R R
Readmissions O/R O/R O/R O/R O/R O/R O/R R R R R
Colectomy O/R O/R O/R O/R O/R O/R O/R R R R R
Additional data collection for colectomy patients
Hospital costs
(excluding drugsa)
O O O O O O O O R
Other NHS costs P P P P P P P P
Patient-reported AEs P P P P P P P
Patient-borne costs P P P P P P P P P
Patient views P P
Professional views Interviews conducted
O, operational clinical data extracted from hospital records; P, data collected by research professionals direct from patient
(patient data collected at specified time points); R, routinely collected data (Hospital Episode Statistics, Office for National
Statistics, Patient Episode Database Wales, standardised mortality ratio), operational and routine data collected at specific
time points indicated but cover period since last data collection.
a All drugs included under ‘other NHS costs’ even if dispensed in hospital.
Source: CONSTRUCT Protocol V3–3 31 March 2012.
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Appendix 8 Participant Baseline Questionnaire
 
 
 
 
 
 
 
Participant Baseline Questionnaire 
  (v9-0 22Mar2012) 
 
 
 
 
 
 
 
 
 
 
CONSTRUCT  
Swansea University College of Medicine, Singleton Park, Swansea SA2 8PP 
Phone: +44(0)1792 513411/513405   Fax: +44 (0)1792 606599  
Email:  
 
 
Thank you for agreeing to participate in this study.  The answers you give for this questionnaire will help 
us to find out whether the treatments you receive are helpful for your condition. 
 
The information you provide will be completely confidential and will not be accessible by any third parties. 
 
Please answer all the questions.  Although it may seem that some questions are asked more than once, 
it is still important that you answer every one.   
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If you find it difficult to answer a question, please do the best you can.  If you are unsure what the question 
is asking, please ask the research nurse to explain it. 
 
Please follow the instructions for each section of the questionnaire carefully as the sections ask you to 
think back about different periods of time. 
 
 
 
 
Date questionnaire started:  d d m m y y y y 
 
Time questionnaire started:  h h m m ( using 24h clock) 
 
Date questionnaire completed:  d d m m y y y y 
 
Time questionnaire 
completed:  
h h m m ( using 24h clock) 
 
Patient initials:     
 
 
 
 
 
For completion by the researcher only 
Name of researcher completing this questionnaire: ___________________________________ 
Has the patient completed the questionnaire without you being present? 
 Yes in full  
 Yes in part  
 No  
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The following questions ask for your views about your bowel problem and how it has affected your life 
over the last two weeks.   
 
Please answer all the questions.  If you are unsure about how to answer any question, just give the best 
answer you can.  Do not spend too much time answering, as your first thoughts are likely to be the most 
accurate.  
 
If you do not wish to answer a question, please leave it blank and complete page 9 with details of the 
question and reason(s) why it was not answered. 
  
 
 
1. On how many days over the last two weeks have you had loose or runny bowel movements? 
 
 days 
 
 
 
2. On how many days in the last two weeks have you noticed blood in your stools?  
 
 days 
 
 
 
3. On how many days over the last two weeks have you felt tired?  
 
 days 
 
 
 
4. In the last two weeks have you felt frustrated? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
5. In the last two weeks, has your bowel condition prevented you from carrying out your work or 
other normal activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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6. On how many days over the last two weeks have you opened your bowels more than three times 
a day?  
 
 days 
 
 
 
 
7. On how many days over the last two weeks have you felt full of energy?  
 
 days 
 
 
 
8. In the last two weeks did your bowel condition prevent you from going out socially? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
  
9.   On how many days over the last two weeks have your bowels opened accidentally?  
 
 days 
 
 
10.   On how many days over the last two weeks have you felt generally unwell?  
 
 days 
 
 
 
11.   In the last two weeks have you felt the need to keep close to a toilet? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
12.   In the last two weeks, has your bowel condition affected your leisure or sports activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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13.   On how many days over the last two weeks have you felt pain in your abdomen?  
 
 days 
 
 
 
 
14.   On how many nights over the last two weeks have you been unable to sleep well (days if you 
are a shift worker)?  
 
 nights (or days) 
 
 
 
 
 
15.   On how many nights in the last two weeks have you had to get up to use the toilet because of 
your bowel condition after you have gone to bed? 
 
 nights  
 
 
 
16.   In the last two weeks have you felt depressed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
17.   In the last two weeks have you had to avoid attending events where there was no toilet close at 
hand? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
18.   On how many days over the last two weeks, have you had a problem with large amounts of 
wind?  
 
 days 
 
 
 
19.   On how many days over the last two weeks have you felt off your food?  
 days 
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 20.   Many patients with bowel problems have worries about their illness.  How often during the last 
two weeks have you felt worried? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
21.   On how many days over the last two weeks has your abdomen felt bloated?  
 
 days 
 
 
 
 
22.   In the last two weeks have you felt relaxed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
23.   In the last two weeks have you been embarrassed by your bowel problem?  
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
24.   On how many days over the last two weeks have you wanted to go back to the toilet 
immediately after you thought you had emptied your bowels?  
 
 days 
 
 
 
25.   In the last two weeks have you felt upset? 
 
a) No, not at all 
b) Yes, some of the time 
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c) Yes, most of the time 
d) Yes, all of the time  
 
 
26.   On how many days over the last two weeks have you had to rush to the toilet?  
 
 days 
 
 
 
 
27.   In the last two weeks have you felt angry as a result of your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
28.   In the last two weeks, has your sex life been affected by your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
  
 
 
29.    On how many days over the last two weeks have you felt sick?  
 
 days 
 
 
 
 
30.   In the last two weeks have you felt irritable? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
31. In the last two weeks have you felt lack of sympathy from others? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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32.   In the last two weeks have you felt happy? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
If you did not complete any of these questions, please record the question number(s) below and, 
if possible, give a reason why it was not completed.  
Question No Reason for non-completion  
  
  
  
  
 
 
Please circle which one of the five statements below best describes the effect of your bowel condition over 
the last three months? 
1 2 3 4 5 
Unwell all 
of the time 
Unwell most 
of the time 
Unwell about 
half of the time 
Well most of 
the time 
Well all of 
the time
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This survey asks for your views about your health. This information will help keep track of how you feel 
and how well you are able to do your usual activities.  
For each of the following questions, please tick the one box that best describes your 
answer. 
1. In general, would you say your health is: 
 
Excellent  Very good  Good  Fair  Poor 
         
 
 
2. The following questions are about activities you might do during a typical day.  Does your health 
now limit you in these activities?  If so, how much? 
 
 Yes, limited  
a lot 
Yes, limited 
a little 
No, not 
limited at all 
a) Moderate activities, such as moving a table,       
pushing a vacuum cleaner, or playing golf   
      
b) Climbing several flights of stairs      
   
 
 
3. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health?  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Were limited in the 
kind of work or other  
          
Activities           
 
 
4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Did work or other 
activities less carefully  
          
than usual           
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5. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
 
Not at all  A little bit  Moderately  Quite a bit  Extremely 
         
 
 
 
6. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time during the 
past 4 weeks  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Have you felt calm 
and peaceful? 
          
           
b) Did you have lots of 
energy? 
          
           
c) Have you felt 
downhearted and low? 
          
 
 
 
 
7. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
 
All of  
the time 
 Most of  
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
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By placing a tick in one box in each group below, please indicate which statements best describe your 
own health state today. 
 
 
Mobility 
I have no problems in walking about  A 
I have some problems in walking about  B 
I am confined to bed  C 
 
 
Self-Care 
I have no problems with self-care  A 
I have some problems washing or dressing myself  B 
I am unable to wash or dress myself  C 
 
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  A 
I have some problems with performing my usual activities  B 
I am unable to perform my usual activities  C 
 
 
Pain/Discomfort 
I have no pain or discomfort  A 
I have moderate pain or discomfort  B 
I have extreme pain or discomfort  C 
 
 
Anxiety/Depression 
I am not anxious or depressed  A 
I am moderately anxious or depressed  B 
I am extremely anxious or depressed  C 
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To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can 
imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion.  
 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good 
or bad your health state is today. 
 
100 
Worst 
imaginable 
health state 
Best  
imaginable 
health state 
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This section is about the health care you have received – apart from any services at the hospital where 
you were recruited. 
  
All questions refer to the three months before your admission for this episode. 
 
We would like to know about contacts you have had with health professionals in the last three months for 
any reason - not just with regard to your bowel condition.  
 
Please ensure that if you tick “Yes”, that you also enter the number of times alongside the corresponding 
healthcare professional.  Where there is no number written in a box, we will assume that the answer is 
zero. 
 
 
1. In the last 3 months, have you been seen for any reason by any of the following at your GP 
surgery? 
· Your own or another GP 
· Nurse 
· Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No     Please go to Question 2   
Yes    Please enter the number of times for     
    
· Your own or another GP   
    
· Nurse    
   
· Other (please specify)    
      
 
 
2.  In the last 3 months, have you been seen for any reason by any of the following at home? 
· Your own or another GP 
· Nurse 
· Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No     Please go to Question 3   
Yes    Please enter the number of times for     
    
· Your own or another GP   
    
· Nurse    
   
· Other (please specify)    
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3. In the last 3 months, have you had a telephone discussion with any of the following about any health 
issue (NOT just to make or change appointments)? 
· With anyone at your GP surgery 
· With anyone at any hospital  
· With NHS Direct (NHS 24 if in Scotland) 
· With a health professional at another location  
 
No     Please go to Question 4   
Yes    Please enter the number of times .     
    
· With anyone at your GP surgery    
    
· With anyone at any hospital    
    
· With NHS Direct / NHS 24   
    
· With a health professional at another location   
      (Please specify)    
 
 
4. In the last 3 months, have you visited an accident and emergency (A&E) department other than at 
the hospital where you were recruited to the study? 
 
No    Please go to Question 5  
Yes    Please enter the number of times you visited another A&E    
 
 
 
5. In the last 3 months, have you been admitted as an in-patient (i.e. stayed overnight in hospital) for 
any reason at a hospital other than at the hospital where you were recruited to the study? 
 
No    Please go to Question 6  
Yes    Please enter the number of nights you spent in hospital                 
 
 
 
6.    If you are in work, did you take any time off work either due to illness or in order to see any health 
professional, for any reason, in the last 3 months? If you do not work, select “No”. 
 
No    Please go to Section F   
Yes    Please enter the number of day (to the nearest half day)  
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 Section F concerns ONLY prescribed drugs taken regularly in the three months prior to the 
admission. 
 
Please do NOT include any of the following  
1) drugs purchased without a prescription,  
2) drugs given as an inpatient at the study centre during the admission  
3) drugs which were prescribed to be taken on an “as required” basis.  
Please give details of how each drug was INTENDED to be taken (i.e. the prescription details), rather than 
how it WAS taken. 
 
 
Have you been given a prescription for any of the following drugs in the last three months?  If so, please 
record the strength of each tablet, the number to be taken per dose and the dose frequency.  If the course 
was less than 3 months, please record the number of days it was prescribed for. 
Drugs for colitis (listed in alphabetical order) 
Name of Drug Strength of each tablet  
Number taken 
per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Asacol MR            
Azathioprine        
Budenofalk        
Codeine phosphate        
Colazide        
Dipentum        
Entocort        
Continued overleaf 
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Name of Drug Strength of each tablet  
Number taken 
per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Imodium        
Lomotil        
Mercaptopurine        
Mesavant XL        
Methotrexate        
Pentasa        
Prednisolone by mouth*        
Salazopyrin        
Salofalk        
Tacrolimus        
 
 
 
*For oral prednisolone with reducing dose, please provide details below.  
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Suppositories for colitis  
Have you been given a prescription for any of the following suppositories in the last three months? If so, 
please record the strength of each tablet, the number to be taken per dose and the dose frequency.  If the 
course was less than 3 months, please record the number of days it was prescribed for. 
 
Name of Suppository Strength   Number taken per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Asacol        
Pentasa        
Salofalk        
Predsol        
 
 
Enemas for colitis 
Have you been given a prescription for any of the following prescribed enemas in the last three months?  
If so, please state how many you were prescribed. 
 
  
Asacol  
 
Colifoam  
 
Pentasa  
 
Predenema  
 
Predfoam  
 
Predsol  
 
Salofalk  
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Medication for general GI disorders 
Have you been given a prescription for any of the following prescribed drugs in the last three months? 
If so, please record the strength of each tablet, the number to be taken per dose and the dose frequency.  
If the course was less than 3 months, please record the number of days it was prescribed for. 
Name of Drug Strength 
of each 
tablet 
 Number to be 
taken per dose 
 Dose 
frequency 
 Duration 
(days) if short 
course 
Axid (Nizatidine)        
Buscopan (Hyoscine)        
Colofac (Mebeverine)        
Colpermin (Peppermint oil)        
Fybogel (Ispaghula husk)        
Maxolon (Metoclopramide)        
Merbentyl (Dicycloverine)        
Motilium (Domperidone)         
Nexium (Esomeprazole)        
Losec (Omeprazole)        
Pariet (Rabeprazole)        
Pepcid (Famotodine)            
Protium (Pantoprazole)        
Questran (Colestyramine)         
Spasmonal (Alverine)        
Tagamet (Cimetidine)        
Zantac (Ranitidine)        
Zoton (Lansoprazole)           
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Medication not listed  
Have you been given a prescription for any other drugs in the three months prior to your admission that 
have not been listed here such as antibiotics or drugs for any health condition, not just your bowel 
condition.   
 
If so, please enter the details of the drug(s) in the table below. 
REMEMBER - do not include: 
1) any drugs purchased without prescription 
2) drugs which were prescribed to be taken on an “as required” basis.  
 
Please give details of how each drug was INTENDED to be taken (i.e. the prescription details), rather than 
how it WAS taken. 
 
Drug Name 
 
Strength of 
each tablet 
No taken per 
dose 
Dose 
frequency 
Duration 
(days) if short 
course 
     
     
     
     
     
     
     
     
     
     
     
     
     
Please record any additional drugs or comments on the blank page overleaf. 
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Appendix 9 Participant Follow-Up Questionnaire
 
 
 
 
 
Participant Follow up Questionnaire 
  (v3-0 22Mar2012) 
 
 
 
 
 
 
 
 
 
 
 
 
CONSTRUCT  
Swansea University College of Medicine, Singleton Park, Swansea SA2 8PP 
Phone: +44(0)1792 513411/513405   Fax: +44 (0)1792 606599  
Email: construct@swansea.ac.uk
 
 
Follow up interval (please tick one): 
3 month  
6 month  
12 month  
18 month  
24 month  
30 month  
36 month  
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Thank you for agreeing to continue participating in this study.  The answers you give for this questionnaire 
will help us to find out whether the treatments you receive are helpful for your condition.  The information 
you provide will be completely confidential and will not be accessible by any third parties. 
 
You may wish to complete this questionnaire prior to your appointment with the CONSTRUCT Research 
Professional.  If you do, please do not complete it until the day before your appointment.  If you cannot 
complete some of the questions, please ask the Research Professional for advice when you meet.  They 
will help you with any queries you have.  Alternatively, you may wish to bring the blank questionnaire with 
you to your appointment with the Research Professional and complete it with them. 
 
Please answer all the questions.  Although it may seem that some questions are asked more than once, it 
is still important that you answer every one.  If you find it difficult to answer a question, please do the best 
you can.  If you are unsure what the question is asking, please ask the research professional to explain it 
when you meet. 
 
Please follow the instructions for each section of the questionnaire carefully as the sections ask you to 
think back about different periods of time. 
 
If you have any queries about the questionnaire, please contact us on XXXX or email XXXX.  
 
 
Date questionnaire started:  d d m m y y y y 
 
Time questionnaire started:  h h m m ( using 24h clock) 
 
Date questionnaire completed:  d d m m y y y y 
 
Time questionnaire 
completed:  
h h m m ( using 24h clock) 
 
Patient initials:     
 
 
For completion by the research professional only 
Name of researcher helping to complete this questionnaire: ____________________________ 
Has the participant completed the questionnaire without you being present? 
  Yes in full  Yes in part  No 
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The following questions ask for your views about your bowel problem and how it has affected your life 
over the last two weeks.   
 
The terms bowel problem or bowel condition refer to all aspects of your bowel illness and its related 
treatments.  If you do not have a bowel, please answer using the “not applicable” response for questions 
1, 2, 6, 9, 24 and 26. 
 
Please answer all the questions.  If you are unsure about how to answer any question, just give the best 
answer you can.  Do not spend too much time answering, as your first thoughts are likely to be the most 
accurate.   
 
1. On how many days over the last two weeks have you had loose or runny bowel movements? 
 
 days  Not Applicable 
 
2. On how many days in the last two weeks have you noticed blood in your stools?  
 
 days  Not Applicable 
 
3. On how many days over the last two weeks have you felt tired?  
 
 days 
 
4. In the last two weeks have you felt frustrated? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
5. In the last two weeks, has your bowel condition prevented you from carrying out your work or 
other normal activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
6. On how many days over the last two weeks have you opened your bowels more than three times 
a day?  
 
 days  Not Applicable 
 
 
7. On how many days over the last two weeks have you felt full of energy?  
 
 days 
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8. In the last two weeks did your bowel condition prevent you from going out socially? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
  
9.   On how many days over the last two weeks have your bowels opened accidentally?  
 
 days  Not Applicable 
 
 
 
10.   On how many days over the last two weeks have you felt generally unwell?  
 
 days 
 
 
 
11.   In the last two weeks have you felt the need to keep close to a toilet? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
12.   In the last two weeks, has your bowel condition affected your leisure or sports activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
13.   On how many days over the last two weeks have you felt pain in your abdomen?  
 
 days 
 
 
14.   On how many nights over the last two weeks have you been unable to sleep well (days if you 
are a shift worker)?  
 
 nights (or days) 
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15.   On how many nights in the last two weeks have you had to get up to use the toilet because of 
your bowel condition after you have gone to bed? 
 
 nights  
 
 
 
16.   In the last two weeks have you felt depressed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
17.   In the last two weeks have you had to avoid attending events where there was no toilet close at 
hand? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
18.   On how many days over the last two weeks, have you had a problem with large amounts of 
wind?  
 
 days 
 
 
 
19.   On how many days over the last two weeks have you felt off your food?  
 
 days 
 
 
20.   Many patients with bowel problems have worries about their illness.  How often during the last 
two weeks have you felt worried? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
21.   On how many days over the last two weeks has your abdomen felt bloated?  
 
 days 
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22.   In the last two weeks have you felt relaxed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
23.   In the last two weeks have you been embarrassed by your bowel problem?  
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
 
24.   On how many days over the last two weeks have you wanted to go back to the toilet 
immediately after you thought you had emptied your bowels?  
 
 days  Not Applicable 
 
 
25.   In the last two weeks have you felt upset? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
26.   On how many days over the last two weeks have you had to rush to the toilet?  
 
 days  Not Applicable 
 
 
 
27.   In the last two weeks have you felt angry as a result of your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
28.   In the last two weeks, has your sex life been affected by your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
178
c) Yes, most of the time 
d) Yes, all of the time  
  
 
29.    On how many days over the last two weeks have you felt sick?  
 
 days 
 
 
30.   In the last two weeks have you felt irritable? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
31. In the last two weeks have you felt lack of sympathy from others? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
 
32.   In the last two weeks have you felt happy? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time 
 
 
33.   How has your quality of life changed since the last time you filled in a questionnaire?   Please circle 
one of the five statements below: 
1 2 3 4 5 
Much better 
now 
Somewhat 
better 
About the 
same 
Somewhat 
worse 
Much worse
 
 
What date did you complete the last questionnaire? 
  
 d d m m y y y y 
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Supplementary question 
Do you have a stoma? 
    
  Yes Please continue with the questions below 
 
  No Please go straight to Section B on page 13 
 
 
For patients with stoma  
 
The following questions ask for your views about your stoma and how it has affected your life over the 
last two weeks.   
 
Please choose only one answer for each of the questions.  If you are unsure about how to answer any 
question, just give the best answer you can.  Do not spend too much time answering, as your first 
thoughts are likely to be the most accurate.   
 
1  On how many days over the last two weeks have you been afraid that other people might hear 
your stoma? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
2  On how may days over the last two weeks have you been worried that other people might smell 
your stools? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
3 On how many days over the last two weeks have you been worried about possible leakage from 
your stoma bag? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
4  On how many days over the last two weeks have you had problems with care for your stoma? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
5  On how many days over the last two weeks have you found the skin around your stoma 
irritated? 
 
  a) None 
  b) On one or two days only 
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  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
6  In the last two weeks have you felt embarrassed because of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
7  In the last two weeks have you felt less complete because of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
8  In the last two weeks have you felt less attractive as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
9  In the last two weeks have you felt less feminine / masculine as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
10 In the last two weeks have you been dissatisfied with your body as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
 
If you did not complete any of the questions asked so far, please record the question number(s) 
below and, if possible, give a reason why it was not completed.  
Question No Reason for non-completion  
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Please circle which one of the five statements below best describes the effect of your bowel condition over 
the last three months?
1 2 3 4 5 
Unwell all 
of the time 
Unwell most 
of the time 
Unwell about 
half of the time 
Well most of 
the time 
Well all of 
the time
This survey asks for your views about your health. This information will help keep track of how you feel 
and how well you are able to do your usual activities.  
For each of the following questions, please tick the one box that best describes your 
answer. 
 
8. In general, would you say your health is: 
 
Excellent  Very good  Good  Fair  Poor 
         
 
9. The following questions are about activities you might do during a typical day.  Does your health 
now limit you in these activities?  If so, how much? 
 
 Yes, limited  
a lot 
Yes, limited 
a little 
No, not 
limited at all 
a) Moderate activities, such as moving a table,       
pushing a vacuum cleaner, or playing golf   
      
b) Climbing several flights of stairs      
   
 
10. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health?  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Were limited in the 
kind of work or other  
          
activities           
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11. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Did work or other 
activities less carefully  
          
than usual           
 
 
 
12. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
 
Not at all  A little bit  Moderately  Quite a bit  Extremely 
         
 
 
 
13. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time during the 
past 4 weeks  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Have you felt calm 
and peaceful? 
          
           
b) Did you have lots of 
energy? 
          
           
c) Have you felt 
downhearted and low? 
          
 
 
 
 
14. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
 
All of  
the time 
 Most of  
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
         
 
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
  
By placing a tick in one box in each group below, please indicate which statements best describe your 
own health state today. 
 
 
Mobility 
I have no problems in walking about  A 
I have some problems in walking about  B 
I am confined to bed  C 
 
 
Self-Care 
I have no problems with self-care  A 
I have some problems washing or dressing myself  B 
I am unable to wash or dress myself  C 
 
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  A 
I have some problems with performing my usual activities  B 
I am unable to perform my usual activities  C 
 
 
Pain/Discomfort 
I have no pain or discomfort  A 
I have moderate pain or discomfort  B 
I have extreme pain or discomfort  C 
 
 
Anxiety/Depression 
I am not anxious or depressed  A 
I am moderately anxious or depressed  B 
I am extremely anxious or depressed  C 
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To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can 
imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion.  
 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good 
or bad your health state is today. 
 
Best  
imaginable 
health state 
100 
Worst 
imaginable 
health state 
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This section is about the health care you have received – apart from any services at the hospital where 
you were recruited. 
  
All questions refer to the three months before your follow up appointment. 
  
We would like to know about contacts you have had with health professionals in the last three months 
for any reason - not just with regard to your bowel condition. 
 
Please ensure that if you tick “Yes”, that you also enter the number of times alongside the corresponding 
healthcare professional.  Where there is no number written in a box, we will assume that the answer is 
zero. 
 
 
1. In the last 3 months, have you been seen for any reason by any of the following at your GP 
surgery? 
· Your own or another GP 
· Nurse 
· Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No     Please go to Question 2   
Yes    Please enter the number of times for     
    
· Your own or another GP   
    
· Nurse    
   
· Other (please specify)    
      
 
 
2.  In the last 3 months, have you been seen for any reason by any of the following at home? 
· Your own or another GP 
· Nurse 
· Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No     Please go to Question 3   
Yes    Please enter the number of times for     
    
· Your own or another GP   
    
· Nurse    
   
· Other (please specify)    
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4. In the last 3 months, have you had a telephone discussion with any of the following about any health 
issue (NOT just to make or change appointments)? 
· With anyone at your GP surgery 
· With anyone at any hospital  
· With NHS Direct (NHS 24 if in Scotland) 
· With a health professional at another location  
 
No     Please go to Question 4   
Yes    Please enter the number of times .     
    
· With anyone at your GP surgery    
    
· With anyone at any hospital    
    
· With NHS Direct / NHS 24   
    
· With a health professional at another location   
      (Please specify)  
 
 
4. In the last 3 months, have you visited an accident and emergency (A&E) department other than at 
the hospital where you were recruited to the study? 
 
No    Please go to Question 5  
Yes    Please enter the number of times you visited another A&E    
 
 
 
5. In the last 3 months, have you been admitted as an in-patient (i.e. stayed overnight in hospital) for 
any reason at a hospital other than at the hospital where you were recruited to the study? 
 
No    Please go to Question 6  
Yes    Please enter the number of nights you spent in hospital                 
 
 
 
6.    If you are in work, did you take any time off work either due to illness or in order to see any health 
professional, for any reason, in the last 3 months? If you do not work, select “No”. 
 
No    Please go to Section F   
Yes    Please enter the number of day (to the nearest half day)  
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
187
 Have you been given a prescription for any of the following drugs in the last three months?  If so, please 
record the strength of each tablet, the number to be taken per dose and the dose frequency.  If the course 
was less than 3 months, please record the number of days it was prescribed for. 
Drugs for colitis (listed in alphabetical order) 
Name of Drug Strength of each tablet  
Number taken 
per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Asacol MR            
Azathioprine        
Budenofalk        
Codeine phosphate        
Colazide        
Dipentum        
Continued overleaf 
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Name of Drug Strength of each tablet  
Number taken 
per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Entocort        
Imodium        
Lomotil        
Mercaptopurine        
Mesavant XL        
Methotrexate        
Pentasa        
Prednisolone by mouth*        
Salazopyrin        
Salofalk        
Tacrolimus        
 
 
*For oral prednisolone with reducing dose, please provide details below.  
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Suppositories for colitis  
Have you been given a prescription for any of the following suppositories in the last three months? If so, 
please record the strength of each tablet, the number to be taken per dose and the dose frequency.  If the 
course was less than 3 months, please record the number of days it was prescribed for. 
Name of Suppository Strength   Number taken per dose  
Dose 
frequency 
 Duration 
(days) if short 
course  
Asacol        
Pentasa        
Salofalk        
Predsol        
 
 
 
Enemas for colitis 
Have you been given a prescription for any of the following prescribed enemas in the last three months?  
If so, please state how many you were prescribed. 
 
  
Asacol  
 
Colifoam  
 
Pentasa  
 
Predenema  
 
Predfoam  
 
Predsol  
 
Salofalk  
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Medication for general GI disorders 
Have you been given a prescription for any of the following prescribed drugs in the last three months? 
If so, please record the strength of each tablet, the number to be taken per dose and the dose frequency.  
If the course was less than 3 months, please record the number of days it was prescribed for. 
Name of Drug Strength 
of each 
tablet 
 Number to be 
taken per dose 
 Dose 
frequency 
 Duration 
(days) if short 
course 
Axid (Nizatidine)        
Buscopan (Hyoscine)        
Colofac (Mebeverine)        
Colpermin (Peppermint oil)        
Fybogel (Ispaghula husk)        
Maxolon (Metoclopramide)        
Merbentyl (Dicycloverine)        
Motilium (Domperidone)         
Nexium (Esomeprazole)        
Losec (Omeprazole)        
Pariet (Rabeprazole)        
Pepcid (Famotodine)            
Protium (Pantoprazole)        
Questran (Colestyramine)         
Spasmonal (Alverine)        
Tagamet (Cimetidine)        
Zantac (Ranitidine)        
Zoton (Lansoprazole)           
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Medication not listed  
Have you been given a prescription for any other drugs in the three months prior to your admission that 
have not been listed here such as antibiotics or drugs for any health condition, not just your bowel 
condition.   
 
If so, please enter the details of the drug(s) in the table below. 
 
 
Drug Name 
 
Strength of 
each tablet 
No taken per 
dose 
Dose 
frequency 
Duration 
(days) if short 
course 
     
     
     
     
     
     
     
     
     
     
     
     
     
Please record any additional drugs or comments on a blank page and attach it. 
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Section G: Participant-reported adverse events 
Continued overleaf  
 
a)  Have you had any of the following diagnoses since you were last seen by the Research 
Professional for your CONSTRUCT-related appointment?   
- If “Yes” is ticked, record the site(s) of the condition and the date(s) of the diagnosis.   
- Please note that further information will be required to complete an Adverse 
Event (AE) Screening Form for that diagnosis.  You will be asked for a brief 
description during your follow up appointment with the Research Professional. 
 
Incidence of . No Yes Site(s) of condition (on the body) Date of diagnosis 
Colorectal 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Other 
gastrointestinal 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Non- 
gastrointestinal 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Pneumonia    d d m m y y y y 
 d d m m y y y y 
Abscesses    d d m m y y y y 
 d d m m y y y y 
Other serious 
bacterial infections 
   d d m m y y y y 
 d d m m y y y y 
Renal disorders    d d m m y y y y 
 d d m m y y y y 
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b) Have you experienced any NEW problems or symptoms since you were last seen by the Research 
Professional for your CONSTRUCT study-related appointment which was not listed on p25?   
 
 No The questionnaire is now complete.  Please record the date and time of  
completion on p3.   
 
 Yes Please provide details of the new problem(s) / symptom(s) separately below 
 
Start date 
(dd/mm/yyyy) 
 
End date (if 
appropriate) 1 
(dd/mm/yyyy) 
Brief description of the problem / symptom 
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Appendix 10 Cohort case report form
 
 
 
 
 
 
 
 
 
 
 
 
Please begin to complete this Case Report Form (CRF) once the 
participant has consented to the CONSTRUCT cohort study. 
 
 The CRF should be completed using black ink and BLOCK CAPITALS.   
 Once Section 1 has been completed, it should be detached from the rest of the 
CRF, faxed separately from the rest of the CRF and stored in a secure location for 
data protection purposes. 
 RCT eligibility criteria questions are written in bold.  Those responses that make 
the participant ineligible for the RCT are in bold and have a [X].   
 Once each page has been completed, the person completing it should initial and sign 
their name and record the date of completion at the bottom of that page. 
 Any amendments to the CRF should be done by crossing out the error once, initialling 
and dating that action.  The new entry should be written in alongside as clearly as 
possible. 
 If you have any queries relating to the completion of this CRF, please contact the 
CONSTRUCT Helpdesk by email on CONSTRUCTHelpdesk@swansea.ac.uk  
 Please fax all pages in accordance with the instructions written on the relevant pages of 
this CRF to the CONSTRUCT Trial Office on 01792 606599.   
Centre / Hospital Name 
 
Participant study ID 
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Participant study ID 
       
  
Section 1a: Participant demographics 
 
Title:  Mr  Mrs  Miss  Ms  Dr Other (specify) 
Surname:  
Forename(s):  
  
Date of birth:  d d m m y y y y NOT eligible for the RCT if <18y [X] 
  
Gender:        Male   Female 
  
NHS No:           
 
Hospital No:           
Home address:  
  
  
Postcode:               
 
  
Tel. No: 0              
 
  
Ethnic group:  White  Mixed 
  Black  Any other ethnic group (specify) 
  Asian   
 
 
 
 
 
 
 
 
 
Section 1b: Participant’s GP details  
GP full name:  GP ID code:  
Practice name:  GP Practice code:  
Practice address:   
  
  
Practice postcode:         
 
Once Section 1 has been completed, detach it, fax it to the CONSTRUCT Trial Office on 
01792 606599 and then store it in a secure location away from the rest of the CRF. 
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Section 2: Details of presenting complaint(s)  
 
What are the relevant presenting complaints for this episode?   
(Tick all appropriate responses) 
 
  No relevant symptoms  
  Diarrhoea   If so, record stool frequency   (per day) 
  Bloody diarrhoea   If so, record bloody stool frequency   (per day) 
  Abdominal pain          
   Tiredness     
  Malaise (feeling unwell)  
  Weight loss                           
  Other(s) (specify)  
   
   
   
    
 
    
Duration of current symptoms for this episode?  (days)  
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Section 3: Past medical & surgical history 
3a – Inflammatory Bowel Disease (IBD) history 
Has the participant been previously diagnosed with IBD?  
  No If No, go straight to Section 3b  
  Yes If Yes, please indicate which IBD was diagnosed and complete the sub-questions  
 
  Ulcerative colitis (UC) (please answer sub-question a) 
 a) Extent of disease  E1 – Ulcerative proctitis (limited to rectum) 
   E2 – Left sided UC (distal to splenic flexure) 
   E3 – Extensive UC (extends proximal to splenic flexure) 
   Unknown disease extent 
 
  Crohn’s disease (please answer sub-questions a-e) 
 a) Age at diagnosis  Below 16 years old 
   Between 17 and 40 years old 
   Above 40 years old 
   Unknown age at diagnosis 
 
 b)  Location of disease  Ileal Crohn’s 
   Colonic Crohn’s 
   Ileocolonic Crohn’s 
   Isolated upper GI disease 
   Disease location unknown 
c) Is there a concomitant upper GI disease?  Yes  No  Unknown 
 
 d) Disease behaviour  Non-stricturing, non-penetrating 
   Stricturing 
   Penetrating 
e) Is there a concomitant perianal disease?  Yes  No  Unknown 
 
  Indeterminate colitis (please answer sub-question a) 
 a) Extent of disease  Proctitis (limited to rectum) 
   Left sided colitis (distal to splenic flexure) 
   Extensive colitis (extends proximal to splenic flexure) 
   Unknown disease extent 
 
  Microscopic colitis  
 
  Unknown type of IBD 
 
Date of diagnosis (nearest month and year): m m y y y y 
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3b – Drug history 
Please tick to indicate which drug(s) the participant has been prescribed and how long ago 
it was last taken.  Then record the month and year the drug was first prescribed. 
NOTE: PARTICIPANT IS INELIGIBLE FOR RCT IF ANY BOXES MARKED WITH [X] ARE TICKED 
* Duration of current steroid treatment (days):  
  
  
 
 
 
Drugs list 
When drugs last taken   
 
 
Date first prescribed 
N
ev
er
 p
re
sc
rib
ed
  
In
 th
e 
pa
st
  
(b
ut
 n
ot
 la
st
 3
m
) 
In
 la
st
 3
m
  
(b
ut
 n
ot
 c
ur
re
nt
ly
) 
Ta
ke
n 
fo
r c
ur
re
nt
 
ep
is
od
e 
 
Oral steroid therapy  
e.g. prednisolone 
   *  m m y y y y 
            
            
Biological therapies  
e.g. Infliximab   
  [X] [X]  m m y y y y 
Rosuvastatin    
(Crestor®) 
  [X] [X]  m m y y y y 
Ciclosporin 
(Sandimmun®, Neoral®) 
  [X] [X]  m m y y y y 
Tacrolimus 
(Prograf® / Fujimycin) 
  [X] [X]  m m y y y y 
Azathioprine 
     m m y y y y 
Methotrexate       
     m m y y y y 
Mercaptopurine          
(6-MP / Puri-Nethol®) 
     
m m y y y y 
Sulfazalazine 
     m m y y y y 
Mesalazine 
     m m y y y y 
Other aminosalicylate  
     m m y y y y 
 (please specify)  
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3c – Drug allergies 
Does the participant have a history of hypersensitivity to any of the following: 
NOTE: PARTICIPANT IS INELIGIBLE FOR RCT IF ANY BOXES MARKED WITH [X] ARE TICKED 
 Yes  No  
Infliximab (Remicade®) [X]    
Ciclosporin (Sandimmun® / Neoral® / Deximune®) [X]    
Polyethoxylated oils [X]    
 
3d  – Co-morbidities 
Please indicate which statement is correct by ticking the relevant box. 
NOTE: PARTICIPANT IS INELIGIBLE FOR RCT IF ANY BOXES MARKED WITH [X] ARE TICKED 
Ischaemic heart disease (IHD)  No history 
  IHD but no recent MI 
 [X] Acute MI in last month  
 
Heart failure  No history 
 [X] Moderate / severe heart failure  
 
Cerebrovascular disease (CVD) 
& stroke 
 No history 
 CVD but no acute stroke 
 [X] Acute stroke within last month  
 
Respiratory disease   No history 
  Chronic respiratory disease 
 [X] Respiratory failure  
 
Renal disease  No history 
  Chronic renal disease 
 [X] Renal failure  
   
Hepatic (liver) disease  No history 
  Chronic liver disease 
 [X] Hepatic failure  
 
Immunodeficiency  No current diagnosis of immunodeficiency
 [X] Current diagnosis of immunodeficiency 
 
Active tuberculosis  No active / suspected active tuberculosis 
 [X] Active / suspected active tuberculosis 
 
Severe infection  No severe infection 
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 [X] Severe infection present 
 
 
Malignancy  No current malignancy (excl. BCC)  
 [X] Current malignancy diagnosed (not including BCC)  
 
Severe cognitive impairment  No 
 [X] Severe cognitive impairment diagnosed  
 
Diabetes mellitus  No diagnosis of diabetes mellitus 
  Type 1 diabetes mellitus 
  Type 2 diabetes mellitus
  Other diabetes type e.g. LADA
  Diabetes type unknown 
  Unknown whether participant has diabetes mellitus 
 
 
Hypertension  No hypertension 
  Participant has hypertension 
  Unknown whether participant has hypertension  
 
 
Hypercholesterolaemia  
requiring treatment 
 No hypercholesterolaemia requiring treatment 
 Participant has hypercholesterolaemia requiring treatment 
 Unknown whether participant has hypercholesterolaemia  
 
 
3e – Previous surgical procedures 
Please tick to indicate whether the participant has had any of the following surgical 
procedures? If they have, please record the year of surgery. 
 
Procedures Unknown No Yes  If Yes, year of surgery  
Colonic surgery     y y y y 
Small bowel surgery    y y y y 
Gastric surgery    y y y y 
Appendicectomy    y y y y 
Cholecystectomy    y y y y 
Open urological surgery    y y y y 
Open gynaecological surgery *    y y y y 
  *Tick “No” if participant is male 
 
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
201
Section 4: Family & social history 
4a – Family history 
Does the participant have a first degree relative previously diagnosed with an IBD? 
  No  (If No, go to Section 4b) 
  Yes If Yes, please complete below 
 
 
Please indicate which diagnosis the parent(s) had by ticking in the relevant column. 
Relationship Ulcerative 
Colitis 
Crohn’s 
disease 
Indeterminate 
colitis 
Microscopic 
colitis 
Unknown 
Mother                           
Father      
 
Please enter the number of siblings and children with a diagnosis of each IBD in the relevant column 
Relationship Ulcerative 
Colitis 
Crohn’s 
disease 
Indeterminate 
colitis 
Microscopic 
colitis 
Unknown 
Sibling(s)       
Child(ren)      
 
4b – Social history 
For each question, please indicate which ONE statement is correct: 
 
4b.i  Participant’s smoking status: 
   Current smoker     
 Ex-smoker  
 Non-smoker (history unknown)  
 Never smoked  
 Unknown    
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4b.ii Pregnancy / lactation status:  
Date of pregnancy test:     d d m m y y y y 
  
   Not applicable (participant is female and menstruating / participant is female and 
post-menopausal / participant is male) 
 Participant not currently pregnant or lactating (MUST be confirmed by negative 
pregnancy test if of child bearing age and to be considered for RCT)
[X] Participant is currently pregnant (MUST be confirmed by pregnancy test 
wherever appropriate) 
[X] Participant is currently lactating and breastfeeding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4b.iii Participant’s participation in other clinical trials: 
   Participant not in any other clinical trials    
[X] Participant in another clinical trial(s)   
(If so, please specify which one(s)) 
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Section 5: Baseline clinical data 
Please record test results that correspond closest to the date of admission for this episode. 
Place a cross in the final column if the test was not done (routinely / on this occasion). 
5a – Clinical measurements on admission  
Measurement Result  Test NOT done 
X 
Weight   (Kg)    
Height   (m)    
Pulse   (bpm)    
Temperature   (ºC)    
Systolic blood pressure   (mm Hg)    
Diastolic blood pressure   (mm Hg)    
 
5b – blood results on admission  
Haemoglobin  (g/dL)    
Urea   (mmol/L)    
Creatinine   (mmol/L)    
Sodium  (mmol/L)    
Potassium  (mmol/L)    
Chloride  (mmol/L)    
Bicarbonate  (mmol/L)    
C-Reactive protein (CRP)  (mg/L)    
Erythrocyte Sedimentation Rate (ESR)  (mm/hr)    
Alanine transaminase (ALT)  (U/L)    
Aspartate transaminase (AST)  (U/L)    
Alkaline phosphatase (ALP)  (U/L)    
Total bilirubin  (µmol/L)    
Gamma glutamyl transpeptidase (GGT)  (U/L)    
Albumin  (g/L)    
Total cholesterol   (mmol/L)    
Truelove & Witts score (see overleaf)  (range 0-4)    
Glomerular Filtration Rate (GFR)  (mL/min/m2)    
Calculating the Truelove & Witts score - 1st stage T&W score to be calculated by determining if the patient had 
bloody stool frequency of 6 or more daily and any one of the following additional criteria:  
· pulse >90 bpm;  
· haemoglobin <10.5 g/dL;  
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· temperature >37.8oC;  
· ESR >30 mm/hr or CRP > 30 mg/L.   
o Count the number of additional criteria met by the patient (up to 4) and insert this number as their 
T&W score.  
o If the patient only has a bloody stool frequency of more than 6 per day, enter “0”.  
o If the patient does not have a bloody stool frequency of more than 6 per day, enter “0”. 
5c – Endoscopy performed  
 
Was an endoscopy performed?  
  Yes 
  No If No, clinical judgement of disease severity: 
    
Severe colitis  
[X] Not severe colitis  
 
 
 
 
 
 
 
 
 
Date of endoscopy: d d m m y y y y 
 
Endoscopic findings: 
 
 [X] NORMAL or inactive disease (score = 0)  
 [X] MILD: erythema, decreased vascularity, mild friability (score = 1)  
 MODERATE: marked erythema, absent vascularity, friability, erosions (score = 2)  
  SEVERE: Spontaneous bleeding, ulceration (score = 3)  
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5d – Stool culture results  
 
Please indicate which of the following statements is correct: 
  Stool culture normal (negative for infection) 
  Growth on stool (see notes below) 
 
Date of stool culture results:  d d m m y y y y 
  
 
Growth identified as: [X] Campylobacter on stool culture 
 [X] Salmonella on stool culture 
 [X] Shigella on stool culture 
  C difficile  
  [X] C difficile on stool culture 
   C difficile on toxin ELISA (see note #3 below) 
  Number of positive toxin ELISA tests  
 [X] Cytomegalovirus (CMV) on stool culture 
 [X] Amoebiasis on stool culture 
 [X] Unclassified / other infection (please specify) 
    
  Equivocal stool test result (please give details)  
  
 
NOTES:  
1) If the participant is proven to have infective colitis with NO evidence of any other IBD, they must be 
excluded from the cohort study by completing the Cohort Exclusion Form. 
2) If the participant has infective colitis alongside another IBD, they may remain in the cohort. 
3) A positive C difficile result on ELISA can be overridden by a clinical decision if the test is considered 
unreliable (see Section 5f). C difficile on stool culture excludes the patient from the RCT. 
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5e – Histology results  
Please indicate which of the three following statements is correct: 
  Histology not done – participant known to have ulcerative colitis (go to Section 5f) 
 [X] Histology reported as normal  
  Abnormalities reported on histology  
 
Date of histology results:  d d m m y y y y 
 Abnormality reported as: 
  Ulcerative colitis  
 [X] Crohn’s disease  
  Indeterminate colitis which is   Clinically ulcerative colitis 
   [X] Clinically Crohn’s disease 
 [X] Cytomegalovirus (CMV) colitis 
 [X] Microscopic colitis 
 [X] Other histology results (please specify) 
   
 
 
 
5f – Clinical conclusion after all test results received 
Conclusion:  UC only – no other abnormal test results 
  UC + results that do not exclude from RCT (e.g. C diff on ELISA) 
 [X] UC + infection that excludes from RCT 
 [X] UC + other cause of exclusion from RCT (e.g. age <18y, pregnancy, etc) 
 [X] Other IBD (not UC) 
 [X] Infective colitis only 
 [X] Other non-IBD diagnosis (specify)  
 
Please fax all pages completed so far to 01792 606599 as soon as possible. 
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 NOTE: When entering data onto GeneCIS, Section 6 of the 
Cohort CRF: Progress (after 2 days of IV steroids) can be 
found on the separate questionnaire: '04 - Cohort Progress'  
 
Date of transfer from IV to oral steroids: d d m m y y y y 
Date of decision regarding response to IV steroids: d d m m y y y y 
  Inadequate response within approx 2-5 days  
  Criteria for non-response decision: 
   Stool frequency >8 per day 
   Stool frequency of 3-8 per day with CRP > 45mg/L 
   Clinical judgement (state basis for opinion) 
    
    
Section 6: Progress (after 2 days IV steroid treatment) 
After 2 days treatment with intravenous (IV) hydrocortisone, a decision should be made 
regarding the participant’s response. 
6a – Steroid treatment 
6a.i  Has IV hydrocortisone treatment been initiated at any point following admission?   
 [X] No Go to Section 6b 
  Yes  
Date IV steroid therapy initiated: d d m m y y y y 
 
Time IV steroid therapy initiated: h h m m (using 24h clock) 
 
 
 
 
 
6a.ii  Participant’s response to IV  hydrocortisone treatment: 
 [X] Good response within approx 2-5 days  
  Truelove & Witts score on day 5 / at discharge (whichever is sooner):  
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
208
6b – Surgery 
Is clinical judgement that the participant requires a colectomy without further medical 
treatment? 
  No  - COHORT CRF COMPLETED 
 [X] Yes  
Which type of surgery was performed: 
  Panproctocolectomy 
  Subtotal colectomy 
  Ileoanal pouch with stoma 
  Ileoanal pouch without stoma 
  Formation of ileostomy 
  Other surgical procedure (please state) 
   
 
 
 
Date of surgery: d d m m y y y y  
 
 
 
You have now reached the end of the Cohort CRF.   
Please fax all pages to the CONSTRUCT Trial Office on 01792 606599 as soon as possible. 
If some information is outstanding, please record it as soon as possible and refax that page.
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Appendix 11 Randomised controlled trial case
report form
 
www.construct.swansea.ac.uk  EudraCT Number: 2008-001968-36   Email: CONSTRUCTHelpdesk@swansea.ac.uk 
Participant study ID: 
       
 
 
 
 
 
 
Complete Sections 1 & 2 of this CRF 7 days prior to the participant’s scheduled follow up 
appointment to assess the participant’s eligibility for follow up and fax to the Trial Office. 
 
Complete Sections 3 to 11 after the participant’s routine follow up appointment for their ulcerative 
colitis approximately 3m after their trial treatment.  These sections refer to the time from the date 
of randomisation/discharge up to and including the date of their 3m follow up appointment. 
 Once each page has been completed, the person completing it should initial and sign 
their name and record the date of completion at the bottom of that page. 
 Section 10 relates to blood ciclosporin levels and should only be completed if the 
participant was randomised to receive Sandimmun®. 
 Any amendments to the CRF should be done by crossing out the error once, initialling 
and dating that action.  The new entry should be written in alongside as clearly as 
possible. 
 If you have any queries relating to the completion of this CRF, please contact the 
CONSTRUCT Helpdesk by email on CONSTRUCTHelpdesk@swansea.ac.uk  
 
 
 
Study Centre Name (i.e. Trust / Health Board name) 
 
Study Site Name (i.e. Hospital name) 
 
Participant study ID 
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Participant study ID: 
       
 
Please complete 7 days before the participant’s routine 3m follow up 
appointment with the healthcare professional is due. 
 
 
· If any of this section of the CRF has been completed with a “Yes”, please detach it and fax it 
separately to the CONSTRUCT Trial Office.   
· Section 1 must be filed separately in a secure place. 
 
 
 
Section 1: Participant demographics - update  
Please check whether any of the following information about the participant has changed 
since the date of discharge.   
 If there is no change to existing data, tick “No”. 
 If information about the participant has changed, tick “Yes” and record the new 
details. 
 
Field No  Yes  Change to  
Title      
 
Surname      
 
Address      
      
      
 
Postcode      
 
Tel number       
 
GP name      
 
GP practice      
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Please complete 7 days before the participant’s routine 3m follow up 
appointment with the healthcare professional is due. 
 
 
 
 
 
 
Section 2: Patient eligibility for follow up 
2a) Details of death of participant 
Has the participant died since the date of discharge? 
  No (Go to Section 2b) 
  Yes (Please record date of death and also complete an AE Screening Form for  the event 
  leading to the death) 
 Date of death: d d m m y y y y 
2b) Details of withdrawal of participant 
Has the participant withdrawn from any aspect of the trial since the date of discharge? 
  No (Go to Section 3) 
  Yes (Complete a Participant Withdrawal Form and also complete below) 
Which of the following has the participant withdrawn from? (Instructions for completion of 
follow up data collection forms are in brackets) 
  Access to medical records AND completion of participant questionnaires  
(3m RCT CRF - UP TO DATE OF WITHDRAWAL.  Do not send PFQ)  
  Access to medical records only  
(3m RCT CRF - UP TO DATE OF WITHDRAWAL.  PFQ can be sent) 
  Completion of participant questionnaires only  
(3m RCT CRF – complete in full.  Do not send PFQ) 
  Completion of trial treatment only  
(3m RCT CRF – complete in full.  PFQ can be sent) 
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Participant study ID: 
       
Complete Sections 3-10 as soon as possible after the participant’s 3m 
follow up appointment with their healthcare professional as part of 
their ongoing care for their ulcerative colitis. 
Please ensure that the information in this CRF corresponds to the information collected since the 
date of the randomisation up to and including the date of the participant’s 3m follow up 
appointment with the PI / other authorised person. 
All tests, etc done since the 3m follow up appointment will be collected in the 6m RCT CRF.  To 
prevent double-counting, please ensure that the data in this CRF relates to information up to and 
including the 3m follow up appointment date but not beyond. 
 
DATES FOR REFERENCE: 
Date of randomisation: Date of 3m follow up appointment: 
d d m m y y y y d d m m y y y y 
 
 
 
 
 
Section 3: Treatment continuation 
Was the trial treatment discontinued prematurely by the PI (or other authorised person)? 
  No (Go to Section 4) 
  Yes (Please complete the rest of Section 3) 
 
 
Date treatment discontinued: d d m m y y y y 
 
Reason for discontinuation:  
  Adverse event occurred (If so, also complete an AE Screening Form) 
  
  Surgery required (If so, also complete an AE Screening Form) 
 
  Other (please state) 
 
 
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
214
Participant study ID: 
       
 
 
 
 
 
 
 
 
 
Section 4: Surgery details 
Has the participant had colitis-related surgery since the date of randomisation? 
  No (Go to Section 5) 
  Yes (Complete the rest of Section 4 AND also complete an AE Screening Form) 
 
Type of surgery Date surgery performed Tick if done as 
an emergency 
Panproctocolectomy d d m m y y y y     
Subtotal colectomy d d m m y y y y     
Ileoanal pouch with stoma d d m m y y y y     
Ileoanal pouch without stoma d d m m y y y y     
Formation of ileostomy d d m m y y y y     
A reversal procedure d d m m y y y y     
Resuture procedure d d m m y y y y     
Abscess drainage d d m m y y y y     
Other colitis-related surgical procedure(s) (please state what, the date it was performed 
and whether it was done as an emergency) 
  d d m m y y y y     
Date of admission:  d d m m y y y y   
Date of discharge:  d d m m y y y y   
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Please enter any additional sites and dates under the headings listed on the Additional 
Comments Form if there is insufficient space on this page.  
 
 
 
Section 5: Participant follow up events - New conditions 
Please tick in the “Yes” or “No” column to indicate whether, according to the hospital notes, 
the participant has been diagnosed with any of the following since they were randomised 
up to and including the date of the 3m follow up appointment (include all diagnoses 
made during the 3m follow up appointment in this CRF).  
The participant will be asked the same questions during their follow up appointment in the 
PFQ to capture all non-hospital diagnoses (e.g. GP diagnosis of a serious infection).  
If “Yes” is ticked, record the site(s) of the condition and the date(s) of the diagnosis.   
IMPORTANT: AN AE SCREENING FORM IS REQUIRED FOR EACH CONDITION. 
Incidence of . No Yes Site(s) of condition Date of diagnosis 
Colorectal 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Other GI 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Non-GI 
malignancies 
   d d m m y y y y 
 d d m m y y y y 
Pneumonia    d d m m y y y y 
 d d m m y y y y 
Abscesses    d d m m y y y y 
 d d m m y y y y 
Other serious 
bacterial 
infections  
   d d m m y y y y 
 d d m m y y y y 
Renal disorders    d d m m y y y y 
 d d m m y y y y 
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For Section 6 onwards, please complete the data that relates to the study centre (i.e. the Trust / 
Health Board) where they were recruited, not just that particular hospital and include tests for any 
condition, not just their bowel condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Section 6:  Healthcare contacts / episodes 
Complete this section with counts of the number of contacts / episodes by the participant at the 
study centre (not just at the hospital where they were recruited). 
 
 
Contact type (for any condition) Number of contacts  
 
1. Clinic visits (Include further Remicade® infusions (if relevant) 
            and the 3m follow up appointment) since randomisation 
  
 
      2.    A&E attendances since randomisation 
 
  
 
Nights spent as an inpatient (for any condition) Number of nights  
 
1. Number of nights as an inpatient during the original episode that  
             led to them being entered into the trial 
  
 
2. Number of nights as an inpatient since their discharge  following 
            their first infusion 
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Section 7: Drugs given as an inpatient since randomisation 
Complete the details of any drugs given as an inpatient since the date of randomisation to 
the date of the 3m follow up appointment.  Include any drugs given in response to an adverse 
event (AE) whilst an inpatient.  Some common drugs have been listed for your convenience.  
Please write in any additional drugs not listed in the empty rows. 
 
Drug name Strength   Number 
per dose 
Dose 
frequency 
Number of 
days given  
(in total) 
Used to 
treat an 
AE? 
Adalimumab      
Azathioprine       
Mercaptopurine      
Methotrexate      
Prednisolone      
Septrin      
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Section 8: Tests & procedures performed 
Complete the number of each test listed performed at that study centre for any condition 
between date of randomisation and date of 3m follow up appointment.   
INCLUDE all tests done as part of the 3m follow up appointment in this section. 
Test type No. of tests / procedures performed  
BLOOD TESTS 
1. Ciclosporin levels     
2. Full blood count    
3. C-Reactive Protein (CRP)    
4. Erythrocyte Sedimentation Rate (ESR)     
5. Urea & electrolytes     
6. Calcium & phosphate     
7. Liver function tests (LFTs)    
8. Clotting profile    
9. Thiopurine Methyltransferase (TPMT)     
PROCEDURES 
10. Oesophogastroduodenoscopy (OGD)    
11. Barium meal    
12. Barium follow through    
13. Barium enema     
14. Colonoscopy with biopsy    
15. Colonoscopy without biopsy    
16. Flexible sigmoidoscopy    
17. Rigid sigmoidoscopy     
18. CT scan    
19. MRI scan    
20. Abdominal x-ray    
21. Chest x-ray    
22. Stool culture/testing    
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9a – Clinical measurements at 3m follow up appointment   
Measurement Result  Test NOT requested (X) 
Weight   (Kg)    
Pulse   (bpm)    
Temperature   (ºC)    
Systolic blood pressure   (mm Hg)    
Diastolic blood pressure   (mm Hg)    
Stool frequency  (per day)    
Bloody stool frequency   (per day)    
(Continued overleaf) 
Section 9: 3m follow up appointment test results 
Please record the results of the tests done at the 3m follow up appointment with the healthcare 
professional.   
· Where tests use different units of measurement, please record the information as it 
is displayed locally, remembering to include local units of measurement 
· Place a cross in the final column if the test has not been requested, either routinely 
or on this occasion. 
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9b – Blood results at 3m follow up appointment   
Measurement Result  Test NOT requested (X) 
Haemoglobin   (g/dL)    
Urea   (mmol/L)    
Creatinine   (mmol/L)    
Sodium  (mmol/L)    
Potassium  (mmol/L)    
Chloride  (mmol/L)    
Bicarbonate  (mmol/L)    
C-Reactive protein (CRP)   (mg/L)    
Erythrocyte Sedimentation Rate (ESR)   (mm/hr)    
Alanine transaminase (ALT)  (U/L)    
Aspartate transaminase (AST)  (U/L)    
Alkaline phosphatase (ALP)  (U/L)    
Total bilirubin  (µmol/L)    
Gamma glutamyl transpeptidase (GGT)  (U/L)    
Albumin  (g/L)    
Total cholesterol   (mmol/L)    
Glomerular Filtration Rate (GFR)  (mL/min/m2)   
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Section 10: Blood ciclosporin levels  
 
Participant allocated to Sandimmun® & Neoral®:  No – Go to Section 11 
  Yes – complete section below 
 
Date of each test Result (ng/mL) 
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
d d m m y y y y    
 
 
 
 
Once completed, fax this CRF to the CONSTRUCT Trial Office on 01792 606599.   
 
Do not wait for Section 11 to be completed before faxing.  Refax this page once the 6m follow up 
appointment date is known. 
 
 
 
 
 
Section 11: Date of 6m follow up appointment  
 
Complete this section when a date 
has been allocated d d m m y y y y 
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Appendix 12 Post-Colectomy Questionnaire
 
 
 
www.construct.swansea.ac.uk    EudraCT number: 2008-001968-36
Participant study ID:    
    
 
 
 
 
 
 
Post Colectomy Questionnaire 
  (v1-0 30Apr2012) 
(for completion by patients with colectomy or reversal) 
 
Please tick to indicate which time period this 
questionnaire refers to: 
On discharge   
4 weeks post discharge  
8 weeks post discharge  
12 weeks post discharge  
 
 
 
 
CONSTRUCT  
Swansea University College of Medicine, Singleton Park, Swansea SA2 8PP 
Phone: +44(0)1792 513411/513405   Fax: +44 (0)1792 606599 
  
Email: construct@swansea.ac.uk 
Website: www.construct.swansea.ac.uk  
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Please read all the instructions before completing this questionnaire. 
 
 
Thank you for agreeing to continue participating in this study.  The answers you give for this questionnaire 
will help us to find out whether the treatments you receive are helpful for your condition. 
 
The information you provide will be completely confidential and will not be accessible by any third parties. 
 
Please answer all the questions.  Although it may seem that some questions are asked more than once, it 
is still important that you answer every one.   
 
If you find it difficult to answer a question, please do the best you can.  If you are unsure what the question 
is asking, please ask the research professional to explain it when you meet. 
 
Please follow the instructions for each section of the questionnaire carefully as the sections ask you to 
think back about different periods of time. 
 
Please return the completed questionnaire to CONSTRUCT, College of Medicine, Swansea University, 
FREEPOST SWC4951, Swansea SA2 8ZZ  
 
 
If you have any questions about the questionnaire, please contact us on XXXX or email XXXX.  
 
 
Date questionnaire started:  d d m m y y y y 
 
Time questionnaire started:  h h m m ( using 24h clock) 
 
Date questionnaire completed:  d d m m y y y y 
 
Time questionnaire 
completed:  
h h m m ( using 24h clock) 
 
Patient initials:     
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The following questions ask for your views about your bowel problem and how it has affected your life 
over the last two weeks.   
 
The terms bowel problem or bowel condition refer to all aspects of your bowel illness and its related 
treatments.  If you have had some bowel surgery you may wish to answer questions 1, 2, 6, 9, 24 and 26 
using the “not applicable” response. 
 
Please answer all the questions.  If you are unsure about how to answer any question, just give the best 
answer you can.  Do not spend too much time answering, as your first thoughts are likely to be the most 
accurate.  
 
1. On how many days over the last two weeks have you had loose or runny bowel movements? 
 
 days  Not Applicable 
 
2. On how many days in the last two weeks have you noticed blood in your stools?  
 
 days  Not Applicable 
 
3. On how many days over the last two weeks have you felt tired?  
 
 days 
 
4. In the last two weeks have you felt frustrated? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
5. In the last two weeks, has your bowel condition prevented you from carrying out your work or 
other normal activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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6. On how many days over the last two weeks have you opened your bowels more than three times 
a day?  
 
 days  Not Applicable 
 
7. On how many days over the last two weeks have you felt full of energy?  
 
 days 
 
8. In the last two weeks did your bowel condition prevent you from going out socially? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
9.   On how many days over the last two weeks have your bowels opened accidentally?  
 days  Not Applicable 
 
10.   On how many days over the last two weeks have you felt generally unwell?  
 
 days 
 
11.   In the last two weeks have you felt the need to keep close to a toilet? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
12.   In the last two weeks, has your bowel condition affected your leisure or sports activities? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time 
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13.   On how many days over the last two weeks have you felt pain in your abdomen?  
 
 days 
 
14.   On how many nights over the last two weeks have you been unable to sleep well (days if you 
are a shift worker)?  
 
 nights (or days) 
 
15.   On how many nights in the last two weeks have you had to get up to use the toilet because of 
your bowel condition after you have gone to bed? 
 
 nights  
 
16.   In the last two weeks have you felt depressed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
17.   In the last two weeks have you had to avoid attending events where there was no toilet close at 
hand? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
18.   On how many days over the last two weeks, have you had a problem with large amounts of 
wind?  
 
 days 
 
19.   On how many days over the last two weeks have you felt off your food?  
 days 
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20.   Many patients with bowel problems have worries about their illness.  How often during the last 
two weeks have you felt worried? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
21.   On how many days over the last two weeks has your abdomen felt bloated?  
 
 days 
 
 
22.   In the last two weeks have you felt relaxed? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
23.   In the last two weeks have you been embarrassed by your bowel problem?  
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
24. On how many days over the last two weeks have you wanted to go back to the toilet immediately 
after you thought you had emptied your bowels?  
 
 days  Not Applicable 
 
 
25.   In the last two weeks have you felt upset? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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26.   On how many days over the last two weeks have you had to rush to the toilet?  
 
 days  Not Applicable 
 
 
27.   In the last two weeks have you felt angry as a result of your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
28.   In the last two weeks, has your sex life been affected by your bowel problem? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
  
29.    On how many days over the last two weeks have you felt sick?  
 
 days 
 
 
30.   In the last two weeks have you felt irritable? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
31. In the last two weeks have you felt lack of sympathy from others? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
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32.   In the last two weeks have you felt happy? 
 
a) No, not at all 
b) Yes, some of the time 
c) Yes, most of the time 
d) Yes, all of the time  
 
 
33.   How has your quality of life changed since the last time you filled in a questionnaire?   Please circle 
one of the five statements below: 
1 2 3 4 5 
Mucn better 
now 
Somewhat 
better 
About the 
same 
Somewhat 
worse 
Much worse
 
 
What date did you complete the last questionnaire? 
  
 d d m m y y y y 
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Supplementary question 
 
Do you have a stoma? 
    
  Yes Please continue with the questions below 
 
  No Please go straight to Section B on page 13 
 
 
For patients with a stoma  
 
The following questions ask for your views about your stoma and how it has affected your life over the 
last two weeks.   
 
Please choose only one answer for each of the questions.  If you are unsure about how to answer any 
question, just give the best answer you can.  Do not spend too much time answering, as your first 
thoughts are likely to be the most accurate.  
  
 
1  On how many days over the last two weeks have you been afraid that other people might hear 
your stoma? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
 
2  On how may days over the last two weeks have you been worried that other people might smell 
your stools? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
 
3 On how many days over the last two weeks have you been worried about possible leakage from 
your stoma bag? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
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4  On how many days over the last two weeks have you had problems with care for your stoma? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
 
5  On how many days over the last two weeks have you found the skin around your stoma 
irritated? 
 
  a) None 
  b) On one or two days only 
  c) On three to seven days 
  d) On eight to fourteen days (i.e. more than every other day) 
 
 
6  In the last two weeks have you felt embarrassed because of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
7  In the last two weeks have you felt less complete because of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
8  In the last two weeks have you felt less attractive as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
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9  In the last two weeks have you felt less feminine / masculine as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
 
 
10 In the last two weeks have you been dissatisfied with your body as a result of your stoma? 
 
  a) No, not at all 
  b) Yes, some of the time 
  c) Yes, most of the time 
  d) Yes, all of the time 
 
If you did not complete any of the questions in Section A (including the stoma questionnaire), please 
record the question number(s) below and, if possible, give a reason why it was not completed.  
Question No Reason for non-completion  
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This survey asks for your views about your health. This information will help keep track of how you feel 
and how well you are able to do your usual activities.  
For each of the following questions, please tick the one box that best describes your 
answer. 
 
 
1. In general, would you say your health is: 
 
Excellent  Very good  Good  Fair  Poor 
         
 
 
 
2. The following questions are about activities you might do during a typical day.  Does your health 
now limit you in these activities?  If so, how much? 
 
 Yes, limited  
a lot 
Yes, limited 
a little 
No, not 
limited at all 
a) Moderate activities, such as moving a table,       
pushing a vacuum cleaner, bowling, or playing golf   
      
b) Climbing several flights of stairs      
   
 
 
 
3. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your 
physical health?  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Were limited in the 
kind of work or other  
          
activities           
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4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Accomplished less 
than you would like 
          
           
b) Did work or other 
activities less carefully  
          
than usual           
 
 
 
5. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
 
Not at all  A little bit  Moderately  Quite a bit  Extremely 
         
 
 
 
6. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time during the 
past 4 weeks  
 
  All of 
the time 
 Most of 
the time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
a) Have you felt calm 
and peaceful? 
          
           
b) Did you have lots of 
energy? 
          
           
c) Have you felt 
downhearted and low? 
          
 
 
 
7. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
 
All of the 
time 
 Most of the 
time 
 Some of 
the time 
 A little of 
the time 
 None of 
the time 
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By placing a tick in one box in each group below, please indicate which statements best describe your 
own health state today. 
 
 
Mobility 
I have no problems in walking about  A 
I have some problems in walking about  B 
I am confined to bed  C 
 
 
Self-Care 
I have no problems with self-care  A 
I have some problems washing or dressing myself  B 
I am unable to wash or dress myself  C 
 
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  A 
I have some problems with performing my usual activities  B 
I am unable to perform my usual activities  C 
 
 
Pain/Discomfort 
I have no pain or discomfort  A 
I have moderate pain or discomfort  B 
I have extreme pain or discomfort  C 
 
 
Anxiety/Depression 
I am not anxious or depressed  A 
I am moderately anxious or depressed  B 
I am extremely anxious or depressed  C 
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To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can 
imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion.  
 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good 
or bad your health state is today. 
 
100 
Best  
imaginable 
health state 
Worst 
imaginable 
health state 
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Appendix 13 First interview schedule
(randomised controlled trial only)
 
First interview schedule for CONSTRUCT participants (RCT only) 
Pt Interview Schedule V3-0 05Aug2011 
 
Patients will be contacted to arrange a convenient date/time.  Explanation about interview will include 
‘Your information will be very valuable/helpful and inform us of things we don’t know about and therefore I 
would like to speak to you uninterrupted for up to one hour’. 
 
At the start, brief background information will be requested, eg when diagnosed, when admitted, which 
drug given as inpatient, whether treated with infliximab or ciclosporin in the past.  
 
Firstly, I want to ask you questions about your health and well-being and then I will ask you questions 
about the treatment you received (make sure patient knows which episode of treatment).  The next 
questions are about your health and well-being. 
 
1. What is important to you about your health? 
 
2. What does good health mean to you? } 
} if time short, drop these 
3. What does bad health mean to you? } 
 
4. What were the main difficulties your illness was causing you before the treatment? 
(past symptoms / quality of life) 
 
5. How has the illness affected your quality of life? 
 
Before we move on to the second part of the interview about your recent treatment, when I will ask 9 
questions, are there any other comments you would like to make about your health that we have not 
covered. 
 
I would now like to ask you some questions about the treatment you received (make sure patient 
understands which episode of treatment). 
 
6. In what form were the medicines administered? 
7. How easy was that to manage? 
8. What were the positive aspects of having the medicines given in this way? 
9. What were the challenging aspects of having the medicines given in this way? 
10. How has the treatment affected you? 
(side effects) 
11. How long do you think the effects, good or bad, of the treatment lasted? 
12. If you found that the positive effects were short-term, do you consider it was worthwhile 
having the treatment? 
13. Can you describe what difference the treatment has made to your daily life 
14. How does the treatment regimen that you are on now compare with other therapies or 
treatments you might have had in the past? 
(Perceptions of safety & implications of having this treatment.  Surgery – if last resort why?) 
15. To conclude, we have covered a whole range of issues, I would like to finish by asking what 
are your views of the medicines you are currently taking? 
 
I have finished asking the set questions - are there any other comments you would like to make? 
NB –remember to say will be contacting again in 9 months’ time to interview again 
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Appendix 14 First interview schedule (colectomy)
 
First interview schedule for CONSTRUCT RCT participants who have colectomy 
Surgery Pt Interview Schedule V2-0 05Aug2011 
 
Patients will be contacted to arrange a convenient date/time.  Explanation about interview will include 
‘Your information will be very valuable/helpful and inform us of things we don’t know about and therefore I 
would like to speak to you uninterrupted for up to one hour’. 
 
At the start, brief background information will be requested, eg when diagnosed, when admitted, whether 
treated with infliximab or ciclosporin in the past.  
 
Firstly, I want to ask you questions about your health and well-being and then I will ask you questions 
about the treatment you received (make sure patient knows which episode of treatment).  The next 
questions are about your health and well-being. 
 
1. What is important to you about your health? 
 
2. What does good health mean to you? } 
} if time short, drop these 
3. What does bad health mean to you?  } 
 
4. What were the main difficulties your illness was causing you before the treatment? 
(past symptoms / quality of life) 
 
5. How has the illness affected your quality of life? 
 
Before we move on to the second part of the interview about your recent treatment, when I will ask 10 
questions, are there any other comments you would like to make about your health that we have not 
covered. 
 
I would now like to ask you some questions about the treatment you received (make sure patient 
understands which episode of treatment). 
 
 
6. I understand you have had surgery, when was this? 
7. When you agreed to take part in CONSTRUCT you were going to be given a drug treatment.  
Did you have this before the operation?  (clarify which one and what they thought about it)? 
8. Why did you have the operation? 
9. Can you describe what difference the operation  has made to your daily life? 
10. How has the operation affected your quality of life? 
11. How are you coping with the ileostomy (mentally and phsically)? 
12. How has it affected your relationships with others? 
13. Do you think you would you prefer to be on long term treatment for your colitis rather than 
have had a colectomy? 
 (Perceptions of safety & implications of having different treatments.  Surgery – if last resort 
why?) 
14. Do you feel the decision to go ahead with the operation was good or bad? 
15. To conclude, we have covered a whole range of issues, are there any other comments you 
would like to make? 
 
 
NB –remember to say will be contacting again in 9 months’ time to interview again 
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Appendix 15 Second interview schedule
(randomised controlled trial and surgery)
 
Second interview schedule (12 months) for CONSTRUCT participants 
 
 
*** 
Patients will be contacted to arrange a convenient date/time.  Explain that this is the second of the 
interviews they agreed to take part in when they consented to CONSTRUCT, information will be very 
valuable, help us to understand what happens after treatment and therefore I would like to speak to you 
uninterrupted for up to one hour. 
 
1st transcript to be read before interview, pertinent things said by patient to be noted and available to aid 
interview.  Will also help with validation of previous interview and understanding of change over time. 
 
*** 
Firstly, I want to ask you questions about your health and well-being and then I will ask you questions 
about the treatment you received.  The next questions are about your health and well-being. 
 
1. When I spoke to you 9 months ago, you told me the following things  were having an 
effect on your health or your views about your health.  Have those changed in any way, for the 
better or perhaps for the worse? 
 
2. 9 months ago you told me a range of practical and personal problems relating to UC.  Are you 
aware of any changes that I should know about? 
 
3. Has anything about your quality of life changed since 9 months ago? 
(social, physical, emotional, mental) 
 
Before we move on to the second part of the interview are there any other comments you would like to 
make about your health that we have not covered. 
 
I am interested in what has happened treatment-wise over the past 9 months since we last spoke, so the 
next questions will be about this. 
 
4. Nine months ago you described the treatment you were having as xxxx. What treatment(s) 
have you had since then? 
(have to hand the date of CONSTRUCT treatment) 
 (A ? Has had more of the drug they were randomised to - infliximab or ciclosporin) 
(B ? Has had treatment with the drug they were not randomised to) 
(C  ? Had different drug treatments) 
(D ? pt may have had surgery since last interview) 
 
5. What are your views about the treatment(s) you have received in the last 9 months? 
a. What were the positive aspects of  the medicines you were given? 
b. What were the challenging aspects of the medicines you were given 
(+&- about impact on UC) 
(side effects, treatment lasted or not, ? worth it) 
c. Positive and challenging aspects of the way the medicines were administered? 
 
6. Has there been a change in your daily life compared to 9 months ago  
(Treatment, care, lifestyle, routine?) 
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Questions for drug treatment only Questions for surgery pts 
If participant has been treated with both 
infliximab & ciclosporin since randomisation in 
CONSTRUCT ask: 
 
7. Which of the medicines/treatments did 
you prefer and why? 
a. If had infliximab & ciclosporin – 
specifically which preferred 
b. ? because that treatment regime suits 
your lifestyle? 
 
I would now like to ask:  
 
8. What do you think of the care you are 
currently receiving for UC? 
(trying to find out about access to 
service/IBD nurses etc) 
 
9. What is your opinion about the time that 
it takes you to access that care? 
 
10. What has changed in your relationship 
with doctors and nurses since we last 
spoke 
(way communicate or interact) 
a. Is that because 
i. Change in treatment / drugs? 
ii. Lack of change in treatment / drugs? 
iii. ? surgery 
iv. Better or worse communication with 
you? 
v. Something else? 
b. What has brought about that 
change or lack of change (in 
treatment, drugs, surgery, 
something else)? 
 
11. Does bringing up your illness with you 
again now, through questionnaires and 
interviews, bother you? 
 
 
 
CONSTRUCT Pt Interview Schedule RCT V3-0 05Aug2011.doc 
 
7. Thinking back to the drug treatment you had a 
year ago, what are your views about it now? 
If have been treated with infliximab & ciclosporin 
over the year, which did they prefer? 
 
8. Since your surgery, can you describe what 
difference the operation has made to your daily 
life? 
 
9. Since the surgery, how has the operation 
affected your quality of life? 
 
10. Have you had a reversal operation since the 
surgery? 
 If yes, when was that and how are you now? 
 If no, do you anticipate having a reversal? 
 
11. Since I last asked, how are you coping with the 
ileostomy (mentally, emotionally, phsically)? 
a. Has that changed? 
 
12. How has it affected your relationships with 
others? 
a.  Friends & family 
b. Doctors and nurses and other healthcare 
professionals 
 
13. Do you think you would you prefer to be on long 
term treatment for your ulcerative colitis rather 
than have had a colectomy?  Have your views 
changed? 
 (Perceptions of safety & implications of having 
different treatments.  Surgery – if last resort 
why?) 
 
14. Do you feel the decision to go ahead with the 
operation was good or bad?  Have your views 
changed since we last spoke? 
 
15. Of all the treatments you have had for UC 
which would you consider as the most 
successful and why? 
 
CONSTRUCT Surgery Pt Interview Schedule V2-0 05Aug2011.doc 
 
 
 
 
I have finished asking the set questions - are there any other comments you would like to make? 
 
NB –remember to thank the participant for taking part in 2 interviews 
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Appendix 16 Health-care professional interview
schedule 1
Health Care Professional interview schedule – high trial recruitment 
PI/Nurse interviews.  Judgement sampling, sites with high trial recruitment. 
 
1. What are your views about administering IV ciclosporin? 
 
2. What are your views about administering infliximab? 
 
3. a.    What are your views about treating a patient with infliximab? 
 
b. What are your views about treating a patient with ciclosporin? 
 
4. a.  What are your views about treating a patient with infliximab in the longer term? 
Outcomes for pt 
b. What are your views about treating a patient with ciclosporin in the longer term? 
Outcome for pt 
 
5. a.  Consultant only 
What do you think your nursing staff feel about administering these drugs – are their 
views different to yours and if so, why? 
 
b. Nurse only  
What do you think the doctors feel about administering these drugs – do they have a 
different perspective on administering the drug to you? 
 
6. Do you have a treatment preference?  Why? 
 
7. What are your views about colectomy as a treatment for acute severe colitis as opposed to 
medical intervention? 
 
8. What are your views on NICE guidance which states that infliximab can only be used in acute 
severe UC when ciclosporin is contraindicated? 
 
9. NICE also allows use of infliximab in research because there is not enough evidence.  Should 
it be used ‘only in research’, ie in CONSTRUCT – what are your views about that?  
(depending on answer to above, can explore question of equipoise – in context of trial do you 
have an open mind about both the drugs?  Trying to find out if have patients who they think 
should have infliximab so didn’t put into the trial) 
 
Nurse interviews only: 
10. Can you give me a feel for roughly how long during an infusion of ciclosporin you were 
prevented from doing other duties? 
(if they can put a figure on it, that’s great but they may well not be able to be that specific.  It 
may be that they say it didn’t prevent them but they just kept a close eye on the participant, 
kept checking them out of the corner of their eye) 
 
PI interviews only: 
In summary, you have told us about your personal preference regarding the two drugs and your views on 
NICE guidelines and negotiating care with patients, but it is very important to us that we have a good 
understanding of your site’s view on the two drugs, as issues of equipoise have already arisen in other site 
interviews, so: 
 
11. Can you clarify where your site stands on the effectiveness of the two drugs, what we might 
call “scientific equipoise”? 
 
12. And, we would also like clarification on where your site stands on the experience of using the 
two drugs, what we might call “administering equipoise”? 
 
13. Do you feel that this has in any way influenced your site’s participation in the trial? 
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Appendix 17 Health-care professional interview
schedule 2
Health Care Professional interview schedule – high cohort recruitment, no or low trial 
recruitment/poor overall recruitment 
PI interviews.  Judgement sampling, sites which have high cohort recruitment with no or low trial 
recruitment or poor overall recruitment. 
 
 
1. What are your views about administering IV ciclosporin? 
a. If not administering ciclosporin – What are the reasons for this? 
 
 
2. What are your views about administering infliximab? 
a. If not administering infliximab – What are the reasons for this? 
 
 
3. As you are aware the methods of delivery are different for the two drugs with ciclosporin 
having longer administration time.  Do you think this has an effect on which drug is 
administered? 
 
4. Infliximab and ciclosporin have different cost implications: Ciclosporin in considered to be 
cheaper than infliximab. 
a. Do you have any views on whether this has an effect on which drug is administered? 
 
 
5. a.    What are your views about treating a patient with infliximab? 
b. What are your views about treating a patient with ciclosporin? 
 
 
6. a.  What are your views about treating a patient with infliximab in the longer term? 
Outcomes for pt 
b. What are your views about treating a patient with ciclosporin in the longer term? 
Outcome for pt 
 
7. If you are not currently administering either of the drugs:   
 
a. Have you ever administered them in the past? (ciclosporin/infliximab) 
b. If yes, what were your views on administering them? 
c. Do you think this has affected your treatment preference now? Why? 
 
8. Consultant – what do you think your nursing staff feel about administering these drugs – are 
their views different to yours and if so, why? 
 
9. Do you have a treatment preference?  Why? 
 
10. Do you have any views on whether there is a conflict between professional preference and 
what is available to prescribe for treatment of ulcerative colitis. (ciclosplorin/infliximab) 
 
11. What are your views about colectomy as a treatment for acute severe colitis as opposed to 
medical intervention? 
 
12. What are your views on NICE guidance which states that infliximab can only be used in acute 
severe UC when ciclosporin is contraindicated? 
 
13. NICE also allows use of infliximab in research because there is not enough evidence.  Should 
it be used ‘only in research’, ie in CONSTRUCT – what are your views about that?  
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Appendix 18 McMaster IBDQ, UKIBDQ, CUCQ
and CUCQ+ questions and response options
McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
How frequent have your
bowel movements been
during the last 2 weeks?
McMaster response option A
On how many days over
the last 2 weeks have you
had loose or runny bowel
movements?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you had
loose or runny bowel
movements?
CUCQ response option A
On how many days over the
last 2 weeks have you had
loose or runny bowel
movements?
CUCQ+ response option C
How often has the feeling
of fatigue or of being tired
and worn out been a
problem for you during the
last 2 weeks?
McMaster response option B
On how many days over
the last 2 weeks have you
felt tired?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
tired?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
tired?
CUCQ+ response option A
How often during the last
2 weeks have you felt
frustrated, impatient, or
restless?
McMaster response option B
In the last 2 weeks have
you felt frustrated?
UK-IBDQ response option B
In the last 2 weeks have
you felt frustrated?
CUCQ response option B
In the last 2 weeks have
you felt frustrated?
CUCQ+ response option B
How often during the last
2 weeks have you been
unable to attend school or
do your work because of
your bowel problem?
McMaster response option B
In the last 2 weeks has your
bowel condition prevented
you from carrying out your
work or other normal
activities?
UK-IBDQ response option B
In the last 2 weeks has your
bowel condition prevented
you from carrying out your
work or other normal
activities?
CUCQ response option B
In the last 2 weeks has your
bowel condition prevented
you from carrying out your
work or other normal
activities?
CUCQ+ response option B
How much of the time
during the last 2 weeks have
your bowel movements
been loose?
McMaster response option B
On how many days over
the last 2 weeks have you
opened your bowels more
than three times a day?
UK-IBDQ response option A
On how many days over
the last 2 weeks have you
opened your bowels more
than three times a day?
CUCQ response option A
On how many days over
the last 2 weeks have you
opened your bowels more
than three times a day?
CUCQ+ response option C
How much energy have
you had during the last
2 weeks?
McMaster response option C
On how many days over
the last 2 weeks have you
felt full of energy?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
full of energy?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
full of energy?
CUCQ+ response option A
How often during the last
2 weeks did you feel
worried about the possibility
of needing to have surgery
because of your bowel
problem?
McMaster response option B
In the last 2 weeks have
you been worried about
being admitted to hospital
because of your bowel
problem?
UK-IBDQ response option B
No comparable question No comparable question
How often during the last
2 weeks have you had to
delay or cancel a social
engagement because of
your bowel problem?
McMaster response option B
In the last 2 weeks did your
bowel condition prevent
you from going out
socially?
UK-IBDQ response option B
In the last 2 weeks did your
bowel condition prevent
you from going out socially?
CUCQ response option B
In the last 2 weeks did your
bowel condition prevent
you from going out socially?
CUCQ+ response option B
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
No comparable question On how many days over
the last 2 weeks have
your bowels opened
accidentally?
UK-IBDQ response option A
On how many days over
the last 2 weeks have
your bowels opened
accidentally?
CUCQ response option A
On how many days over
the last 2 weeks have
your bowels opened
accidentally?
CUCQ+ response option C
How often during the last
2 weeks have you felt
generally unwell?
McMaster response option B
On how many days over
the last 2 weeks have you
felt generally unwell?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
generally unwell?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
generally unwell?
CUCQ+ response option A
How often during the last
2 weeks have you been
troubled because of fear of
not finding a washroom?
McMaster response option B
In the last 2 weeks have
you felt the need to keep
close to a toilet?
UK-IBDQ response option B
In the last 2 weeks have
you felt the need to keep
close to a toilet?
CUCQ response option B
In the last 2 weeks have
you felt the need to keep
close to a toilet?
CUCQ+ response option B
How much difficulty have
you had, as a result of your
bowel problems, doing
leisure or sports activities
you would have liked to
have done during the last
2 weeks?
McMaster response
option D
In the last 2 weeks has your
bowel condition affected
your leisure or sports
activities?
UK-IBDQ response option B
In the last 2 weeks has your
bowel condition affected
your leisure or sports
activities?
CUCQ response option B
In the last 2 weeks has your
bowel condition affected
your leisure or sports
activities?
CUCQ response option B
How often during the last
2 weeks have you been
troubled by pain in the
abdomen?
McMaster response option B
On how many days over
the last 2 weeks have you
felt pain in your abdomen?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
pain in your abdomen?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
pain in your abdomen?
CUCQ+ response option A
How often during the last
2 weeks have you had
problems getting a good
night’s sleep, or been
troubled by waking up
during the night?
McMaster response option B
On how many nights over
the last 2 weeks have you
been unable to sleep well
(days if you are a shift
worker)?
UK-IBDQ response option A
On how many nights over
the last 2 weeks have you
been unable to sleep well
(days if you are a shift
worker)?
CUCQ response option A
On how many nights over
the last 2 weeks have you
been unable to sleep well
(days if you are a shift
worker)?
CUCQ+ response option A
How often during the last
2 weeks have you felt
depressed or discouraged?
McMaster response option B
In the last 2 weeks have
you felt depressed?
UK-IBDQ response option B
In the last 2 weeks have
you felt depressed?
CUCQ response option B
In the last 2 weeks have
you felt depressed?
CUCQ+ response option B
How often during the last
2 weeks have you had to
avoid attending events
where there was no
washroom close at hand?
McMaster response option B
In the last 2 weeks have
you had to avoid attending
events where there was no
toilet close at hand?
UK-IBDQ response option B
In the last 2 weeks have
you had to avoid attending
events where there was no
toilet close at hand?
CUCQ response option B
In the last 2 weeks have
you had to avoid attending
events where there was no
toilet close at hand?
CUCQ+ response option B
Overall, in the last 2 weeks
how much of a problem
have you had with passing
large amounts of gas?
McMaster response option E
On how many days over
the last 2 weeks have you
had a problem with large
amounts of wind?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you had a
problem with large amounts
of wind?
CUCQ response option A
On how many days over the
last 2 weeks have you had a
problem with large amounts
of wind?
CUCQ+ response option A
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
No comparable question On how many days over
the last 2 weeks have you
felt off your food?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
off your food?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
off your food?
CUCQ+ response option A
Many patients with bowel
problems often have worries
and anxieties related to their
illness. These include worries
about getting cancer,
worries about never feeling
any better and worries
about having a relapse. In
general, how often during
the last 2 weeks have you
felt worried or anxious?
McMaster response option B
Many patients with bowel
problems have worries
about their illness. How
often during the last
2 weeks have you felt
worried?
UK-IBDQ response option B
Many patients with bowel
problems have worries
about their illness. How
often during the last
2 weeks have you felt
worried?
CUCQ response option B
Many patients with bowel
problems have worries
about their illness. How
often during the last
2 weeks have you felt
worried?
CUCQ+ response option B
How much of the time
during the last 2 weeks have
you been troubled by a
feeling of abdominal
bloating?
McMaster response option B
On how many days over
the last 2 weeks has your
abdomen felt bloated?
UK-IBDQ response option A
On how many days over
the last 2 weeks has your
abdomen felt bloated?
CUCQ response option A
On how many days over
the last 2 weeks has your
abdomen felt bloated?
CUCQ+ response option A
How often during the last
2 weeks have you felt
relaxed and free of tension?
McMaster response option B
In the last 2 weeks have
you felt relaxed?
UK-IBDQ response option B
In the last 2 weeks have
you felt relaxed?
CUCQ response option B
In the last 2 weeks have
you felt relaxed?
CUCQ+ response option B
How much of the time
during the last 2 weeks have
you had a problem with
rectal bleeding with your
bowel movements?
McMaster response option B
On how many days over
the last 2 weeks have you
noticed blood with your
bowel movements?
UK-IBDQ response option A
On how many days in the
last 2 weeks have you
noticed blood in your
stools?
CUCQ response option A
On how many days in the
last 2 weeks have you
noticed blood in your
stools?
CUCQ+ response option C
How much of the time
during the last 2 weeks have
you felt embarrassed as a
result of your bowel
problem?
McMaster response option B
In the last 2 weeks have
you been embarrassed by
your bowel problem?
UK-IBDQ response option B
In the last 2 weeks have
you been embarrassed by
your bowel problem?
CUCQ response option B
In the last 2 weeks have
you been embarrassed by
your bowel problem?
CUCQ+ response option B
How much of the time
during the last 2 weeks have
you been troubled by a
feeling of having to go to
the bathroom even though
your bowels were empty?
McMaster response option B
On how many days over
the last 2 weeks have you
wanted to go back to the
toilet immediately after you
thought you had emptied
your bowels?
UK-IBDQ response option A
On how many days over
the last 2 weeks have you
wanted to go back to the
toilet immediately after you
thought you had emptied
your bowels?
CUCQ response option A
On how many days over the
last 2 weeks have you
wanted to go back to the
toilet immediately after you
thought you had emptied
your bowels?
CUCQ+ response option C
How much of the time
during the last 2 weeks have
you felt tearful or upset?
McMaster response option B
In the last 2 weeks have
you felt upset?
UK-IBDQ response option B
In the last 2 weeks have
you felt upset?
CUCQ response option B
In the last 2 weeks have
you felt upset?
CUCQ+ response option B
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
How much of the time
during the last 2 weeks have
you been troubled by
accidental soiling of your
underpants?
McMaster response option B
On how many days over
the last 2 weeks have you
had to rush to the toilet?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you had
to rush to the toilet?
CUCQ response option A
On how many days over the
last 2 weeks have you had
to rush to the toilet?
CUCQ+ response option C
How much of the time
during the last 2 weeks have
you felt angry as a result of
your bowel problem?
McMaster response option B
In the last 2 weeks have
you felt angry as a result of
your bowel problem?
UK-IBDQ response option B
In the last 2 weeks have
you felt angry as a result of
your bowel problem?
CUCQ response option B
In the last 2 weeks have
you felt angry as a result of
your bowel problem?
CUCQ+ response option B
To what extent has your
bowel problem limited
sexual activity during the last
2 weeks?
McMaster response option F
In the last 2 weeks has your
sex life been affected by
your bowel problem?
UK-IBDQ response option B
In the last 2 weeks has your
sex life been affected by
your bowel problem?
CUCQ response option B
In the last 2 weeks has your
sex life been affected by
your bowel problem?
CUCQ+ response option B
How much of the time
during the last 2 weeks have
you been troubled by
nausea or feeling sick to
your stomach?
McMaster response option B
On how many days over
the last 2 weeks have you
felt sick?
UK-IBDQ response option A
On how many days over the
last 2 weeks have you felt
sick?
CUCQ response option A
On how many days over the
last 2 weeks have you felt
sick?
CUCQ+ response option A
How much of the time
during the last 2 weeks have
you felt irritable?
McMaster response option B
In the last 2 weeks have
you felt irritable?
UK-IBDQ response option B
In the last 2 weeks have
you felt irritable?
CUCQ response option B
In the last 2 weeks have
you felt irritable?
CUCQ+ response option B
How often during the past
2 weeks have you felt a lack
of understanding from
others?
McMaster response option B
In the last 2 weeks have
you felt lack of sympathy
from others?
UK-IBDQ response option B
In the last 2 weeks have
you felt lack of sympathy
from others?
CUCQ response option B
In the last 2 weeks have
you felt lack of sympathy
from others?
CUCQ+ response option B
How satisfied, happy, or
pleased have you been with
your personal life during the
past 2 weeks?
McMaster response
option G
In the last 2 weeks have
you felt happy?
UK-IBDQ response option B
In the last 2 weeks have
you felt happy?
CUCQ response option B
In the last 2 weeks have
you felt happy?
CUCQ+ response option B
How often during the last
2 weeks have you been
troubled by cramps in your
abdomen?
McMaster response option B
No comparable question No comparable question No comparable question
Overall, in the last 2 weeks,
how much of a problem
have you had maintaining or
getting to, the weight you
would like to be at?
McMaster response option E
No comparable question No comparable question No comparable question
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
No comparable question No comparable question On how many nights in the
last 2 weeks have you had
to get up to use the toilet
because of your bowel
condition after you have
gone to bed?
CUCQ response option A
On how many nights in the
last 2 weeks have you had
to get up to use the toilet
because of your bowel
condition after you have
gone to bed?
CUCQ+ response option A
Stoma-specific questions
No comparable question No comparable question No comparable question On how many days over the
last 2 weeks have you been
afraid that other people
might hear your stoma?
CUCQ+ response option D
No comparable question No comparable question No comparable question On how many days over the
last 2 weeks have you been
worried that other people
might smell your stools?
CUCQ+ response option D
No comparable question No comparable question No comparable question On how many days over the
last 2 weeks have you been
worried about possible
leakage from your stoma
bag?
CUCQ+ response option D
No comparable question No comparable question No comparable question On how many days over the
last 2 weeks have you had
problems with care for your
stoma?
CUCQ+ response option D
No comparable question No comparable question No comparable question On how many days over the
last 2 weeks have you
found the skin around your
stoma irritated?
CUCQ+ response option D
No comparable question No comparable question No comparable question In the last 2 weeks have
you felt embarrassed
because of your stoma?
CUCQ+ response option B
No comparable question No comparable question No comparable question In the last 2 weeks have
you felt less complete
because of your stoma?
CUCQ+ response option B
No comparable question No comparable question No comparable question In the last 2 weeks have
you felt less attractive as a
result of your stoma?
CUCQ+ response option B
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
253
McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
No comparable question No comparable question No comparable question In the last 2 weeks have
you felt less masculine/
feminine as a result of your
stoma?
CUCQ+ response option B
No comparable question No comparable question No comparable question In the last 2 weeks have
you been dissatisfied with
your body as a result of
your stoma?
CUCQ+ response option B
Questionnaire response options
McMaster IBDQ
response options UK-IBDQ response options CUCQ response options CUCQ+ response options
A:
1= Bowel movements as or
more frequent that they
have ever been
2= Extremely frequent
3=Very frequent
4=Moderate increase in
frequency of bowel
movements
5= Some increase in
frequency of bowel
movements
6= Slight increase in
frequency of bowel
movements
7=Normal, no increase in
frequency of bowel
movements
B:
1=All of the time
2=Most of the time
3=A good bit of the time
4= Some of the time
5=A little of the time
6=Hardly any of the time
7=None of the time
A:
None, 1–2; 3–7; 8–14 (i.e.
more than every other) days
B:
No, not at all; yes, some of
the time; yes, most of the
time; yes, all of the time
A:
Open response option
(0–14)
B:
No, not at all; yes, some of
the time; yes, most of the
time; yes, all of the time
A:
Open response option
(0–14)
B:
No, not at all; yes, some of
the time; yes, most of the
time; yes, all of the time
C:
Open response (0–14)
Not applicable option for
bowel surgery patients
D:
None, 1–2; 3–7; 8–14 (i.e.
more than every other) days
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
C:
1=No energy at all
2=Very little energy
3=A little energy
4= Some energy
5=A moderate amount of
energy
6=A lot of energy
7= Full of energy
D:
1=A great deal of difficulty;
activities made impossible
2=A lot of difficulty
3=A fair bit of difficulty
4= Some difficulty
5=A little difficulty
6=Hardly any difficulty
7=No difficulty; the bowel
problems did not limit sports
or leisure activities
E:
1=A major problem
2=A big problem
3=A significant problem
4= Some trouble
5=A little trouble
6=Hardly any trouble
7=No trouble
F:
1=No sex as a result of
bowel disease
2=Major limitation as a
result of bowel disease
3=Moderate limitation as a
result of bowel disease
4= Some limitation as a
result of bowel disease
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McMaster IBDQ: question
and response
UK-IBDQ: question
and response
CUCQ: question
and response
CUCQ+: question
and response
5=A little limitation as a
result of bowel disease
6=Hardly any limitation as
a result of bowel disease
7=No limitation as a result
of bowel disease
G:
1=Very dissatisfied,
unhappy most of the time
2=Generally dissatisfied,
unhappy
3= Somewhat dissatisfied,
unhappy
4=Generally satisfied,
pleased
5= Satisfied most of the
time, happy
6=Very satisfied most of
the time, happy
7= Extremely satisfied, could
not have been more happy
or pleased
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Appendix 19 Health professional interview
analysis framework
Introduction 
This document presents the analysis framework which was constructed using thematic lines of 
enquiry from Health Professional interviews (consultants and nurses). 
 
Health Professional Interviews 
A total of 23 semi-structured interviews were carried out with consultants (15 Principal 
Investigators from high (n=8) and low recruiting sites (n=7)) and nurses responsible for 
administrating and monitoring infliximab and ciclosporin (n=8 from high recruiting sites) from 
across the 52 CONSTRUCT sites.  Interviews addressed the ease of handling a range of drugs for 
Ulcerative Colitis, aspects of provision which might influence professional preference for one drug 
over another, and impressions about other groups’ contribution to treatment and care.  
 
Data Analysis 
Transcripts underwent rigorous analysis by standard thematic analysis based on the health 
professional interview schedule.  Thematic analysis is in keeping with a structured approach to data 
collection, analysis focuses on examining and identifying explicit and implicit themes within the 
data.  The method emphasises organisation and rich description of the data using a coding process 
which recognises important moments in the data. Three researchers individually coded transcripts 
from the health professional interviews as they were completed.  Following coding of four of the 
interviews with consultants, the three researchers worked together to agree a coding structure and 
developed an analysis framework.  This analysis framework then guided coding of the remaining 
consultant interview transcripts and data were entered as interviews were completed. Following 
analysis of the nurse interview transcripts, the three researchers convened again to asses and amend, 
if necessary, the framework in light of any differences between nurse and consultant data.  No 
amendments were made to the framework at this point and data from nurse interviews were entered 
into the existing framework.   
 
The following framework presents the outcomes of analysis.  Each section contains quotes from 
participants which are labelled by participant code name and the line number in the transcript that 
the quote has been taken from. Data presented within this framework is a representation of the full 
dataset collected.  Comments specific to ciclosporin appear in the left column and to infliximab in 
the right column, with more general comments across the two columns at the bottom of each 
section. 
 
Key - Colour of typeface 
 Level of recruitment by site Interview ID 
 Poor overall recruitment HP2, HP5, HP6 
 High cohort, low or no RCT HP1, HP3, HP4, HP7 
 High RCT recruitment (PIs) HP9, HP10, HP11, HP12, HP13, HP14, HP16 
 High RCT recruitment (N) HPN18, HPN19, HPN20, HPN21, HPN22, 
HPN23a, HPN24, HPN25a, HPN25b 
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r o
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 th
at
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 re
al
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 s
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ht
fo
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ar
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 (5
8)
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P
N
25
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It’
s 
ea
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 to
 m
ak
e,
 it
’s
 e
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y 
to
 g
iv
e 
an
d 
ju
st
 g
iv
e 
th
e 
fir
st
, h
er
e 
w
e 
gi
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 th
e 
fir
st
 th
re
e 
in
fu
si
on
s 
ov
er
 tw
o 
ho
ur
s 
an
d 
th
en
 s
ub
se
qu
en
t i
nf
us
io
ns
 o
ve
r a
n 
ho
ur
 s
o 
it’
s 
re
al
ly
 q
ui
te
 s
im
pl
e 
(6
4)
  
-v
e 
-v
e 
 H
P
2 
M
or
e 
tro
ub
le
so
m
e 
th
an
 In
fli
x 
(p
er
ha
ps
 b
ec
au
se
 u
se
d 
le
ss
 fr
eq
ue
nt
ly
, l
es
s 
ge
ne
ra
l 
co
nf
id
en
ce
 in
 it
, o
r h
ig
he
r d
os
e 
w
he
n 
fir
st
 in
tro
du
ce
d 
th
an
 n
ow
 m
ak
es
 le
ve
l m
on
ito
rin
g 
m
or
e 
im
po
rta
nt
) (
32
) 
 H
P
6 
C
ic
lo
sp
or
in
 n
ot
 u
se
d 
m
uc
h 
in
 th
is
 h
os
pi
ta
l (
14
) 
 H
P
6 
no
t t
he
 le
ng
th
 o
f a
dm
in
is
te
rin
g 
th
at
 is
 th
e 
pr
ob
le
m
, r
at
he
r t
he
re
 a
re
 m
or
e 
sa
fe
ty
 
as
pe
ct
s,
 it
 is
 a
 m
or
e 
da
ng
er
ou
s 
dr
ug
 (4
4)
 
 H
P
1 
N
o 
ex
pe
rie
nc
e 
of
 C
ic
l I
V
 in
 U
C
 b
ef
or
e 
(2
3)
 
 H
P
1 
on
ly
 a
dm
in
is
te
re
d 
to
 o
ne
 p
at
ie
nt
 s
o 
fa
r a
nd
 th
at
 w
as
 1
0 
ye
ar
s 
ag
o,
 b
ef
or
e 
be
co
m
in
g 
co
ns
ul
ta
nt
, a
nd
 th
at
 w
as
 a
 fa
ile
d 
m
ed
ic
al
 th
er
ap
y 
ex
pe
rie
nc
e 
(n
eg
at
iv
e 
ex
pe
rie
nc
e)
 (1
2/
17
) 
 H
P
3 
ad
m
in
is
te
rin
g 
[in
fli
xi
m
ab
] i
s 
tim
e 
co
ns
um
in
g 
bu
t n
ot
 a
s 
tim
e 
co
ns
um
in
g 
as
 C
ic
l (
16
) 
 H
P
3 
ad
m
in
is
te
rin
g 
is
 ti
m
e 
co
ns
um
in
g 
fo
r s
ta
ff 
(1
1)
 
 H
P
3 
th
ey
 [n
ur
se
s]
 th
in
k 
it’
s 
qu
ite
 la
bo
ur
in
g 
an
d 
ne
ed
 e
xt
ra
 w
or
k 
(7
8)
 
 H
P
3 
‘is
 a
 b
it 
de
ba
te
ab
le
 a
lth
ou
gh
 I 
us
e 
it’
 (2
9)
 - 
W
or
ry
 a
bo
ut
 to
xi
ci
ty
 a
nd
 th
e 
liv
er
, u
se
 it
 
ha
lf-
he
ar
te
dl
y,
 w
he
n 
no
 c
ho
ic
e 
(th
at
 o
r c
ol
ec
to
m
y)
 (3
2/
33
) 
 H
P
3 
ha
ss
le
 to
 a
dm
in
is
te
r a
nd
 ta
ke
s 
a 
lo
ng
 p
er
io
d 
of
 ti
m
e 
(7
/1
1/
33
) 
 H
P
3 
lo
t o
f w
or
k 
fo
r p
ha
rm
ac
y 
(1
02
) 
 H
P
4 
sl
ig
ht
 w
or
rie
s 
ab
ou
t a
va
ila
bi
lit
y 
of
 C
ic
l l
ev
el
s 
(1
2)
 m
ak
es
 p
eo
pl
e 
pe
rc
ei
ve
 it
’s
 a
 
m
or
e 
di
ffi
cu
lt 
dr
ug
 to
 u
se
 (1
8,
 2
5)
 
 H
P
7 
di
sa
dv
an
ta
ge
 is
 s
lig
ht
 –
 c
on
tin
ua
l i
nf
us
io
n 
ov
er
 lo
ng
 p
er
io
d 
of
 ti
m
e,
 h
av
e 
to
 c
he
ck
 
le
ve
ls
 (1
7)
 
 H
P
9 
I g
ue
ss
 th
er
e 
is
 a
 s
lig
ht
 d
is
ad
va
nt
ag
e 
to
 c
ic
lo
sp
or
in
, b
ec
au
se
 it
’s
 th
e 
in
fu
si
on
, i
t’s
 
co
nt
in
uo
us
 th
in
g 
ra
th
er
 th
an
 in
fli
xi
m
ab
 w
hi
ch
 is
 s
or
t o
f g
iv
e 
it 
an
d 
th
en
 d
on
e 
(3
0)
 
 H
P
3 
‘la
bo
ur
in
g 
w
or
k’
 b
ut
 w
or
ks
 w
el
l (
25
) 
 H
P
7 
tre
at
in
g 
pe
op
le
 w
ith
 In
fli
x 
go
 th
ro
ug
h 
ris
k 
co
un
se
lli
ng
, u
nk
no
w
n 
ris
ks
, n
o 
da
ta
 re
 c
an
ce
r o
r 1
0-
15
 y
ea
rs
 h
en
ce
, p
ot
en
tia
lly
 g
re
at
er
 a
dv
er
se
 e
ffe
ct
s 
ne
ed
 to
 m
ak
e 
pa
tie
nt
s 
aw
ar
e 
of
 th
at
 (3
5)
 
 H
P
10
 h
av
e 
gr
ea
te
r a
nx
ie
ty
 in
 a
dm
in
is
te
rin
g 
in
fli
xi
m
ab
 in
 a
cu
te
 s
ev
er
e 
U
C
 th
an
 
ci
cl
os
po
rin
...
..c
on
ce
rn
ed
 a
bo
ut
 d
ur
at
io
n 
th
at
 in
fli
xi
m
ab
 s
ta
ys
 in
 th
e 
ci
rc
ul
at
io
n 
(2
4)
 
 H
P
10
 if
 th
ey
 h
av
e 
ha
d 
an
 in
fe
ct
iv
e 
co
m
pl
ic
at
io
n 
th
en
 in
fli
xi
m
ab
 s
til
l a
ro
un
d.
...
po
te
nt
ia
l f
or
 
ex
ac
er
ba
tin
g 
it 
 (s
ho
ul
d 
be
 a
dm
in
is
te
re
d 
in
 a
 “t
im
el
y 
m
an
ne
r”
 if
 s
ur
ge
ry
 is
 n
ee
de
d)
(2
7)
 
 H
P
11
 w
e 
of
te
n 
fin
d 
th
er
e 
is
 a
 p
ro
bl
em
s 
at
 w
ee
ke
nd
s 
ad
 o
ut
 o
f h
ou
rs
 if
 w
e 
ar
e 
go
in
g 
to
 p
re
sc
rib
e 
it.
.. 
lo
gi
st
ic
al
 p
ro
bl
em
s 
w
ith
 p
ha
rm
ac
y 
(3
3)
 
 H
P
14
 a
fte
r i
nf
lix
 th
ey
’re
 g
oi
ng
 to
 h
av
e 
it 
fo
r 1
9 
w
ee
ks
 th
ey
’re
 g
oi
ng
 to
 b
e 
im
m
un
os
up
pr
es
se
d,
 y
ou
 
kn
ow
 fo
r a
 lo
ng
 w
hi
le
 (i
ss
ue
s 
w
ith
 s
ur
ge
ry
) (
16
4)
 
 H
P
16
 th
e 
on
ly
 c
on
ce
rn
 w
e 
ha
ve
 is
 if
 y
ou
 g
iv
e 
it 
an
d 
it 
do
es
n’
t w
or
k,
 if
 it
’s
 s
til
l i
n 
th
e 
sy
st
em
 (2
49
) 
 H
P
N
18
 w
e 
ne
ed
ed
 to
 in
fo
rm
 th
e 
IB
D
 C
lin
ic
al
 N
ur
se
 S
pe
ci
al
is
t b
ec
au
se
 th
ey
 n
ee
d 
to
 e
ns
ur
e 
th
at
 
th
e 
pa
tie
nt
 w
as
 g
iv
en
 th
e 
bl
oo
d 
fo
rm
 to
 h
av
e 
bl
oo
d 
ta
ke
n 
a 
w
ee
k 
la
te
r a
t a
 G
P
 s
ur
ge
ry
, s
o 
w
he
n 
th
ey
 c
am
e 
in
 fo
r t
he
ir 
se
co
nd
 in
fu
si
on
 w
hi
ch
 w
ou
ld
 h
av
e 
be
en
 d
on
e 
in
 a
 c
om
pl
et
el
y 
di
ffe
re
nt
 
se
tti
ng
 b
ec
au
se
 it
 w
ou
ld
 h
av
e 
be
en
 a
s 
an
 in
pa
tie
nt
, t
ha
t t
he
 b
lo
od
s 
w
er
e 
in
 k
ee
pi
ng
 w
ith
 w
ha
t’s
 
st
an
da
rd
 fo
r g
iv
in
g 
in
fli
x,
 s
o 
th
er
e 
w
er
e 
is
su
es
 w
ith
 th
at
 (7
4)
  
 H
P
13
 th
er
e 
ar
e 
di
ffe
re
nc
es
 in
 re
co
m
m
en
da
tio
ns
 n
or
th
 a
nd
 s
ou
th
 o
f t
he
 b
or
de
r s
o 
w
e 
ju
st
 c
an
’t 
us
e 
it 
(in
fli
x)
 u
nl
es
s 
w
e 
go
 th
ro
ug
h 
a 
pr
oc
es
s 
ca
lle
d 
th
e 
In
di
vi
du
al
 P
at
ie
nt
 T
re
at
m
en
t P
an
el
 (S
M
C 
re
st
ric
tio
ns
)  
(2
29
) 
 H
P
19
 it
’s
 n
ot
 ju
st
 a
s 
if 
yo
u’
ve
 h
as
 th
e 
do
se
 o
ve
r, 
yo
u 
kn
ow
 c
os
 y
ou
 g
o 
on
to
 ta
bl
et
s 
an
d 
th
er
ef
or
e 
do
n’
t h
av
e 
to
 c
om
e 
ba
ck
 in
to
 h
os
pi
ta
l a
s 
su
ch
 o
th
er
 th
an
 m
on
ito
rin
g.
.. 
I t
hi
nk
 th
er
e 
ar
e 
pr
os
 a
nd
 
co
ns
 to
 b
ot
h 
(1
34
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 H
P
10
 th
e 
6 
hr
 in
fu
si
on
 m
ak
es
 it
 s
lig
ht
ly
 m
or
e 
la
bo
ur
 in
te
ns
iv
e 
th
an
 th
e 
2h
r i
nf
us
io
n 
of
 
in
fli
xi
m
ab
 (1
6)
 
 H
P
12
 d
iff
ic
ul
t (
9)
 
 H
P
12
 fa
irl
y 
cu
m
be
rs
om
e 
bo
th
 fo
r t
he
 s
ta
ff 
an
d 
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lly
 im
po
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 fo
r p
at
ie
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s 
be
ca
us
e 
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ce
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re
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ed
 to
 th
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ip
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te
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dr
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t s
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t s
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t o
f r
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s 
pa
tie
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s 
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ov
in
g 
ar
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 (1
0)
 
 H
P
12
 th
e 
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f f
in
d 
it 
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y 
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al
le
ng
in
g 
(1
2)
 
 H
P
12
 c
ha
ng
in
g 
it 
ev
er
y 
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rs
, t
he
 b
ag
s 
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c,
 w
ou
ld
 b
e 
an
d 
w
ill
 b
e 
ch
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le
ng
in
g 
(1
6)
 
 H
P
13
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 g
oe
s 
on
 o
ve
r a
 lo
ng
er
 p
er
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of
 ti
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ob
vi
ou
sl
y,
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ne
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 c
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up
 b
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th
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r a
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ng
er
 ti
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ra
th
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 ju
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ne
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ff 
in
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 (2
5)
 
 H
P
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 th
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is
 a
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ng
 c
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 w
ith
 c
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l 
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 y
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ot
 fa
m
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ar
 w
ith
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  (
12
3,
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6)
 
 H
P
14
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 d
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ul
t t
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th
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uo
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si
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 (1
3)
 
 H
P
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to
 g
et
 th
e 
rig
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 d
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d 
yo
u 
ha
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 to
 g
et
 th
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pa
tie
nt
 c
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ne
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 u
p 
to
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co
nt
in
uo
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 d
rip
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nd
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 to
 g
et
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in
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 th
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es
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 th
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 it
 ta
ke
s 
8 
ho
ur
s 
in
st
ea
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of
 6
 to
 g
iv
e 
ea
ch
 b
ag
 (1
4)
 
 H
P
14
 it
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qu
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s 
th
e 
pa
tie
nt
 to
 b
e 
on
 th
e 
w
ar
d 
an
d 
no
t g
o 
an
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he
re
 a
nd
 u
m
 I 
th
in
k 
it’
s 
a 
bi
t c
um
be
rs
om
e 
(1
9)
 
 H
P
14
 it
’s
 m
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e 
cu
m
be
rs
om
e 
to
 g
iv
e 
(2
89
) 
 H
P
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 k
no
w
in
g 
th
at
 w
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re
 g
iv
in
g 
th
e 
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ht
 d
ru
g 
at
 th
e 
rig
ht
 le
ve
l a
nd
 fi
rs
t o
f a
ll 
th
at
 th
e 
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si
on
s 
ar
e 
co
nt
in
uo
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, t
ha
t t
he
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 p
ut
 u
p,
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re
 th
e 
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ow
 lo
ng
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 it
 b
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e 
th
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 u
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 s
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t o
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es
 c
au
se
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P
16
 y
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 e
nd
 u
p 
w
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 h
av
in
g 
pe
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 o
f d
el
ay
 w
he
re
 p
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ie
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s 
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t g
et
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ei
r d
ru
g.
.. 
I t
hi
nk
 th
at
’s
 p
ot
en
tia
lly
 a
 s
ig
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fic
an
t p
ro
bl
em
...
 a
nd
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’s
 d
iff
ic
ul
t t
o 
ge
t a
ro
un
d 
th
at
 
(8
7,
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6)
 
 H
P
16
 w
e 
do
n’
t h
av
e 
ci
cl
os
po
rin
 le
ve
ls
 o
n 
si
te
 s
o 
w
e 
se
nd
 th
em
 o
ff.
.. 
in
 p
ra
ct
ic
e 
th
at
 
ge
ne
ra
lly
 m
ea
ns
 th
at
 th
ou
gh
 y
ou
 c
an
 g
et
 a
 le
ve
l b
ac
k,
 y
ou
 p
ro
ba
bl
y 
ca
n’
t g
et
 a
 le
ve
l 
ba
ck
 a
nd
 a
ct
 o
n 
it 
(le
ve
ls
 o
f c
ic
l i
n 
bl
oo
d)
 (1
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) 
 H
P
16
 it
’s
 c
er
ta
in
ly
 m
or
e 
of
 a
 fa
ff 
fo
r t
he
 n
ur
si
ng
 s
ta
ff 
an
d 
yo
u’
ve
 g
ot
 th
at
 m
or
e 
pr
ol
on
ge
d 
pe
rio
d 
of
 ti
m
e 
to
 w
ai
t a
nd
 tr
y 
an
d 
ke
ep
 th
e 
pa
tie
nt
 in
 (2
85
) 
 H
P
16
 I 
th
in
k 
th
ey
 (n
ur
se
s)
 fi
nd
 it
 fa
r m
or
e 
di
ffi
cu
lt,
 m
or
e 
co
m
pl
ex
, m
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e 
tim
e 
co
ns
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in
g,
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th
er
e’
s 
m
ay
be
 a
 li
ttl
e 
bi
t o
f a
 fa
m
ili
ar
ity
 is
su
e 
(3
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) 
 H
P
15
 it
s 
tim
e 
co
ns
um
in
g 
an
d 
sl
ig
ht
ly
 m
es
sy
.  
Y
ou
 k
no
w
 it
’s
 c
om
pl
ic
at
ed
 a
nd
 e
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 it
’s
 
w
or
k 
fo
r t
he
 n
ur
si
ng
 s
ta
ff 
(1
9)
 
 H
P
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 T
he
y 
ha
ve
 to
 c
ha
ng
e 
th
e 
in
fu
si
on
 e
ve
ry
 s
ix
 h
ou
rs
 b
ec
au
se
 th
e 
is
su
e 
ab
ou
t n
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in
g 
st
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le
 in
 th
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nt
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ne
rs
 a
nd
 it
’s
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nc
e 
fo
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at
ie
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to
 b
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 d
rip
 a
ll 
of
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tim
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P
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 m
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P
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 to
 b
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at
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uo
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on
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 to
 b
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 c
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p 
it 
.  
N
ow
 th
e 
is
su
e 
w
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 b
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av
in
g 
co
nt
in
uo
us
 c
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l t
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ve
 g
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 c
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th
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 w
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t o
f m
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 p
ut
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ra
l e
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r t
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th
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 n
ee
de
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to
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in
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 s
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hi
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 p
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ie
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 w
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cu
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 H
P
N
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ag
 c
ha
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e)
 (4
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) 
 H
P
N
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 ti
m
e 
co
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um
in
g 
(1
7)
 
 H
P
N
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 h
av
in
g 
to
 m
ak
e 
it 
up
 e
ve
ry
 s
ix
 h
ou
rs
 w
as
 ti
m
e 
co
ns
um
in
g,
 c
ha
ng
in
g 
lin
es
, 
al
w
ay
s 
ha
vi
ng
 to
 h
av
e 
tw
o 
nu
rs
es
 to
 c
he
ck
 it
, b
ec
au
se
 th
e 
w
ay
 th
e 
G
I U
ni
t i
s 
sp
lit
 h
er
e 
is
 th
er
e’
s 
a 
co
rr
id
or
 u
p 
be
tw
ee
n 
th
e 
tw
o 
w
ar
ds
 s
o 
ob
vi
ou
sl
y 
be
d 
co
ve
r e
tc
 e
tc
 b
ut
 o
nl
y 
ha
ve
 o
ne
 tr
ai
ne
d 
ea
ch
 s
id
e 
so
 th
is
 a
 b
it 
at
 ti
m
es
, a
 b
it 
di
ffi
cu
lt.
...
ge
og
ra
ph
y 
of
 th
e 
w
ar
ds
...
w
e’
ve
 n
o 
on
e 
el
se
 to
 c
he
ck
 th
e 
dr
ug
 (2
1,
 2
8,
 2
9)
 
 H
P
N
19
 y
ou
 p
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e 
yo
ur
 li
ne
 w
ith
 y
ou
r m
ed
ic
at
io
n 
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 w
el
l, 
w
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 ru
n 
th
e 
ba
g 
fo
r 4
 h
ou
rs
 
th
en
 p
ut
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h 
up
 to
 g
et
 th
e 
la
st
 2
 h
rs
 o
f t
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 c
ic
lo
sp
or
in
 th
at
 w
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 in
 th
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lin
e,
 s
o 
yo
u’
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in
g 
ba
ck
 to
 th
e 
pa
tie
nt
 q
ui
te
 a
 lo
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) 
 H
P
N
20
 y
ou
 n
ee
d 
tw
o 
re
gi
st
er
ed
 n
ur
se
s 
co
s 
ou
r s
tu
de
nt
 n
ur
se
s 
ar
en
’t 
al
lo
w
ed
 to
 c
he
ck
 
an
yt
hi
ng
 li
ke
 th
at
...
.P
ro
ba
bl
y 
10
 –
 1
5 
m
in
s.
  M
ak
e 
up
 th
e 
ba
gs
, g
o 
to
 th
e 
pa
tie
nt
, c
he
ck
 
th
e 
pa
tie
nt
, c
ha
ng
e 
th
e 
ba
g 
fo
ur
 ti
m
es
 a
 d
ay
, p
ro
ba
bl
y 
an
 h
ou
r a
ny
w
ay
...
. o
ve
r a
 2
4 
ho
ur
 p
er
io
d 
pr
ob
ab
ly
 a
bo
ut
 ¾
 - 
1h
r w
ou
ld
 b
e 
sp
en
t d
ea
lin
g 
on
ly
 w
ith
 c
ic
lo
sp
or
in
. 
(2
63
...
27
0)
 
 H
P
N
21
 b
ec
au
se
 th
e 
pa
tie
nt
 is
 o
n 
an
 in
fu
si
on
 fo
r l
on
ge
r t
he
y 
ca
n 
be
 a
 li
ttl
e 
bi
t 
fru
st
ra
te
d.
..l
on
ge
r p
er
io
d 
of
 ti
m
e 
th
an
...
in
fli
x 
(9
8)
  
 H
P
N
22
 th
ey
 (n
ur
se
s)
 a
re
 a
 li
ttl
e 
bi
t u
nc
om
fo
rta
bl
e 
w
ith
 it
, b
ut
 o
nl
y 
be
ca
us
e 
th
ey
 a
re
 n
ot
 
fa
m
ili
ar
 w
ith
 it
 (2
7)
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H
P
N
22
 a
ny
 n
ew
 d
ru
g 
th
at
 y
ou
’re
 n
ot
 fa
m
ili
ar
 w
ith
, i
ts
 ti
m
e 
co
ns
um
in
g,
 a
nd
 o
f c
ou
rs
e 
w
ith
 ti
m
e 
pr
es
su
re
s 
on
 th
e 
w
ar
d,
 th
ey
 c
an
 fi
nd
 th
at
 q
ui
te
 d
iff
ic
ul
t (
29
) 
 H
P
N
24
 It
’s
 d
iff
ic
ul
t w
ith
 th
e 
ci
cl
 b
ec
au
se
 w
e 
w
er
e 
to
ld
 w
e 
ar
e 
no
t s
up
po
se
d 
to
 s
to
p 
it 
w
e 
ha
ve
 to
 c
on
tin
ue
, n
ot
 s
up
po
se
d 
if 
pa
tie
nt
 g
oe
s 
of
f w
ar
d 
an
d 
ne
ed
s 
to
 b
e 
co
nt
in
ue
d.
...
. 
th
er
e 
w
ill
 b
e 
si
de
 e
ffe
ct
s 
if 
w
e 
st
op
 it
 (2
4,
 3
9)
 
 H
P
N
24
 it
 w
as
 a
 b
it 
di
ffi
cu
lt 
an
d 
al
so
 w
e 
ha
ve
 to
 w
or
k 
ou
t a
bo
ut
 h
ow
 m
an
y 
m
ls
, b
ec
au
se
 
w
e 
di
dn
’t 
w
or
k 
it 
ou
t o
ur
se
lv
es
 it
 w
as
 th
e 
D
R
 w
ho
 g
av
e 
us
e 
th
e 
pr
es
cr
ip
tio
n 
so
 n
o-
on
e 
ha
s 
ac
tu
al
ly
 ta
ug
ht
 u
s 
ho
w
 to
 d
o 
it.
..e
ve
n 
th
e 
ph
ar
m
ac
y 
th
ey
 a
ls
o 
ha
d 
di
ffi
cu
lty
 (4
6)
 
 H
P
N
25
a 
m
y 
ex
pe
rie
nc
e 
is
 fr
om
 y
ea
rs
 a
nd
 y
ea
rs
 a
nd
 y
ea
rs
 a
go
 w
he
n 
I w
or
ke
d 
on
 a
 
w
ar
d 
an
d 
it 
w
as
 a
 b
it 
of
 a
 n
ui
sa
nc
e.
...
it 
w
as
 ju
st
 a
 n
ui
sa
nc
e 
fo
r m
e 
as
 th
e 
nu
rs
e 
lo
ok
in
g 
af
te
r t
en
 o
th
er
 p
at
ie
nt
s.
 (2
9,
 3
8)
 
 H
P
N
25
b 
pa
tie
nt
s 
do
n’
t p
ar
tic
ul
ar
ly
 li
ke
 b
ei
ng
 h
oo
ke
d 
up
 to
 it
 fo
r s
uc
h 
a 
lo
ng
 p
er
io
d.
...
its
 
re
st
ric
tiv
e 
(5
2,
 5
7)
 
 H
P
N
25
b 
it’
s 
in
te
ns
iv
e 
in
 th
at
 fi
rs
t p
er
io
d.
..i
t’s
 a
 fa
irl
y 
si
gn
ifi
ca
nt
 d
ru
g 
to
 b
e 
ad
m
in
is
te
rin
g 
(2
08
, 2
11
) 
 H
P
14
 if
 y
ou
 g
et
 ri
d 
of
 th
e 
IV
 th
en
 y
ou
 g
et
 ri
d 
of
 th
e 
qu
es
tio
n 
of
 th
e 
di
ffi
cu
lty
 w
e 
ha
ve
 
w
ith
 c
ic
l w
hi
ch
 is
 th
e 
ad
m
in
is
tra
tio
n 
be
ca
us
e 
it 
th
en
 le
ap
 fr
og
s 
ov
er
 in
fli
x 
an
d 
be
co
m
es
 
th
e 
ea
si
er
 d
ru
g 
to
 a
dm
in
is
te
r r
at
he
r t
ha
n 
th
e 
m
or
e 
di
ffi
cu
lt 
to
 a
dm
in
is
te
r (
26
3)
 
 H
P
N
19
 I 
su
pp
os
e 
th
er
e 
ar
e 
a 
fe
w
 d
ow
ns
id
es
 w
ith
 c
ic
l, 
no
t t
ha
t t
he
re
 a
re
n’
t w
ith
 
in
fli
x.
..w
ith
in
 th
e 
tri
al
, t
he
y 
w
en
t o
nt
o 
ci
cl
 ta
bl
et
s 
an
d 
ha
d 
to
 b
e 
m
on
ito
re
d 
m
or
e 
fre
qu
en
tly
 th
at
 s
ay
 in
fli
x 
so
 th
at
’s
 s
lig
ht
ly
 m
or
e 
lo
gi
st
ic
s 
fo
r t
he
 p
at
ie
nt
 s
o 
th
at
 k
in
d 
of
 
sc
en
ar
io
 (1
34
) 
G
en
er
al
 c
om
m
en
ts
 a
bo
ut
 th
e 
ad
m
in
is
tr
at
io
n 
of
 c
ic
lo
sp
or
in
 &
 in
fli
xi
m
ab
 
 H
P
3 
nu
rs
es
 n
ee
d 
tra
in
in
g 
up
 (t
o 
ad
m
in
is
te
r b
ot
h 
dr
ug
s)
 (7
2)
 
 H
P
4 
A
dm
in
is
te
rin
g 
is
 a
 c
ha
lle
ng
e 
fo
r t
hi
s 
pa
rti
cu
la
r u
ni
t, 
ac
tu
al
ly
 th
at
 is
 n
ot
 e
nt
ire
ly
 tr
ue
...
(6
) 
 H
P
4 
Th
e 
co
nc
er
n 
is
 th
e 
av
ai
la
bi
lit
y 
of
 c
ic
lo
sp
or
in
 le
ve
ls
 a
nd
 p
eo
pl
e’
s 
pe
rc
ep
tio
n 
is
 it
’s
 a
 m
or
e 
di
ffi
cu
lt 
dr
ug
 b
ut
 n
ot
 tr
ue
.  
N
o 
di
ffe
re
nt
 a
dm
in
is
te
rin
g 
ei
th
er
 d
ru
g 
no
t d
iff
ic
ul
t t
o 
do
, w
e 
sh
ou
ld
 b
e 
cl
ea
r a
bo
ut
 th
at
 (1
3)
 
 H
P
4 
th
er
e 
is
 a
 p
er
ce
pt
io
n 
th
at
 C
ic
l i
s 
di
ffi
cu
lt 
dr
ug
 to
 u
se
 b
ut
 re
al
ity
 is
 th
er
e 
is
 e
qu
al
 a
cc
es
s 
to
 b
ot
h 
dr
ug
s 
an
d 
eq
ua
l a
va
ila
bi
lit
y 
of
 b
ot
h 
(1
8)
 
  H
P
9 
w
e 
ba
si
ca
lly
 o
rd
er
 it
 a
nd
 th
e 
nu
rs
es
 a
re
 v
er
y 
ex
pe
rie
nc
ed
 in
 g
iv
in
g 
bo
th
, s
o 
it 
do
es
n’
t r
ea
lly
 c
au
se
 u
s 
pr
ob
le
m
s 
(3
4)
 
 H
P
9 
at
 o
ne
 s
ta
ge
 I 
fe
lt 
ci
cl
os
po
rin
 m
ig
ht
 b
e 
th
e 
sl
ig
ht
ly
 m
or
e 
ef
fe
ct
iv
e 
of
 th
e 
tw
o 
dr
ug
s 
bu
t t
ha
t i
nf
lix
im
ab
 w
as
 a
 b
it 
ea
si
er
 to
 m
an
ag
e,
 s
o 
th
e 
tw
o 
w
er
e 
re
as
on
ab
le
 o
ffs
et
 b
y 
ea
ch
 o
th
er
 (4
7)
 
 H
P
10
 th
e 
bu
rd
en
 o
f a
dm
in
is
tra
tio
n,
 is
 in
 m
ak
in
g 
it 
up
, s
et
tin
g 
it 
up
, r
at
he
r t
ha
n 
m
on
ito
rin
g 
du
rin
g 
th
e 
in
fu
si
on
 (b
ot
h 
dr
ug
s)
 (5
6)
 (w
e 
m
ak
e 
it 
up
 o
n 
th
e 
w
ar
d 
(1
36
))
 
 H
P
12
 c
ic
l w
e 
kn
ow
 b
ec
au
se
 th
er
e 
is
 s
o 
m
uc
h 
da
ta
 o
ut
 th
er
e.
  I
nf
lix
 th
e 
an
sw
er
 is
 y
et
 to
 b
e 
re
so
lv
ed
 a
nd
 s
o 
so
m
e 
pe
op
le
 m
ig
ht
 ta
ke
 th
at
 a
s 
a 
ne
ga
tiv
e 
as
pe
ct
 in
 re
la
tio
n 
to
 in
fli
x 
(5
1)
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 H
P
14
 s
o 
on
 th
e 
on
e 
ha
nd
 y
ou
’v
e 
go
t t
he
 c
on
ve
ni
en
ce
 o
f d
oi
ng
 in
fli
xi
m
ab
 a
nd
 o
n 
th
e 
ot
he
r h
an
d 
yo
u’
ve
 g
ot
 th
e 
co
nv
en
ien
ce
 o
f b
ei
ng
 a
bl
e 
to
 s
to
p 
ci
cl
 (1
51
) 
 H
P
14
 if
 I 
th
in
k 
th
ey
 a
re
 re
al
ly
 h
ea
di
ng
 h
om
e 
bu
t t
he
y 
ne
ed
 a
 b
it 
m
or
e 
th
en
 I’
d 
gi
ve
 th
em
 in
fli
x 
an
d 
if 
th
ey
 a
re
 re
al
ly
 h
ea
di
ng
 fo
r s
ur
ge
ry
 b
ut
 th
ey
 w
an
t l
as
t r
ol
l o
f t
he
 d
ic
e 
I’d
 g
iv
e 
th
em
 c
ic
l 
(1
74
) 
 H
P
15
 I 
w
ou
ld
 s
tre
ss
 th
at
 th
e 
di
ffe
re
nc
es
 a
re
 n
ot
 m
as
si
ve
 (4
55
) 
 H
P
N
18
 I 
do
n’
t r
ea
lly
 h
av
e 
an
y 
vi
ew
s 
on
 a
dm
in
is
te
rin
g 
it 
(c
ic
l) 
it’
s 
a 
dr
ug
, w
e 
ad
m
in
is
te
r i
t (
14
, 1
8)
 
 H
P
N
19
 it
’s
 (c
ic
l) 
m
or
e 
in
vo
lv
ed
 b
ec
au
se
 it
’s
 a
 lo
ng
er
 p
er
io
d 
bu
t i
t’s
 s
lig
ht
ly
 le
ss
 in
vo
lv
ed
 b
ec
au
se
 it
’s
 a
 lo
ng
er
 p
er
io
d,
 if
 y
ou
 k
no
w
 w
ha
t I
 m
ea
n,
 s
o 
on
ce
 y
ou
 s
et
 it
 g
oi
ng
, a
s 
lo
ng
 a
s 
yo
u 
do
n’
t 
co
m
pl
et
el
y 
ig
no
re
 th
em
, y
ou
 k
no
w
, i
t’s
 s
or
t o
f d
on
e 
fo
r 2
4 
ho
ur
s 
so
 it
’s
 k
in
d 
of
 u
p 
an
d 
do
w
n 
as
 to
 w
he
th
er
 it
’s
 h
el
pf
ul
 to
 h
av
e 
a 
lo
ng
er
 in
fu
si
on
 o
r a
 s
ho
rte
r o
ne
 (3
0)
 
 H
P
N
21
 I 
ca
n’
t s
ay
 I’
ve
 s
ee
n 
an
y 
so
rt 
of
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
tw
o 
re
ga
rd
in
g 
ad
m
in
is
tra
tio
n 
(9
5)
  
 H
P
N
22
 I 
do
n’
t s
ee
 th
er
e’
s 
m
uc
h 
di
ffe
re
nc
e 
to
 b
e 
ho
ne
st
 w
ith
 y
ou
 in
 th
e 
pr
ac
tic
al
iti
es
 o
f i
t (
in
fli
x 
vs
 c
ic
l) 
(6
7)
 
E
ffe
ct
iv
en
es
s 
C
ic
lo
sp
or
in
 
In
fli
xi
m
ab
 
 H
P
4 
te
nd
 to
 u
se
 c
ic
lo
sp
or
in
 a
s 
ac
tin
g 
m
or
e 
qu
ic
kl
y 
(1
71
) 
 H
P
7 
ha
d 
go
od
 b
en
ef
its
 w
ith
 g
oo
d 
ef
fe
ct
s 
fro
m
 c
ic
lo
sp
or
in
 p
ts
 in
 p
as
t (
92
) 
 H
P
9 
fe
lt 
ci
cl
os
po
rin
 m
ay
 b
e 
th
e 
sl
ig
ht
ly
 m
or
e 
ef
fe
ct
iv
e 
of
 th
e 
tw
o 
dr
ug
s 
(4
7)
 
 H
P
9 
w
e’
ve
 a
lw
ay
s 
be
en
 v
er
y 
ca
ut
io
us
 w
ith
 it
 a
nd
 a
s 
I s
ay
 I’
ve
 a
lw
ay
s 
of
fs
et
 th
at
 b
y 
th
in
ki
ng
 
it 
w
as
 a
n 
ef
fe
ct
iv
e 
dr
ug
 (6
3)
 
 H
P
11
 o
ne
 o
f t
he
 th
in
gs
 I 
lik
e 
ab
ou
t i
t (
ci
cl
) i
s 
th
e 
re
sp
on
se
 o
r n
on
 re
sp
on
se
 is
 v
er
y 
cl
ea
r 
an
d 
cl
ea
r c
ut
 a
nd
 h
as
 a
 v
er
y 
sh
or
t t
im
e 
sc
al
e 
(8
1)
 
 H
P
16
 I 
th
in
k 
ci
cl
 is
 e
ffe
ct
iv
e 
(2
72
) 
 H
P
16
 I 
do
n’
t s
ee
 it
 b
ei
ng
 a
ny
 m
or
e 
ef
fe
ct
iv
e 
th
an
 in
fli
x 
bu
t I
’d
 a
cc
ep
t t
ha
t i
t p
ro
ba
bl
y 
do
es
 
w
or
k 
an
d 
it 
pr
ob
ab
ly
 w
or
ks
 w
el
l (
27
6)
 
 H
P
N
24
 it
 ta
ke
s 
a 
w
hi
le
 to
 s
et
tle
 d
ow
n.
  A
s 
fa
r a
s 
I c
an
 re
m
em
be
r i
t t
oo
k 
a 
w
hi
le
 fo
r t
ha
t 
pa
tie
nt
 to
 s
et
tle
 d
ow
n 
w
ith
 h
is
 b
ow
el
s 
...
da
y 
3 
th
ey
 s
til
l f
ee
l b
as
 th
ey
 s
til
l f
ee
l w
or
se
 
(1
02
,1
05
)  
 H
P
N
25
b 
th
e 
pa
tie
nt
s 
th
at
 h
av
e 
be
en
 u
si
ng
 it
 s
ee
m
 to
 h
av
e 
re
sp
on
de
d 
re
al
ly
 w
el
l I
’v
e 
no
t 
se
en
 a
ny
bo
dy
 th
at
’s
 h
ad
 to
 g
o 
on
to
 y
ou
 k
no
w
 to
 a
ny
th
in
g 
el
se
 h
av
in
g 
ha
d 
ci
cl
os
po
rin
 
ev
er
yo
ne
 th
at
 I’
ve
 s
ee
n 
us
in
g 
it 
ha
ve
 re
sp
on
de
d 
w
el
l. 
(7
4)
 
 H
P
3 
se
ns
ib
le
 a
nd
 g
oo
d 
ex
pe
rie
nc
e 
of
 th
is
 d
ru
g 
‘w
he
n 
it 
w
or
ks
 it
 is
 fa
nt
as
tic
’ (
23
-2
5)
 
 H
P
3 
‘la
bo
ur
in
g 
w
or
k’
 b
ut
 w
or
ks
 w
el
l (
25
) 
 H
P
7 
da
ta
 s
ug
ge
st
s 
it 
is
 e
ffe
ct
iv
e,
 e
as
ie
r t
o 
ad
m
in
is
te
r, 
si
m
pl
er
 re
gi
m
e,
 le
ss
 p
al
av
a 
(2
8)
 
 H
P
11
 th
is
 is
 th
e 
on
e 
th
in
g 
I d
on
’t 
lik
e 
ab
ou
t i
nf
lix
 b
ec
au
se
 th
er
e 
is
 n
o 
da
ta
 to
 g
iv
e 
us
 a
 c
le
ar
 
tim
es
ca
le
 o
r t
im
el
in
e 
fo
r d
ec
is
io
n 
m
ak
in
g 
(9
4)
 
 H
P
12
 th
e 
ot
he
r s
lig
ht
 is
su
e 
w
ith
 in
fli
x 
is
 th
e 
sp
ee
d 
of
 re
sp
on
se
 (3
9)
 
 H
P
12
 th
e 
re
sp
on
se
 is
 s
lig
ht
ly
 s
or
t o
f s
lo
w
er
 (4
5)
 
 H
P
12
 s
om
et
im
es
 it
 is
 a
 b
it 
ch
al
le
ng
in
g 
th
at
 y
ou
 h
av
e 
gi
ve
n 
th
e 
in
fli
x 
if 
th
ey
 a
re
 g
oi
ng
 to
 ta
ke
 a
 
so
rt 
of
 w
ee
k 
to
 1
0 
da
ys
 ti
m
e,
 w
ou
ld
 y
ou
 h
ol
d 
th
e 
ne
rv
e 
(4
7)
 
 H
P
12
 it
’s
 a
t l
ea
st
 a
s 
ef
fe
ct
iv
e 
as
 c
ic
lo
sp
or
in
 w
ith
 th
e 
ad
di
tio
na
l b
en
ef
it 
of
 c
on
ve
ni
en
ce
 a
nd
 
po
te
nt
ia
lly
 le
ss
 to
xi
c 
(2
22
) 
 H
P
16
 it
’s
 v
er
y 
cl
ea
r t
o 
m
e 
it’
s 
a 
ve
ry
 e
ffe
ct
iv
e 
tre
at
m
en
t f
or
 a
 p
ro
po
rti
on
 o
f p
at
ie
nt
s 
w
ith
 re
al
ly 
se
ve
re
 c
ol
iti
s 
an
d 
th
er
e’
s 
no
 d
ou
bt
 th
at
 w
e’
ve
 h
ad
 s
om
e 
pa
tie
nt
s 
w
ith
 to
xi
c 
di
al
at
io
n,
 w
ho
’v
e 
re
al
ly
 b
ee
n 
at
 th
e 
fa
r e
nd
 o
f t
he
 s
pe
ct
ru
m
 w
ho
 h
av
e 
re
sp
on
de
d 
pe
rfe
ct
ly
 im
m
ed
ia
te
ly
 (2
15
) 
 H
P
16
 I 
th
in
k 
th
at
 th
e 
ef
fic
ac
y 
is
 b
es
t..
.a
t w
or
st
 is
 b
ro
ad
ly
 s
im
ila
r (
40
9)
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H
P
16
 th
ou
gh
 a
ne
cd
ot
al
ly
 I 
w
ou
ld
 p
ro
ba
bl
y 
fe
el
 th
at
 m
y 
in
fli
xi
m
ab
 re
sp
on
se
 ra
te
 ..
.th
e 
in
fli
x 
w
or
ks
 b
et
te
r (
41
4)
 
 H
P
15
 th
e 
go
od
 th
in
g 
ab
ou
t i
nf
lix
im
ab
 is
 th
at
 y
ou
 k
no
w
 fa
irl
y 
ra
pi
dl
y 
w
he
th
er
 it
 is
 g
oi
ng
 to
 w
or
k 
an
d 
on
ce
 it
’s
 w
or
ke
d 
an
d 
pa
tie
nt
s 
ha
ve
 a
 d
ra
m
at
ic
 b
en
ef
it 
(1
06
) 
 H
P
15
 It
’s
 q
ui
te
 d
iff
ic
ul
t t
o 
st
op
 it
 a
nd
 th
at
’s
 a
ct
ua
lly
 o
ne
 o
f t
he
 b
ig
ge
st
 is
su
es
, t
he
 c
lin
ic
al
 
de
ci
si
on
 is
 a
bo
ut
 w
he
n 
to
 s
to
p 
th
e 
dr
ug
 (1
08
) 
 H
P
16
 y
ou
 p
ro
ba
bl
y 
ge
t p
at
ie
nt
s 
ou
t o
f h
os
pi
ta
l q
ui
ck
er
 w
ith
 in
fli
x 
(2
87
) 
 H
P
N
18
 I 
fe
lt 
th
at
 w
he
n 
th
ey
 w
er
e 
ra
nd
om
is
ed
 to
 in
fli
xi
m
ab
 th
ey
 h
as
 a
 g
re
at
er
 c
ha
nc
e 
of
 n
ot
 
go
in
g 
to
 s
ur
ge
ry
 ..
. b
ut
 th
at
’s
 m
y 
pe
rs
on
al
 g
ut
 fe
el
in
g 
(2
19
, 2
24
) 
 H
P
N
20
 th
e 
pa
tie
nt
s 
th
at
 w
er
e 
on
 th
e 
tri
al
, t
he
 v
as
t m
aj
or
ity
 o
f t
he
 in
fli
x 
on
es
 s
ee
m
ed
 to
 d
o 
be
tte
r (
17
9)
 
 H
P
N
20
 v
er
y 
be
ne
fic
ia
l (
81
) 
 H
P
N
23
a 
I t
hi
nk
 th
os
e 
th
at
 a
re
 s
en
si
tiv
e 
to
 it
, i
t w
or
ks
 v
er
y 
ve
ry
 w
el
l (
57
) 
  H
P
N
23
a 
I t
hi
nk
 w
e 
de
fin
ite
ly
 s
ee
 m
uc
h 
m
or
e 
pr
og
re
ss
 w
ith
 p
eo
pl
e 
on
 in
fli
x 
(1
22
)  
 H
P
N
24
 it
 w
or
ke
d 
re
al
ly
 w
el
l o
n 
th
at
 p
at
ie
nt
 (3
3)
  
 H
P
N
24
 th
er
e’
s 
a 
qu
ic
ke
r r
es
po
ns
e 
w
ith
 in
fli
x.
..p
at
ie
nt
s 
pa
ss
 c
om
m
en
ts
 a
nd
 th
ey
 a
lw
ay
s 
te
ll 
m
e 
I f
ee
l m
uc
h 
be
tte
r a
fte
r t
hi
s 
on
e 
(1
18
) 
 H
P
N
25
a 
it 
se
em
s 
lik
e 
a 
ve
ry
 g
oo
d 
dr
ug
 b
ec
au
se
 I’
ve
 s
ee
n 
so
 m
an
y 
su
cc
es
sf
ul
 o
ut
co
m
es
...
 b
ut
 
th
at
’s
 m
ai
nl
y 
w
ith
 C
hr
on
’s
 d
is
ea
se
 a
nd
 m
y 
vi
ew
s 
ab
ou
t u
lc
er
at
iv
e 
co
lit
is
 a
re
 s
lig
ht
ly
 m
ix
ed
 
be
ca
us
e 
th
e 
ou
tc
om
es
 h
av
en
’t 
be
en
 a
s 
su
cc
es
sf
ul
 b
ut
 I 
th
in
k 
pe
rh
ap
s 
th
ey
’v
e 
be
en
 tr
ea
te
d 
a 
lit
tle
 b
it 
la
te
r (
87
, 9
2,
 9
5)
 
 
G
en
er
al
 c
om
m
en
ts
 a
bo
ut
 th
e 
ef
fe
ct
iv
en
es
s 
of
 c
ic
lo
sp
or
in
 &
 in
fli
xi
m
ab
 
 H
P
6 
in
 te
rm
s 
of
 e
ffi
ca
cy
 –
 s
or
t o
f g
oo
d 
si
m
ila
r e
xp
er
ie
nc
es
 w
ith
 b
ot
h 
dr
ug
s 
(8
7)
 
 H
P
9 
in
fli
xi
m
ab
 a
s 
sa
fe
r a
nd
 e
as
ie
r t
o 
m
an
ag
e 
bu
t m
ay
be
 n
ot
 q
ui
te
 s
o 
ef
fe
ct
iv
e 
an
d 
ci
cl
os
po
rin
 a
s 
a 
bi
t m
or
e 
so
rt 
of
 a
 fi
dd
le
, l
itt
le
 b
it 
m
or
e 
ris
ky
 fo
r t
he
 p
at
ie
nt
 b
ut
 p
er
ha
ps
 a
 li
ttl
e 
bi
t m
or
e 
ef
fe
ct
iv
e 
(9
1)
 
 H
P
N
19
 in
fli
x 
w
as
 th
e 
ne
w
 b
oy
 o
n 
th
e 
bl
oc
k 
as
 s
uc
h 
an
d 
ci
cl
 w
as
 m
ay
be
 s
ee
n 
as
 b
it o
ld
er
, y
ou
 k
no
w
 m
ay
be
 le
ss
 e
ffe
ct
iv
e 
dr
ug
 (2
6)
 
 H
P
N
21
 th
ey
 a
ll 
se
em
 to
 d
o 
qu
ite
 w
el
l o
n 
it 
(in
fli
x)
 th
e 
sa
m
e 
w
ith
 c
ic
l (
84
) 
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 A
dv
er
se
 e
ve
nt
s 
C
ic
lo
sp
or
in
 
In
fli
xi
m
ab
 
H
P
5 
I h
av
e 
ha
d 
pr
ob
le
m
s 
w
ith
 s
ep
si
s 
of
 p
el
vi
s 
w
he
n 
w
e 
do
n’
t l
oo
k 
ca
re
fu
lly
 e
no
ug
h 
(3
9)
 
 H
P
5 
In
fli
x 
is
 e
as
ie
r t
ha
n 
C
ic
l a
s 
yo
u 
do
n’
t h
av
e 
to
 w
or
ry
 a
bo
ut
 e
le
ct
ro
ly
te
s 
an
d 
re
ac
tio
ns
 (1
8)
 
 H
P
5 
O
ut
 o
f p
er
so
na
l c
ho
ic
e,
 In
fli
x 
an
d 
w
ith
 y
ou
ng
er
 p
eo
pl
e 
us
in
g 
it 
as
 fi
rs
t l
in
e 
of
 
tre
at
m
en
t a
s 
le
ss
 to
xi
c 
[th
an
 c
ic
lo
sp
or
in
] (
26
/3
2)
 
 H
P
6 
sa
fe
ty
 a
sp
ec
ts
 –
 th
ou
gh
t c
ic
lo
sp
or
in
 w
as
 m
or
e 
of
 a
 d
an
ge
ro
us
 d
ru
g 
to
 g
iv
e 
(4
4/
49
), 
 U
se
d 
in
f b
ec
au
se
 o
f s
af
et
y 
as
pe
ct
 (7
2)
 
 H
P
6 
do
n’
t r
ea
lly
 w
an
t t
o 
co
nt
in
ue
 lo
ng
 te
rm
 b
ec
au
se
 o
f s
id
e 
ef
fe
ct
s 
(9
9)
 
 H
P
3 
w
or
ry
 a
bo
ut
 to
xi
ci
ty
 &
 li
ve
r, 
us
e 
it 
ha
lf-
he
ar
te
dl
y,
 w
he
n 
no
 c
ho
ic
e 
(th
at
 o
r 
co
le
ct
om
y)
 (3
2/
33
) 
 H
P
7 
ad
ve
rs
e 
si
de
s 
to
 it
, b
ut
 e
qu
al
ly
 w
el
l a
cc
ep
te
d 
an
d 
w
el
l e
st
ab
lis
he
d 
(1
9)
 
 H
P
9 
po
te
nt
ia
lly
 q
ui
te
 s
ig
ni
fic
an
t s
id
e 
ef
fe
ct
s 
th
at
 c
an
 h
ap
pe
n
 s
lig
ht
ly
 u
nc
om
fo
rta
bl
e 
fe
el
in
g 
ab
ou
t i
t (
60
) 
 H
P
9 
th
er
e’
s 
th
e 
ha
ss
le
 o
f t
he
 le
ve
ls
 a
nd
 a
 lo
t o
f p
at
ie
nt
s 
in
 m
y 
ex
pe
rie
nc
e,
 e
nd
 u
p 
w
ith
 
to
xi
ci
ty
, t
re
m
or
 p
ar
tic
ul
ar
ly
 (1
53
) 
 H
P
11
 I 
th
in
k 
th
at
 in
 th
e 
lo
ng
 te
rm
 th
e 
ris
ks
 o
f r
en
al
 fa
ilu
re
 a
re
 s
ig
ni
fic
an
t (
12
5)
 
 H
P
11
 T
he
 p
at
ie
nt
 n
ee
ds
 to
 b
e 
co
un
se
lle
d 
on
 th
e 
ris
ks
 (1
1)
 
 H
P
11
 p
at
ie
nt
s 
ar
e 
m
os
t w
or
rie
d 
ab
ou
t a
re
 s
ur
pr
is
in
gl
y 
se
iz
ur
es
,,,
, r
en
al
 to
xi
ci
ty
 (6
8)
 
 H
P
11
 re
na
l t
ox
ic
ity
 is
 w
ha
t w
or
rie
s 
m
e 
m
os
t o
f a
ll 
if 
I d
on
’t 
ha
ve
 a
 re
lia
bl
e 
sy
st
em
 to
 
m
ak
e 
su
re
 th
at
 th
es
e 
pa
tie
nt
s 
ar
e 
m
on
ito
re
d 
(7
2)
 
 H
P
12
 c
om
or
bi
di
tie
s 
in
 re
la
tio
n 
to
 to
xi
ci
ty
 a
nd
 h
yp
er
te
ns
io
n 
et
c,
 re
na
l t
ox
ic
ity
 a
nd
 
hy
pe
rte
ns
io
n 
ag
ai
n 
in
 th
e 
sa
m
e 
gr
ou
p 
el
de
rly
 (7
6)
 
 H
P
16
 I’
m
 a
lw
ay
s 
a 
lit
tle
 b
it 
m
or
e 
ne
rv
ou
s 
w
ith
 it
.. 
an
d 
I t
hi
nk
 th
at
’s
 fr
om
 th
e 
si
de
 e
ffe
ct
s,
 
of
 re
na
l i
m
pa
irm
en
t..
.I 
th
in
k 
th
e 
si
de
 e
ffe
ct
 p
ro
fil
e 
of
 c
ic
l a
lth
ou
gh
 it
’s
 m
ay
be
 n
ot
 c
om
e 
ou
t i
n 
st
ud
ie
s 
st
ill
 c
on
ce
rn
s 
us
 m
or
e 
(2
78
, 2
81
) 
 H
P
15
 R
is
k 
be
ne
fit
 ra
tio
 c
om
pa
re
d 
to
 in
fli
x 
is
 s
lig
ht
ly
 w
or
se
 (8
2)
 
 H
P
15
 w
e’
ve
 tr
ea
te
d 
lo
ts
 a
nd
 lo
ts
 o
f p
at
ie
nt
s 
w
ith
 c
ic
lo
sp
or
in
 o
ve
r m
an
y 
ye
ar
s 
an
d 
m
os
t 
H
P
6 
ca
n 
w
at
ch
 o
ut
 fo
r a
ny
 in
fu
si
on
 s
id
e 
ef
fe
ct
s 
ea
si
ly
, w
ith
 re
gu
la
r o
bs
 e
ve
ry
 ½
 h
r o
r s
o 
(7
8)
 
 H
P
5 
In
fli
x 
is
 e
as
ie
r t
ha
n 
C
ic
l a
s 
yo
u 
do
n’
t h
av
e 
to
 w
or
ry
 a
bo
ut
 e
le
ct
ro
ly
te
s 
an
d 
re
ac
tio
ns
 (1
8)
 
 H
P
4 
pa
tie
nt
s 
te
nd
 to
 to
le
ra
te
 in
fli
xi
m
ab
 b
et
te
r t
ha
n 
ci
cl
o 
(1
84
) 
  H
P
7 
tre
at
in
g 
pe
o 
w
ith
 In
fli
x 
go
 th
ro
ug
h 
ris
k 
co
un
se
llin
g,
 u
nk
no
w
n 
ris
ks
, n
o 
da
ta
 re
 c
an
ce
r o
r 
10
-1
5 
ye
ar
s 
he
nc
e,
 p
ot
en
tia
lly
 g
re
at
er
 a
dv
er
se
 e
ffe
ct
s 
ne
ed
 to
 m
ak
e 
pa
tie
nt
s 
aw
ar
e 
of
 th
at
 
(3
5)
 
 H
P
11
 It
 c
er
ta
in
ly
 h
as
 a
 ri
sk
 o
f s
id
e 
ef
fe
ct
s 
pr
of
ile
 w
hi
ch
 is
 n
o 
le
ss
 w
or
ry
in
g 
th
an
 c
ic
l (
58
) 
 H
P
11
 a
na
ph
yl
ac
tic
 re
ac
tio
n 
(1
49
) 
 H
P
12
 h
ol
d 
of
f o
n 
in
fli
x 
fo
r o
ld
er
 in
di
vi
du
al
s 
(6
8)
 
 H
P
16
 y
ou
 d
on
’t 
ha
ve
 th
is
 c
on
ce
rn
 o
f c
an
ul
la
s 
tis
su
in
g 
(1
71
) 
 H
P
16
 a
ne
cd
ot
al
ly
 w
e 
do
n’
t s
ee
 a
 s
ig
ni
fic
an
t i
nc
re
as
e 
in
 c
om
pl
ic
at
io
ns
 o
r i
nf
ec
tio
ns
 p
os
t-
op
er
at
iv
el
y 
in
 th
os
e 
pa
tie
nt
s 
(in
fli
x 
re
m
ai
ns
 in
 s
ys
te
m
) (
25
9)
 
 H
P
15
 th
er
e 
ar
e 
le
ss
 ri
sk
s 
(6
9)
 
 H
P
N
19
 m
os
t o
f t
he
 ti
m
e 
it 
go
es
 w
ith
ou
t i
nc
id
en
t (
83
) 
 H
P
N
21
 h
av
e 
on
ly
 e
ve
r s
ee
n 
m
in
or
 re
ac
tio
ns
 to
 th
e 
in
fli
x,
 p
at
ie
nt
s 
do
n’
t s
ee
m
 to
o 
w
or
rie
d 
by
 it
 
(8
2)
 
 H
P
N
24
 th
er
e 
w
er
e 
no
 s
id
e 
ef
fe
ct
s 
(9
9)
  
 H
P
N
25
a 
I’v
e 
ha
d 
ve
ry
 fe
w
 p
ro
bl
em
s 
w
ith
 in
fu
si
on
 re
ac
tio
ns
. (
59
) 
 H
P
11
 E
ve
ry
 b
ad
 re
ac
tio
n 
I h
av
e 
se
en
 w
ith
 in
fli
xi
m
ab
 h
as
 b
ee
n 
in
 o
ld
er
 p
at
ie
nt
s 
(2
20
) 
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of
 th
em
 a
re
 O
K
, b
ut
 th
ey
 a
re
 m
or
e 
lik
el
y 
to
 g
et
 h
yp
er
te
ns
io
n,
 ..
..s
lig
ht
 p
ar
at
he
si
a,
 
m
os
t..
.v
er
y 
su
bt
le
 c
ha
ng
e 
in
 re
na
l f
un
ct
io
n.
.. 
so
m
e 
of
 g
et
 o
th
er
 n
eu
ro
lo
gi
ca
l s
id
e 
ef
fe
ct
s,
 s
lig
ht
 tr
em
or
 (8
7)
 
 H
P
N
20
 it
’s
 m
or
e 
th
e 
po
te
nt
ia
l f
or
 re
ac
tio
n 
to
 th
es
e 
dr
ug
s 
an
d 
th
e 
in
cr
ea
se
d 
ob
se
rv
at
io
ns
 re
al
ly
 th
at
 p
os
e 
a 
pr
ob
le
m
 fo
r a
 b
us
y 
un
it 
(5
6)
 
 H
P
N
25
b 
in
 th
e 
ea
rly
 s
ta
ge
s 
w
e 
w
ou
ld
 m
on
ito
r t
he
m
 fo
r t
he
 fi
rs
t f
ew
 h
ou
rs
 to
 m
ak
e 
su
re
 
th
ey
 w
er
en
’t 
ha
vi
ng
 a
ny
 re
ac
tio
ns
 (1
82
) 
 H
P
N
24
 w
e 
ha
ve
 to
 m
on
ito
r t
hi
s 
pa
tie
nt
 c
lo
se
ly
 fo
r a
ny
 s
id
e 
ef
fe
ct
s 
...
 it
 ta
ke
s 
3 
hr
s 
be
ca
us
e 
yo
u’
ve
 g
ot
 to
 d
o 
ob
s 
fo
r a
 c
ou
pl
e 
of
 h
ou
rs
, b
ut
 th
en
 s
om
et
im
es
 w
e 
te
nd
 to
 
fo
rg
et
 b
ec
au
se
 w
e 
ge
t b
us
y 
w
ith
 o
th
er
 p
at
ie
nt
s.
.. 
so
 id
ea
lly
 it
 s
ho
ul
d 
be
 o
ne
 to
 
on
e.
.b
ec
au
se
 w
e 
ha
nd
le
 9
 p
at
ie
nt
s 
(2
49
, 2
55
) 
 M
on
ito
ri
ng
 
C
ic
lo
sp
or
in
 
In
fli
xi
m
ab
 
 H
P
2 
In
fli
x 
[n
ur
se
s]
 m
or
e 
us
ed
 to
 it
, a
dv
an
ta
ge
s 
ov
er
 C
ic
l n
o 
m
on
ito
rin
g 
ne
ed
ed
 
co
m
pa
re
d 
to
 le
ve
l f
or
 C
ic
l (
42
) 
 H
P
4 
co
nc
er
ns
 re
 a
va
ila
bi
lit
y 
of
 c
ic
lo
 le
ve
ls
 (5
4)
, s
en
t t
o 
an
ot
he
r h
os
pi
ta
l, 
ta
ke
 a
pp
ro
x 
3 
da
ys
 fo
r r
es
ul
t (
61
) 
 H
P
7 
di
sa
dv
an
ta
ge
 is
 s
lig
ht
 –
 c
on
tin
ua
l i
nf
us
io
n 
ov
er
 lo
ng
 p
er
io
d 
of
 ti
m
e,
 h
av
e 
to
 c
he
ck
 
le
ve
ls
 (1
7)
 
 H
P
12
 m
on
ito
rin
g 
is
 s
or
t o
f m
or
e 
la
bo
ur
 in
te
ns
iv
e 
fo
r n
ur
si
ng
 s
ta
ff 
po
in
t o
f v
ie
w
 (1
39
) 
 H
P
12
 th
ey
 h
av
e 
m
or
e 
m
on
ito
rin
g 
af
te
r t
he
y 
le
av
e 
ho
sp
ita
l (
27
6)
 
 H
P
15
 y
ou
 h
av
e 
to
 m
on
ito
r t
he
 le
ve
ls
 w
hi
ch
 d
on
’t 
cu
rr
en
tly
 d
o 
fo
r i
nf
lix
 (9
2)
 
 H
P
N
18
 o
nc
e 
th
e 
pa
tie
nt
 h
as
 b
ee
n 
on
 c
ic
l f
or
 2
4 
ho
ur
s 
th
ey
 h
av
e 
to
 h
av
e 
bl
oo
ds
 a
nd
 if
 
th
e 
ci
cl
 a
re
 to
o 
hi
gh
 th
en
 th
ey
 te
nd
ed
 to
 s
to
p 
it 
.  
N
ow
 th
e 
is
su
e 
w
e 
ha
ve
 is
 b
ec
au
se
 
th
ey
 a
re
 h
av
in
g 
co
nt
in
ou
s 
ci
cl
 th
ey
 h
av
e 
go
t c
ic
 g
oi
ng
 th
ro
ug
h 
th
ei
r v
ei
ns
, s
o 
th
ei
r 
le
ve
ls
 w
ou
ld
 a
lw
ay
s 
be
 to
o 
hi
gh
. S
o 
th
ey
 te
nd
ed
 to
  s
or
t o
f m
es
s 
ab
ou
t a
nd
 p
ut
tin
g 
th
em
 o
n 
or
al
 e
ar
lie
r t
ha
n 
th
ey
 n
ee
de
d 
to
 a
nd
 th
in
gs
 s
o 
I t
hi
nk
 fr
om
 th
at
 p
oi
nt
 o
f v
ie
w
 it
 
w
as
 d
iff
ic
ul
t (
32
) 
 H
P
N
18
 m
os
t r
es
ea
rc
h 
st
af
f a
re
 o
nl
y 
ar
ou
nd
 M
on
da
y 
to
 F
rid
ay
 9
-5
 it
 is
 v
er
y 
di
ffi
cu
lt 
to
 
m
on
ito
r w
ha
t i
s 
go
in
g 
on
 w
ith
 th
e 
pa
tie
nt
 (4
4)
 
 H
P
N
18
 th
ey
 d
on
’t 
m
on
ito
r t
he
 p
at
ie
nt
, t
he
 p
at
ie
nt
 d
oe
sn
’t 
ne
ed
 a
ny
 m
on
ito
rin
g 
(1
2 
ho
ur
 
 H
P
N
20
 w
e 
ki
nd
 o
f t
re
at
 b
ot
h 
as
 th
e 
sa
m
e,
 w
e 
m
ak
e 
su
re
 th
e 
in
di
vi
du
al
 is
 m
on
ito
re
d 
ev
er
y 
30
 
m
in
s 
fo
r a
 p
er
io
d 
of
 ti
m
e.
. T
he
 o
nl
y 
di
ffe
re
nc
e 
w
ith
 in
fli
x 
is
 th
at
 th
e 
in
fu
si
on
 o
nl
y 
la
st
 2
 h
ou
rs
 
bu
t y
ou
’re
 o
bs
er
vi
ng
 th
at
 p
at
ie
nt
 fo
r 4
 h
ou
rs
, s
o 
re
al
ly
 w
he
n 
yo
u 
pu
t t
he
 tw
o 
to
ge
th
er
 th
ey
 
ar
e 
ve
ry
 s
im
ila
r (
66
) 
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in
fu
si
on
 s
ite
) (
44
2)
 
 H
P
N
21
 ti
m
e 
co
ns
um
in
g 
w
ith
 re
ga
rd
s 
to
 o
bs
er
va
tio
n,
 p
ar
tic
ul
ar
ly
 o
n 
a 
bu
sy
 w
ar
d 
w
he
n 
yo
u’
ve
 g
ot
 o
ne
 n
ur
se
 to
 1
0 
pa
tie
nt
s,
 it
 c
an
 ta
ke
 q
ui
te
 a
 h
ug
e 
pa
rt 
of
 y
ou
r w
or
kl
oa
d 
(1
6)
 
 H
P
N
20
 w
e’
re
 d
oi
ng
 o
bs
er
va
tio
ns
 v
er
y,
 v
er
y 
fre
qu
en
tly
 w
ith
in
 a
 3
0 
m
in
ut
es
 p
er
io
d 
ov
er
 
m
ay
be
 4
-6
 h
ou
rs
 ju
st
 to
 m
ak
e 
su
re
 th
at
 th
e 
in
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 I 
do
n’
t h
av
e 
an
yb
od
y 
le
ft 
on
 it
 a
nd
 I’
ve
 tr
ie
d 
bu
t f
or
 o
ne
 re
as
on
 o
r a
no
th
er
 p
eo
pl
e 
ha
ve
 
fa
ile
d 
tre
at
m
en
t a
nd
 c
om
e 
of
f i
t (
14
1)
 
 H
P
13
 if
 y
ou
 re
sc
ue
d 
so
m
eb
od
y 
lik
e 
th
at
 w
ith
 in
fli
x 
th
en
 th
ey
 s
ho
ul
d 
co
nt
in
ue
 o
n 
th
e 
dr
ug
 
(1
79
) 
 H
P
14
 I 
th
in
k 
th
e 
cu
rr
en
t N
IC
E
 g
ui
de
lin
es
 a
re
 u
m
, a
 b
it 
tri
ck
y 
be
ca
us
e 
I t
hi
nk
 if
 y
ou
 a
re
 g
oi
ng
 
to
 g
iv
e 
a 
pa
tie
nt
 in
fli
xi
m
ab
 y
ou
 n
ee
d 
to
 g
iv
e 
th
em
., 
an
d 
th
en
 th
ey
 re
sp
on
d 
to
 it
, i
f t
he
y 
do
 
re
sp
on
d 
to
 it
 y
ou
 w
an
t t
o 
be
 a
bl
e 
to
 c
on
tin
ue
 th
e 
tre
at
m
en
t a
nd
 I 
th
in
k 
it 
m
ay
 h
av
e 
m
or
e 
of
 a
 
lo
ng
 te
rm
 u
se
 th
an
 th
e 
N
IC
E
 g
ui
de
lin
es
 th
at
 w
e’
re
 c
ur
re
nt
ly
 u
si
ng
 (3
8)
 
 H
P
14
 if
 a
 p
at
ie
nt
 is
 re
sp
on
di
ng
 w
el
l t
o 
in
fli
xi
m
ab
 I 
th
in
k 
th
er
e’
s 
a 
ca
se
 fo
r t
he
m
 c
on
tin
ui
ng
 it
 
(5
4)
 
 H
P
14
 It
’s
 w
ha
t w
e 
do
 in
 C
ro
hn
’s
 d
is
ea
se
, w
e’
re
 fa
m
ili
ar
 w
ith
 d
oi
ng
 it
, i
t f
ee
ls
 c
om
fo
rta
bl
e,
 
pa
tie
nt
s 
do
 w
el
l a
nd
 I 
do
n’
t h
av
e 
an
y 
pr
ob
le
m
 w
ith
 it
 (7
1)
 
 H
P
16
 if
 y
ou
 g
et
 s
om
eo
ne
 w
ho
 re
sp
on
ds
 v
er
y 
w
el
l t
he
n 
w
e 
w
ill
 g
iv
e 
th
em
 th
re
e 
do
se
s 
an
d 
w
e 
w
ill
 tr
y 
an
d 
as
se
ss
 th
em
 a
t t
he
 e
nd
 o
f t
hi
s 
an
d 
if 
th
ey
 a
re
 b
et
te
r w
e’
ll 
st
op
 it
 b
ut
 if
 th
ey
 re
la
ps
e 
th
en
 w
e 
w
ill
 c
on
tin
ue
 (3
32
) 
 H
P
15
 it
 w
or
ks
 fa
nt
as
tic
 (1
02
) 
 H
P
15
 it
 is
 g
en
er
al
ly
 w
el
l t
ol
er
at
ed
 in
 y
ou
ng
 p
eo
pl
e 
(lo
ng
 te
rm
) .
.. 
an
d 
ac
tu
al
ly
 w
he
n 
th
ey
 a
re
 
on
 it
 a
nd
 h
av
e 
ha
s 
a 
re
al
ly
 d
ra
m
at
ic
 re
sp
on
se
 it
’s
 m
uc
h 
m
or
e 
di
ffi
cu
lt 
th
en
 to
 w
ith
dr
aw
 it
 
(2
00
,2
05
) 
 H
P
N
18
 th
e 
pa
tie
nt
s 
se
em
 to
 d
o 
qu
ite
 w
el
l o
n 
it 
ge
ne
ra
lly
 (2
01
) 
 H
P
N
19
 w
e 
no
w
 h
av
e 
to
 re
qu
es
t t
he
 fu
nd
in
g 
fo
r p
at
ie
nt
s 
w
ith
 U
C
 o
n 
lo
ng
 te
rm
 in
fli
x.
..s
o 
th
at
’s 
a 
bi
t o
f a
 c
ha
lle
ng
e 
an
d 
it 
m
ea
ns
 th
at
 d
ec
is
io
ns
 a
re
 m
ad
e 
di
ffe
re
nt
ly
 to
 w
he
th
er
 a
 p
at
ie
nt
 is
 
go
in
g 
on
 to
 m
ai
nt
en
an
ce
 in
fli
x 
(1
54
, 1
56
) 
 H
P
N
19
 (d
is
cu
ss
in
g 
lo
ng
er
 te
rm
 in
fli
x)
 it
 s
om
et
im
es
 c
om
es
 d
ow
n 
to
 a
 v
er
y 
in
di
vi
du
al
is
ed
 
de
ci
si
on
 b
ec
au
se
 it
 d
ep
en
ds
 o
n 
ho
w
 th
e 
pa
tie
nt
s 
ar
e,
 h
ow
 th
ey
 fe
el
 y
ou
 k
no
w
.(1
83
) 
 H
P
N
22
 It
’s
 a
lre
ad
y 
an
 is
su
e 
be
ca
us
e 
w
e 
ca
n’
t r
ea
lly
 tr
ea
t a
s 
m
ai
nt
en
an
ce
 w
ith
 in
fli
x 
so
 
ob
vi
ou
sl
y 
if 
a 
pa
tie
nt
 re
sp
on
ds
 w
el
l w
e’
ve
 h
ad
 to
 g
et
 e
xc
ep
tio
na
l f
un
di
ng
 a
nd
 th
in
g 
lik
e 
th
at
 
an
d 
so
 th
er
e 
is
 a
 c
as
e 
fo
r i
t I
 th
in
k 
(1
03
) 
 H
P
N
23
a 
S
om
e 
(p
at
ie
nt
s)
 p
re
fe
r i
t l
on
ge
r b
ut
 s
om
e 
go
 o
nt
o 
H
um
ira
, t
he
 A
da
lim
um
ab
, t
he
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in
je
ct
io
ns
 th
at
 th
ey
 h
av
e 
bu
t s
om
e 
ar
e 
ha
pp
y 
to
 ju
st
 h
av
e 
th
e 
in
fli
x 
an
d 
it 
w
or
ks
 fo
r t
he
m
 ..
. I
 
th
in
k 
th
ey
 a
re
 q
ui
te
 h
ap
py
 to
 h
av
e 
th
at
 d
on
e 
be
ca
us
e 
th
ey
 fe
el
 g
re
at
 b
en
ef
it 
fro
m
 it
 (7
1,
 7
8)
  
 H
P
N
23
a 
W
e’
ve
 g
ot
 s
om
e 
w
ho
 h
av
e 
be
en
 h
av
in
g 
it 
in
 e
xc
es
s 
of
 5
 y
ea
rs
 (8
6)
 
 H
P
N
25
a 
M
os
t o
f t
he
 p
at
ie
nt
s 
w
e 
tre
at
 h
av
e 
ha
ve
 b
ee
n 
on
 it
 lo
ng
 te
rm
 o
r d
o 
co
nt
in
ue
 to
 h
av
e 
it 
lo
ng
 te
rm
...
.o
ve
r a
 y
ea
r..
. A
nd
 m
an
y 
of
 o
ur
 p
at
ie
nt
s 
ha
ve
 b
ee
n 
on
 it
 fo
r m
uc
h 
lo
ng
er
 th
an
 
th
at
...
 a
 lo
t o
f t
he
 p
at
ie
nt
s 
th
at
 w
e 
try
 to
 w
ith
dr
aw
 tr
ea
tm
en
t e
nd
 u
p 
go
in
g 
ba
ck
 o
n 
it 
be
ca
us
e 
th
ey
 re
la
ps
e.
 (1
22
, 1
26
, 1
30
, 1
33
) 
 
G
en
er
al
 c
om
m
en
ts
 a
bo
ut
 th
e 
us
e 
of
 c
ic
lo
sp
or
in
 &
 in
fli
xi
m
ab
 a
s 
lo
ng
er
 te
rm
 m
ai
nt
en
an
ce
 
 H
P
5 
In
 a
n 
ac
ut
e 
si
tu
at
io
n 
yo
u 
ta
ilo
r y
ou
r s
up
po
rt 
ac
co
rd
in
g 
to
 y
ou
r g
ut
 fe
el
in
g 
(7
6)
 
 H
P
1 
D
ep
en
ds
 w
ha
t i
s 
be
st
 fo
r t
he
 p
at
ie
nt
 (5
4/
56
) 
 Pe
rs
on
al
 p
re
fe
re
nc
e 
an
d 
in
vo
lv
em
en
t i
n 
th
e 
tr
ia
l 
C
on
su
lta
nt
s’
 p
er
so
na
l p
re
fe
re
nc
es
 
C
ic
lo
sp
or
in
 
In
fli
xi
m
ab
 
 H
P
5 
I h
av
e 
m
or
e 
ex
pe
rie
nc
e 
of
 C
ic
l a
nd
 a
m
 m
or
e 
ca
ut
io
us
, l
oo
ki
ng
 fo
r i
nf
ec
tio
n 
fo
ci
 
(3
8)
 
 H
P
5 
I h
av
e 
a 
lo
t o
f g
oo
d 
ex
pe
rie
nc
e 
w
ith
 th
is
 d
ru
g 
bu
t I
 a
m
 m
or
e 
w
ar
y 
th
an
 I 
am
 w
ith
 
In
fli
x 
(4
2)
 
 H
P
6 
la
st
 ti
m
e 
I r
ea
lly
 u
se
d 
a 
lo
t o
f c
ic
lo
 w
as
 1
0-
11
 y
rs
 a
go
 b
ut
 o
nl
y 
ab
ou
t 3
 o
r 4
 p
ts
 (8
4)
 
 H
P
4 
O
nl
y 
te
nd
 to
 u
se
 C
ic
l a
s 
ac
tin
g 
m
or
e 
qu
ic
kl
y 
(1
71
) 
 H
P
9 
 a
 s
or
t o
f s
lig
ht
ly
 u
ne
as
y 
fe
el
in
g 
ab
ou
t c
ic
lo
sp
or
in
 th
at
 I 
th
in
k 
I d
o 
ha
ve
 (5
6)
 
 H
P
10
 ra
th
er
 m
or
e 
re
la
xe
d 
ab
ou
t i
t, 
pa
ra
do
xi
ca
lly
, s
im
pl
y 
be
ca
us
e 
I k
no
w
 w
he
n 
th
e 
IV
 
in
fu
si
on
 is
 s
to
pp
ed
, t
he
 d
ru
g 
di
sa
pp
ea
rs
 (7
5)
 
 H
P
11
 I 
m
ig
ht
 re
ac
h 
a 
pr
ef
er
en
ce
 w
ith
 c
ic
l a
 th
e 
m
om
en
t (
15
5)
 
 H
P
11
 I’
ve
 u
se
d 
it 
fo
r a
 lo
ng
 ti
m
e 
an
d 
I’m
 c
om
fo
rta
bl
e 
w
ith
 it
 (1
60
) 
 H
P
13
 if
 I 
w
as
 lo
ok
in
g 
at
 th
e 
da
ta
 a
nd
 a
ss
um
in
g 
ef
fic
ac
y 
is
 e
qu
al
 I 
wo
ul
d 
fa
vo
ur
 c
ic
l 
(2
70
) 
 H
P
13
 u
nl
es
s 
yo
u’
ve
 g
ot
 a
 b
lo
od
y 
go
od
 re
as
on
 y
ou
 s
ho
ul
d 
be
 u
si
ng
 c
ic
l (
44
4)
 
 
 H
P
2 
I’m
 m
or
e 
fa
m
ili
ar
 w
ith
 it
 (4
7)
  
 H
P
5 
M
y 
ow
n 
pe
rs
on
al
 p
re
fe
re
nc
e 
w
ou
ld
 b
e 
In
fli
x 
(1
03
) 
 H
P
5 
O
ut
 o
f p
er
so
na
l c
ho
ic
e,
 In
fli
x 
an
d 
w
ith
 y
ou
ng
er
 p
eo
pl
e 
us
in
g 
it 
as
 fi
rs
t l
in
e 
of
 tr
ea
tm
en
t 
as
 le
ss
 to
xi
c 
(2
6/
32
) 
 H
P
6 
pe
rs
on
al
ly
 p
re
fe
r I
nf
lix
 s
ee
 re
su
lts
 m
or
e 
qu
ic
kl
y 
ca
n 
w
at
ch
 o
ut
 fo
r s
id
e 
ef
fe
ct
s,
 s
ee
n 
go
od
 o
ut
co
m
es
, I
 w
ou
ld
 c
ho
os
e 
it 
if 
I h
ad
 th
e 
ch
oi
ce
 (7
7)
 
 H
P
1 
tre
at
m
en
t p
re
fe
re
nc
e 
ba
se
d 
on
 fa
m
ili
ar
ity
 fo
r n
ur
se
s 
an
d 
m
e 
(fr
om
 C
ro
hn
s 
tre
at
m
en
t) 
(8
6)
 
 H
P
3 
se
ns
ib
le
 a
nd
 g
oo
d 
ex
pe
rie
nc
e 
of
 th
is
 d
ru
g 
‘w
he
n 
it 
w
or
ks
 it
 is
 fa
nt
as
tic
’ (
23
-2
5)
 
 H
P
3 
In
fli
x 
pe
rs
on
al
 p
re
fe
re
nc
e,
 ‘a
bs
ol
ut
el
y’
 b
ut
 fo
llo
w
s 
N
IC
E
 g
ui
de
lin
es
 (u
nf
or
tu
na
te
ly
) (
11
6)
 
 H
P
3 
w
ou
ld
 g
o 
fo
r I
nf
lix
 if
 n
o 
co
nt
ra
in
di
ca
tio
n.
 If
 c
on
tra
in
di
ca
te
d 
w
ou
ld
 h
av
e 
to
 g
o 
fo
r C
ic
l (
40
) 
 H
P
4 
I s
us
pe
ct
 m
y 
pr
ej
ud
ic
e 
is
 to
w
ar
ds
 in
fli
xi
m
ab
, i
f I
 h
ad
 to
 h
av
e 
on
e.
 P
ro
ba
bl
y 
be
ca
us
e 
of
 
la
ck
 o
f a
va
ila
bi
lit
y 
of
 C
ic
l a
nd
 n
ot
 h
av
in
g 
th
e 
ab
ili
ty
 to
 m
on
ito
r i
t c
lo
se
ly
 a
s 
I w
ou
ld
 li
ke
 (1
64
) 
 H
P
7 
ne
w
er
 th
an
 C
ic
l (
on
ly
 1
5 
ye
ar
s)
 m
or
e 
us
ed
 to
 u
si
ng
 it
 w
ith
 C
ro
hn
s 
th
an
 U
C
 (2
4)
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H
P
14
 i 
do
n’
t m
uc
h 
lik
e 
it 
(9
) 
 H
P
14
 I 
w
ou
ld
 b
e 
m
or
e 
lik
el
y 
to
 u
se
 o
ra
l c
ic
l t
ha
n 
I w
ou
ld
 IV
 c
ic
l .
.. 
I d
on
’t 
th
in
k 
IV
 
ci
cl
os
po
rin
 is
 w
ha
t I
 w
ou
ld
 u
se
 in
 th
e 
fu
tu
re
 b
ut
 w
e’
ve
 u
se
d 
it 
fo
r t
he
 tr
ia
l (
25
9,
 2
62
) 
 H
P
16
 I’
m
 a
 li
ttl
e 
bi
t r
el
un
ct
an
t t
o 
tre
at
 w
ith
 c
ic
l a
ny
bo
dy
 w
ho
’s
 a
lre
ad
y 
on
 a
za
th
io
pr
in
e 
(3
13
) 
H
P
9 
pr
ob
ab
ly
 s
lig
ht
ly
 in
 fa
vo
ur
 o
f i
nf
lix
im
ab
 ju
st
 d
ue
 to
 e
as
e 
an
d 
so
rt 
of
 s
lig
ht
 fe
el
in
g 
th
at
 it
’s 
a 
bi
t m
or
e 
pr
ed
ic
ta
bl
e 
an
d 
th
e 
si
de
 e
ffe
ct
s 
ar
e 
ea
si
er
 to
 m
an
ag
e 
(1
90
) 
 H
P
11
 I 
pe
rs
on
al
ly
 a
m
 y
et
 to
 b
e 
co
nv
in
ce
d 
th
at
 it
 h
as
 a
ny
th
in
g 
to
 o
ffe
r i
n 
te
rm
s 
of
 a
dv
an
ta
ge
 
ov
er
 a
nd
 a
bo
ve
 c
ic
l (
36
) 
 H
P
11
 I 
do
n’
t f
ee
l c
om
fo
rta
bl
e 
us
in
g 
it 
(6
0)
 
 H
P
11
 (o
n 
in
fli
x)
 if
 th
er
e 
is
 d
at
a 
to
 s
ug
ge
st
 th
at
 it
 s
ig
ni
fic
an
tly
 b
et
te
r i
n 
te
rm
s 
of
 a
vo
id
in
g 
su
rg
er
y 
in
 te
rm
s 
of
 s
uc
ce
ss
 o
f t
re
at
m
en
t t
he
n 
I’m
 w
ill
in
g 
to
 c
ha
ng
e 
m
y 
m
in
d 
(6
2)
 
 H
P
12
 th
at
 is
 a
 d
iff
ic
ul
t o
ne
 b
ut
 I 
w
ou
ld
 s
ay
 y
es
 a
t t
he
 m
om
en
t i
f I
 h
ad
 to
 c
ho
os
e 
be
tw
ee
n 
th
e 
tw
o 
I w
ou
ld
 g
o 
fo
r i
nf
lix
im
ab
 b
ec
au
se
 th
er
e 
is
, a
lth
ou
gh
 n
ot
 g
oo
d 
qu
al
ity
 R
C
T 
da
ta
...
 b
ut
 th
er
e 
is
 c
lin
ic
al
 e
xp
er
ie
nc
e 
da
ta
 (8
5)
 
 H
P
12
 I 
m
ea
n 
pe
rs
on
al
 p
re
fe
re
nc
e 
w
ou
ld
 b
e 
fo
r o
ffe
rin
g 
in
fli
xi
m
ab
 a
nd
 th
en
 c
ol
ec
to
m
y 
(1
59
) 
 H
P
14
 if
 th
e 
2 
w
er
e 
eq
ua
lly
 e
ffi
ca
ci
ou
s 
an
d 
eq
ua
lly
 c
os
t e
ffe
ct
iv
e,
 I 
w
ou
ld
 c
ho
os
e 
in
fli
xi
m
ab
 
be
ca
us
e 
of
 th
at
 re
as
on
 (p
ra
ct
ic
al
ity
 o
f a
dm
in
is
tra
tio
n)
 (1
38
) 
 H
P
16
 m
y 
tre
at
m
en
t p
re
fe
re
nc
e 
is
 in
fli
x.
..m
y 
re
as
on
in
g 
fo
r t
ha
t i
s 
th
at
 I 
th
in
k 
th
at
 th
e 
ef
fic
ac
y 
is
 b
es
t..
...
at
 w
or
st
 b
ro
ad
ly
 s
im
ila
r (
40
5,
 4
09
) 
 H
P
15
 M
y 
pe
rs
on
al
 v
ie
w
 is
 th
at
 th
ey
 p
ro
ba
bl
y 
ha
ve
 e
qu
al
 e
ffi
ca
cy
, I
 th
in
k 
in
fli
x 
ha
ve
 o
ve
ra
ll 
m
y 
cl
in
ic
al
 im
pr
es
si
on
 is
 th
at
 it
 h
as
 le
ss
 s
id
e 
ef
fe
ct
s 
so
 if
 I 
w
as
 g
iv
en
 a
 fr
ee
 c
ho
ic
e,
 if
 it
 w
as
 
as
ki
ng
 it
 fo
r m
e 
or
 if
 m
y 
lo
ve
d 
on
es
, I
 w
ou
ld
 o
pt
 fo
r i
nf
lix
im
ab
 (6
5)
 
 H
P
15
 m
y 
tre
at
m
en
t p
re
fe
re
nc
e 
is
 s
lig
ht
ly
 in
 th
e 
di
re
ct
io
n 
of
 in
fli
x 
(2
22
) 
 H
P
15
 w
he
n 
a 
pa
tie
nt
 w
as
 g
iv
en
 in
fli
x 
I w
as
 ra
th
er
 p
le
as
e 
an
d 
w
he
n 
th
ey
 w
er
e 
gi
ve
n 
ci
cl
 I 
w
as
 
le
ss
 e
nt
hu
si
as
tic
...
w
e 
w
on
de
re
d 
ab
ou
t t
he
 to
le
ra
nc
e 
fo
r t
he
 p
at
ie
nt
 a
nd
 th
e 
co
nv
en
ie
nc
e 
fo
r 
th
e 
pa
tie
nt
s 
(3
80
, 3
94
 
 
G
en
er
al
 c
om
m
en
ts
 o
n 
PI
 p
er
so
na
l p
re
fe
re
nc
e 
 H
P
4 
th
e 
su
bt
le
tie
s 
of
 w
hi
ch
 s
ub
-g
ro
up
 o
f p
eo
pl
e 
re
sp
on
d 
to
 a
 c
er
ta
in
 d
ru
g,
 y
ou
 w
ill
 a
lw
ay
s 
be
 s
lig
ht
ly
 b
ia
se
d 
by
 p
er
so
na
l p
re
fe
re
nc
e 
(1
83
) 
 H
P
4 
fin
d 
th
at
 p
at
ie
nt
s 
te
nd
 to
 to
le
ra
te
 In
fli
x 
be
tte
r t
ha
n 
C
ic
l, 
bu
t t
ha
t i
s 
ge
ne
ra
l i
m
pr
es
si
on
, n
ot
 d
at
a-
ba
se
d,
 b
ut
 I 
am
 m
or
e 
in
 fa
vo
ur
 o
f e
ns
ur
in
g 
ap
pr
op
ria
te
 m
ed
ic
al
 re
sc
ue
 is
 p
ro
vi
de
d 
ra
th
er
 th
an
 g
iv
in
g 
pr
ef
er
en
ce
 to
 o
ne
 d
ru
g 
(1
85
) 
 H
P
7 
I d
on
’t 
ha
ve
 a
 tr
ea
tm
en
t p
re
fe
re
nc
e 
ha
pp
y 
to
 a
dm
in
is
te
r e
ith
er
 (9
0)
 
 H
P
14
 I 
w
an
t t
he
 o
ne
 th
at
’s
 m
or
e 
ef
fe
ct
iv
e 
(1
41
) 
 H
P
14
 s
om
e 
pa
tie
nt
s 
I’d
 c
ho
os
e 
an
d 
so
m
e 
ot
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 M
ys
el
f i
t w
ou
ld
 b
e 
in
fli
xi
m
ab
 b
ut
 b
as
ic
al
ly
 m
y 
re
as
on
 fo
r t
ha
t..
m
y 
ba
ck
gr
ou
nd
 it
 
ha
em
at
ol
og
y/
on
co
lo
gy
 a
s 
w
e 
us
ed
 a
 lo
t o
f t
he
 g
ro
up
 o
f M
A
B
 th
er
ap
ie
s.
.. 
w
e 
ha
ve
 h
as
 s
om
e 
re
al
ly
 g
oo
d,
 y
ou
 k
no
w
 re
ac
tio
ns
 w
ith
 th
em
 (2
64
) 
 H
P
N
19
 I’
m
 h
ap
py
 to
 tr
ea
t p
at
ie
nt
s 
w
ith
 it
 (9
3)
 
 H
P
N
19
 I 
th
in
k 
th
er
e 
ar
e 
pr
os
 a
nd
 c
on
s 
to
 b
ot
h 
to
 b
e 
qu
ite
 h
on
es
t..
...
 I 
do
n’
t r
ul
e 
ou
t c
ic
l a
s 
a 
tre
at
m
en
t, 
bu
t I
 th
in
k 
it’
s 
st
ill
, p
at
ie
nt
 w
is
e 
an
d 
ot
he
r n
ur
se
s 
an
d 
I t
hi
nk
 th
e 
ge
ne
ra
l f
ee
lin
g 
it 
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th
at
 in
fli
xi
m
ab
 is
 s
ee
n 
as
 b
et
te
r r
ig
ht
ly
 o
r w
ro
ng
ly
 (1
44
, 1
46
) 
 H
P
N
19
 p
ro
ba
bl
y 
st
ill
 s
ay
 it
 is
 in
fli
x.
.. 
an
d 
I p
ro
ba
bl
y 
fa
ll 
in
to
 th
e 
sa
m
e 
ca
te
go
ry
 o
r i
t’s
 a
 re
ce
nt
 
dr
ug
 a
nd
 it
s.
..m
ay
be
 a
ga
in
 it
’s
 p
er
so
na
l e
xp
er
ie
nc
e 
be
ca
us
e 
I’v
e 
pr
ob
ab
ly
 s
ee
n 
th
e 
ef
fe
ct
s 
of
 
in
fli
x 
m
or
e.
.. 
I s
pe
ak
 to
 p
at
ie
nt
s 
an
d 
fin
d 
ou
t t
he
ir 
ex
pe
rie
nc
es
 a
nd
 I 
do
n’
t s
ee
 c
ic
l (
23
2,
 2
36
) 
 H
P
N
21
 it
’s
 q
ui
te
 a
 g
oo
d 
dr
ug
 to
 b
e 
ho
ne
st
 w
ith
 y
ou
 (1
19
) 
 H
P
N
21
 P
er
so
na
lly
 I 
fe
el
 th
at
 th
e 
in
fli
x 
is
 b
et
te
r b
ut
 th
at
’s
 o
nl
y 
be
ca
us
e 
of
 th
e 
ex
pe
rie
nc
es
 
w
e’
ve
 h
ad
 w
ith
 th
e 
in
fli
x 
ra
th
er
 th
an
 th
e 
ci
cl
 ..
. s
ee
n 
pa
tie
nt
s 
do
 v
er
y 
w
el
l o
n 
it,
 p
ar
tic
ul
ar
ly
 
w
he
n 
be
fo
re
 th
er
e 
pe
rh
ap
s 
w
ou
ld
n’
t h
av
e 
be
en
 a
ny
 o
th
er
 o
ut
co
m
e 
th
an
 s
ur
ge
ry
 fo
r t
he
m
 
(2
09
...
21
7)
 
 H
P
N
22
 I’
ve
 a
lw
ay
s 
co
ns
id
er
ed
 in
fli
xi
m
ab
 is
 a
 g
oo
d 
dr
ug
 (7
7)
 
 H
P
N
22
 I 
ki
nd
 o
f l
ea
n 
to
w
ar
ds
 in
fli
x 
bu
t o
bv
io
us
ly
, y
ou
 k
no
w
 if
 th
e 
ev
id
en
ce
 te
ll 
us
 s
om
et
hi
ng
 
di
ffe
re
nt
...
.ju
st
 b
ec
au
se
 I’
m
 m
or
e 
fa
m
ili
ar
 w
ith
 it
, t
ha
t I
 s
ee
 m
or
e 
pa
tie
nt
s 
ha
ve
 a
 g
oo
d 
ef
fe
ct
 
fro
m
 it
, b
ut
 th
at
’s
 p
ro
ba
bl
y 
ju
st
 b
ec
au
se
 w
e’
ve
 u
se
d 
it 
m
or
e 
(1
45
, 1
50
) 
 H
P
N
23
a 
fo
r m
os
t o
f t
he
 p
at
ie
nt
s 
it 
a 
w
on
de
r d
ru
g,
 s
o 
I’m
 d
ef
in
ite
ly
 a
ll 
fo
r i
t (
28
) 
 H
P
N
23
a 
m
y 
ow
n 
ex
pe
rie
nc
e 
w
ith
 in
fli
x 
is
 a
 p
os
iti
ve
 o
ne
, y
ou
 k
no
w
 fo
r p
at
ie
nt
s 
so
 I 
ca
n 
on
ly
 
th
in
k 
th
at
 it
’s
 a
 g
re
at
 th
in
g 
to
 h
av
e 
(1
90
) 
 H
P
N
23
a 
I j
us
t t
hi
nk
 it
’s
 a
 g
re
at
 tr
ea
tm
en
t, 
I t
hi
nk
 it
’s
 v
er
y 
go
od
 it
’s
 v
er
y 
ef
fe
ct
iv
e 
an
d 
it’
s 
ni
ce
 to
 
se
e 
th
at
 it
’s
 a
ct
ua
lly
 b
ei
ng
 u
se
d 
w
id
el
y 
w
ith
 it
 b
ei
ng
 s
uc
h 
an
 e
xp
en
si
ve
 o
ne
 (2
54
) 
 H
P
N
25
a 
I d
on
’t 
ha
ve
 a
ny
th
in
g 
to
 d
o 
w
ith
 c
ic
lo
sp
or
in
 s
o 
I p
ro
ba
bl
y 
if 
I w
as
 o
n 
a 
w
ar
d 
th
ou
gh
 I 
w
ou
ld
 p
re
fe
r t
o 
us
e 
in
fli
xi
m
ab
 b
ec
au
se
 it
’s
 e
as
ie
r t
o 
m
ix
...
. I
t’s
 (c
ic
l) 
m
uc
h 
m
or
e 
hi
gh
 
m
ai
nt
en
an
ce
 fo
r t
he
 n
ur
se
 s
o 
if 
I w
as
 o
n 
th
e 
w
ar
d 
an
d 
ha
d 
th
e 
ch
oi
ce
 I 
pr
ob
ab
ly
 w
ou
ld
 s
til
l g
o 
fo
r i
nf
lix
im
ab
 (1
74
) 
  
G
en
er
al
 c
om
m
en
ts
 o
n 
nu
rs
es
 p
er
so
na
l p
re
fe
re
nc
es
 
 H
P
N
20
 I 
ca
n’
t s
ay
 I 
do
, I
 c
an
’t 
sa
y 
I d
on
’t 
(1
79
) 
 N
ur
se
s’
 v
ie
w
s o
n 
co
ns
ul
ta
nt
s’
 p
re
fe
re
nc
es
 
C
ic
lo
sp
or
in
 
In
fli
xi
m
ab
 
      
H
P
N
18
 M
y 
fe
el
in
g 
, t
ha
t t
he
 d
oc
to
rs
 th
in
k 
th
at
 th
er
e 
is
  m
or
e 
va
lu
e 
in
 g
iv
in
g 
so
m
eo
ne
 
in
fli
xi
m
ab
 th
an
 p
er
ha
ps
 c
on
tin
ui
ng
 w
ith
 s
ta
nd
ar
d 
ca
re
 (c
ic
l) 
(2
37
) 
 H
P
N
19
 I 
th
in
k 
th
er
e 
is
 s
til
l t
he
 p
er
ce
pt
io
n 
th
at
 th
er
e 
is
 s
til
l t
he
 p
er
ce
pt
io
n 
th
at
 in
fli
x 
is
 
be
tte
r..
..b
ec
au
se
 it
 is
 th
e 
ne
w
 o
ne
...
no
t n
ec
es
sa
ril
y 
th
e 
co
ns
ul
ta
nt
s 
bu
t m
ay
be
 th
e 
do
ct
or
s 
w
ho
 
ar
en
’t 
as
 e
xp
er
ie
nc
ed
 o
r a
 n
ew
 ro
ta
tio
n 
or
 n
ew
 in
to
 it
 a
s 
su
ch
 th
at
 m
ay
be
 th
ey
 d
on
’t 
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ne
ce
ss
ar
ily
 k
no
w
 c
ic
 (2
11
,2
14
)  
 H
P
N
25
a 
I d
on
’t 
kn
ow
 th
at
 th
at
’s
 w
ha
t t
he
y 
w
ou
ld
 c
ho
os
e 
bu
t I
 th
in
k 
no
w
 if
 th
ey
 c
ou
ld
 u
se
 
in
fli
xi
m
ab
 th
ey
 p
ro
ba
bl
y 
w
ou
ld
. A
nd
 if
 th
ey
 c
an
 u
se
 it
 th
ey
 d
o 
(1
55
, 1
60
) 
 
G
en
er
al
 c
om
m
en
ts
 o
n 
nu
rs
es
 v
ie
w
s 
of
 c
on
su
lta
nt
 p
re
fe
re
nc
es
 
 I 
th
in
k 
th
ey
’re
 h
ap
py
 to
 d
o 
bo
th
 (2
11
) 
 H
P
N
20
 (d
oc
to
rs
 c
on
si
de
rin
g 
pr
ac
tic
al
iti
es
 fo
r n
ur
se
s)
 N
o 
th
ey
 g
iv
e 
no
 c
on
si
de
ra
tio
n 
w
ha
ts
oe
ve
r I
 w
ou
ld
 s
ay
 (l
au
gh
s)
 (1
68
) 
 H
P
N
20
 I 
do
n’
t t
hi
nk
 th
ey
 k
no
w
 e
no
ug
h 
ab
ou
t i
t, 
if 
I’m
 b
ei
ng
 h
on
es
t w
ith
 y
ou
, b
ec
au
se
 w
e 
ha
ve
 a
 3
 m
on
th
 c
ha
ng
eo
ve
r f
or
 o
ur
 m
ed
ic
al
 te
am
 o
n 
th
e 
w
ar
d 
th
at
 th
ey
 s
im
pl
y 
do
n’
t h
av
e 
en
ou
gh
 c
on
fid
en
ce
 w
ith
 th
e 
dr
ug
, t
he
y 
re
ly
 h
ea
vi
ly
 o
n 
th
e 
nu
rs
es
 to
 te
ll 
th
em
 w
ha
t i
t i
s 
an
d 
ho
w
 th
ey
 m
us
t p
re
sc
rib
e 
it 
 a
nd
 a
ga
in
 if
 th
er
e’
s 
a 
re
ac
tio
n,
 w
ha
t t
he
y 
ne
ed
 to
 d
o 
ab
ou
t i
t, 
th
ey
 d
on
’t 
se
em
 to
 h
av
e 
th
e 
kn
ow
le
dg
e 
ba
se
 a
s 
pe
rh
ap
s 
th
ey
 s
ho
ul
d.
.. 
th
ey
 s
ee
m
 to
 b
e 
qu
ite
 u
nc
on
fid
en
t w
ith
 it
, p
ur
el
y 
fro
m
 a
 la
ck
 o
f e
du
ca
tio
n,
 I 
fe
el
 (1
64
...
17
6)
 
do
n’
t t
hi
nk
 th
ey
 h
av
e 
m
uc
h 
op
in
io
n 
on
 th
e 
pr
ac
tic
al
iti
es
 o
f i
t b
ec
au
se
 it
’s
 n
ot
 fo
r t
he
m
 to
 w
or
ry
 a
bo
ut
...
. Y
eh
 I 
do
n’
t t
hi
nk
 th
ey
 g
iv
e 
an
y 
co
ns
id
er
at
io
n 
to
 th
at
 to
 b
e 
ho
ne
st
 I 
th
in
k 
th
ey
 y
ou
 k
no
w
 th
ey
’re
 m
or
e 
in
te
re
st
ed
 in
 th
e 
ou
tc
om
es
 fo
r t
he
 p
at
ie
nt
. (
16
0,
 1
65
) 
   E
qu
ip
oi
se
 a
nd
 v
ie
w
s o
n 
tr
ia
l 
H
P
2 
E
ffi
ca
cy
 o
f b
ot
h 
dr
ug
s 
is
 e
qu
al
, s
o 
no
t c
ho
os
in
g 
on
e 
ov
er
 th
e 
ot
he
r o
n 
th
os
e 
te
rm
s 
(6
5)
 
H
P
2 
B
ot
h 
dr
ug
s 
ar
e 
eq
ua
lly
 a
va
ila
bl
e 
in
 th
e 
Tr
us
t (
10
3)
 
H
P
2 
N
ot
 a
ll 
co
lle
ag
ue
s 
ar
e 
ha
pp
y 
to
 u
se
 e
ith
er
 d
ru
g 
eq
ua
lly
 (7
3)
 
H
P
5 
w
e 
ha
ve
n’
t b
ee
n 
su
cc
es
sf
ul
 in
 th
e 
Tr
ia
l, 
w
e 
do
n’
t h
av
e 
nu
rs
es
 w
ho
 c
an
 s
up
po
rt 
it 
(1
69
/1
73
) 
H
P
5 
su
pp
or
t f
or
 re
cr
ui
tm
en
t h
as
 n
ot
 b
ee
n 
th
er
e,
 o
nl
y 
on
e 
si
ng
le
-h
an
de
d 
nu
rs
e 
sp
ec
ia
lis
t (
17
9)
 
H
P
5 
‘I’
m
 fi
gh
tin
g 
m
y 
co
rn
er
 a
ga
in
 [f
or
 re
se
ar
ch
 s
up
po
rt]
, a
s 
us
ua
l, 
st
or
y 
of
 m
y 
lif
e’
 (1
80
) 
H
P
5 
Tr
ia
l n
ur
se
s 
su
pp
or
t t
he
 T
ria
ls
 U
ni
t b
ut
 th
ey
 w
on
’t 
co
ve
r t
he
 w
ar
ds
 w
he
re
 p
at
ie
nt
s 
ar
e 
bo
th
 tr
ea
te
d 
an
d 
re
cr
ui
te
d 
(1
89
) 
H
P
5 
th
e 
Tr
ia
l i
s 
go
od
, v
er
y 
us
ef
ul
, v
er
y 
im
po
rta
nt
. (
19
7)
 
H
P
5 
‘I 
w
ou
ld
 li
ke
 to
 m
ak
e 
a 
th
in
g 
ab
ou
t t
he
 T
ria
l’ 
(1
96
) p
ap
er
w
or
k 
is
 h
ar
d 
fo
r u
s 
to
 g
et
, t
oo
 m
uc
h 
of
 it
, t
oo
 m
uc
h 
fo
r d
iff
er
en
t d
ep
ar
tm
en
ts
 to
 h
an
dl
e 
(R
&
D
, p
ha
rm
), 
m
uc
h 
m
or
e 
th
an
 
us
ua
l, 
to
p-
he
av
y 
(1
97
) (
20
7)
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H
P
5 
th
e 
dr
ug
 w
e 
ch
oo
se
 u
lti
m
at
el
y 
de
pe
nd
s 
on
 th
e 
pa
tie
nt
 (7
5)
 
 H
P
5 
yo
u 
ca
n 
al
w
ay
s 
fin
d 
re
as
on
s 
w
hy
 C
ic
l i
s 
co
nt
ra
in
di
ca
te
d!
  S
o 
yo
u 
ca
n 
sa
y 
th
at
 In
fli
x 
is
 in
di
ca
te
d 
fo
r p
at
ie
nt
s 
w
ith
 a
cu
te
 c
ol
iti
s 
be
ca
us
e,
 fo
r e
xa
m
pl
e,
 th
ey
 w
er
e 
at
 ri
sk
 o
f i
nf
ec
tio
n 
(1
42
) 
H
P
1 
I w
ou
ld
 g
iv
e 
bo
th
 In
fli
x 
an
d 
C
ic
l i
nf
o 
to
 p
at
ie
nt
s 
in
 a
n 
op
en
 s
et
tin
g 
if 
th
ey
 w
an
t (
41
) 
H
P
3 
di
d 
no
t h
av
e 
an
y 
ad
m
is
si
on
s 
se
ve
re
 e
no
ug
h 
to
 re
cr
ui
t t
o 
th
e 
R
C
T 
(1
91
)  
H
P
3 
w
e 
ha
d 
lo
ts
 o
f p
eo
pl
e 
in
 th
e 
co
ho
rt 
bu
t a
ll 
re
sp
on
de
d 
to
 s
te
ro
id
s 
(1
91
) 
H
P
3 
lu
ck
ily
 fo
r t
he
 p
at
ie
nt
s 
no
 o
ne
 w
as
 e
lig
ib
le
 u
p 
to
 n
ow
 fo
r t
he
 R
C
T 
(1
92
) 
H
P
3 
no
 p
at
ie
nt
s 
ha
ve
 g
on
e 
to
 to
 C
ic
l o
r h
av
e 
ha
d 
co
le
ct
om
ie
s 
fo
r U
C
 s
o 
no
 o
ne
 re
ad
y 
ye
t (
20
0)
 
H
P
4 
qu
ite
 w
el
l e
qu
ip
oi
se
d 
fo
r t
hi
s,
 s
o 
th
er
e 
w
ou
ld
 n
ot
 h
av
e 
be
en
 a
 c
os
t i
ss
ue
 c
ol
ou
rin
g 
ou
r t
hi
nk
in
g,
 w
e 
do
 u
se
 b
ot
h 
dr
ug
s 
(7
4)
 
 H
P
4 
Th
er
e 
is
 a
 b
ig
 d
iff
er
en
ce
 in
 c
os
t b
ut
 it
 w
ou
ld
n’
t d
riv
e 
ou
r d
ec
is
io
n 
m
ak
in
g 
ou
ts
id
e 
th
is
 tr
ia
l (
80
) 
 H
P
4 
if 
ch
oi
ce
 h
as
 a
lre
ad
y 
be
en
 m
ad
e 
ab
ou
t d
ru
gs
, f
or
 th
os
e 
pa
tie
nt
s 
ob
vi
ou
sl
y 
do
n’
t w
an
t t
o 
be
 ra
nd
om
is
ed
 to
 th
e 
tri
al
 –
 w
ou
ld
 o
bv
io
us
ly
 b
e 
a 
gr
ea
t n
um
be
r o
f p
at
ie
nt
s 
in
 th
at
 s
itu
at
io
n 
(1
29
) 
 H
P
4 
I a
m
 a
w
ar
e 
th
at
 o
ur
 n
um
be
rs
 w
ho
 h
av
e 
go
ne
 to
 ra
nd
om
is
at
io
n 
ar
e 
sm
al
l b
ut
 o
ur
 c
oh
or
t i
s 
re
as
on
ab
ly
 b
ig
, t
ry
in
g 
to
 th
in
k 
w
hy
 th
is
 m
ig
ht
 b
e 
(1
36
) 
 H
P
4 
w
e 
ar
e 
no
t a
ct
iv
el
y 
no
t g
et
tin
g 
th
em
 ra
nd
om
is
ed
 in
to
 th
e 
tri
al
, w
e 
ha
ve
 a
 re
se
ar
ch
 n
ur
se
 a
nd
 d
o 
11
 o
’c
lo
ck
 w
ar
d 
ro
un
d 
to
 p
ic
k 
pa
tie
nt
s 
up
 (1
46
) 
 H
P
4 
yo
u 
ca
n 
us
e 
In
fli
x 
fo
r a
cu
te
 re
sc
ue
 in
 th
e 
co
nt
ex
t o
f t
he
 tr
ia
l, 
w
hi
ch
 is
 g
oo
d 
an
d 
ap
pr
op
ria
te
 fo
r t
he
 tr
ia
l (
20
4)
 
 H
P
4 
“I 
fe
el
 in
cr
ea
di
bl
y 
em
ba
rr
as
se
d 
th
at
 w
e 
ha
ve
 o
nl
y 
ha
d 
1 
ra
nd
om
is
at
io
n 
an
d 
I k
no
w
 I 
am
 v
er
y 
pr
oa
ct
iv
e 
w
he
n 
I a
m
 o
n 
th
e 
w
ar
d 
an
d 
I k
no
w
 s
om
e 
pa
tie
nt
s 
w
ill
 h
av
e 
be
en
 m
is
se
d 
be
ca
us
e 
in
ev
ita
bl
y 
no
 s
ys
te
m
 is
 p
er
fe
ct
” (
24
5)
 
 H
P
4 
“It
 is
 g
oi
ng
 to
 p
ro
m
pt
 m
e 
to
 lo
ok
 b
ac
k 
at
 th
e 
co
ho
rt
 b
ec
au
se
 I 
do
 w
an
t t
o 
un
de
rs
ta
nd
 w
hy
 s
o 
fe
w
 p
eo
pl
e 
ne
ed
ed
 to
 g
o 
on
.is
 p
ro
ac
tiv
el
y 
dr
iv
en
 b
y 
m
y 
co
lle
ag
ue
 it
 e
ith
er
 
m
ea
ns
 a
ll 
ou
r p
at
ie
nt
s 
ar
e 
go
in
g 
in
to
 re
m
is
si
on
 o
r w
e 
ar
e 
fa
ili
ng
 to
 re
co
gn
is
e 
th
at
 th
ey
 n
ee
d 
to
 b
e 
of
fe
re
d 
m
ed
ic
al
 th
er
ap
y a
nd
 th
en
 n
ot
 b
ei
ng
 ra
nd
om
is
ed
 in
 th
e 
co
nt
ex
t o
f t
he
 tr
ia
l
 
do
n’
t q
ui
te
 k
no
w
 w
ha
t a
ll 
th
e 
va
ria
bl
es
 a
re
 to
 e
xp
la
in
 o
ur
 v
er
y 
lo
w
 re
cr
ui
tm
en
t” 
(2
52
) 
 H
P
4 
“it
 is
 h
ig
h 
on
 th
e 
ag
en
da
 a
nd
 o
ur
 n
ur
se
 c
om
es
 to
 a
 d
ai
ly
 w
ar
d 
ro
un
d”
 (2
79
) 
 H
P
4 
“e
xc
ep
tio
na
lly
 w
el
l r
un
 a
nd
 o
rg
an
is
ed
 tr
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) 
 H
P
4 
“I 
th
in
k 
yo
u 
sh
ou
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 b
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P
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 c
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P
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 a
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 d
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03
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9 
w
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t o
f e
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tin
g 
th
at
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 a
 g
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ue
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n 
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at
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ow
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 to
 m
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at
 (3
29
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P
11
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n 
in
fli
x)
 if
 th
er
e 
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 d
at
a 
to
 s
ug
ge
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 th
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 s
ig
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fic
an
tly
 b
et
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r i
n 
te
rm
s 
of
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vo
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in
g 
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rg
er
y 
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 te
rm
s 
of
 s
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ce
ss
 o
f 
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at
m
en
t t
he
n 
I’m
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ill
in
g 
to
 c
ha
ng
e 
m
y 
m
in
d 
(6
2) 
 H
P
11
 w
e 
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ve
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h 
be
en
 v
er
y 
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 to
 g
iv
e 
ev
er
y 
pa
tie
nt
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ith
 c
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s 
w
ho
 w
as
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 th
e 
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cl
us
io
n 
cr
ite
ria
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e 
co
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id
er
ed
 fo
r t
he
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ia
l (
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7)
 
DOI: 10.3310/hta20440 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 44
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
279
 H
P
11
 w
e 
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ve
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t o
f p
at
ie
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s 
w
ho
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 d
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ot
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tri
al
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se
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w
 p
at
ie
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rs
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th
e 
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m
e 
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e 
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ow
 th
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 d
ev
il 
bu
t w
e 
do
n’
t t
ha
t 
m
uc
h 
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ou
t t
he
 o
th
er
 d
ev
il 
bu
t t
he
se
 a
re
 th
e 
pr
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 a
nd
 c
on
s 
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 th
e 
fe
el
in
g 
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m
 th
em
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ll 
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at
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ey
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e 
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m
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bl
e 
(2
59
) 
 H
P
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 w
e 
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e 
co
m
pl
et
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y 
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en
 (2
93
) 
 H
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13
 y
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 s
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t o
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as
 th
is
 fe
el
in
g 
th
at
 in
fli
xi
m
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as
 g
oi
ng
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 b
e 
be
tte
r b
ut
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ct
ua
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s 
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e 
tri
al
 p
ro
gr
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se
d 
I d
on
’t 
th
in
k t
ha
t w
as
 tr
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 (9
9)
 
 H
P
13
 m
y 
at
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ud
e 
ch
an
ge
d 
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er
 th
e 
co
ur
se
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f t
he
 tr
ia
l (
11
0)
 
 H
P
13
 w
e 
co
ul
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’t 
gi
ve
 p
eo
pl
e 
in
fli
xi
m
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 w
ith
ou
t C
O
N
S
TR
U
C
T 
so
 w
e 
tri
ed
 to
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nt
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bo
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.  
I d
on
’t 
th
in
k 
yo
u 
ca
n 
an
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ip
at
e 
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y 
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n 
bi
as
 fr
om
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ur
 p
oi
nt
 o
f v
ie
w
 (3
76
) 
 H
P
13
 th
er
e’
s 
a 
bi
g 
do
w
n 
tim
e 
w
he
n 
pe
op
le
 th
in
k 
ab
ou
t i
t a
nd
 th
en
 y
ou
 s
ta
rt 
to
 p
er
su
ad
e 
pe
op
le
 a
nd
 th
en
 th
ey
 e
nt
er
 o
ne
 a
nd
 it
 ju
st
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ns
 fr
om
 th
at
 (4
11
) 
 H
P
13
 a
nd
 b
y 
th
e 
en
d 
of
 th
e 
st
ud
y 
yo
u 
kn
ow
 it
 w
as
 ju
st
 s
or
t o
f t
ak
en
 a
s 
re
d 
w
ith
in
 th
e 
un
it 
th
at
 if
 s
om
eo
ne
 c
am
e 
in
 w
ith
 a
cu
te
 s
ev
er
e 
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lit
is
 th
ey
 w
ou
ld
 h
av
e 
be
en
 c
on
se
nt
  f
or
 
C
O
N
S
R
U
C
T 
an
d 
th
er
e’
s 
ju
st
 th
e 
tim
e 
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ke
n 
fo
r t
ha
t c
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ng
e 
in
 m
in
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 (4
17
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 H
P
14
 In
 te
rm
s 
of
 th
e 
ou
tc
om
e 
of
 th
e 
tri
al
 y
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, w
e 
w
er
e 
ha
pp
y 
to
 u
se
 e
ith
er
 o
f t
he
m
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I d
id
n’
t f
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 n
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it’
s 
th
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’v
e 
go
t t
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s 
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e 
or
 o
h 
no
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 g
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 th
at
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 w
he
n 
I r
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do
m
is
ed
 th
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py
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) 
 H
P
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 e
qu
al
ly
 e
ffe
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d 
th
er
e 
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 s
ci
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ic
 p
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e 
be
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n 
th
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o 
(2
55
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 H
P
14
 w
e 
w
er
e 
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th
at
 it
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 a
 g
en
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ne
 e
qu
ip
oi
se
 d
ec
is
io
n 
(3
20
) 
 H
P
14
 b
ut
 th
er
e 
w
er
e 
si
te
s,
 I 
m
ea
n 
th
e 
si
te
 u
p 
th
e 
ro
ad
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or
th
 T
yn
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id
e 
up
 th
e 
ro
ad
 s
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d 
w
e 
do
n’
t d
o 
th
at
 tr
ia
l c
os
 w
e 
be
lie
ve
 th
e 
in
fli
xi
m
ab
 is
 b
et
te
r a
d 
w
e’
re
 g
oi
ng
 to
 g
iv
e 
in
fli
x 
(3
24
) 
 H
P
14
 I 
th
in
k 
be
lie
vi
ng
 th
at
 th
e 
qu
es
tio
n 
is
 re
al
 a
nd
 th
at
 th
er
e 
is
 e
qu
ip
oi
se
 is
 fu
nd
am
en
ta
lly
 im
po
rta
nt
 to
 th
e 
re
cr
ui
tm
en
t (
32
7)
 
 H
P
16
 m
os
t o
f m
y 
co
lle
ag
ue
s 
is
 th
at
 th
e 
ef
fic
ac
y 
is
 p
ro
ba
bl
y 
br
oa
dl
y 
si
m
ila
r b
et
w
ee
n 
th
e 
tw
o 
bu
t t
ha
t f
or
 e
as
e 
an
d 
co
nv
en
ie
nc
e 
an
d 
si
de
 e
ffe
ct
 p
ro
fil
e 
an
d 
fa
m
ili
ar
ity
 o
f u
se
 w
ith
in
 a
 
ho
sp
ita
l s
et
tin
g 
a 
bi
ol
og
ic
al
 w
ou
ld
 e
dg
e 
it,
 b
ut
 w
e’
re
 q
ui
te
 h
ap
py
 g
iv
in
g 
ci
cl
 to
 th
e 
ap
pr
op
ria
te
 p
at
ie
nt
s 
(5
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) 
 H
P
16
 if
 th
e 
re
su
lt 
w
as
 th
at
 c
ic
l w
as
 a
 lo
t b
et
te
r w
e’
d 
us
e 
it 
an
d 
it 
th
e 
re
su
lts
 w
er
e 
th
at
 in
fli
x 
w
as
 a
 lo
t b
et
te
r, 
w
e’
d 
us
e 
it 
(6
22
) 
 H
P
16
 fr
om
 th
e 
po
in
t o
f v
ie
w
 fr
om
 p
at
ie
nt
 s
el
ec
tio
n,
 it
 w
ou
ld
 h
av
e 
be
en
 d
iff
ic
ul
t f
or
 u
s 
to
 in
tro
du
ce
 a
n 
en
or
m
ou
s 
am
ou
nt
 o
f b
ia
s 
(6
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) 
 H
P
16
 m
os
t p
at
ie
nt
s 
w
he
n 
th
ey
 re
ad
 a
bo
ut
 it
 p
ro
ba
bl
y 
in
te
nd
ed
 to
 fa
vo
ur
.. 
th
ey
 w
er
e 
ho
pi
ng
 th
ey
 w
ou
ld
 g
et
 in
fli
x,
 fr
om
 re
ad
in
g 
th
e 
lit
er
at
ur
e 
(6
73
) 
 H
P
15
 I 
w
ou
ld
 s
ay
 th
at
 th
er
e 
pr
ob
ab
ly
 is
n’
t e
qu
ip
oi
se
 h
er
e,
 th
at
 w
e’
re
 s
lig
ht
ly
 o
n 
th
e 
si
de
 o
f i
nf
lix
im
ab
...
. b
ut
 o
f c
ou
rs
e 
at
 th
e 
be
gi
nn
in
g 
of
 th
e 
tri
al
 th
at
 v
ie
w
 w
ou
ld
 h
av
e 
be
en
 d
iff
er
en
t 
be
ca
us
e 
of
 c
ou
rs
e 
th
ey
 w
as
 le
ss
 d
at
a 
av
ai
la
bl
e.
..m
or
e 
da
ta
 e
qu
iv
al
en
ce
 o
f e
ffi
ca
cy
, b
ut
 I 
st
ill
 th
in
k 
pe
op
le
 fa
vo
ur
 in
fli
x 
co
s i
t’s
 b
et
te
r t
ol
er
at
ed
...
. p
ut
 a
ll 
pa
tie
nt
s 
in
, w
e 
w
er
e 
ab
so
lu
te
ly
 
fa
ir 
ab
ou
t i
t (
34
5,
 3
50
, 3
60
, 3
68
, 3
72
) 
 H
P
15
 th
e 
di
ffe
re
nc
e 
(b
et
w
ee
n 
dr
ug
s)
 is
 n
ot
 s
uf
fic
ie
nt
ly
 d
ra
m
at
ic
 th
at
 I 
w
ou
ld
 s
ay
 it
 w
as
 u
ne
th
ic
al
 to
 p
ut
 th
em
 in
to
 a
  r
an
do
m
is
ed
 s
tu
dy
 (4
60
) 
 H
P
N
18
 p
re
tty
 m
uc
h 
fro
m
 a
 p
er
so
na
l p
oi
nt
 o
f v
ie
w
, e
ve
ry
 p
at
ie
nt
 th
at
 I 
ap
pr
oa
ch
ed
 c
am
e 
in
to
 th
e 
tri
al
. I
 m
ea
n 
th
ey
 d
id
n’
t a
ll r
an
do
m
is
e,
 th
ey
 d
id
n’
t a
ll 
go
 in
to
 th
e 
R
C
T,
 s
om
et
im
es
 th
at
 
w
as
 c
lin
ic
ia
n’
s 
de
ci
si
on
, s
om
et
im
e 
it 
w
as
 b
ec
au
se
 th
ey
 h
ad
 re
ad
 th
e 
lit
tle
 b
it 
in
 th
e 
in
fli
x 
le
af
le
t t
ha
t s
ug
ge
st
s 
th
at
 th
ey
 c
ou
ld
 e
nd
 u
p 
w
ith
 s
om
e 
ty
pe
 o
f c
an
ce
r (
38
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  H
P
N
19
 s
om
et
im
es
 it
 d
ep
en
de
d 
on
 th
e 
in
di
vi
du
al
 c
lin
ic
ia
n 
pa
rti
cu
la
rly
 in
 th
e 
be
gi
nn
in
g 
I a
lw
ay
s 
go
t t
he
 im
pr
es
si
on
 th
at
 th
er
e 
w
as
 p
eo
pl
e 
ha
d 
sp
ec
ifi
c 
op
in
io
ns
 b
ut
 I 
th
in
k 
on
ce
 th
ey
 
w
or
ke
d 
w
ith
in
 th
e 
tri
al
, w
or
ki
ng
 w
ith
 th
e 
tw
o 
dr
ug
s 
I t
hi
nk
 th
ey
 w
er
e 
a 
lo
t m
or
e 
op
en
 to
 it
 a
s 
it 
de
ve
lo
pe
d 
(3
18
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 H
P
N
22
 I 
ca
n 
th
in
k 
of
 a
 c
ou
pl
e 
of
 o
cc
as
io
ns
 a
 le
as
t o
ve
r t
he
 la
st
 fe
w
 y
ea
rs
, w
he
re
 a
 c
on
su
lta
nt
 d
ec
id
ed
 th
at
 n
o 
th
ey
 w
an
te
d 
on
e 
pa
rti
cu
la
r o
ne
 o
ve
r a
no
th
er
 (1
91
) 
  H
P
15
 I 
w
ou
ld
 s
ay
 th
at
 th
er
e 
pr
ob
ab
ly
 is
n’
t e
qu
ip
oi
se
 h
er
e,
 th
at
 w
e’
re
 s
lig
ht
ly
 o
n 
th
e 
si
de
 o
f i
nf
lix
im
ab
...
. b
ut
 o
f c
ou
rs
e 
at
 th
e 
be
gi
nn
in
g 
of
 th
e 
tri
al
 th
at
 v
ie
w
 w
ou
ld
 h
av
e 
be
en
 d
iff
er
en
t 
be
ca
us
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of
 c
ou
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e 
th
ey
 w
as
 le
ss
 d
at
a 
av
ai
la
bl
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..m
or
e 
da
ta
 e
qu
iv
al
en
ce
 o
f e
ffi
ca
cy
, b
ut
 I 
st
ill
 th
in
k 
pe
op
le
 fa
vo
ur
 in
fli
x 
co
s i
t’s
 b
et
te
r t
ol
er
at
ed
...
. p
ut
 a
ll 
pa
tie
nt
s 
in
, w
e 
w
er
e 
ab
so
lu
te
ly
 
fa
ir 
ab
ou
t i
t (
34
5,
 3
50
, 3
60
, 3
68
, 3
72
) 
 H
P
15
 th
e 
di
ffe
re
nc
e 
(b
et
w
ee
n 
dr
ug
s)
 is
 n
ot
 s
uf
fic
ie
nt
ly
 d
ra
m
at
ic
 th
at
 I 
w
ou
ld
 s
ay
 it
 w
as
 u
ne
th
ic
al
 to
 p
ut
 th
em
 in
to
 a
  r
an
do
m
is
ed
 s
tu
dy
 (4
60
) 
 H
P
N
18
 p
re
tty
 m
uc
h 
fro
m
 a
 p
er
so
na
l p
oi
nt
 o
f v
ie
w
, e
ve
ry
 p
at
ie
nt
 th
at
 I 
ap
pr
oa
ch
ed
 c
am
e 
in
to
 th
e 
tri
al
. I
 m
ea
n 
th
ey
 d
id
n’
t a
ll 
ra
nd
om
is
e,
 th
ey
 d
id
n’
t a
ll 
go
 in
to
 th
e 
R
C
T,
 s
om
et
im
es
 th
at
 
w
as
 c
lin
ic
ia
n’
s 
de
ci
si
on
, s
om
et
im
e 
it 
w
as
 b
ec
au
se
 th
ey
 h
ad
 re
ad
 th
e 
lit
tle
 b
it 
in
 th
e 
in
fli
x 
le
af
le
t t
ha
t s
ug
ge
st
s 
th
at
 th
ey
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ul
d 
en
d 
up
 w
ith
 s
om
e 
ty
pe
 o
f c
an
ce
r (
38
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  H
P
N
19
 s
om
et
im
es
 it
 d
ep
en
de
d 
on
 th
e 
in
di
vi
du
al
 c
lin
ic
ia
n 
pa
rti
cu
la
rly
 in
 th
e 
be
gi
nn
in
g 
I a
lw
ay
s 
go
t t
he
 im
pr
es
si
on
 th
at
 th
er
e 
w
as
 p
eo
pl
e 
ha
d 
sp
ec
ifi
c 
op
in
io
ns
 b
ut
 I 
th
in
k 
on
ce
 th
ey
 
w
or
ke
d 
w
ith
in
 th
e 
tri
al
, w
or
ki
ng
 w
ith
 th
e 
tw
o 
dr
ug
s 
I t
hi
nk
 th
ey
 w
er
e 
a 
lo
t m
or
e 
op
en
 to
 it
 a
s 
it 
de
ve
lo
pe
d 
(3
18
) 
 H
P
N
22
 I 
ca
n 
th
in
k 
of
 a
 c
ou
pl
e 
of
 o
cc
as
io
ns
 a
 le
as
t o
ve
r t
he
 la
st
 fe
w
 y
ea
rs
, w
he
re
 a
 c
on
su
lta
nt
 d
ec
id
ed
 th
at
 n
o 
th
ey
 w
an
te
d 
on
e 
pa
rti
cu
la
r o
ne
 o
ve
r a
no
th
er
 (1
91
) 
 H
P
13
 fr
om
 a
 p
ra
gm
at
ic
 p
oi
nt
 o
f v
ie
w
 b
ec
au
se
 if
 s
om
eo
ne
 c
om
es
 in
 n
ow
 a
nd
 th
ey
’re
 n
ot
 in
 c
on
st
ru
ct
 th
en
 th
ey
 g
et
 c
ic
l b
ec
au
se
 th
e 
S
M
C
 (S
co
tti
sh
 M
ed
ic
in
es
 C
on
so
rti
um
) s
ay
 w
e 
ca
n’
t 
us
e 
in
fli
x 
(2
18
) 
  C
on
su
lta
nt
s’
 a
nd
 n
ur
se
s’
 v
ie
w
s o
n 
su
rg
er
y 
(c
ol
ec
to
m
y)
 
 H
P
2 
ca
nn
ot
 g
en
er
al
is
e 
on
 w
he
th
er
 to
 g
o 
fo
r s
ur
ge
ry
 o
r n
ot
, g
o 
by
 p
at
ie
nt
’s
 e
xp
er
ie
nc
e 
(1
20
) 
 H
P
2 
no
 p
re
fe
re
nc
e 
(s
ur
ge
ry
 o
r k
ee
p 
on
 d
ru
gs
) r
el
y 
on
 c
lin
ic
al
 ju
dg
em
en
t r
e 
in
di
vi
du
al
 p
at
ie
nt
 (1
21
) 
 H
P
6 
so
m
e 
pa
tie
nt
s 
sh
ou
ld
 g
o 
fo
r c
ol
ec
to
m
y 
ot
he
rs
 w
or
th
 tr
yi
ng
 to
 s
al
va
ge
 th
ei
r c
ol
on
s 
w
ith
 d
ru
gs
 (1
46
) 
 H
P
6 
ca
se
 b
y 
ca
se
 d
ec
is
io
n,
 s
ur
ge
ry
 fo
r s
om
e 
is
 n
ot
 a
 fa
ilu
re
 –
 it
 is
 w
ha
t i
s 
ne
ed
ed
 fo
r t
he
m
 a
t t
he
 ti
m
e 
(1
47
) 
 H
P
6 
pa
tie
nt
 s
ho
ul
dn
’t 
re
ga
rd
 c
ol
ec
to
m
y 
as
 fa
ilu
re
 a
s 
su
ch
 (1
48
, 1
55
) 
 H
P
1 
If 
pa
tie
nt
 fi
t f
or
 s
ur
ge
ry
 ( 
lif
e 
sa
vi
ng
) a
nd
 h
av
e 
no
t i
m
pr
ov
ed
 b
y 
5 
da
ys
 w
ou
ld
 ra
th
er
 h
av
e 
it 
(9
2)
 
 H
P
1 
pr
ef
er
en
ce
 fo
r c
ol
ec
to
m
y 
bu
t w
ou
ld
 g
o 
w
ith
 w
ha
t p
at
ie
nt
 w
an
ts
 (c
an
no
t p
ut
 c
ol
on
 b
ac
k)
 (1
16
-1
17
) 
 H
P
3 
an
ti-
su
rg
er
y 
an
d 
m
os
t p
at
ie
nt
s 
ag
re
e 
w
ith
 m
e 
th
ey
 w
an
t t
o 
ke
ep
 c
ol
on
 (1
26
) 
 H
P
4 
C
ol
ec
to
m
y 
st
ill
 a
n 
im
po
rta
nt
 o
pt
io
n 
of
te
n 
de
la
ye
d 
by
 p
oo
r d
ec
is
io
n-
m
ak
in
g 
(2
13
) 
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 N
IC
E
 p
ro
m
ot
in
g 
re
se
ar
ch
 w
he
n 
th
er
e 
is
 a
 q
ue
st
io
n 
to
 a
ns
w
er
 is
 a
 g
oo
d 
th
in
g 
(2
66
) 
 H
P
10
 (r
ef
er
rin
g 
to
 In
fli
xi
m
ab
 a
s 
m
ai
nt
en
an
ce
 th
er
ap
y)
 I 
kn
ow
 N
IC
E
 d
on
’t 
ap
pr
ov
e 
bu
t I
 th
in
k 
th
at
 N
IC
E
 a
re
 b
eh
in
d 
th
e 
tim
es
 a
nd
 n
ot
 fo
r t
he
 fi
rs
t t
im
e 
(8
9)
 
 H
P
10
 it
’s
 a
 n
o-
br
ai
ne
r t
o 
fin
d 
a 
w
ay
 o
f g
et
tin
g 
hi
m
 o
n 
to
 in
fli
xi
m
ab
 a
ga
in
 (1
13
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H
P
10
 I 
th
in
k 
it’
s 
ou
td
at
ed
, i
ts
 m
an
ife
st
ly
 in
ap
pr
op
ria
te
 (1
96
) 
 H
P
10
 I 
th
in
k 
th
at
 th
ey
’v
e 
go
t a
n 
ef
fe
ct
iv
e 
dr
ug
 w
hi
ch
 c
le
ar
ly
 w
or
ks
 a
nd
 I 
th
in
k 
sh
ou
ld
 b
e 
al
lo
w
ed
 to
 u
se
 a
cc
or
di
ng
ly
 to
 li
ce
ns
e 
(2
17
) 
 H
P
11
 p
ro
bl
em
s 
co
m
e 
up
 w
ith
 N
IC
E
, w
e 
ar
e 
ge
tti
ng
 in
cr
ea
si
ng
 p
re
ss
ur
e 
in
 o
ur
 a
re
a,
 to
 s
ho
w
 th
at
 w
e 
ar
e 
fo
llo
w
in
g 
N
IC
E
 g
ui
da
nc
e 
so
 th
at
 b
ec
om
es
 a
 p
ro
bl
em
s 
(1
00
) 
 H
P
11
 I 
th
in
k 
it 
is
 d
iff
ic
ul
t b
ec
au
se
 u
p 
to
 re
ce
nt
ly
 th
er
e 
ha
sn
’t 
be
en
 c
on
vi
nc
in
g 
da
ta
 to
 s
up
po
rt 
it 
to
 b
e 
ho
ne
st
 (2
07
) 
 H
P
11
 I 
th
in
k 
th
at
 N
IC
E
 a
t t
he
 e
nd
 o
f t
he
 d
ay
 is
 a
ls
o 
ab
ou
t h
ea
lth
 e
co
no
m
ic
s 
(2
11
) 
 H
P
11
 b
ut
 I 
w
ou
ld
 s
up
po
rt 
N
IC
E
 a
t t
hi
s 
po
in
t u
nt
il 
th
er
e 
is
 b
et
te
r d
at
a 
(2
25
) 
 H
P
12
 s
ta
te
m
en
t m
ad
e 
at
 a
 ti
m
e 
ba
se
d 
on
 th
e 
tw
o 
lic
en
si
ng
 tr
ia
ls
 w
hi
ch
 d
id
 n
ot
 in
cl
ud
e 
ac
ut
e 
se
ve
re
 p
at
ie
nt
s 
an
d 
th
er
e 
w
as
n’
t e
no
ug
h 
cl
in
ic
al
 p
ra
ct
ic
e 
da
ta
 in
 th
e 
lit
er
at
ur
e.
 S
o 
at
 th
e 
tim
e 
pr
ob
ab
ly
 th
at
 w
as
 a
 ri
gh
t s
ta
te
m
en
t, 
bu
t n
ow
, y
ou
 k
no
w
, i
t i
s 
so
rt 
of
 u
nr
ea
so
na
bl
e.
  
 H
P
12
 (s
ho
ul
d 
in
fli
x 
on
ly
  b
e 
us
ed
 in
 re
se
ar
ch
) n
o,
 b
ec
au
se
...
 it
s 
at
 le
as
t a
s 
ef
fe
ct
iv
e 
as
 c
ic
lo
sp
or
in
 w
ith
 th
e 
ad
di
tio
na
l b
en
ef
it 
of
 c
on
ve
ni
en
ce
 a
nd
 p
ot
en
tia
lly
 le
ss
 to
xi
c 
(2
22
) 
 H
P
13
 N
IC
E
 h
av
e 
w
rit
te
n 
th
at
 g
ui
de
lin
e 
an
d 
I w
ou
ld
 in
te
rp
re
t t
ha
t a
s 
pe
op
le
 c
an
 d
o 
w
ha
t t
he
y 
w
an
t (
la
ug
hs
) 
 B
ut
 w
e 
do
n’
t h
av
e 
th
at
 fr
ee
do
m
 (S
co
tla
nd
 g
ov
er
ne
d 
by
 S
M
C
) (
24
5,
 2
50
) 
 H
P
13
 I’
m
 n
ot
 a
 m
as
si
ve
 N
IC
E
 s
up
po
rte
r b
ut
 I 
ac
tu
al
ly
 th
in
k 
th
ei
r g
ui
da
nc
e 
ha
s 
be
en
 p
re
tty
 s
en
si
bl
e 
(3
46
) 
 H
P
13
 th
ey
 a
s 
a 
na
tio
na
l b
od
y 
ha
ve
 to
 h
av
e 
th
ei
r e
ye
 o
n 
he
al
th
ca
re
 c
os
ts
 a
nd
 I 
th
in
k 
to
 fa
vo
ur
 th
e 
ch
ea
pe
r d
ru
g 
if 
in
 a
 s
itu
at
io
n 
w
he
re
 th
er
e 
is
 s
uc
h 
a 
bi
g 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
2 
dr
ug
s 
is
 s
en
si
bl
e,
 b
ut
 a
ls
o 
to
 a
ck
no
w
le
dg
e 
th
at
 it
’s
 n
ot
 a
bs
ol
ut
el
y 
th
e 
rig
ht
 d
ru
g 
fo
r e
ve
ry
bo
dy
 (4
29
) 
 H
P
14
 I 
th
in
k 
th
e 
cu
rr
en
t N
IC
E
 g
ui
de
lin
es
 a
re
 u
m
, a
 b
it 
tri
ck
y 
be
ca
us
e 
I t
hi
nk
 if
 y
ou
 a
re
 g
oi
ng
 to
 g
iv
e 
a 
pa
tie
nt
 in
fli
xi
m
ab
 yo
u 
ne
ed
 to
 g
iv
e 
th
em
., 
an
d 
th
en
 th
ey
 re
sp
on
d 
to
 it
, i
f t
he
y 
do
 
re
sp
on
d 
to
 it
 y
ou
 w
an
t t
o 
be
 a
bl
e 
to
 c
on
tin
ue
 th
e 
tre
at
m
en
t a
nd
 I 
th
in
k 
it 
m
ay
 h
av
e 
m
or
e 
of
 a
 lo
ng
 te
rm
 u
se
 th
an
 th
e 
N
IC
E
 g
uid
el
in
es
 th
at
 w
e’
re
 c
ur
re
nt
ly
 u
si
ng
 (3
8)
 
 H
P
14
 I 
th
in
k 
it’
s 
un
du
ly
 re
st
ric
tiv
e 
an
d 
I t
hi
nk
 it
 w
ill
 e
ve
nt
ua
lly
 c
ha
ng
e.
  I
 th
in
k 
it’
s 
ac
tu
al
ly
 q
ui
te
 h
ar
d 
to
 a
dh
er
e 
to
 a
ct
ua
lly
 a
s 
w
el
l. 
 I 
m
ea
n 
yo
u’
ve
 g
ot
 a
 p
at
ie
nt
 w
ho
 y
ou
 w
an
t t
o 
gi
ve
 
tre
at
m
en
t t
o,
 y
ou
’re
 d
ut
y 
bo
un
d 
to
 g
iv
e 
th
em
 th
e 
be
st
 tr
ea
tm
en
t a
va
ila
bl
e 
an
d 
in
 s
om
e 
ca
se
s 
th
at
’s
 g
oi
ng
 to
 b
e 
in
fli
x 
(2
08
) 
 H
P
14
 I 
m
ea
n 
th
e 
pr
ob
le
m
 is
 th
at
 th
e 
ex
pe
ns
e 
of
 it
, t
he
y’
ve
 g
ot
 to
 c
om
e 
to
 te
rm
s 
w
ith
 th
e 
co
st
 o
f t
he
 d
ru
g,
 th
at
’s
 th
e 
pr
ob
le
m
 (2
19
) 
 H
P
16
 I 
th
in
k 
it’
s 
co
m
pl
et
el
y 
w
ro
ng
 (r
es
tri
ct
io
n 
of
 in
fli
x)
 (4
47
) 
 H
P
16
 I 
th
in
k 
it’
s 
no
t b
ac
ke
d 
up
 b
y 
da
ta
..s
o 
I t
hi
nk
 N
IC
E
 is
 p
ro
ba
bl
y 
do
in
g 
its
el
f a
 m
aj
or
 d
is
-s
er
vi
ce
 w
ith
 th
is
 p
ar
tic
ul
ar
 g
ui
da
nc
e 
be
ca
us
e 
I t
hi
nk
 th
ey
 lo
se
 c
re
di
bi
lit
y.
.. 
th
is
 is
 a
n 
al
go
rit
hm
 
ba
se
d 
on
 c
os
t e
ffe
ct
iv
en
es
s 
th
at
 is
 p
ro
ba
bl
y 
ou
td
at
ed
. (
46
3)
 
 H
P
16
 I 
th
in
k 
th
er
e’
s 
be
en
 a
n 
in
te
rp
re
ta
tio
n 
of
 th
e 
re
su
lts
 b
y 
N
IC
E
 th
at
 is
 o
ut
 o
f s
te
p 
w
ith
 re
ce
iv
ed
 g
as
tro
en
te
ro
lo
gi
ca
l o
pi
ni
on
 in
 th
e 
U
K
 b
y 
ex
pe
rts
 in
 th
is
 a
re
a 
(5
04
) 
 H
P
16
 It
’s
 v
er
y 
ha
rd
 to
 fi
nd
 a
ny
on
e 
w
ho
 s
up
po
rts
 th
e 
N
IC
E
 g
ui
da
nc
e 
in
 it
s 
pr
es
en
t f
or
m
at
 (5
16
) 
 H
P
16
 I’
m
 p
le
as
ed
 w
e 
ca
n 
ge
t a
cc
es
s 
to
 b
io
lo
gi
ca
l i
n 
tri
al
s 
an
d 
I t
hi
nk
 a
 lo
t o
f o
ur
 p
at
ie
nt
s 
at
 th
e 
m
om
en
t a
re
 in
 tr
ia
ls
 to
 g
et
 a
cc
es
s 
to
 b
io
lo
gi
ca
ls
 (5
19
) 
 H
P
16
 N
IC
E
 g
ui
da
nc
e 
is
 fr
om
 2
00
8 
so
 y
ou
 k
no
w
 th
e 
w
or
ld
 h
as
 m
ov
ed
 o
n 
a 
lo
t f
ro
m
 th
er
e 
(5
28
) 
 H
P
15
 w
e 
be
nd
 th
e 
ru
le
s 
ju
st
 s
lig
ht
ly
 a
nd
 fe
el
 it
’s
 n
ot
 in
 th
ei
r i
nt
er
es
t t
o 
ha
ve
 c
ic
l, 
th
en
 w
e 
co
ul
d 
us
e 
in
fli
x.
.. 
bu
t i
t’s
 b
en
di
ng
 th
e 
ru
le
s 
ju
st
 a
 li
ttl
e 
bi
t a
nd
 I’
m
 a
lw
ay
s 
qu
ite
 w
ar
y 
ab
ou
t t
ha
t 
(1
62
) 
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 H
P
15
 (r
ef
er
rin
g 
to
 N
IC
E
 g
ui
de
lin
e 
re
st
ric
tio
ns
 o
n 
in
fli
x)
 it
’s
 d
on
e 
fo
r f
in
an
ci
al
 re
as
on
s.
...
 it
’s
 c
he
ap
er
 to
 ta
ke
 s
om
eo
ne
’s
 c
ol
on
 o
ut
 a
nd
 th
at
’s
 th
e 
bo
tto
m
 li
ne
 (2
92
,2
97
) 
 H
P
15
 I 
th
in
k 
w
e 
sh
ou
ld
 b
e 
al
lo
w
ed
 to
 u
se
 it
 (i
nf
lix
) f
or
 U
C
 if
 w
e 
us
e 
it 
fo
r C
ro
hn
’s
 d
is
ea
se
 (3
08
) 
 H
P
N
18
 I 
th
in
k 
yo
u 
ha
ve
 to
 h
av
e 
pa
ra
m
et
er
s 
th
er
e 
bu
t I
 th
in
k 
th
er
e 
sh
ou
ld
 b
e 
so
m
e 
ki
nd
 o
f y
ou
 k
no
w
 s
om
e 
le
ew
ay
 w
he
re
 it
 is
 n
ot
 s
et
 in
 s
to
ne
 w
he
re
 s
om
eb
od
y 
ca
n 
m
ak
e 
a 
de
ci
si
on
 a
s 
lo
ng
 a
s 
th
ey
 c
an
 b
ac
k 
it 
up
 w
ith
 s
om
e 
ki
nd
 o
f r
at
io
na
le
 (3
27
) 
 H
P
N
18
 I 
do
n’
t t
hi
nk
 it
 (i
nf
lix
) s
ho
ul
d 
be
 s
pe
ci
fic
al
ly
 ju
st
 fo
r r
es
ea
rc
h 
(3
40
) 
 H
P
N
19
 I 
do
n’
t p
ar
tic
ul
ar
ly
 a
gr
ee
 w
ith
 th
e 
N
IC
E
 g
ui
de
lin
es
...
.N
IC
E
 g
ui
de
lin
es
 a
re
 k
ey
 to
 fu
nd
in
g 
is
su
es
 b
ec
au
se
 th
ey
 g
o 
by
 th
em
 a
nd
 s
tri
ct
ly
 b
y 
th
em
 (2
87
, 2
90
) 
  H
P
N
19
 N
IC
E
 k
in
d 
of
 h
as
 a
 fe
w
 th
in
gs
 to
 a
ns
w
er
 fo
r s
uc
h 
as
 b
ec
au
se
 it
 m
ak
e 
th
es
e 
de
ci
si
on
s 
an
d 
fo
r U
C
 th
er
e 
is
n’
t a
 g
re
at
 d
ea
l o
f o
pt
io
ns
 (2
91
) 
 H
P
N
19
 v
er
y 
pe
rs
on
al
 o
pi
ni
on
 is
 th
at
 a
 b
it 
cl
os
ed
 m
in
de
d 
of
 N
IC
E
, t
he
y 
ne
ed
 to
 b
e 
m
or
e 
op
en
 m
in
de
d 
an
d 
fle
xi
bl
e 
(2
94
) 
 H
P
N
19
 (i
nf
lix
 in
 re
se
ar
ch
) f
ro
m
 a
 p
er
so
na
l p
oi
nt
 o
f v
ie
w
 I 
th
in
k 
ha
vi
ng
 m
or
e 
in
fo
rm
at
io
n,
 h
av
in
g 
m
or
e 
da
ta
 a
bo
ut
 d
iff
er
en
t d
ru
gs
 a
nd
 a
bo
ut
 h
ow
 th
ey
 a
ffe
ct
 p
at
ie
nt
s 
I t
hi
nk
 it
 b
ril
lia
nt
 a
nd
 I 
th
in
k 
it 
sh
ou
ld
 b
e 
en
co
ur
ag
ed
 b
ec
au
se
 it
’s
 th
e 
w
ay
 to
 m
ak
e 
in
fo
rm
ed
 d
ec
is
io
ns
 in
 th
e 
fu
tu
re
 (3
04
) 
 H
P
N
20
 (i
nf
lix
 fo
r r
es
ea
rc
h 
on
ly
) N
o.
..I
t w
or
ks
 (l
au
gh
s)
.  
I m
ea
n 
w
e’
ve
 b
ee
n 
us
in
g 
it 
up
 h
er
e 
fo
r y
ea
rs
 a
nd
 y
ea
rs
 a
s 
ou
r f
irs
t l
in
e 
tre
at
m
en
t f
or
 o
ur
 IB
D
 p
at
ie
nt
s.
 (2
45
, 2
49
) (
S
co
tla
nd
 s
ite
, 
N
IC
E
 g
ui
de
lin
es
 n
ot
 a
pp
lic
ab
le
) 
  H
P
N
21
 (i
nf
lix
 in
 re
se
ar
ch
 o
nl
y)
 I 
th
in
k 
it 
yo
u 
to
ok
 th
at
 e
le
m
en
t o
ut
 p
eo
pl
e 
w
ou
ld
 b
e 
m
or
e 
ha
pp
y 
to
 ta
ke
 it
 o
n 
bo
ar
d 
be
ca
us
e 
w
he
n 
w
e 
m
en
tio
n 
re
se
ar
ch
 I 
th
in
k 
th
ey
 s
ee
m
 to
 fe
el
 th
at
 it
’s
 
m
ay
be
 n
ot
 p
ro
ve
n 
to
 w
or
k.
..t
he
re
’s
 s
tig
m
a 
ar
ou
nd
 it
 a
nd
 a
 b
it 
of
 fe
ar
 (2
65
) 
 H
P
N
22
 I 
th
in
k 
it 
tie
s 
ou
r h
an
ds
 a
 li
ttl
e 
bi
t (
16
7)
 
 H
P
N
22
 It
’s
 a
 c
os
tly
 d
ru
g 
so
 th
er
e 
ha
s 
to
 b
e 
so
m
e 
ki
nd
 o
f g
ui
da
nc
e 
do
es
n’
t t
he
re
 (1
78
) 
 H
P
N
23
a 
m
or
e 
of
 a
n 
ex
pe
ns
iv
e 
tre
at
m
en
t (
16
9)
 
 H
P
N
23
a 
I’m
 s
ur
pr
is
ed
 a
t t
ha
t s
ta
te
m
en
t (
in
fli
xi
m
ab
 fo
r r
es
ea
rc
h 
on
ly
) (
18
5)
 
 H
P
N
25
a 
I d
id
n’
t k
no
w
 w
as
 if
 th
e 
ci
cl
os
po
rin
 is
 c
on
tra
in
di
ca
te
d 
I t
ho
ug
ht
 y
ou
 c
ou
ld
 u
se
 it
 (i
nf
lix
)..
...
 I 
th
ou
gh
t t
ha
t e
rm
 it
 w
ou
ld
 w
e 
w
er
e 
ab
le
 to
 u
se
 it
 fo
r a
cu
te
 U
C
 if
 I 
ha
d 
an
y 
vi
ew
s 
it 
w
ou
ld
 b
e 
th
at
 I 
th
in
k 
it 
sh
ou
ld
 b
e 
ab
le
 to
 b
e 
us
ed
 b
ef
or
e 
it 
w
as
 a
cu
te
ly
 s
ev
er
e.
 (2
21
, 2
31
) 
 H
P
N
25
a 
I d
on
’t 
th
in
k 
it 
sh
ou
ld
 o
nl
y 
be
 in
 re
se
ar
ch
.  
If 
it’
s 
a 
ve
ry
 e
xp
en
si
ve
 tr
ea
tm
en
t I
 c
an
 s
ee
 w
hy
 N
IC
E
 s
ay
 th
at
 b
ec
au
se
 it
’s 
in
cr
ed
ib
ly
 e
xp
en
si
ve
 th
ey
’ll
 p
ro
ba
bl
y 
co
m
pa
re
 th
e 
co
st
 o
f a
 
co
le
ct
om
y 
I c
an
 u
nd
er
st
an
d 
th
at
 p
oi
nt
 c
om
pl
et
el
y 
bu
t I
 d
on
’t 
th
in
k 
if 
I h
ad
 U
C
 th
en
 I 
w
ou
ld
 w
an
t i
t a
va
ila
bl
e 
to
 m
e 
so
 I 
w
ou
ld 
th
in
k 
so
. (
25
1)
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 N
ur
se
 ti
m
e 
on
 c
ic
lo
sp
or
in
 (h
ea
lth
 e
co
no
m
ic
s)
 
N
ur
se
s 
tim
e 
on
 c
ic
lo
sp
or
in
 (H
ea
lth
 E
co
no
m
ic
s 
ad
di
tio
na
l q
ue
st
io
n)
 
 H
P
N
20
 y
ou
 n
ee
d 
tw
o 
re
gi
st
er
ed
 n
ur
se
s 
co
s 
ou
r s
tu
de
nt
 n
ur
se
s 
ar
en
’t 
al
lo
w
ed
 to
 c
he
ck
 a
ny
th
in
g 
lik
e 
th
at
...
.P
ro
ba
bl
y 
10
 –
 1
5 
m
in
s.
  M
ak
e 
up
 th
e 
ba
gs
, g
o 
to
 th
e 
pa
tie
nt
, c
he
ck
 th
e 
pa
tie
nt
, c
ha
ng
e 
th
e 
ba
g 
fo
ur
 ti
m
es
 a
 d
ay
, p
ro
ba
bl
y 
an
 h
ou
r a
ny
w
ay
...
. o
ve
r a
 2
4 
ho
ur
 p
er
io
d 
pr
ob
ab
ly
 a
bo
ut 
¾
 - 
1h
r w
ou
ld
 b
e 
sp
en
t d
ea
lin
g 
on
ly
 w
ith
 c
ic
lo
sp
or
in
. (
26
3.
..2
70
) 
 H
P
N
21
 e
ac
h 
fir
st
 a
dm
in
is
tra
tio
n 
of
 it
 is
 g
oi
ng
 to
 re
qu
ire
 a
t l
ea
st
 4
-5
 h
ou
rs
 o
f m
y 
tim
e,
 b
ul
k 
of
 w
hi
ch
 is
 o
bs
er
va
tio
ns
, s
o 
qu
ite
 a
 b
ig
 c
hu
nk
 re
al
ly
 (l
au
gh
s)
 b
ut
 a
fte
r t
ha
t t
he
 im
pa
ct
 is
 m
uc
h 
re
du
ce
d,
 it
’s
 re
al
ly
 ju
st
 th
e 
in
iti
al
 d
os
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Assessment of quality of interviews
According to Guba106 the following criteria should be applied to qualitative data to assess their
trustworthiness, corresponding to constructs employed by positivistic researchers such as internal and
external validity, reliability and objectivity:
l credibility (in preference to internal validity) – ‘congruence of findings with reality’
l transferability (in preference to external validity/generalisability) – ‘application of findings to
other situations’
l dependability (in preference to reliability) – ‘processes in the study reported in enough detail that
others can repeat the work’
l confirmability (in preference to objectivity) – ‘findings are the result of participants’ experiences and
ideas not researcher preference’.
Credibility can be assessed according to whether or not the operational methods that are being applied
to the concepts under study are applied correctly.108 We would argue that the questions asked in this
study, and the adoption of both face-to-face interviewing methods and telephone interviewing, with both
health-care professionals and participants, over an extended trial period, gave enough detail and sufficient
information to clarify people’s views. Interviews were undertaken not at a static time point but over time,
as participants (patients) were brought on board, at 3 months and then again at 12 months post drug
treatment. This also included patients who had also undergone surgery. The extensive data sets collected
were also rich in detail and captured information across the study aims in accordance with a question
schedule that related not only to both drugs being administered but also to people’s views of their health,
their health care, their relationship with professionals and others, their illness and personal preferences for
drug allocation (professionals’ interviews). Indeed, additional information was obtained from health-care
professionals, using these qualitative methods, about the trial itself and about professionals’ hope for
trial information to guide them in their future practice.
Transferability can be assessed, in qualitative terms, according to Denscombe107 and Stake,110 if a
particular study can be seen as an example within a broader group. This can be assured if sufficient
contextual information is supplied about the sites involved and the participants within those sites, so any
reader can make this kind of transfer.111 In this trial we are confident that we have supplied sufficient
detail of participant characteristics, participant views and trial site allocation across all UK locations for the
reader to build a picture of what occurred and with whom. We have also provided information of how
participants and sites were involved in this trial, differences between locations and differences between
groups of participants. In addition, we have explained how health-care professionals were chosen for
interview and how they were recruited, so that this work can be repeated by others in other settings with
other drug groups if appropriate.
In qualitative data terms, dependability suggests that the work processes should be reported in enough
detail so that any future researcher could repeat the work; thus, the research design can be viewed as a
‘prototype model’.109 Shenton reminds us that this kind of detail allows the reader to also be reassured that
appropriate research practices were followed or, at the very least, that the extent to which they were
followed can be assessed. We have demonstrated in this report how participants were approached, the
kinds of questions they were asked and the order in which those questions were asked. We have also
reported their comments in quotation form and described how we assured participants (both patients and
health-care professionals) that ethical standards would be upheld throughout the trial. This included
assurances about each individual’s anonymity. We provided participants with information about the removal
of aspects of data from the study data sets if they so wished and explained that they could withdraw from
the study at any stage if they so wished. We were keen to clarify the research design in this report and to
explain the qualitative data capture and analysis methods in the ‘methods’ sections, so that others might
follow similar procedures in their own work.
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Confirmability is the ‘qualitative investigator’s comparable concern to objectivity’.109 Confirmability ensures
that findings link clearly and precisely to the study informants’ data rather than to the assumptions,
preferences or personal opinions of any one of the qualitative researchers involved in a study or to others
with whom they work. In this study, we always worked as a team during analytic framework development
and data assessment, in terms of both participant and health-care professional data. We developed out trial
analytic frameworks from both data sets independently, and conferred about all key findings, which were
shared with the wider team. We were aware of the need to achieve consensus of opinion in group
discussion and conferred on not only the iterative process of revealing the thematic results but also the
emergent key and incidental themes. During each group analysis meeting, we made sure that three
qualitative researchers, including the qualitative trial lead, were present to discuss aspects of data capture,
data content and analysis. In addition, we worked with the wider team (seven additional members) through
a half-day group-working session that employed schema analysis to triangulate patient data, and through
the group-working process we were able to add to the veracity of working methods. During schema
analysis the core team (three qualitative researchers) examined whether or not their views aligned
appropriately and sufficiently with the wider group and whether or not data were being appropriately
managed and clarified. We were assured that this was the case, that no new themes were suddenly
revealed and that consensus of opinion regarding key emergent themes could be achieved in a manner
that was uncontested.
We therefore believe that our qualitative data are robust, although the number of interviewees is inevitably
small in comparison with the quantitative data. The data we obtained were extensive, not only about
patient and professional views of the interventions but also about participants’ views about the impact
of colitis on their health and lifestyle. Participants were willing to speak very openly about their disease,
and the views we obtained came from adults of all ages and from across the UK. We thus feel that
the data are important and deserve careful consideration alongside the clinical effectiveness and
cost-effectiveness results.
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Appendix 20 MATRICS proforma
MATRICS
Layer 1: effects soughta
Effects on patients Effects on the NHS specialty being investigated Effects on the rest of NHS and society
a Derived from the aims and objectives of the study.
Layer 2: methods used
Code Method
Layer 3: findings reported
Code(s) Finding(s)
Effects on patients
Effects on NHS specialty being investigated
Effects on the rest of NHS and society
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This document has been drafted using the DAMOCLES template located on the University of Aberdeen 
Health Services Research Unit website (http://www.abdn.ac.uk/hsru/documents/damocles-charter.doc).  
It has been modified to suit the requirements of the CONSTRUCT trial. 
 
 
 
Abbreviation Full text 
CI Chief Investigator 
DMEC Data Monitoring and Ethics Committee 
PI Principal Investigator 
RCT Randomised Controlled Trial 
T&W Truelove & Witts 
TMG Trial Management Group 
TSC Trial Steering committee 
UC Ulcerative Colitis 
 
 
 
The purpose of this document is to describe the roles and responsibilities of the independent Data 
Monitoring and Ethics Committee (DMEC) for the CONSTRUCT trial, including the timing, frequency and 
format of meetings, methods of providing information to and from the DMEC, statistical issues and 
relationships with other committees. 
 
The CONSTRUCT study 
− Comparison of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: a Trial 
(CONSTRUCT)  
− Sponsor’s name & number – Swansea University, RIO 031-08 
− EudraCT number – 2008-001968-36 
− ISRCTN – ISRCTN22663589 
 
The CONSTRUCT study comprises a cohort and an embedded two-arm, multicentre, pragmatic randomised 
controlled trial (RCT) involving 67 centres in the UK.  Inpatients admitted with suspected or known colitis will 
be recruited to the cohort, over a one year period (to include 1400 participants by the end of 2012).  Cohort 
participants with acute severe ulcerative colitis (UC) who fail to respond to treatment using two to five days 
intravenous steroids but do not, at the time of entry to the trial, require surgery, will be recruited to the RCT.  
Consenting RCT patients will be randomised to either infliximab (prescribed as Remicade®) or ciclosporin 
(prescribed as Sandimmun® and Neoral®), with 125 patients in each of the two arms. 
 
Data on all patients (cohort and RCT) will be collected using a centralised securely hosted clinical 
information system, supplemented by record linkage of electronically held routine data.  Designed research 
data collection will continue for two years on all patients.  Operational clinical data collection, routinely 
collected data and record linkage will then continue for the following eight years on all patients. 
 
The overall aim of this trial is to compare the clinical and cost effectiveness of Remicade (Infliximab) and 
Sandimmun/Neoral (Ciclosporin) for patients with steroid resistant UC.  Specific objectives are to: 
 
• Compare QoL across the two treatment groups (Remicade and Sandimmun/Neoral) 
• Compare mortality, disease activity and morbidity across the two treatment groups 
• Compare emergency colectomy rates across the two treatment groups 
• Investigate the views of patients regarding treatments 
• Compare cost effectiveness of the two treatments in terms of lifetime cost per quality-adjusted 
life-year, initially using primary data from the two years of trial and eventually using 10 year 
follow up data from the cohort 
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A further objective of the CONSTRUCT cohort study is to establish comprehensive long-term data collection 
using a web-based clinical information system to enable further research questions to be answered 
regarding clinical progress and outcome following treatment with acute severe UC.   
 
However the DMEC will not have responsibility for the cohort study, and cohort data will only be 
reported as it affects recruitment to the trial. 
 
 
 
The DMEC will consist of at least three members, including a statistician and a clinician.  The members 
should be independent of the trial (e.g. should not be involved with the trial in any other way or have some 
competing interest that could impact on the trial).  Any competing interests, both real and potential, should be 
declared.  A short competing interest form (see Annex 1) should be completed and returned by the DMEC 
members to Mrs Michelle Grey (details overleaf) as soon as possible. 
 
The members of the DMEC for the CONSTRUCT trial are:  
 
NAME Title Email Tel. number 
Prof Tim Peters 
(chair) 
Professor of Primary Care 
Health Services Research 
tim.peters@bristol.ac.uk 0117 331 3834 
Prof Stirling Bryan Associate Director, Centre 
for Clinical Epidemiology 
and Evaluation 
stirling.bryan@ubc.ca  604 875 4776 
Prof Phil Routledge Professor of Clinical 
Pharmacology 
routledgepa@cardiff.ac.uk 029 2074 2051 
Prof Chris Probert Professor of 
Gastroenterology at Bristol 
Royal Infirmary 
Chris.Probert@liverpool.ac.uk  01517 954010 
Peter Canham Crohn's & Colitis UK Patient 
Involvement Adviser  
petercanham@pca.org.uk  01697 352689 
Reporting to the DMEC on behalf of the CONSTRUCT trial team: 
Dr Alan Watkins CONSTRUCT Trial 
Statistician 
A.Watkins@swansea.ac.uk 
  
01792 295853 
Mrs Michelle Grey CONSTRUCT Trial 
Information and Quality 
Manager 
M.K.Grey@swansea.ac.uk  01792 602062 
Dr Hayley Hutchings CONSTRUCT Outcome 
Measures Specialist 
H.A.Hutchings@swansea.ac.uk 01792 513412 
plus any other members of the trial team requested by the DMEC 
 
 
The DMEC members were approved and invited by the CONSTRUCT Trial Management Group (TMG).  The 
Chair, Prof. Peters, has previous experience of serving on DMECs and experience of chairing meetings, and 
will be required to facilitate and summarise discussions.  Prof. Peters, will also act as the DMEC statistician. 
 
The CONSTRUCT trial statistician, Dr Watkins, will produce or oversee the production of the report to the 
DMEC. He will also participate in DMEC meetings, guiding the DMEC through the report, participating in 
DMEC discussions as requested by the DMEC and, on some occasions, taking notes.  The Trial Outcome 
Specialist, Dr Hutchings, may assist or replace Dr Watkins for a particular meeting if the DMEC agrees.  
 
Mrs Grey, the Trial Information and Quality Manager, will attend all DMEC meetings to observe discussions 
and take notes where appropriate.  Where the DMEC require unblinded data, Mrs Grey will be the only 
person allowed to unblind the data so as not to compromise the analysis of the final dataset by the 
statistician.  She will also contribute to the production of the non-confidential sections of the DMEC report 
and will disseminate reports from the DMEC to the TMG where necessary. 
 
At any time during the meeting, the DMEC may require Dr Watkins, Mrs Grey or both to leave.  If neither is 
present, the DMEC chair is responsible for any internal note-taking or minutes they consider necessary. 
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All electronic / written correspondence between the DMEC and the CONSTRUCT trial should be directed in 
the first instance to Mrs Grey using the following contact details: 
 
Tel: 01792 602062; Fax 01792 606599; email: ;  
Postal address: Biobank Suite, Room 244, Grove Building, School of Medicine, Swansea 
University, Singleton Park, Swansea SA2 8PP. 
 
The Chief Investigator, Prof John Williams, may be asked, and should be available, to attend open sessions 
of the DMEC meeting. Other specialists within the team (e.g. health economist) may also be asked to attend 
or give written responses to particular queries. 
 
 
 
The aim of the committee is to safeguard the interests of CONSTRUCT trial participants, assess the safety 
and effectiveness of the interventions during the trial, to advise the trial team so as to protect the validity and 
credibility of the trial, and to monitor the overall conduct of the trial. 
 
 
The DMEC will receive and review the progress and accruing data of this trial and provide advice on the 
conduct of the trial to the Trial Steering Committee (TSC).   
 
The DMEC should inform the Chair of the TSC if, in their view, the results are likely to convince a broad 
range of clinicians, including those supporting the trial and the general clinical community, that one trial arm 
is clearly indicated or contraindicated, and there is a reasonable expectation that this new evidence would 
materially influence patient management 
 
The DMEC’s interim reviews of the trial’s progress will include updated figures on recruitment, data quality, 
and main outcomes and safety data.  More specifically, they will: 
 
• assess data quality, including completeness (and by so doing encourage collection of high 
quality data) 
• monitor recruitment figures and losses to follow-up 
• monitor compliance with the protocol by participants and investigators 
• monitor evidence for treatment differences in the main outcome measures  
• monitor evidence for treatment harm (e.g. serious adverse events) 
• decide whether to recommend that the trial continues to recruit participants or whether 
recruitment should be terminated either for everyone or for some participant subgroups  
• suggest additional data analyses 
• advise on protocol modifications suggested by investigators or sponsors (e.g. to inclusion 
criteria, trial endpoints, or sample size) 
• monitor planned sample size assumptions 
• monitor continuing appropriateness of patient information 
• monitor compliance with previous DMEC recommendations 
• consider the ethical implications of any recommendations made by the DMEC  
• assess the impact and relevance of external evidence assembled by members of the trial team 
 
 
 
All potential DMEC members will have sight of the protocol and the DMEC charter before agreeing to join the 
committee.  Before recruitment begins the trial will have undergone review by the funder/sponsor, scrutiny by 
other trial committees and a research ethics committee.  Therefore, if a potential DMEC member has major 
reservations about the trial (e.g. the protocol or the logistics) they should report these to the trial office and 
may decide not to accept the invitation to join.  DMEC members should be independent and constructively 
critical of the ongoing trial, but also supportive of aims and methods of the trial.  
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The DMEC will meet before the trial starts to discuss the protocol, the trial, analysis plan and future 
meetings, and to have the opportunity to clarify any aspects with the trial team.  The DMEC should meet 
again within one year of recruitment commencing. 
 
 
 
UC is a chronic debilitating disease that affects approximately 150,000 people in the UK.  In about 10% of 
cases, UC presents as acute severe colitis requiring inpatient admission.  Treatment includes intravenous 
steroids but about 40% are steroid resistant.  In the past when no other treatments were available, 
emergency colectomy was the only other option.  Although mortality following emergency colectomy has 
fallen over time, it is still as high as 10% at three months. Thus the condition being treated is acute and life 
threatening. 
 
Infliximab and ciclosporin are two immunosuppressive agents that offer hope for the treatment of steroid 
resistant UC.  There is evidence that both are effective at least in the short term, particularly among people 
who respond partially to steroid treatment, although there are concerns about high rates of later relapses.    
Nevertheless some deaths and a substantial number of adverse reactions to both drugs will be expected.  
This is a pragmatic trial, and analysis will be by intention-to-treat.  This is particularly important when, as 
here, treatment may be withdrawn or changed for a substantial minority of participants.   
 
The primary outcome is patient quality of life.  Details of all secondary outcomes are listed in Annex 4 (taken 
from the CONSTRUCT Protocol v3-3).  This annex supersedes Annex 3 which was described in charter V2-
0, although Annex 3 has been retained in this charter for information. 
 
In this trial: 
• infliximab will be administered as Remicade® 
• ciclosporin will be administered as Sandimmun®/Neoral® 
 
Infliximab is licensed for the treatment of patients with steroid resistant UC in patients receiving oral steroids. 
Ciclosporin is not licensed for the treatment of steroid resistant UC but is used for the treatment of that 
condition. 
 
The trial includes health economic outcomes, including cost effectiveness.  Thus even if no difference in 
effectiveness is found between the two treatments, the trial may still result in a clear distinction between 
treatments. 
 
 
 
The DMEC is completely independent of the CONSTRUCT TSC, sponsor, study PIs and other regulatory 
bodies such as ethics committees and the MHRA.  It does not make decisions about the trial, but rather 
makes recommendations to the chair of the TSC (and TMG in some cases). 
 
Members will be reimbursed for travel and accommodation. Queries about expenses claims should be 
directed to Mrs Grey in the first instance. 
 
Competing interests should be disclosed using the proforma contained in Annex 1.  These are not restricted 
to financial matters – involvement in other trials or intellectual investment could be relevant.  Although 
members may well be able to act objectively despite such connections, complete disclosure enhances 
credibility.  
 
 DMEC members should not use interim results to inform trading in pharmaceutical shares, and should not 
trade in stock of companies affected by the trial until the results are published knowledge. 
 
 
 
The DMEC will meet before the trial starts, and again within six months of starting recruitment.  The exact 
frequency of subsequent meetings will be determined by the DMEC, but will normally be at least once a 
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year.  The wishes of the DMEC and needs of the trial office will be considered when planning each meeting.  
DMEC meetings will in general be scheduled a few weeks before meetings of the Trial Steering Committee, 
to which the DMEC will submit its report and recommendations.   
 
All meetings should be face-to-face if possible, with teleconference as a second option.  Since one of the 
CONSTRUCT DMEC members is located in Canada, he will be allowed access to all meetings via 
teleconference to make his contributions. 
 
Anyone attending the meeting remotely by teleconference is required to email any relevant documents to the 
DMEC chair and Mrs Grey one week before the meeting. 
 
Meetings may consist of a mixture of open and closed sessions.  There will be three levels of categorisation 
of sessions as follows: 
 
Level 1 – Open session.  Open to all invited CONSTRUCT TMG personnel. 
Level 2 – Semi-closed session.  Open only to AW, MG and HH (or other appropriate TMG 
members depending on the topic being discussed). 
Level 3 – Closed session. Only DMEC committee members to attend.  This excludes AW, MG and 
HH unless they are specifically invited to closed sessions.   
 
Any TMG members present will treat DMEC meetings as strictly confidential and not discuss them with any 
other TMG member not invited.  Information about recruitment, data quality and aggregated outcomes and 
safety data will usually be discussed in open sessions. 
 
 
 
Accumulating information relating to recruitment and data quality (e.g. data return rates, treatment 
compliance) will be presented.  Safety data based on pooled data will be presented and overall outcome 
data (numbers of events, or averages of scale measures) may also be presented, at the discretion of the 
DMEC. 
 
In addition to all the material available in the open and semi-closed sessions, the closed session material will 
include safety data and limited outcome data by treatment group.  DMEC members will view blinded data 
produced by the trial statistician.  Where they require the codes facilitating the blinding to be “broken”, Mrs 
Grey will produce the codes to allow unblinded access in a closed session in the absence of the trial 
statistician. 
 
Only the DMEC members will see the full range of accumulating data and interim analysis. 
 
DMEC members do not have the right to share confidential information with anyone outside the DMEC, 
including the CI. 
 
Identification and circulation of external evidence (e.g. from other trials/ systematic reviews) is not the 
responsibility of the DMEC members.  Mrs Grey will be required to do this. 
 
The DMEC will receive the report at least two weeks before any meetings. The report and all other relevant 
documentation will be circulated by Mrs Grey.  
 
The DMEC members should store the papers safely after each meeting so they may check the next report 
against them.  After the trial is reported, the DMEC members should destroy all interim reports.   
 
 
 
 
Possible recommendations could include:- 
• No action needed, trial continues as planned  
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• Early stopping due, for example, to clear benefit or harm of a treatment, futility, or external 
evidence  
• Stopping recruitment within a subgroup  
• Extending recruitment (based on actual control arm response rates being different to 
predicted rather than on emerging differences) or extending follow-up 
• Sanctioning or proposing protocol changes 
 
The DMEC should review and agree any interim analysis plans.  The approved draft tables will be saved 
within the charter as Annex 4. 
 
 
As the trial outcomes include survival, some interim comparative analysis will be needed to inform DMEC 
decisions, but in the first instance this will not be as complex as that planned for the final trial results. The 
analyses to be used will be specified at the first DMEC meeting, but are likely to include cumulative 
comparisons of mortality and colectomy rates.   
 
If the initial comparisons indicate that more information is needed, the DMEC may ask for further interim 
analyses.  These, like the initial comparisons, will use dummy allocation codes to preserve blindness of both 
DMEC and analysts.  If the DMEC requires unblinding before making a decision, Mrs Grey will reveal the 
unblinding codes. 
 
Formal statistical methods are more generally used as guidelines rather than absolute rules.  This is because 
they generally only consider one dimension of the trial.  Thus no specific stopping guideline for the trial has 
been laid down in advance.  However, in general, recommendations should be consistent with the statistical 
evidence (e.g. if based on an imbalance in outcome, that outcome should be unlikely to have arisen by 
chance). 
 
 
The role of the Chair should be to summarise discussions and encourage consensus; thus in each area of 
discussion the Chair should usually give their own opinion last. 
 
Every effort should be made for the DMEC to reach a unanimous decision.  If the DMEC cannot achieve this, 
a vote may be taken, although details of the vote should not be routinely included in the report to the TSC as 
these may inappropriately convey information about the state of the trial data. 
 
It is important that the implications (e.g. ethical, statistical, practical, and financial) for the trial be considered 
before any recommendation is made. 
 
Effort should be made for all members to attend.  The trials office team will try to ensure that a date is 
chosen to enable this.  Members who cannot attend in person should be encouraged to attend by 
teleconference.   
 
If, at short notice, any DMEC members cannot attend at all then the DMEC may still meet if at least one 
statistician and one clinician, including the Chair (unless otherwise agreed), will be present.  There should be 
at least three attendees present for the DMEC to proceed to decision-making. 
 
If the DMEC is considering recommending major action after such a meeting the DMEC Chair should talk 
with the absent members as soon after the meeting as possible to check they agree.  If they do not, a further 
teleconference should be arranged with the full DMEC. 
 
If the report is circulated before the meeting, DMEC members who will not be able to attend the meeting may 
pass comments to the DMEC Chair for consideration during the discussions. 
 
If a member does not attend a meeting, they should be available for the next meeting.  If that member does 
not attend a second meeting, they will be asked if they wish to remain part of the DMEC.  If they do not 
attend a third meeting, they will be replaced. 
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The DMEC will report its recommendations in writing to the TSC chair within two weeks.  Where appropriate, 
this should be copied to Mrs Grey, who will disseminate the findings at the next CONSTRUCT TMG.  
 
The minutes will be taken by Mrs Grey for open sessions and by a nominated member of the DMEC for 
closed sessions.  Separate records will be held for open and closed sessions.  Minutes from closed sessions 
will not be disseminated outside the DMEC unless there are exceptional circumstances.  The DMEC Chair 
should sign off any minutes or notes. 
 
If the DMEC has serious problems or concerns with a TSC decision, a meeting of these groups should be 
held.  The information to be shown would depend upon the action proposed and the DMEC’s concerns.  
Depending on the reason for the disagreement, confidential data may have to be revealed to all those 
attending such a meeting.  The meeting should be chaired by a senior member of the trials office staff or an 
external expert who is not directly involved with the trial. 
 
 
 
At the end of the trial there may be a meeting to allow the DMEC to discuss the final data with principal trial 
investigators/sponsors and give advice about data interpretation and publication.  The DMEC may wish to 
see a statement that the trial results will be published in a correct and timely manner. 
 
DMEC members will be named and their affiliations listed in the main report, unless they explicitly request 
otherwise.  A brief summary of the timings and conclusions of DMEC meetings should be included in the 
body of this paper. 
 
The DMEC may wish to be given the opportunity to read and comment on any publications before 
submission. 
 
Members of the DMEC may only discuss issues from their involvement in the trial 12 months after the 
primary trial results have been published, or when permission is agreed with the overseeing committee. 
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Potential competing interests of Data Monitoring and Ethics Committee members for the 
CONSTRUCT Trial (RIO 031-08) 
 
 
The avoidance of any perception that members of a DMEC may be biased in some fashion is important for 
the credibility of the decisions made by the DMEC and for the integrity of the trial. 
 
Possible competing interest should be disclosed via the trials office.  In many cases simple disclosure up 
front should be sufficient.  Otherwise, the (potential) DMEC member should remove the conflict or stop 
participating in the DMEC.  Table 1 lists potential competing interests. 
 
Table 1: Potential competing interests 
 
• Stock ownership in any commercial companies involved 
• Stock transaction in any commercial company involved (if previously holding stock) 
• Frequent speaking engagements on behalf of either of the interventions  
• Career tied up in a product or technique assessed by trial 
• Hands-on participation in the trial 
• Involvement in the running of the trial 
• Emotional involvement in the trial 
• Intellectual conflict e.g. strong prior belief in either of the trial arms 
• Involvement in regulatory issues relevant to the trial procedures 
• Investment (financial or intellectual) in competing products 
• Involvement in the publication 
 
 
 
Please complete the following section and return to the trials office. 
 
 No, I have no competing interests to declare 
 Yes, I have competing interests to declare (please detail below) 
 
Please provide details of any competing interests:  
 
 
 
 
Name: _______________________________ 
 
Signed: ______________________________     Date: ___________________  
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1. Recruitment 
By centre and overall:  
 Cumulative recruitment and recruitment in the most recent time period 
 Reasons for exclusion 
 Withdrawals split according to treatment group (full – all aspects of data collection or partial – QoL 
questionnaire data collection only).  Reports will refer to both the treatment phase and at follow-up. 
 A CONSORT diagram will be used to illustrate recruitment for the trial by centre and overall. 
 
2. Randomisation 
To include details of how randomisation is proceeding. 
 
3. Data Quality 
Questionnaires: 
 Interviews scheduled, completed, missed at each time point 
 Individual measures within interviews – missing answers (quality of life and health economic 
separately) 
Clinical (GeneCIS) records:  
 Identification process 
 Treatment phase (including compliance with treatment protocol) 
 Main outcomes 
 Trial endpoints 
 
4. Outcomes 
Overall (open, by centre) and by treatment (closed – dummy group allocations):  
 number (%) of deaths; emergency colectomies; other trial endpoints 
QoL overall (open) and by treatment (closed – dummy group allocations):  
 SF-12v2, EQ-5D, UK-IBDQ scores, (mean, SD, n) at baseline and follow-ups.  All data to be used in 
calculating the QoL scores for patients will also be reported. 
 
5. Adverse events (some of these will overlap with outcomes) 
Overall (open, by centre) and by treatment (closed – dummy group allocations; also by centre if overall 
shows a difference):  
 Reported Suspected Unexpected Serious Adverse Events (SUSARs) in detail 
 Other reported adverse reactions, by category (number, %) 
 number (%) of documented adverse events during treatment, adverse reactions (including 
separately those that result in treatment withdrawn)  
 
Basic statistical tests will be done, and any significant imbalances reported.   
All tests will have estimates, confidence intervals and p-values accompanying them in the reports. 
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Outcome measures 
a)      The primary outcome measure will be QoL measured at 24 months using the disease-specific UK-
IBDQ questionnaire. 
b) The generic SF-12 and EQ-5D QoL questionnaires will be secondary outcome measures.  All three 
questionnaires will be administered at baseline and at three, six, 12, 24 months. 
 
Other secondary outcome measures will be: 
c) Emergency and planned colectomy; colectomy may be undertaken based on clinical judgement 
and patient agreement.  The separate incidences of emergency and elective colectomy will be 
measured up to two years post-admission. 
d) Mortality at 24 months. 
e) Re-admissions; including for non-UC specific causes. 
f) Incidence of malignancies; colorectal malignancies, other GI malignancies, other malignancies. 
g) Incidence of serious infections during treatment; bacterial infections, pneumonia, abscess, other 
serious infections. 
h) Incidence of renal disorders during treatment. 
i) Incidence of new symptoms during or attributable to treatment; from among those listed as 
potential side effects in Summary of Product Characteristics for the drugs. 
j) Overall incidence of adverse events: grouped according to their classification as SUSARs, SARs, 
SAEs, ARs or AEs.  These will include those described in c – i above. 
k)       Disease activity; measured by Truelove and Witts criteria.  Full blood count, inflammatory markers 
and albumin will be measured at baseline and at three, six, 12 and 24 months. 
l)     Quality-adjusted survival; to combine the effects of QoL and mortality, will be measured up to two 
years follow-up and then modelled for lifetime Quality-Adjusted Life Years. 
m)      Total NHS costs; measured up to two years follow-up.  These will be combined with quality-
adjusted survival in the economic analysis. 
n)     Patient borne costs; including number of days off work per year and travel costs for health care, up 
to two years follow-up. These will be reported separately from the NHS costs and will not be included 
in the cost utility estimates. 
o)       Patient views; elicited through telephone interviews, following discharge from hospital at 
approximately two to three and six to eight months into follow-up.  These will be conducted for 24 
patients, 12 (5%) in each of the two treatment arms. 
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RECRUITMENT 
Table 1 Recruitment and progress of centres 
Number of centres that have reached: Date1 (last reported) Date2 (now) 
Full trial   
Pilot phase   
Set-up (approval obtained)   
Seeking ethical approval   
Considering/negotiating participation   
Total   
 
 
 
Table 2 Recruitment of participants  
Centre 
Date Number randomised Rate per month Projected 
at end 
trial 
Start 
pilot 
Start 
full trial 
Recent 
(past 3mth) Total 
Recent 
(past 3mth) 
Since 
started 
1. XXXXXXXX        
2. YYYYYYYY        
etc        
All live centres --- ---      
 
 
 
 
Figure 1: Recruitment graph (all centres combined: cumulative number of participants randomised by time 
since start of trial; reference line of number required to reach target if recruit at constant rate) 
 
 
 
Table 3 Exclusions, withdrawals and deaths 
 Number (%) by Date1 Number (%) by Date2 
Identified as potential participants: 
steroids started 
a a 
Status interim: still potentially eligible b b 
Identified (status resolved) c=a-b c=a-b 
Responded to IV steroids d (% of c) d (% of c) 
Emergency colectomy e (% of c) e (% of c) 
Failed other eligibility 
(inclusion/exclusion) criteria 
f (% of c) f (% of c) 
Refused consent g (% of c) g (% of c) 
Randomised h (% of c) h (% of c) 
Withdrawn (full) i (% of h) i (% of h) 
Withdrawn (partial)# j (% of h) j (% of h) 
Died (not withdrawn) k (% of h) k (% of h) 
Alive and not withdrawn l (% of h) l (% of h) 
NB: d-g are not eligible, d+e+f+g+h=c; i+j+k+l=h.  i and j may include patients who subsequently died. 
#: Partial withdrawal is from patient-assessed QoL/resource use only (continue collection of other data). 
 
 
 
Figure 2: Current CONSORT Diagram (includes extra path for interim status. Final full CONSORT Diagram 
will include withdrawals and deaths during each of the 5 follow-up periods) 
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DATA QUALITY 
Table 4 QoL/resource use questionnaires possible to date, and those which took place.  
  
Withdrawn 
therefore 
missed 
Died or q’re 
prior to 
death 
missed 
Number 
missed for 
other 
reasons 
Still 
pending 
Number 
complete 
Total 
possible 
(excluding 
pending) 
% complete 
Baseline        
Three month        
Six month        
One year        
18 months        
2 years        
Total        
 
 
 
Table 5 QoL/resource use questionnaires possible, and those which took place, by centre.  
 Centre (Any time point) Number complete Total possible % complete  
1. XXXXXXXX...    
2. etc    
    
Total    
 
 
 
Table 6 QoL/resource use questionnaires: missing items.  
  
Number 
of 
questionn
aires 
Number 
(mean) 
UK-IBDQ 
items 
missing 
Number (%) 
with at least 
one UK-
IBDQ item 
missing 
Number (%) 
with at least 
one EQ-5D 
item missing 
Number 
(mean) 
resource use 
items missing 
Number (%) with 
at least one 
resource use 
item missing 
Baseline       
Three 
month       
Six month       
One year       
2 years       
Total       
 
APPENDIX 21
NIHR Journals Library www.journalslibrary.nihr.ac.uk
310
DEMOGRAPHIC AND BASELINE COMPARISONS 
 
Table 7  Demographic and baseline characteristics by treatment group (coded).  
Number (%) unless stated   Group A Group B Whole sample 
Male    
    
    
Baseline QoL measures: 
Mean (sd) min, max   
 
UK-IBDQ (range 0-100, 0 good):    
     Dimension 1    
     Dimension 2    
     Dimension 3    
     Dimension 4    
     Dimension 5     
     Global (average)    
EQ-5D    
Euroqol VAS    
    
SF-12: physical    
SF-12: mental    
Total    
 
NOTE: UK-IBDQ dimensions and global measure (if any) may change after pre-pilot and development work 
 
 
OUTCOMES 
Table 8  Survival by treatment group (coded).  
Number (%) Status Total  Survival analysis 
  Alive Dead  Significance Hazard ratio (95% CI) 
 Group A        Group B    
Total      
 
Note: the trial has no formal stopping rule, but significance levels are included to inform DMEC judgement 
 
 
Figure 3: Survival by allocation group (two survival curves on one graph, all centres combined) 
 
 
Table 9  Emergency colectomy and other incidences by treatment group (coded).  
Number (%) Group A Group B Total Relative risk  (95% CI) 
Significance 
level  
Emergency colectomy      
Elective colectomy      
Malignancy      
Readmission      
      
During treatment:      
Serious Infections      
Renal disorders      
New symptoms      
Treatment stopped/changed      
Total      
 
Note: the trial has no formal stopping rule, but significance levels are included to inform DMEC judgement 
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Table 10  UK-IBDQ (primary outcome measure) at baseline and follow-up by treatment group 
(coded): responses by survivors.  
 Number A, B A: mean (sd) B: mean (sd) Difference (95% CI) 
Baseline     
3 month     
6 month     
12 month     
24 month     
Total     
 
Notes:  
(1) primary outcome measure to be finalised after pre-pilot & development work: global or dimension 
(2) this table does not include imputed values from missing interviews or death 
(3) these comparisons, unlike Table 11, are subject to survival bias 
 
 
Table 11  UK-IBDQ (primary outcome measure) at baseline and follow-up by treatment group 
(coded). If dead, value is minimum observed UK-IBDQ.  
 Number A, B A: mean (sd) B: mean (sd) Difference (95% CI) 
Baseline     
3 month     
6 month     
12 month     
24 month     
Total     
 
Notes:  
(1) primary outcome measure to be finalised after pre-pilot & development work: global or dimension 
(2) this table does not include imputed values from missing interviews 
 
 
ADVERSE EVENTS 
Table 12  Adverse events.  
Number (% rate per 
participant) Events Rate ratio 
(95% CI) 
People with at least 
one event Relative risk 
(95% CI) Type of event Group A 
Group 
B Total 
Group 
A 
Group 
B Total 
SUSAR (individual details 
in text)         
Serious Adverse Reaction:         
- leading to treatment 
withdrawal         
- all SARs         
         
Serious Adverse Event 
(unrelated to Ciclo/Inflix)         
Non-trivial adverse 
reaction listed as known 
side-effect of infliximab 
        
Non-trivial adverse 
reaction listed as known 
side-effect of ciclosporin 
        
Total         
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Note: The DMEC are notified of all SUSARs as they occur.  The DMEC report will summarise these 
individually in text following this table. 
 
 
Tables 13 and 14, and Figure 4 - only made available at the final DMEC meeting. 
 
If other comparisons show a large imbalance between groups earlier in the trial, the UK-IBDQ (primary 
outcome) will be compared in the same way at the latest time point for which adequate participant numbers 
are available.   
 
For the final analysis report, parameter estimates and confidence intervals for covariates and interactions (if 
any) in the final model will be included in the Table.   
 
Table 13  Primary outcome, and UK-IBDQ, EQ-5D, SF-12 at 24 months by treatment group (coded): 
imputed#.  
 Number A, B 
A:  
mean (sd) 
B:  
mean (sd) Difference 
Adjusted 
Difference  
(95% CI) 
UK-IBDQ (primary 
outcome)      
UK-IBDQ dimensions at 
24m      
...........etc.      
EQ-5D      
Euroqol VAS      
SF-12: physical      
SF-12: mental      
Total      
 
#: Deaths before 24 months replaced by 0.0 for EQ-5D, or by minimum observed value at that time in either 
group for UK-IBDQ or SF-12; other missing values for those who have already had 24 months follow-up 
imputed if information available.  
 
 
Table 14  Quality-adjusted survival by treatment group (coded).  
Number (%) Survival (QALY) Survival analysis 
  Mean Median Significance Hazard ratio (95% CI) 
 Group A       Group B   
Total     
 
 
 
Figure 4: Quality-adjusted survival by allocation group (two survival curves on one graph, all centres 
combined. Time axis measured in QALY’s – quality-adjusted life years) 
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Appendix 22 A personal experience
I am a 64-year-old male who prior to retirement was a Senior Officer in the Fire and Rescue Service.In 1999 I was diagnosed with Inflammatory Bowel Disease (IBD) and in 2005 I had a total colectomy
following a steroid-resistant flare-up. I have been a member of Crohn’s and Colitis UK for 15 years and it
was via them that I was invited to join the Trial Management Group (TMG) of the Construct Trial.
My first encounter with the professional researchers working on the trial was not easy and for the first few
meetings I did feel out of my depth. I initially had the fear that I was only there because the National
Institute for Health Research (NIHR) make public/patient involvement mandatory in the trials they sponsor.
After my first couple of meetings it became apparent that my earlier misgivings were unfounded and could
not be further from the truth. The Lead Researcher, Professor Williams, always made a point of involving
me in discussions and my views were considered along with those of the other members.
I found that my membership of the TMG was a two-way process and that I was able to feed in
information from my personal experience of IBD. This I believe helped the professional researchers to more
fully understand how IBD impacts on the life of individuals. I also gained a lot more knowledge about
Ulcerative Colitis and its medical effects on the body and the various treatments which are available.
One of the main ways I was able to get involved outside of the normal TMG meetings was in the
production of the health questionnaires. In particular the one which dealt with patients who had had
surgery when their treatment failed. In these cases the individuals are left with a temporary or permanent
Stoma. My personal experience of both the physical and mental trauma of this procedure and the
long-term effects were helpful in shaping some of the questions. It is all too easy when you are highly
trained in a subject to devise questions which are not explicit or easy for people to understand. I worked
on the theory that if I could understand the questions other patients would have a fighting chance.
At one point in the trial we had a recurring problem with patients who where taking part in the trial but
not returning questionnaires. It was agreed that a joint letter from Professor Williams and myself would be
sent to the individuals who had not returned the questionnaires. This did have some impact, which may
have been because the recipients of the letters were influenced by the fact that a fellow sufferer was
writing to them in conjunction with the Lead Researcher.
Being a member of a Trial Management Group is a long-term commitment covering years rather than
months. My advice would be if you have the time, energy and the will, you may be able to help improve
the lives of people you are unlikely to meet and that can be very rewarding.
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Appendix 23 Participant recruitment
Hull and East Yorkshire Hospitals NHS Trust
NHS Lothian
Gloucestershire NHS FT
Cardiff and Vale University Health Board
Oxford Radcliffe Hospitals NHS Trust
Nottingham University NHS Trust
Newcastle upon Tyne Hospitals NHS FT
Winchester and Eastleigh NHS Trust
Royal Bouremouth and Christchurch NHS FT
West Middlesex University NHS Trust
Southampton University NHS Trust
Taunton and Somerset NHS FT
Royal Wolverhampton Hospitals NHS Trust
Gateshead Health NHS FT
Brighton and Sussex University NHS Trust
University College London Hospitals NHS FT
Derby Hospitals NHS FT
University Hospital of Bristol
Royal Liverpool and Broadgreen University NHS Trust
Frimley Park Hospital NHS FT
Barking, Havering and Redbridge NHS Trust
Aneurin Bevan Health Board
Chelsea and Westminster NHS FT
St. George’s Healthcare NHS Trust
Highland Health Board
Leeds Teaching Hospitals NHS Trust
Barts Health NHS Trust
Abertawe Bro Morgannwg Health Board
Royal Devon and Exeter NHS FT
South Tees Hospitals NHS FT
Chesterfield Royal Hospital NHS FT
Sheffield Teaching Hospitals NHS FT
NHS Forth Valley
The Lewisham Hospital NHS Trust
South Devon Healthcare NHS FT
Bradford Teaching Hospitals NHS FT
North Tees and Hartlepool NHS FT 
Shrewsbury and Telford NHS Trust
Weston Area Health NHS Trust
Dorset County Hospital NHS FT
Western Sussex Hospitals NHS Trust
Colchester University NHS FT
South Manchester NHS FT
Countess of Chester NHS FT
Rotherham NHS FT
Salford Royal NHS FT
Blackpool Teaching Hospitals NHS FT
South Tyneside NHS FT
Sunderland NHS FT
Wringhtington, Wigan and Leigh NHS FT
North Cumbria University Hospitals NHS Trust
Maidstone and Tunbridge Wells NHS Trust
York Teaching Hospital NHS FT
Warrington and Halton NHS FT
Basildon and Thurrock University NHS FT
Dudley Group of Hospitals NHS Trust
Pennine Acute Hospitals NHS Trust
Doncaster and Bassetlaw Hospitals NHS FT
Sherwood Forest NHS FT
Central Manchester University NHS FT
Coventry and Warwickshire NHS Trust
Heart of England NHS FT
University Hospitals Birmingham NHS FT
South London Healthcare Trust
Wye Valley NHS Trust
Stockport NHS FT
Tameside Hospital NHS FT
0 10 20 30 40 50 60 70 80 90 100
Number of RCT patients
Number of cohort patients
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Appendix 24 Participant analysis framework
1. Longevity of disease.
Living with UC.
Time.
Course of disease: over longer period; short-term unpredictability.
2. Serious suffering.
Description of suffering.
Intensity of suffering.
Negative experience of suffering.
Loss of bodily control/function: gradual/sudden demise.
Unpredictability of symptoms/relapse.
(Toileting.) (Pain.)
3. Acceptance, coping, toleration.
Positive perception of life.
Surprise at positive moments.
Counter-intuitive return to better state.
Normalising illness/wellness/taken for granted.
Trivialising illness (within relationships).
4. Knowledge and information sharing.
Nurse.
Crohn’s and Colitis UK: self-help group low profile/some groups disbanded.
Internet.
Shared decision-making.
Media: UC low profile, not publicised.
Health-care professional/service want issues highlighted.
Containment: people not forthcoming about illness.
Trial removes treatment decision.
5. Life changes.
Being overwhelmed by illness.
Taking different and unexpected paths.
Taken off guard.
Stopping doing things.
Giving up control/taking control.
Restriction/constraint: unpredictability of disease.
6. Body: core of disease.
Within the body but ability to reflect on.
Failure of the body to function: different type of failure to other chronic conditions/physical
consequences.
IBD inside/outside.
Loss of body parts.
Defining self (loss of colon).
Body centric.
Visceral notion of UC.
7. Physical, mental and emotional impact.
Trajectory from physical to mental, to social to emotional impact.
Stress (leading to flare-ups).
Directional change (physical becomes mental).
Fear and despair/uncertainty.
Impact of physical, mental, emotional impact on relationships.
(Defining self by symptoms.)
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Loss of hope.
Physically fit/mentally vulnerable.
8. Expectations of health and well-being.
‘Normal’ life.
Happy/unhappy life.
Comfort/discomfort.
Inconvenience.
Managing life/practicalities.
Freedom/imprisonment.
Having energy.
Being fit and healthy.
Link between good and bad health.
9. Cacophony of drugs.
Other treatments alongside drugs.
Other treatments instead of drugs.
Number of drugs taken together.
Complex drugs pathway.
Unpredictable drug pathway.
10. Process and outcome of treatment.
Treatment practicalities.
What treatment has achieved/meant to patients.
Surgical intervention.
Side effects.
Unpredictability of treatment.
Proactive: difficult for health-care professional because of unpredictably.
Health-care professional aim is for people to live normal live.
11. Hindsight.
Post-surgery views.
Changes in perception.
Living with colostomy.
Views about reversal.
Stoma.
Submissive regarding choices.
12. Relationships.
Family, friends, professionals.
Support.
Understanding.
Giving.
Sharing/withholding information: work.
Infertility: awareness/lack of impact of disease (male and female).
Pregnancy: awareness/lack of impact of disease (male and female).
Disclosure.
Lack of awareness of others.
Lack of awareness of concerns.
13. Work.
Impact before treatment on work.
Positive effects of treatment on work.
Aftermath: future work arrangements.
Work identity: share with colleagues.
Impact of UC on career/work.
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